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Summary of each chapter 
This report, written following European Monitoring Centre for Drugs and Drug Addiction 
(EMCDDA) guidelines,1 is divided into two parts. Part A is an overview of new 
developments and trends in the drugs area in Ireland for 2008 and, in some cases, for 
the first six months of 2009. These are covered under the following headings: 
1. Drug policy: legislation, strategies and economic analysis 
2. Drug use in the general population and specific targeted-groups 
3. Prevention 
4. Problem drug use 
5. Drug-related treatment: treatment demand and treatment availability 
6. Health correlates and consequences 
7. Responses to health correlates and consequences 
8. Social correlates and social reintegration 
9. Drug-related crime, prevention of drug-related crime and prison  
10. Drug Markets 
 
Part B examines two specific issues considered to be important at an EU level. The 
Selected Issues are: 
11. History, methods and implementation of national treatment guidelines  
12. Mortality related to drug use: a comprehensive approach and public health 
implications 
 
 
Main points from Part A 
1. Drug policy: legislation, strategies and economic analysis 
The main drug policy issue facing the Irish government in the reporting year was the 
rapid proliferation of „head shops‟ selling „legal highs‟, i.e. psychoactive substances that 
were not in breach of the existing law.  In 2010 the Irish government took steps to 
outlaw these substances. In May it implemented a declaration order, declaring 
approximately 200 legal highs to be controlled drugs under the Misuse of Drugs Acts. 
In July the Criminal Justice (Psychoactive Substances) Act 2010 was passed, making it 
a criminal offence to sell or supply substances which might not be specifically 
controlled under the MDA but which have psychoactive effects. The new legislation 
was enacted to introduce more general control by way of criminal justice legislation to 
deal with head shop products as they emerge.  
 
The Steering Group established in late 2009 to develop proposals and make 
recommendations on a National Substance Misuse Strategy, combining illicit drugs and 
alcohol in the one strategy, is due to submit its proposals to the Minister for Health and 
Children and the Minister for Drugs by the end of 2010. The combined Strategy will 
then be submitted to the government for consideration. 
 
In response to the continuing economic downturn, Ireland‟s drug-related budget for 
2010 is expected to show a decrease of approximately 4.5% on last year, down from 
€277 million to €264 million.  
 
2. Drug use in the general population and specific sub-groups 
In the reporting year, no new information was published from the last iterations of the 
main drug prevalence surveys administered in Ireland. A comparison was made of 
drug use prevalence among young people, according to the data collected in the All 
Ireland Drug Prevalence, HBSC and ESPAD surveys, and a discrepancy found 
between the 2006 HBSC and 2007 ESPAD surveys. It is suggested that the marked 
                                               
1
 A copy of the EMCDDA guidelines is available from the EMCDDA website at www.emcdda.eu.int 
The guidelines require each Focal Point to write its National Report in a prescribed format using standard 
headings and covering each topic using a check list of items. This helps to ensure comparability of 
reporting across the EU. 
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decrease in cannabis use reported in the ESPAD survey of 2007 might represent a 
genuine fall in the use of cannabis, a change in the profile (age, gender or socio-
economic group) of the sample chosen, or in the way the questionnaire was 
administered.  
 
The results of a study undertaken in 2008, comparing drug use among early school 
leavers and school attendees, showed that substance use is more common (with the 
exception of alcohol) among early school leavers.  
 
An exploratory study of the mental health and well-being of lesbian, gay, bisexual and 
transgender (LGBT) people and their „coping strategies‟ for dealing with stress reported 
on the use of alcohol, cigarettes, anti-depressants, prescription and illegal drugs by 
research participants.  
 
At a conference in January 2010 Dr Des Corrigan, chair of the National Advisory 
Committee of Drugs, presented an overview of the products available in headshops in 
Ireland, their ingredients and their effects. Dr Pierce Kavanagh and colleagues (at 
Trinity College and the Drug Treatment Board) presented their work on identifying the 
active ingredients and other constituents in 51 products sold in headshops in Dublin.  
 
3. Prevention 
A majority of secondary-school students aged 12–16 who responded to a survey on 
their experience of the Social, Personal and Health Education (SPHE) programme, a 
school-based universal health promotion programme, reported that alcohol, drug and 
solvent use was the most emphasised theme in the SPHE syllabus. A majority also 
reported learning how to make good decisions while participating in SPHE.  
 
The Office of the Minister for Children and Youth Affairs (OMCYA) has published a 
best-practice guide and an accompanying toolkit for maintaining and developing youth 
cafés. In addition, the OMYCA recently published the National Quality Standards 
Framework for youth work, which provides for youth organisations and groups working 
with young people in Ireland to be subject to external assessment.   
 
A number of recent publications have enhanced understanding of young people 
deemed to be at-risk of substance misuse and social exclusion. A study by the Irish 
Youth Justice Service identifies individual, family, educational and neighbourhood risk 
factors among young people who engage with Garda Youth Diversion Projects. A 
recently-published study of early school-leavers reports that patterns of early school-
leaving in Ireland are strongly differentiated by gender and social class, with males 
from working-class and/or unemployed households being the most likely to leave 
school early.  The report of the Commission to Inquire into Child Abuse, published in 
May 2009, acknowledges the association between state care and future poor outcomes 
for children who have been in state care, including addiction and homelessness. 
 
4. Problem drug use (PDU) 
A repeat of a prevalence study in 2001, using a three-source capture-recapture 
method, has estimated that in 2006 there were 11,807 opiate users aged 15–64 years 
known to services in Ireland, and an estimated 8,983 users not known to the services. 
The national point estimate increased by 42%, from 14,681 in 2001 to 20,790 in 2006. 
The 2006 estimate is an over estimate for a number of reasons. 
 
According to the annual report of the National Registry of Deliberate Self-Harm, 
presentations of deliberate self-harm to hospital emergency departments in 2009 
increased by 5% over the 2008 figure.  
 
A study of the usage of Mephedrone, Methylone and BZP among attendees at 
methadone maintenance programmes at the Drug Treatment Centre Board showed 
significant use of the compounds. A separate study of the extent, and the experience, 
of „bath salts‟ use among problem drug users living in a hostel for homeless people in 
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Dublin city centre, revealed that 12 out of 17 respondents had tried bath salts on at 
least one occasion, and some had tried more than one product.  
 
Information on drug testing in prisons in 2009 indicated that, excluding methadone, 
between one-tenth and two-fifths of those screened, tested positive for at least one 
drug; the common metabolites detected indicated use of cannabis, benzodiazepines 
and opiates.  
 
A study of current or former heroin users attending general practice for methadone 
treatment estimated that 35% were problem alcohol users, and that 14% were 
dependent users.  
 
5. Drug-related treatment: treatment demand and treatment availability 
During 2010 the Health Service Executive (HSE) prioritised integrating the 
recommendations of the national drugs and homeless strategies and set up a national 
framework for rehabilitation within the addiction services.  
 
Two nurses working in the Drug Treatment Centre Board graduated in late 2009 as the 
first nurse prescribers in addiction in Ireland. A study of nursing services in Irish prisons 
found that nursing care for substance misuse was one of the most frequently 
performed clinical tasks and there was a need for specialist training. 
 
Detoxification was the subject of three separate studies: examining the factors 
associated with early relapse following opiate detoxification; determining the outcomes 
and the factors influencing outcomes among a cohort of opiate users starting 
detoxification; and evaluating a community detoxification pilot project. 
 
Trends in drug-related treatment for 2008, the most recent year for which data are 
available, showed that the incidence of treated problem drug use among 15–64-year-
olds living in Ireland, per 100,000 of the population, increased from 79.6 in 2007 to 85.8 
in 2008, and prevalence increased by 5%, from 444 in 2007 to 466 in 2008. An opiate 
(mainly heroin) was the most common main problem drug reported by cases entering 
treatment, and alcohol was reported as an additional problem substance in 41.4% of all 
treated cases.  
 
6. Health correlates and consequences 
In 2009, 27% of reported HIV cases in Ireland were probably infected through injecting 
drug use. A rolling centred three-year average for the number of new HIV cases 
infected through injecting drug use each year indicates that since 2006 there has been 
a declining trend. 
 
Between 2008 and 2009, reported cases of hepatitis B decreased by 12%. Among the 
cases in 2009 for which risk factor data were reported, 2.8% reported injecting drug 
use as the main risk factor. The number of such cases remained consistently low 
between 2006 and 2009, indicating the effectiveness of routine administration of the 
hepatitis B vaccine. 
 
Reported cases of hepatitis C dropped between 2008 and 2009 by 18%. Among the 
cases for which risk factors were reported in 2009, 70.9% reported injecting drug use 
as the main risk factor.  
 
Among all reported cases of overdose in 2008, non-opioid analgesics, including 
paracetamol, were present in 34.8% of cases; psychotropic agents in 21.5% and 
benzodiazepines in 20.8% of cases; and narcotic or hallucinogenic drugs in 12.6% of 
cases. There was evidence of alcohol consumption in 14.0% of cases.  
 
In 2008, the rate of drug-related first admissions per 100,000 of the population to Irish 
psychiatric facilities increased marginally, from 6.3 in 2007 to 6.8. Of the 791 
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discharges with a drug disorder in 2008, 51% had spent less than one week in hospital 
and just under 15% spent more than one month in hospital. 
 
The first combined annual report of Ireland‟s six sexual assault treatment units 
(SATUs), for 2009, reported that half (51%) of all patients who attended had consumed 
at least four units of alcohol in the 12 hours prior to the incident reported, 8% had taken 
illegal drugs and 3% were concerned that drugs had been used to facilitate sexual 
assault.   
 
Three reports on research into health-related consequences of drug use, either 
conducted in Ireland or with an Irish component, have been published recently, 
including studies of learning and memory defects in ecstasy users; the prevalence and 
influence of substance misuse (drug/alcohol dependence of abuse) on age at onset of 
psychosis and psychopathology among patients with first-episode psychosis; and acute 
reverse reactions to cocaine use, leading to admission to emergency departments.  
 
7. Responses to health correlates and consequences 
While people who have overdosed on drugs and been admitted to an intensive care 
unit (ICU) mostly survive hospitalisation, a 3-year evaluation of the functional outcomes 
and recovery patterns of 43 such patients found that of the 24 patients surviving after 
31 months, 16% were in custody and 54% unemployed.  
 
In response to the proliferation of „legal high‟ drugs available in head shops, various 
Dublin-based community-based organisations published information leaflets, a web 
page and a booklet with advice and guidelines on how to minimise harm. 
 
The plan to roll-out of needle exchange-services through community pharmacies in 65 
new locations across Ireland continued during the reporting year, with the HSE and the 
Irish Pharmacy Union recruiting a national liaison pharmacist to support pharmacists 
participating in the scheme outside Dublin.  
 
In June 2010, the independent group set up by the government to monitor 
implementation of A vision for change, Ireland‟s national mental health policy, reported 
that in 2009 there had been no further progress at national level in developing mental 
health services for persons with co-morbid severe mental illness and substance abuse 
problems.  
 
A review of progress in implementing the recommendations of a 2006 report on how to 
reduce the high level of suicide in Irish society found that progress had been patchy, 
and the few recommendations that had been implemented now needed financial 
resources and political support to be effective. 
 
8. Social correlates and social reintegration 
Early school-leaving and homelessness among individuals reporting for drug treatment 
showed a modest increase between 2004 and 2008. According to a recent report, most 
children aged 12–17 who were subject to an application for special care in 2007 had 
problems with alcohol and/or substance misuse.  New research comparing self-
reported substance use among a cohort of early-school leavers and school-attending 
students aged 15–18 in Ireland has concluded that relations between young people, 
their family and educational institutions can have a major impact on a young person‟s 
decision with regard to substance use.  
 
The National Drugs Rehabilitation Implementation Committee (NDRIC) has published a 
National Drugs Rehabilitation Framework to enhance the provision of rehabilitation 
services to current and former drug users by creating integrated care pathways (ICPs).  
 
A census of homeless adults living in temporary accommodation found that drug 
addiction had more than doubled and superseded alcohol as the main addiction among 
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the homeless population. The Homeless Agency has published a case management 
guidebook to assist those working in the area of homelessness and drugs.  
 
A review of a community-based  Education Bursary Fund that targets recovering drug 
users among other groups reports that the fund is perceived as useful to getting some 
recovering drug users into further education. FÁS, the national training agency, has 
developed a set of nine revised conditions to improve the operation and accessibility of 
vocational training for recovering drug users. 
 
9. Drug-related crime, prevention of drug-related crime and prison 
The link between the illicit drug market and an increase in gun crime in Ireland was the 
subject of an article in the British Journal of Criminology. The author concluded that 
policy responses to gun crime needed to consider the link between masculinity, 
poverty, the drug market and gun crime.  
 
The Drug Treatment Court which operates on a multi-agency basis as an alternative to 
imprisonment is to be continued for a further eighteen months. A review of the Court 
recommends the establishment of an Advisory Committee to oversee the project. This 
will consider the entry requirements to the programme, expectations of participants and 
measures of success and how the numbers of participants in the programme can be 
increased quickly. 
 
Pat Carey TD, Minister for Community, Equality and Gaeltacht Affairs (with 
responsibility for the National Drugs Strategy) announced his intention to extend the 
Dial to Stop Drug Dealing Campaign across local and regional drugs task forces. 
 
The National Advisory Committee on Drugs (NACD) is currently in the process of 
commissioning a study to estimate the prevalence of drug use, including intravenous 
drug use, among the prisoner population in Ireland. A recently published paper based 
on data from the National Drug-Related Deaths Index (NDRDI) for the years 1998–
2005 examined the relationship between date of release from prison and drug-related 
death. This was the first study of its kind in Ireland. Between 1998 and 2005, 2,442 
drug-related deaths were recorded on the NDRDI. One hundred and thirty of the 
individuals who died had a documented history of imprisonment.. 
 
10. Drug markets 
Customs Drug Law Enforcement (CDLE) reports an increase in the detections of herbal 
cannabis sent through the post in 2009. Also, the trend in domestic cultivation of 
cannabis appears to be continuing; over the past 18 months there has been a 
noticeable increase in detections of sapling cannabis plants and seeds. CDLE also 
states that the economic downturn and scarcity of criminal funding has resulted in 
Organised Crime Groups resorting more frequently to the „little but often‟ technique‟, 
i.e. using drug couriers to transport small quantities of drugs frequently.  
 
In 2009 there was a further decrease in the total number of drugs seized, which can be 
partly explained by the significant decrease in cannabis-type substances seized, down 
by just over 59%. Cocaine seizures also fell during 2009. Seizures of cocaine, heroin 
and ecstasy-type substances have also significantly declined since 2007.  
 
Main points from Part B 
11. History, methods and implementation of national treatment guidelines 
The first move to standardise treatment for drug dependence in Ireland coincided with 
the public health scare in the mid 1980s regarding the spread of HIV/AIDS, and the 
recognition that risky practices associated with injecting drug use were contributing to 
the spread of HIV infections. Guidelines for the prescription of methadone were first 
issued in 1987. 
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The current methadone treatment protocol (MTP), adopted in 1998, covers the 
statutory and regulatory issues around methadone prescribing and dispensing and 
does not deal with any clinical or treatment guidelines per se (buprenorphine is not 
currently available in Ireland). Guidelines specifically for general practitioners and for 
pharmacists managing opiate users in the primary care setting have been drawn up. 
Guidelines have also been developed for drug treatment in prison settings, and for 
clinicians prescribing benzodiazepines. The MTP was reviewed in 2002, and a further 
review was initiated in mid 2010.  
 
A study in 2005 of drug users‟ experiences of the Irish health services revealed many 
problems, including negative or discriminatory attitudes and treatment by health care 
staff. This finding led to steps to ensure that, in future, the opinions of drug users would 
be sought and taken into account when planning and delivering services, including the 
MTP. A study of Irish GPs‟ attitudes to the MTP in 2006 found that the vast majority 
thought it beneficial to patients.  
 
12. Mortality related to drug use: a comprehensive approach and public health 
implications 
Between 1998 and 2007 there were 3,465 drug-related deaths and deaths among drug 
users in Ireland. Of these deaths, 2,120 were due to poisoning and 1,345 were due to 
traumatic or medical causes (non-poisoning).  Over the reporting period, the annual 
number of deaths by poisoning increased from 178 in 1998 to 274 in 2007. A study of 
positive toxicology reports of drug users who died owing to trauma between 1998 and 
2005 showed that in many cases, more than one substance was present. The same 
study also looked at the history of drug use among those who died from medical 
causes between 1998 and 2005. This showed that the majority of drug users who died 
of medical causes had a history of opiate use, probably reflecting the long-term effects 
of problem drug use on a person.  
 
For each death recorded by the NDRDI, any history of a blood-borne virus, including 
HIV, is documented if such data are recorded.  However, this information is not always 
available.  In total, between 1998 and 2007 there were 84 deaths where the individuals 
were HIV positive and 19 deaths where AIDS/HIV was in some way implicated in the 
death.  The HPSC reported 84 AIDS deaths during the same period.  Small numbers 
over the 10-year period make it difficult to discern trends. 
 
Data from the NDRDI illustrate the total burden of mortality related to drug use in 
Ireland.  The upward trend in deaths both by poisoning and by non-poisoning has both 
immediate and longer term implications and requires appropriate public health 
strategies.   
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Part A: New Developments and Trends 
1. Drug policy: legislation, strategies and economic analysis 
1.1 Introduction 
The classification of drugs and precursors in Ireland is made in accordance with the 
three United Nations conventions of 1961, 1971 and 1988. Irish legislation defines as 
criminal offences the importation, manufacture, trade in and possession, other than by 
prescription, of most psychoactive substances. The principal criminal legislative 
framework is laid out in the Misuse of Drugs Acts (MDA) 1977 and 1984, and the 
Misuse of Drugs Regulations 1988. The offences of drug possession (s.3 MDA) and 
possession for the purpose of supply (s.15 MDA) are the principal forms of criminal 
charge used in the prosecution of drug offences in Ireland. The Misuse of Drugs 
Regulations 1988 list under five schedules the various substances to which the laws 
apply. 
The National Drugs Strategy (interim) 2009–2016 provides the implementation 
framework for illicit drugs policy in Ireland (Department of Community Rural and 
Gaeltacht Affairs 2009). The Strategy has an overall strategic objective, „To continue to 
tackle the harm caused to individuals and society by the misuse of drugs through a 
concerted focus on the five pillars of supply reduction, prevention, treatment, 
rehabilitation and research‟. Implementation is based on a „partnership‟ approach, 
whereby over 20 statutory agencies, multiple service providers and community and 
voluntary groups work together in a nationwide network of regional and local drugs task 
forces (DTFs) to deliver the Strategy, with the statutory agencies critical in terms of 
core service provision. Two central entities provide national oversight: (1) the Office of 
the Minister for Drugs (OMD), and (2) the Oversight Forum on Drugs (OFD), 
comprising senior representatives of the various statutory agencies involved in 
delivering on the Strategy, and representatives from the community and voluntary 
sectors. 
 
Priorities for public expenditure on the drugs issue are set out in the National Drugs 
Strategy and the National Development Plan. Public funds are allocated by way of the 
annual parliamentary Estimates process, which allocates funds to departmental Votes. 
Funding for regional or local initiatives may be either directly from government 
agencies and funds such as the Young People‟s Facilities and Services Fund (YPFSF), 
administered by the Office of the Minister for Children and Youth Affairs, or via the 
regional and local DTFs. Funding by DTFs proceeds from „initial‟ to „mainstreamed‟ 
funding as follows: 
 Initial funding: DTF projects are initially set up as pilot projects with funding provided 
through the Drugs Initiative, administered by the Department of Community, Rural 
and Gaeltacht Affairs (DCRGA). The government department or agency most 
closely associated with the nature of the project acts as the channel of funding to the 
project during this pilot phase.  
 Mainstreamed funding: after the pilot phase, each project is evaluated and a 
decision taken with regard to mainstreaming it in the appropriate government 
department or agency.  Once a project is mainstreamed, the responsibility for the 
funding of the project transfers to that department or agency and DCRGA is no 
longer involved. DTFs continue to have a monitoring role in relation to 
mainstreamed projects. 
 
Other public funding mechanisms include the Dormant Accounts Fund and the national 
lottery. The statutorily-based Dormant Accounts Fund contains unclaimed monies 
transferred by credit institutions and insurance undertakings. The Dormant Accounts 
legislation provides that these funds may be allocated to projects and programmes 
designed to alleviate poverty and social deprivation. 
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1.2 Legal framework 
1.2.1 Laws, regulations, directives or guidelines in the field of drug issues 
(demand & supply) 
This update covers drug-related Acts and Bills of the Oireachtas introduced or 
progressed during the reporting year. It also identifies new substances brought under 
control within the terms of the Misuse of Drugs legislation. Subject to the obligations of 
European Union membership as provided in the Constitution of Ireland, the sole and 
exclusive power of making laws for the State is vested in the Oireachtas (Parliament). 
The Oireachtas consists of the President and two Houses, Dáil Éireann (House of 
Representatives) and Seanad Éireann (Senate). Bills are proposals for new laws. They 
are usually approved by a Minister or another member of the Government. 
Occasionally, a Private Member‟s Bill is proposed by a member of the Opposition. 
Such Bills, because they have not originated in Government, are less likely than 
Government-sponsored Bills to become Law. To become law a Bill must first be 
approved by both the Dáil and the Seanad, although the Dáil can override a Seanad 
refusal to pass a Bill. Joint Committees are groups of members of Parliament, including 
both government members and members of the opposition, which discuss proposed 
legislation and make recommendations for amendments to the Minister. Once the Bill 
has been passed by the Oireachtas, the Taoiseach (Prime Minister) presents it to the 
President to sign into law, and then it becomes an Act. Acts do not come into operation 
until a Commencement Order is issued in the form of a Statutory Instrument. Notice of 
the making of the Commencement Order is published in the Oireachtas newsletter Iris 
Oifigiúil. 
 
New psychoactive substances brought under control 
 
The NDS, launched in September 2009, flagged as an emerging issue, the sale in 
Ireland of psychoactive substances that were not in breach of the existing law, 
commonly referred to as „legal highs‟; these substances were generally being sold in 
„headshops‟. Two actions in the NDS called for ongoing monitoring of the legislative 
framework.2 Subsequently, as headshops continued to spring up across the country at 
a rapid rate, the government gave priority to implementing these two actions. The 
legislative and regulatory measures that have been introduced are described here, 
along with the wider policy debate that has taken place. (The full suite of interventions 
adopted to date by the government, spanning the Supply Reduction, Prevention and 
Research pillars of the NDS, are summarised in Section 1.3.2 below.) 
 
In January 2010 John Curran TD, then Minister of State with responsibility for the 
National Drugs Strategy, opened a national conference on „legal highs‟ organised by 
the regional drugs task forces (Long, Jean 2010). Minister Curran said that he had 
asked the Minister for Health and Children, who has responsibility in relation to the 
importation, exportation, production, supply and possession of a range of named 
narcotic drugs and psychotropic substances under the Misuse of Drugs Acts, 'to ensure 
that every effort is made to expedite the response to this issue through the early control 
of substances under that Act'. He had also asked the then Department of Enterprise, 
Trade and Employment to examine issues relating to insurance and consumer 
protection. 
At its meeting on 2 March 2010, the government agreed to a proposal from the Minister 
for Health and Children, Mary Harney TD, to make a Declaration Order under the 
Misuse of Drugs Act 1977 declaring a range of so-called „legal highs‟ to be controlled 
drugs. Following this government decision, a draft Declaration Order and associated 
draft Statutory Instruments were drawn up and on 1 April 2010 these were notified to 
                                               
2
 Action 14: Monitor the activities of head shops, and all businesses involved in the sale of psychoactive substances, 
with the objective of ensuring that no illegal activity is undertaken. Ensure that steps are taken to reform legislation in 
this respect where it is deemed to be appropriate. Action 15: Keep drugs-related legislation under continuous review, 
with particular focus of new synthetic substances, new or changed uses of psychoactive substances, and against the 
background of EU and broader international experience and best practice. 
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the European Commission in accordance with the Technical Standards Directives 
98/34/EC and 98/48/EC, which require member states to notify draft technical 
regulations that may impact on trade. This process involves a three-month stand-still 
period. However, in light of growing concerns about the health risks associated with the 
use of legal highs, application was subsequently made to the Commission to use an 
urgency procedure and forego the three-month stand-still. The Commission advised on 
10 May 2010 that the legislation could be implemented without awaiting the expiry of 
the three-month period. 
At its meeting on 11 May 2010 the government made the Misuse of Drugs Act 1977 
(Controlled Drugs) (Declaration) Order 2010 (S.I. 199 of 2010), declaring a range of 
legal highs to be controlled drugs. To give effect to this decision, on the same day the 
Minister for Health and Children also signed the Misuse of Drugs (Amendment) 
Regulations 2010 (S.I. 200 of 2010), the Misuse of Drugs (Designation) (Amendment) 
Order 2010 (S.I. 201 of 2010), and the Misuse of Drugs (Exemption) (Amendment) 
Order 2010 (S.I. 202 of 2010). 
Under these statutory instruments, approximately 200 individual „legal high‟ 
substances, which had been on sale in headshops and which included the vast 
majority of products of public health concern, were declared to be controlled drugs. 
They include broadly: 
 synthetic cannabinoids (contained in SPICE products),  
 benzylpiperazine (BZP) and piperazine derivatives (commonly known as „party 
pills‟),  
 mephedrone, methylone, methedrone, butylone, flephedrone, MDPV (i.e. 
cathinones, often sold as baths salts or plant food), and 
 Gamma butyrolactone (GBL) and 1,4 Butanediol. 
In addition, the Declaration Order made under the Misuse of Drugs Act 1977 includes 
ketamine and tapentadol, substances that have legitimate uses as medicines but which 
can be subject to misuse. The Declaration Order also covers certain narcotic and 
psychotropic substances which Ireland is obliged to bring under control in order to 
comply with the UN Single Convention on Narcotic Drugs and the UN Convention on 
Psychotropic Substances.  It is anticipated that, towards the end of 2010, further 
amendments to existing Acts will regulate other head shop products.  
 
The process of introducing controls under the Misuse of Drugs Act is complex, 
particularly for substances which have legitimate uses but also have the potential to be 
misused. Some of the substances which have been controlled have legitimate uses in 
the pharmaceutical and chemicals industries, e.g. two of the BZP derivatives are used 
to manufacture authorised medicines, and GBL and 1,4 BD are widely used in the 
manufacture of plastics, as industrial solvents, as well as in many consumer products 
such as paints, toiletries, cleaning products, food products and others. Consequently it 
was necessary to engage with other government departments and organisations to 
ensure that appropriate and proportionate controls were introduced. 
 
On 18 June 2010 the Minister for Justice and Law Reform, Dermot Ahern TD, 
published the Criminal Justice (Psychoactive Substances) Bill 2010. The intention of 
the Bill was to make it a criminal offence to sell or supply substances which might not 
be specifically controlled under the Misuse of Drugs Acts but which had psychoactive 
effects. Introduced in the upper house of the Oireachtas, Seanad Éireann, on 23 June 
2010, just three weeks later the Criminal Justice (Psychoactive Substances) Act 2010 
was signed into law on 14 July 2010. Notwithstanding the regulations introduced on 11 
May, described above, the government recognised that new psychoactive substances 
could emerge quickly and there would always be a time lag before such substances 
could be made subject to control under the Misuse of Drugs Acts. This legislation was 
enacted to introduce more general control by way of criminal justice legislation to deal 
with head shop products as they emerged. The Act also gives appropriate powers to 
the Gardaí and to the courts to intervene quickly, by way of prohibition notices and 
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prohibition orders, to prevent the sale of psychoactive substances. The Act includes the 
following provisions: 
 Section 3 provides for the offences of selling, importing and exporting psychoactive 
substances for human consumption. Section 3 (1) provides for the offence of selling 
a psychoactive substance,  knowing or being reckless as to whether it is being 
acquired or supplied for human consumption. 
 Section 4 creates the offence of selling an object, knowing that it will be used to 
cultivate by hydroponic means any plant. Hydroponic cultivation is the cultivation of 
plants in liquid containing nutrients, without soil, and under controlled conditions of 
light, temperature and humidity. This method of cultivation is known to be used for 
the purpose of growing cannabis indoors. 
 Section 5 provides for the offence of advertising a psychoactive substance or object 
to which Section 4 applies. 
 Section 7 provides that a Garda Superintendent (or higher) may serve a prohibition 
notice on a person where he or she believes that the person is selling, importing or 
exporting psychoactive substances for human consumption, selling objects for use 
in cultivating by hydroponic means any plant. 
 Section 20 provides that a person guilty of an offence under the Act is liable on 
summary conviction to a fine of up to €5,000 or imprisonment for up to 12 months 
or both, or on conviction on indictment to a fine or to imprisonment not exceeding 5 
years or both. 
 
Having responded in line with Actions 14 and 15 of the NDS, the Irish government has 
also acknowledged that the issue is a complex and evolving one that needs to be dealt 
with on a number of fronts. The government continues to examine best practice and 
developments internationally, and has invited members of both Houses of Parliament 
and relevant committees to contribute ideas on how to tackle it. The on-going debate 
on the merits of outright banning versus strict regulation is summarised here.  
 
Acknowledging the difficulties of introducing an effective ban on psychoactive 
substances, opposition parties have proposed measures, including new legislation, to 
license and regulate the market in „legal highs‟. These have included: 
 a requirement for head shops to have an operating licence (Reilly 2010, 17 
February), 
 an amendment to Ireland‟s planning and development legislation to ensure head 
shops are required to obtain planning permission (Costello 2010, 25 February), 
 the establishment of a new statutory authority to regulate, register and license the 
sale, importation, distribution and production of non-medicinal psychoactive 
substances (Ó Snodaigh 2010, 28 April), and  
 a requirement for all substances sold in head shops to be passed by the Food 
Safety Authority and the Irish Medicines Board (Reilly 2010, 1 June). 
 
To date, the government has preferred to focus on outlawing the substances in 
preference to controlling their production, distribution, sale and use. On 2 July 2010, 
former Minister of State with responsibility for the National Drugs Strategy, John Curran 
TD, stated: „People indicated or suggested we should have planning laws relating to 
head shops. I have never supported this or licensing for head shops because my view 
is that it is the products they sell that are the problem. Therefore, we should not have 
the shops at all. … People have suggested that by closing head shops and closing off 
home delivery services and Internet sales, we reduce the problem but do not remove it, 
because the substances being sold will eventually be sold as illegal drugs and that this 
would not be much different from what we deal with in terms of ecstasy, cocaine or 
heroin currently. However, I believe closing them is hugely significant, because when 
head shops emerged, a number of people experimented with head shop products who 
never would have dealt with or used illegal drugs. ... However, just because something 
is not illegal does not mean any quality control or standards are applied. It is because 
people felt a sense of security and safety in experimenting with some of these products 
that for some time I have been of the opinion that licensing, regulation or planning 
around head shops was not sufficient. My view is that the products being sold are 
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absolutely dangerous and that our target should be to close them down. That is the 
direction we are going.‟ (Curran 2010, 2 July) pp. 672–673.  
 
In the interests of maintaining a balanced response, one contributor called for the full 
range of possible responses to be considered, not just legislative and regulatory 
measures: „When we debate legislation aimed at a particular mischief and introducing 
prohibition orders, we are focusing on criminal law approaches but we must take a 
holistic and cross-departmental approach when addressing the broader picture of drug 
use and addiction. The then Minister of State accepted the need to be rational in 
considering the issue of drugs. We must also devise credible measures to reduce the 
harm associated with drug abuse and, in particular, to reduce the number of tragic 
deaths resulting from abuse.‟ (Bacik 2010, 23 June): p. 542.  
 
Other Acts passed  
 The Housing (Miscellaneous Provisions) Act 2009 obliges local housing authorities 
to adopt a strategy to prevent and reduce anti-social behaviour in their housing 
stock, with the additional objectives of the co-ordination of services and the 
promotion of co-operation with other agencies to that end.  The Act also broadens 
the definition of anti-social behaviour in the Housing (Miscellaneous Provisions) Act 
1997 to include significant or persistent impairment of a person‟s use or enjoyment 
of their home, and damage to or defacement of any property.  
 The Health (Miscellaneous Provisions) Act 2009 makes arrangements for 
progressing the integration of health service agencies in line with government 
policy on the rationalisation of public sector agencies. Part 5 of the Act provides for 
the dissolution of the Drug Treatment Centre Board and the transfer of its rights, 
liabilities, land and any other assets to the Health Service Executive. 
 The Criminal Justice (Money Laundering and Terrorist Financing) Act 2010 
provides for offences of, and related to, money laundering in and outside the State; 
to give effect to Directive 2005/60/EC of the European Parliament and of the 
Council of 26 October 2005 on the prevention of the use of the financial system for 
the purpose of money laundering and terrorist financing. 
 The Criminal Procedure Act 2010 makes provisions for a modification of the rule 
against double jeopardy in order to allow a person who has been acquitted of an 
offence to be re-tried in circumstances where new and compelling evidence 
emerges or where the acquittal is tainted due, for example, to corruption or 
intimidation of witnesses or jurors or perjury. The rule against double jeopardy 
provides that no person may be put at risk of being punished twice for the same 
offence. The legislation applies to a number of drug-related offences. 
 The Road Traffic  Act 2010 provides for a reduction in the blood alcohol content 
(BAC) limit for drivers and also provides powers to assist the Garda Síochána in 
forming an opinion as to whether a driver is under the influence of an intoxicant 
(drug or drugs) and to carry out a preliminary impairment test on such drivers. 
 
Legislative Bills 
 
Table 1.2.1 Bills progressing through the Oireachtas 
Title and Explanatory Memorandum Parliamentary Stage  
as at July 2010 
The Spent Convictions Bill 2007 (No 48 of 2007) is intended to apply 
where a prison sentence not exceeding six months or a fine or penalty 
have been imposed, and then only after a certain number of years have 
elapsed without a further conviction.  The purpose of the Bill is to help 
rehabilitate convicted persons through facilitating their reintegration into 
the workforce and allowing them to build new careers.  
 
Private Member‟s Bill. Barry 
Andrews, Fianna Fáil. Referred 
to Select Committee on 
Justice, Equality and Women‟s 
Rights, 18 December 2008 
 
The Communications (Retention of Data) Bill 2009 (No 52 of 2009) 
requires service providers, those engaged in the provision of a publicly 
electronic communication service or a public communication network by 
means of fixed line or mobiles or the internet to retain data relating to 
fixed and mobile telephony, for 1 year, and data relating to internet 
access, internet email and internet telephony for 2 years, and provides 
for disclosure in relation to the investigation of specified offences 
Seanad Éireann. Second 
reading, 29 April 2010 
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Title and Explanatory Memorandum Parliamentary Stage  
as at July 2010 
including Customs offences. 
 
The Criminal Justice (Forensic Evidence and DNA Database 
System) Bill 2010 (No 2 of 2010), among other things, replaces the 
existing statutory and common law arrangements governing the taking 
of samples for forensic testing from suspects for use as evidence in 
criminal investigations and proceedings with an updated statute-only 
regime, provides for the establishment of a DNA database system for 
use by the Garda Síochána as an intelligence source for criminal 
investigations, provides for the taking of samples for the purposes of the 
DNA Database System and other matters relating to the System, and 
implements the DNA-related elements of the Council Decision 
2008/615/JHA of 23 June 2008 on the stepping up of cross-border 
cooperation, particularly in combating terrorism and cross-border crime. 
 
Referred to Select Committee 
on Justice, Equality, Defence 
and Women‟s Rights, 4 March 
2010 
 
The Criminal Justice (Public Order) Bill 2010 (No 7 of 2010) 
prohibits harassment or intimidation of members of the public by 
persons who engage in begging and confers powers on members of the 
Garda Síochána to give directions to persons to desist from begging, in 
certain circumstances such as where they are begging near cash 
machines or in front of places of business. It also provides for a series 
of sanctions including fines and possible imprisonment for breaches of 
the law. 
 
Referred to Select Committee 
on Justice, Equality, Defence 
and Women‟s Rights, 10 June 
2010 
 
The Planning and Development (Amendment) Bill 2010 (No 10 of 
2010) provides that a change of use of a structure to use as a Head 
Shop or a Sex Shop shall not be exempted development, so as to 
ensure that such premises would have to obtain planning permission 
under the relevant Planning legislation 
 
Private Member‟s Bill. Deputies 
Joe Costello and Jan 
O‟Sullivan, Labour Party. First 
stage, 25 February 2010 
 
The Non-Medicinal Psychoactive Substances Bill 2010 (No 18 of 
2010) establishes a new body known as An tÚdarás Rialála um 
Shubstaintí Neamhleigheasacha  Sícighníomhacha (Non-Medicinal 
Psychoactive Substances Regulatory Authority). This Authority will 
regulate the sale, production, import, distribution and marketing of non-
medicinal psychoactive substances and products that can have an 
effect on perception, health and wellbeing when consumed or otherwise 
used by persons. 
 
Private Member‟s Bill. Deputy 
Aengus Ó Snodaigh, Sinn 
Féin. First stage, 28 April 2010 
 
The Proceeds of Crime (Amendment) Bill 2010 (No 30 of 2010) 
amends the Proceeds of Crime Act 1996. The purpose of the Bill is to 
reduce from 7 years to 2 years the waiting period before the Criminal 
Assets Bureau can apply to the High Court for the disposal and 
forfeiture of assets frozen under section 3 of the Proceeds of Crime Act 
1996.  
 
Private Member‟s Bill. Deputy 
Pat Rabbitte, Labour Party. 
First stage, 3 June 2010 
 
Other regulations 
In September 2009 the European Communities (Road Haulage and Road Passenger 
Transport Operator‟s Licences) Regulations 2009 (SI No 318 of 2009) came into effect. 
Under the regulations, where a person is convicted of a drug trafficking offence then for 
a period of between 2 and 5 years depending on the seriousness of the offence the 
person is disqualified from holding an operator‟s licence. 
 
1.2.2 Laws implementation 
Compulsory Random Drug Testing (CRDT) in Defence Forces 
In October 2002 a Compulsory Random Drug Testing (CRDT) programme aimed at 
deterrence was introduced in the Irish Defence Forces. In November 2009, the then 
Minister for Defence, Willie O‟Dea TD, reported that, to date, 10,178 tests had been 
conducted with 41 tests yielding a positive result (4.0%), and that a total of 25 
members of the Defence Forces had been discharged as a result of a positive test 
result (O'Dea 2009, 19 November). 
 
New regulations with regard to psychoactive substances sold in ‘headshops’ 
On 1 June 2010 the chief pharmacist at the Department of Health and Children 
reported to the Joint Oireachtas Committee on Health and Children (Kinsella 2010, 1 
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June) that, the day after the banning of the 200 substances, referred to in Section 1.2.1 
above, the Garda Síochána visited all 102 head shops then in existence throughout 
Ireland. They requested that the proprietors of the shops voluntarily provide their 
merchandise to the garda who was visiting. The chief pharmacist also reported that 36 
head shops were still in operation on 1 June 2010 (Department of Health and Children 
2010, 1 June). Following the introduction of the Criminal Justice (Psychoactive 
Substances) Act 2010, the gardaí visited head shops in early September, and found 
only 19 were open and none were selling psychoactive substances (Garda Síochána, 
personal communication 2010). 
 
 
1.3  National action plan, strategy, evaluation and co-ordination 
1.3.1 National action plan and/or strategy 
The content of the National Drugs Strategy (interim) 2009–2010 (NDS) (Department of 
Community Rural and Gaeltacht Affairs 2009) was outlined in last year‟s national report 
(Alcohol and Drug Research Unit 2009): Section 1.3.1. In November 2009, in line with 
Action 1 of the NDS, a Steering Group, comprising representatives of the statutory, 
community, voluntary and industry sectors, was established to develop proposals and 
make recommendations on a National Substance Misuse Strategy that will incorporate 
the interim strategy. Its approach was described by the then Minister of State with 
responsibility for the Drugs Strategy, John Curran TD: 
 
„ ... the Steering Group will review existing policies and reports, including at EU 
and international level, and will set out an evidence-based framework through which to 
address the issues identified. While the Group will also be looking at what are the 
appropriate structures and frameworks for the effective and efficient implementation of 
the combined Strategy, the possible level of involvement of Local and Regional Drugs 
Task Forces in this regard has yet to be considered. 
 
The Steering Group is due to submit its proposals to the Minister for Health and 
Children and myself by the end of October 2010. The combined Strategy will then be 
submitted to Government for consideration. 
 
Finally, it should be noted that my Department has received 60 submissions from a 
range of organisations and individuals following the placing of an advertisement in the 
national newspapers in December last. The submissions are currently being reviewed 
and the issues arising will be considered by the Steering Group as part of its ongoing 
deliberations.‟ (Curran 2010, 18 February): p. 855. 
 
At the time of compiling this National Report, the date for submitting the proposals to 
the two ministers had been put back to the end of 2010. 
 
1.3.2 Implementation and evaluation of national action plan and/or strategy 
In its renewed programme for government, agreed in October 2009, under the heading 
of „Community and Social Economy‟, the government pledged to implement the new 
NDS, launched in September 2009, and under the heading of „Justice and Crime‟, it 
pledged to maintain its focus on tackling gang criminality and to continue to target 
Garda actions within communities experiencing significant anti-social behaviour and 
drug crime (Fianna Fáil and the Green Party 2009): p. 20.  
 
In June 2010 the Minister with responsibility for the NDS, Pat Carey TD, gave a brief 
report on overall progress in implementing the NDS: 
 
„Solid progress is being made on the implementation of the various Actions of the 
Strategy. ... An Garda Síochána and Revenue‟s Customs Service continue to prioritise 
the targeting of those involved in the supply of drugs and I congratulate them on their 
recent successes in this area, both nationally and abroad. 
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Significant progress continues to be made in regard to treatment and rehabilitation 
services for recovering drug users. New opiate substitution facilities, greater 
opportunities for detoxification and the roll-out of a comprehensive needle exchange 
programme across the country are among the improvements that are coming on 
stream. Progress is also being made towards providing comprehensive rehabilitation 
services. In that regard, my officials have recently agreed on a way forward in regard to 
residential rehabilitation services with the HSE and the voluntary sector. It is envisaged 
that significant improvements can be achieved through interagency co-operation and 
comprehensive care planning for the individual clients.‟ (Carey, Pat 2010, 9 June): p. 
964–965. 
 
Two particular developments relevant to implementation are described below – (1) the 
emergence of „head shops‟, and (2) the reconfiguration of ministerial portfolios, 
including responsibility for the NDS, in March 2010. 
 
Responding to the emergence of ‘head shops’ 
The emergence of „head shops‟, which sell legal psychoactive substances, was 
recognised and addressed by two actions in the NDS published in September 2009.3   
As head shops continued to spring up across the country at a rapid rate, the 
government used the institutional mechanisms provided for in the NDS to explore the 
options for responding. The suite of interventions adopted by the government to date 
span the Supply Reduction, Prevention and Research Pillars of the NDS, and are a 
result of cross-departmental and cross-agency co-operation. 
 A two-pronged legislative approach has been adopted, including (1) regulations 
under the Misuse of Drugs Acts 1977 and 1984 to control approximately 200 
specific substances (see Section 1.2.1 above), and (2) a new law making the sale 
or supply for human consumption of substances not specifically proscribed under 
the Misuse of Drugs Acts, but which have psychoactive effects, a criminal offence 
(see Section 1.2.1 above). 
 As part of the interdepartmental/agency response to the issue, relevant government 
departments and agencies continue to review existing legislative provisions to 
establish whether head shops are in compliance with the existing legislative 
provisions.  
 An Garda Síochána and Revenue‟s Customs Service closely monitor the activities 
of head shops, with a view to ensuring that no illegal substances are sold.   
 The HSE, in association with partner agencies under the national drugs strategy, 
has launched a national drugs awareness campaign focusing on the dangers of 
psychoactive substances available through head shops and the internet.  See 
Chapter 3.2. 
 The NACD commissioned research to look at (1) the risk factors associated with 
the consumption of products sold in head shops, and (2) measures taken in other 
jurisdictions to restrict psychoactive substances. At the time of going to press, this 
study had not been completed. 
Reconfiguring ministerial portfolios 
A reorganisation of government departments and state agencies in March 2010 
resulted in a reallocation of responsibilities, which may impact on the implementation of 
the NDS. 
 
The Office of the Minister for Drugs (OMD) is now located in the new Department of 
Community, Equality and Gaeltacht Affairs (DCEGA), and the new Minister for 
Community, Equality and Gaeltacht Affairs, Pat Carey TD, has responsibility for the 
                                               
3
 Action 14: Monitor the activities of head shops, and all businesses involved in the sale of psychoactive 
substances, with the objective of ensuring that no illegal activity is undertaken. Ensure that steps are taken 
to reform legislation in this respect where it is deemed to be appropriate. Action 15: Keep drugs-related 
legislation under continuous review, with particular focus of new synthetic substances, new or changed 
uses of psychoactive substances, and against the background of EU and broader international experience 
and best practice. 
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NDS and the OMD.  Responsibility previously sat with a Minister of State, who was 
outside the Cabinet. 
 
Explaining the reconfiguration, the Taoiseach (Prime Minister) outlined how the new 
DCEGA would be better equipped to tackle the issues associated with social inclusion 
in a more integrated and coherent fashion:  
 
„ ... the Department of Community, Rural and Gaeltacht Affairs will become the 
Department of Community, Equality and Gaeltacht Affairs and will incorporate 
responsibility for social inclusion policy and family policy from the Department of Social 
and Family Affairs and for equality, disability, integration and human rights from the 
Department of Justice, Equality and Law Reform‟ (Cowen 2010, 23 March): p. 9. 
 
1.3.3 Other drug policy developments e.g. government declaration, civil society 
initiatives 
In the last two years the government has been engaged in researching, deliberating 
and consulting on the content of two planned White Papers4 – on crime, and on 
strengthening local democracy – both of which may be expected to impact on the drugs 
policy domain. The options for strengthening local democracy, including examples of 
how the governance arrangements for local drug-related service providers might be 
strengthened, are discussed here; the White Paper on Crime is discussed in Section 
9.4.2. 
 
The decision-making relationships between national, local and community-level bodies 
– the governance framework – have attracted considerable attention in recent years. 
Following its establishment in 2002 the Department of Community, Rural and Gaeltacht 
Affairs undertook a „cohesion process‟, whereby it significantly reduced the number of 
community-based  bodies involved in providing local and community development and 
social inclusion programmes while seeking to maintain service provision across the 
country. Most recently, in January 2010, the Department merged its own two 
community development and local development social inclusion programmes into one 
integrated programme – the Local and Community Development Programme (LCDP) 
(Carey, Pat 2010, 11 May).  In the drugs area the work of the National Drugs Strategy 
Team, which was made up of representatives of relevant departments, state agencies 
and the voluntary and community sectors and supported the work of the local and 
regional drugs task forces, has been absorbed into the Office of the Minister for Drugs, 
which is located in the Department of Community, Equality and Gaeltacht Affairs 
(Alcohol and Drug Research Unit 2009).  
 
The assumptions underpinning these cohesion and rationalisation processes have 
recently been challenged by Ireland‟s National Economic and Social Forum (McInerney 
and Adshead 2010). Exploring local participatory governance in Ireland, the authors 
argue that a certain level of seeming duplication is necessary to ensure that the 
complex array of needs and circumstances can be accommodated, that „different 
opportunities for participation and, most importantly, for the realisation of social 
inclusion‟  are provided. Mapping the landscape of participatory processes, they have 
divided it into four zones: 
1. in-house participatory government, e.g. strategic policy committees; 
2. moving towards governance „out there‟, e.g. county/city development boards, 
RAPID; 
3. participating governance „out there‟, e.g. area-based/community partnerships, local 
and regional drugs task forces; and  
4. civil society organisations, e.g. community platforms. 
 
Rather than streamlining structures, collapsing the range of governance frameworks 
into a one-size-fits-all, the authors argue that greater attention should be given to 
                                               
4
 A White Paper provides a high-level statement of government policy, its rationale and the strategies to 
give effect to that policy. 
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supporting participation and to strengthening performance within each of the „zones‟. In 
Zone 3, where the authors locate the drugs task forces, they suggest that participation 
could be enhanced by strengthening co-operation between the entities and elected 
local representatives; by promoting an approach to problem-solving based on 
reference to organisational values, such as social inclusion and finding a voice, rather 
than stressing rules and procedures, and ensuring that the local development culture is 
not weakened. 
 
The authors of the NESF report expressed the hope that their analysis might feed into 
deliberations leading to the development of the government‟s White Paper on stronger 
local democracy. In the Green Paper published as a preliminary step towards the White 
Paper (Department of the Environment Heritage and Local Government 2008b), the 
government suggested that community participatory structures could be  
strengthened by giving local authorities the leadership role in the county/city  
development boards, which are intended to bring all state and local agencies together 
and co-ordinate their work. Unlike single focus agencies, local government is regarded 
as having the flexibility to be creative about new services it can provide.  
 
Creating the conditions for innovation is easier said than done.  In a separate initiative, 
a study was undertaken to investigate how to develop a capacity for foresight and 
innovation across the Irish economy and society as well as in the processes of 
governance and decision-making, in short, how to turn Ireland into a „learning society‟ 
(FuturesIreland 2009). 
The project reached four key conclusions: 
1. Cross-fertilisation between the economy, society and public governance enhance 
the ability to learn and innovate. 
2. Innovation and learning are systematic, almost always combining initiative, 
disciplined review and a willingness to confront challenges – institutional, inter-
personal and personal.  
3. Systematic review provides the basis for both innovation and accountability. 
4. Organisational systems, particularly our systems of control and accountability in the 
public sector, need to be completely changed in order to promote innovation and 
learning.  
 
SAOL – Service Provision for Women with Addiction Problems – based in inner-city 
Dublin was one several case studies that led to the fourth conclusion. The authors 
described how the rapid change from heroin to crack cocaine use rendered many of 
SAOL‟s services ineffective and they had very quickly to refocus their services. They 
did this following extensive consultations with colleagues in the Netherlands – known to 
them through joint work on European projects – in drug treatment services who had 
already dealt with this problem. SAOL piloted, tested and reviewed the new approach 
with women in their rehabilitation project. Notwithstanding this thorough review 
process, SAOL found it difficult to have this shift accepted by their statutory funding 
body. FuturesIreland suggested that, „To a large degree, the difference between the 
staff delivering the service and the people in the funding body centred on the 
willingness, ability and familiarity with data and methods of review.‟ (FuturesIreland 
2009): p. 41. 
 
Finally, philanthropy was identified in the Green Paper on strengthening local 
democracy as an option worth further investigation: „Philanthropy is considerably less 
developed in Ireland than abroad and there are opportunities to increase its role.‟ In 
launching the NDS in September 2009, the Minister for Drugs, John Curran TD, 
announced that needle exchanges would be rolled out in 65 new locations across 
Ireland using funding received from the Elton John AIDS Foundation (Curran 2009). 
 
1.3.3 Co-ordination arrangements 
The new streamlined co-ordinating mechanisms, introduce in the NDS, were described 
in last year‟s National Report (Alcohol and Drug Research Unit 2009): Chapter 1.3.3. 
Within the OMD, a Drugs Advisory Group has also been set up to advise the Minister 
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on operational and policy matters relating to the NDS and to oversee and support the 
work of the drugs task forces. It comprises members drawn from across the statutory, 
community and voluntary sectors (Curran 2009, 17 November).  
 
1.4 Economic analysis 
1.4.1 Public expenditures 
The most recent information available on public expenditure on the drug problem in 
Ireland is for the year ended 31 December 2009 (Table 1.4.1.1). The figures should be 
interpreted as indicative only. They relate to services that are broadly directly 
attributable to dealing with the drugs issue, i.e. „labelled‟ drug-related public 
expenditure. They do not take account of mainstream services that also help to tackle 
the issue, i.e. „non-labelled‟ drug-related expenditure. At present, it is not feasible to 
disentangle the funding aimed at assisting problem drug users from that aimed at the 
wider community. 
 
Table 1.4.1.1 Expenditure directly attributable to drugs programmes for government 
departments/agencies, 2008 and 2009 
 
Department/Agency 
2008 
Expenditure 
€m 
2009 
Expenditure 
€m 
 
Office of the Minister for Drugs 
 
65.207 
 
39.377 
Office of the Minister for Children and Youth Affairs – 28.501 
Department of Education and Skills 12.386 3.643 
Department of Health and Children 1.033 0.949 
Health Service Executive 101.867 104.867 
FÁS 18.8 18.8 
Department of Environment, Heritage and Local Government 0.496 0.461 
Department of Justice and Law Reform 12.340 14.801 
Irish Prison Service 5.0 5.0 
An Garda Síochána 44.4 45.004 
Revenue‟s Customs Service 14.9 15.837 
 
Total 
 
276.429 
 
277.240 
Source: Unpublished data from OMD, August 2010 
 
The OMD‟s drug-related budget dropped from €65.207 million in 2008 to under €40 
million in 2009; this was due for the most part to the transfer of funding for the Young 
People‟s Facilities and Services Fund (YPFSF) to the Office of the Minister for Children 
and Youth Affairs (OMYCA). A breakdown of expenditure under the Drugs Initiative in 
2009 was published by the Minister for Drugs, Pat Carey TD, in May 2010 and these 
figures are shown in Table 1.4.1.2. 
 
Table 1.4.1.2 Public expenditure on the Drugs Initiative, administered by OMD, 2009 
Project Amount 
(€ million) 
Total 
(€ million) 
 
LDTFs – 340 projects 
 
22.000 
 
 
32.00 RDTFs – 146 projects 
 
10.000 
Specific projects dealing with cocaine – 14       0.550  
 
 
1.360 
Specific projects addressing rehabilitation – 10 0.350 
Specific drug-related projects dealing with the homeless – 3 0.460 
 
Large-scale capital projects predominantly in RDTF areas, including 
targeted funding for Limerick City – 6 
 
2.12 
 
 
 
2.564 Small-scale capital projects in 23 task force areas to cover costs of 
refurbishments, renovations and the purchase of equipment – 100 
0.552 
 
Regional Youth Initiative – 6 projects 
 
 
 
0.471 
 
Dormant Accounts Fund – 80 substance misuse projects with a family 
support focus in task force areas 
 
 
 
1.560 
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Project Amount 
(€ million) 
Total 
(€ million) 
Total 37.955 
Source: Carey, 2010 
 
The UN‟s statistical framework COFOG and Peter Reuter‟s  (Reuter 2004) „effects of 
interventions‟ framework, first applied to Ireland‟s  labelled drug-related public 
expenditure for 2005, as reported in the Selected Issue „Public expenditure on drugs‟ 
(Alcohol and Drug Research Unit 2007), has not been applied to the 2008–2009 data.  
Although it is believed that it would reveal a similar pattern of drug-related public 
expenditure, the analysis has not been repeated as there were significant gaps in the 
original data that have not yet been filled.   
 
1.4.2 Budget 
For 2010, the provisional allocation estimate is expected to show a decrease of 
approximately 4.5% to €264 million (Eddie Arthurs, OMD, personal communication, 
August 2010).  
 
Ministers in government departments with responsibilities for the drugs issue have 
been seeking ways of maintaining service levels while reducing expenditure. For 
example, Ministers are seeking to maintain and develop the level of services by 
introducing administrative efficiencies and by using once-off funding to kick-start 
initiatives that will be integrated with and leverage existing projects.   
 
Administrative efficiencies 
Arising from the budget process 2010 the government decided that funding for the 38 
DTF projects mainstreamed in the Department of Education and Skills would be 
reduced from €3.643 million in 2009 to €2.461million in 2010, and that funding would 
cease altogether in 2011 (O'Keeffe, Batt 2010, 9 February).  During 2010 the 
Department of Education and Skills has been reviewing the mainstreamed projects in 
LDTF areas that it has been funding. Key questions being addressed in the course of 
the review include (1) is the Department of Education and Skills the appropriate 
location for these projects or would funding be more appropriately channelled through 
another Department or agency, for example would projects which involve a significant 
element of youth work be more appropriately located in the Office of the Minister for 
Children and Youth Affairs; (2) do some projects duplicate  the work of other 
departmental initiatives aimed at preventing early school leaving; and (3) would some 
projects which concentrate on treatment or rehabilitation work be better located in 
other government departments? The review had not been completed at the time of 
completing this national report (Coughlan 2010, 1 June). 
 
Integration and leveraging of existing programmes 
On 12 April 2010 Minister for Children and Youth Affairs, Barry Andrews TD, 
announced details of a funding scheme of €1.5 million from the Dormant Accounts 
Fund for youth cafés. (See section 3.2.3 for an account of the best-practice guide and 
toolkit for setting up and running a youth café, launched on the same day.) The 
purpose of the funding scheme is the structured promotion and development of new 
and existing youth cafés around the country.  As it is a once-off funding scheme, the 
focus is on capital outlay and initial set-up costs. However, the criteria for the scheme 
also focus on the broader issues of long-term sustainability and service planning.  
 
In clarifying expectations of the scheme, Minister of State Áine Brady explained that the 
scheme is not designed to provide for ongoing staffing costs but instead encourages 
realignment of existing services for young people to help achieve more focused 
delivery (Brady 2010, 2 June). Priority will be given to applications from consortiums 
(which may comprise statutory, community or voluntary stakeholders), which 
demonstrate leverage of funding from other resources for finance, staffing or site 
provision. This is intended to place an emphasis on sustainable and tangible service 
delivery. Minister of State Brady emphasised that it will be a highly competitive process 
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and only those proposals which demonstrate clear and sustainable improvements in 
the services available to young people in their catchment areas will be successful 
under the programme. 
 
1.4.3 Social costs 
See National Report 2009 for most recent information (Alcohol and Drug Research Unit 
2009) 
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2. Drug Use in the General Population and Specific Targeted 
Groups 
2.1 Introduction 
Drug prevalence surveys of the general and school-child population are important 
sources of information on patterns of drug use, both demographically and 
geographically, and, when repeated, can reveal changes over time. In Ireland such 
surveys are conducted every three to four years. These surveys increase 
understanding of drug use, which, in turn, helps in the formulation and evaluation of 
drug policies. They also enable informed international comparisons, provided countries 
conduct surveys in a comparable manner. The four main data collection tools in Ireland 
are described below. 
 
An All Ireland Drug Prevalence Survey was initiated in 2002 by the National Advisory 
Committee on Drugs (NACD) in Ireland and the Public Health Information and 
Research Branch (PHIRB), formerly known as the Drug and Alcohol Information and 
Research Unit (DAIRU), within the Department of Health, Social Services and Public 
Safety (DHSSPS) in Northern Ireland. The main focus of the survey is to obtain 
prevalence rates for key illegal drugs, such as cannabis, ecstasy, cocaine and heroin, 
on a lifetime (ever used), last year (recent use), and last month (current use) basis. 
Similar prevalence questions are also asked about alcohol, tobacco, and other drugs 
such as sedatives, tranquillisers and anti-depressants. Attitudinal and demographic 
information is also sought from respondents.  
 
The questionnaire and methodology for this drug prevalence survey are based on best-
practice guidelines drawn up by the EMCDDA. The questionnaires are administered 
through face-to-face interviews with respondents aged between 15 and 64 normally 
resident in households in Ireland and Northern Ireland. Thus, persons outside these 
age ranges, or who do not normally reside in private households, have not been 
included in the survey. This approach is commonly used throughout the EU and 
because of the exclusion of those living in institutions (for example, prisons, hostels) 
this type of prevalence survey is usually known as a general population survey. 
 
The first iteration of this general population drug prevalence survey was undertaken in 
2002/3 (National Advisory Committee on Drugs and Drug and Alcohol Information and 
Research Unit 2005), and a second iteration in 2006/7 (National Advisory Committee 
on Drugs and Drug and Alcohol Information and Research Unit 2008). A series of 
bulletins reporting the findings of the 2002/3 and 2006/7 iterations have been published 
and can be found at http://www.nacd.ie/publications/index.html 
The third survey will be conducted in 2010/11.  
 
As with other European surveys, people over the age of 64 are excluded from this 
survey, as they grew up in an era when both the use and availability of illegal drugs 
were very limited. Therefore, surveys with older people have, to date, shown very low 
rates of use even on a lifetime basis. This situation will change over time as the 
younger population grows older: lifetime prevalence rates are likely to increase for a 
considerable period of time. When examining the data and comparing results over 
time, last-year use is the best reflection of changes as it refers to recent use. Last-
month use is valuable insofar as it refers to current use. 
 
The Survey of Lifestyles, Attitudes and Nutrition (SLÁN) is a national survey of the 
lifestyles, attitudes and nutrition of people living in Ireland. To date, three surveys have 
been completed – in 1998 (Friel, et al. 1999), 2002 (Kelleher, et al. 2003) and 2007 
(Morgan, et al. 2008) – and have examined the health and social status, and related 
health service use, of adults aged 18 years and older living in private households. 
SLÁN 1998 and SLÁN 2002 were postal surveys, based on samples from the electoral 
register, and involved 6,539 respondents in 1998 (62% response rate) and 5,992 in 
2002 (53% response rate). SLÁN 2007 interviewed 10,364 respondents face-to-face in 
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their homes, based on samples from the GeoDirectory (62% response rate). The SLÁN 
data are not comparable with the results of the 2002/3 and 2006/7 all-Ireland general 
population drug prevalence survey as the SLÁN survey excludes those aged between 
15 and 17 years and includes those aged over 65 years. 
 
The Health Behaviour in School-aged Children (HBSC) is a cross-national research 
study conducted in collaboration with the WHO (World Health Organization) Regional 
Office for Europe. The study aims to gain insights into, and increase our understanding 
of, young people's health and well-being, health behaviours and their social context. 
HBSC was initiated in 1982 and is conducted every 4 years.  It is a school-based 
survey with data collected through self-completion questionnaires administered by 
teachers in the classroom.  
 
The Health Promotion Research Centre, National University of Ireland, Galway was 
invited to join the HBSC network in 1994 and conducted the first survey of Irish 
schoolchildren in 1998 (Friel, et al. 1999); the survey has been repeated in Ireland in 
2002 (Kelleher, et al. 2003) and 2006 (Nic Gabhainn, et al. 2007). HBSC Ireland 
surveys school-going children aged 10–18 years. To obtain the Irish HBSC participant 
sample, lists of primary and post primary schools are obtained from the Department of 
Education and Science, and schools across the country are randomly selected and 
invited to participate. The HBSC survey instrument is a standard questionnaire 
developed by the international research network and used by all participating countries. 
It contains a core set of questions looking at background factors, individual and social 
resources, health behaviours and health outcomes. Questions about smoking, alcohol 
use and cannabis use are asked under the heading of health behaviours. 
 
The European School Survey Project on Alcohol and Other Drugs (ESPAD) is a 
collaborative effort of independent research teams in about 40 European countries. 
Data on alcohol and illicit drug use among 15–16-year-olds have been collected every 
four years since 1995, using a standardised method and a common questionnaire.  
The Swedish Council for Information on Alcohol and Other Drugs (CAN) initiated the 
project in 1993. Support has been provided by the Pompidou Group at the Council of 
Europe, the Swedish Ministry of Health and Social Affairs, the Swedish National 
Institute of Public Health and the European Monitoring Centre for Drugs and Drug 
Addiction (EMCDDA). The data collection in the individual countries is funded by 
national sources. The rationale for the survey is that school students are easily 
accessible and are at an age when onset of substance use is likely to occur. (By 
definition, early school leavers, a group known to be vulnerable to alcohol and drug 
use, are not represented.)  
 
The fourth iteration of the survey was conducted in 35 European countries, including 
Ireland, in the spring of 2007 and the results were published in March 2009 (Hibell, et 
al. 2009). The fourth survey collected information on alcohol and illicit drug use among 
15–16-year-olds; 2,249 students from 94 randomly-selected schools participated, 
which represents a response rate of 78%. Fewer schools and students participated in 
2007 than in 2003.  The Irish data showed a marked decrease in lifetime use of any 
illicit drug between 2003 (40%) and 2007 (22%). As the majority of those who had tried 
any illicit drug had used cannabis (marijuana or hashish), the decrease in illicit drug 
use was influenced by the considerable decrease in the number of students who had 
tried cannabis at some point in their lives, from 39% in 2003 to 20% in 2007 (European 
average 19%).  
 
2.2 Drug use in the general population (based on probabilistic sample) 
2.2.1 Drug use in the general population 
According to the 2007 iteration of the all-Ireland general population drug prevalence 
survey, one in four people in Ireland used an illicit drug at some point in their life in 
2006/7 and one in five used cannabis (National Advisory Committee on Drugs and 
Drug and Alcohol Information and Research Unit 2008). Cocaine use increased in 
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2006/7 compared to 2002/3: the proportion of adults who reported using cocaine 
(including crack) at some point in their lives increased from 3% to 5% (National 
Advisory Committee on Drugs and Public Health Information and Research Branch 
2008). 
 
The 2007 SLÁN survey found that 6% of respondents reported that they had used an 
illegal drug in the year prior to the survey (Table 2.2.1.1). The reported use of such 
drugs was higher for men (9%) than for women (4%) (Morgan, et al. 2008). As 
expected, cannabis was the most commonly-used drug. The percentage of those who 
used cocaine in the last year was surprisingly low at 1%.  
 
In general, these data are not comparable to the results of the 2006/7 general 
population survey by the NACD as the SLÁN survey excludes those aged between 15 
and 17 years and includes those over 65 years. In addition, the use of confidence 
intervals allows commentators to rule out sampling variation when comparing the SLÁN 
surveys, both over time and with other surveys completed at the same time.  
 
Table 2.2.1.1   Last-year prevalence of illegal drug use in Ireland, 2007  
 Adults 18 years or over Males 18 years or over Females 18 years or over 
 % % % 
Illegal drug use* 6.0 9.0 4.0 
Cannabis 5.0 8.0 3.0 
Ecstasy 1.0 1.0 <1.0 
Cocaine 1.0 2.0 <1.0 
* Illegal drugs include amphetamines, cannabis, cocaine powder, crack, ecstasy, heroin, LSD, magic mushrooms, 
poppers and solvents. 
Source: (Morgan, 2008) 
 
2.2.2 Sedative, tranquilliser and anti-depressant use in Ireland 
The sixth bulletin of results from the 2006/7 all-Ireland general population drug 
prevalence survey, which focused on sedative or tranquilliser and anti-depressant use 
in the adult population (15–64 years) (National Advisory Committee on Drugs and Drug 
and Public Health Information and Research Branch 2009b), was reported on in the 
2009 National Report (Alcohol and Drug Research Unit 2009). 
 
2.2.3 Polydrug use in Ireland 
The fifth bulletin of results from the 2006/7 all-Ireland general population drug 
prevalence survey , which focused on polydrug use in the adult population (15–64 
years) and patterns of polydrug use (National Advisory Committee on Drugs and Drug 
and Public Health Information and Research Branch 2009a), was reported on in the 
National Report 2009 (Alcohol and Drug Research Unit 2009). 
 
2.2.4 NACD general population survey on drug use 2010/11 
Ethical approval for the conduct of the third iteration of the all Ireland general 
population drug prevalence survey was sought from and granted by the Royal College 
of Physicians in Ireland. The 2010/11 general population survey tender and 
questionnaire were prepared between January and March 2010. The questionnaire 
includes measures of alcohol use based on the European Comparative Alcohol Study 
(ECAS) guidelines and expert advice. The questionnaire will also be able to measure 
cannabis dependence using SDS (Severity of Dependence Scale which was developed 
for treatment surveys in order to measure dependence) and MCIDI (which is used in 
clinical settings to measure dependence). It was hoped to measure cocaine 
dependence but the potential sample was too small to ensure a reliable estimate.  
 
A call for expressions of interest in conducting the 2011 general population drug 
prevalence survey was advertised in late December 2009 and three potential 
companies were invited to tender. The tender for data collection, validation and initial 
analysis was awarded to IPSOS/MORI in May 2010.  
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The full questionnaire was piloted in July 2010. In addition, the MCIDI cannabis 
dependence measures were translated from German to English and English to 
German. The translations were checked by two independent fluent German speakers 
and two independent English speakers. A small number of changes were made to 
ensure a common translation. The SDS and MCIDI were then tested with 19 cannabis 
users to ascertain whether their understanding of each question was the same as the 
researchers understanding. Following these interviews, a number of further changes 
were made to ensure that the questions will be clearly understood by survey 
respondents. At present the computer programme that will be used for all data 
collection is being revised. In September 2010 there will be survey training. Data 
collection will commence in October 2010 and be completed in June 2010 (Jean Long 
NACD committee member, 2010).  
  
2.3 Drug use in the school and youth population (based on 
probabilistic sample) 
2.3.1 Drug use among early school leavers compared with school attendees 
A new study (Haase and Pratschke 2010) estimated drug use among 479 early school 
leavers and 512 school attendees, aged 16–18 years, and identified risk and protection 
factors for substance use. Data were collected throughout Ireland during two periods: 
March–May and September–December 2008. The participants were interviewed face-
to-face and their answers were recorded using computer-assisted personal 
interviewing devices. The proportions using each drug are presented in Table 2.3.1.1. It 
is clear that substance use is more common (with the exception of alcohol) among 
early school leavers than among school attendees. Table 2.3.1.2 presents the 
prevalence of drug use among the school attendees in this NACD study compared to 
drug use reported by participants in the 2007 ESPAD survey (Hibell, et al. 2009); the 
proportions in the two studies who reported use of each drug were very similar with the 
exceptions of crack cocaine and volatile inhalants.  
 
Table 2.3.1.1 Proportion of early school leavers (479) and school attendees (512) using different 
substances, 2008 
 Lifetime Year prior to the survey Month prior to the survey 
 Early 
school 
leavers 
% 
School 
attendees* 
 
% 
Early school 
leavers 
 
% 
School 
attendees* 
 
% 
Early 
school 
leavers 
% 
School 
attendees* 
 
% 
Tobacco 81.6 53.3 73.7 38.3 68.9 27.1 
Alcohol 89.6 85.7 84.3 78.1 65.3 54.4 
Cannabis 57.0 24.2 43.0 14.5 33.6 7.6 
Cocaine 25.9 3.7 14.8 2.5 5.4 0.2 
Crack 1.3 1.2 0.4 1.0 0.0 0.0 
Amphetamines 18.4 3.1 5.6 1.0 0.8 0.0 
LSD 5.6 2.0 2.3 2.0 0.0 0.0 
Magic mushrooms 12.1 2.5 5.4 0.4 0.4 0.0 
Heroin 1.3 0.0 0.4 0.0 0.0 0.0 
Tranquillisers 3.8 1.2 1.9 0.2 0.8 0.0 
„Legal‟ party pills 23.4 6.8 13.2 3.9 2.9 0.2 
Anti-depressants 8.4 2.0 5.4 0.4 2.1 0.4 
Ecstasy 27.3 4.9 17.5 2.3 7.1 0.4 
Solvents 14.4 5.5 2.9 0.4 0.8 0.0 
Anabolic steroids 0.8 0.02 0.2 0.2 0.2 0.0 
*Proportions for school attendees are adjusted by age and gender to match the composition of early school leavers. 
Source: (Haase, 2010) 
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Table 2.3.1.2 Proportion of school attendees (512) using different substances in 2008 (NACD study) 
compared to school attendees (2,249) in 2007 (ESPAD survey) 
 
Lifetime Year prior to the survey 
Month prior to the 
survey 
 NACD 
school 
attendees 
(16-18yrs)* 
 
 
% 
ESPAD 
school 
attendees* 
(15-16 yrs) 
 
 
% 
NACD 
school 
attendees 
(16-18yrs)* 
 
 
% 
ESPAD 
school 
attendees* 
(15-16 yrs) 
 
 
    % 
NACD 
school 
attendees 
(16-
18yrs)* 
     % 
ESPAD 
school 
attendees* 
(15-16 yrs) 
 
 
% 
Tobacco 53.3 52 38.3  27.1 33 
Alcohol 85.7 86 78.1 78 54.4 56 
Cannabis 24.2 20 14.5 15 7.6 9 
Cocaine 3.7 4 2.5  0.2  
Crack 1.2 4 1.0  0.0  
Amphetamines 3.1 3 1.0  0.0  
Magic 
mushrooms 
2.5 4 0.4  0.0  
Heroin 0.0 1 0.0  0.0  
Ecstasy 4.9 4 2.3 3 0.4 1 
Solvents 5.5 15 0.4 8 0.0 3 
Anabolic steroids 0.02 2 0.2  0.0  
*Proportions for school attendees are adjusted by age and gender to match the composition of early school leavers. 
Source: (Hibell, 2009) 
 
See section 8.2.2 for an account of the risk and protection factors for substance use 
among the interviewees. 
 
2.3.2 Drug use among young people: comparison between All Ireland Drug 
Prevalence Survey, ESPAD and HBSC 
According to the first two iterations of the NACD general population survey (National 
Advisory Committee on Drugs and Drug and Alcohol Information and Research Unit 
2005), (National Advisory Committee on Drugs and Drug and Alcohol Information and 
Research Unit 2008), the proportion of young adults (15–34 yrs) who reported using an 
illegal drug in the year prior to the survey increased from 10% in 2002/3 to 12% in 
2006/7 (Figure 2.3.2.1). The proportions using cannabis in the previous year showed a 
similar increase, rising by almost two percentage points, to over 10%. The proportions 
using cocaine increased for all three time parameters and the proportions using 
ecstasy in the 12 months prior to the survey increased marginally. 
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2002/3 2006/7 2002/3 2006/7 2002/3 2006/7 2002/3 2006/7
Illegal drug use Cannabis use Ecstasy use
Cocaine 
(including crack 
use)
Lifetime 26.0 31.4 24.0 28.6 7.1 9.0 4.7 8.2
Last year 9.7 12.1 8.6 10.4 2.0 2.4 2.0 3.1
Last month 5.2 4.8 4.3 4.2 0.6 0.6 0.7 1.0
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Figure 2.3.2.1   Lifetime, last-year and last-month prevalence of illegal drug use among 15–34-year-
olds in Ireland, NACD/DAIRU 2002/3 and 2006/7 
Source: National Advisory Committee on Drugs and Drug and Alcohol Information and Research Unit (2005, 2008) 
 
In the ESPAD surveys, the proportion of 15–16-year-old school children who reported 
use of any illicit drug at some point in their life decreased markedly between 2003 
(40%) and 2007 (22%), a fall of 18 percentage points (Figure 2.3.2.2). As the majority 
of those who have tried any illicit drug have used cannabis (marijuana or hashish), the 
decrease in illicit drug use was influenced by the considerable decrease in the 
percentage of students who had tried cannabis at some point in their lives, from 39% in 
2003 to 20% in 2007 (European average 19%). Lifetime use of solvents/inhalants 
decreased from 18% in 2003 to 15% in 2007, but remained higher than the European 
average (9%). In the case of amphetamines and cocaine powder, the proportions 
reporting lifetime use increased marginally to equal or exceed the European average of 
3%. In 2007, one in ten of the survey participants reported that they had taken 
prescribed tranquillisers or sedatives at some point in their lives; the use of such drugs 
had decreased marginally since 1999. 
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Any illicit 
drug
Cannabis
Tranquilise
r/sedative 
prescribed
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inhalants
Magic 
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and drugs
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2003 40 39 10 2 18 4 5 1 2 2 3 1 9
2007 22 20 10 3 15 4 4 3 3 4 4 1 7
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Figure 2.3.2.2   Lifetime use of drugs among 15–16-year-old school children in Ireland, ESPAD 
1999, 2003 and 2007 
Source: ESPAD (2000, 2004, 2009) 
 
As shown in Figure 2.3.2.3, trends in the use of cannabis and volatile inhalants in the 
12 months prior to the ESPAD survey mirror the trends in lifetime use reported above. 
 
Cannabis Volatile inhalants Ecstasy
1999 26 12
2003 31 10 2
2007 15 8 3
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Figure 2.3.2.3   Use of drugs in the 12 months prior to the survey among 15–16-year-old school 
children in Ireland, ESPAD 1999, 2003 and 2007 
Source: ESPAD (2000, 2004, 2009) 
 
The 2006 HBSC survey (Nic Gabhainn, et al. 2007) found that 16% of children 
reported using cannabis during their lifetime, compared with 12% in 2002. Cannabis 
use was highest among those aged 15–17, with about one in five in this age group 
using cannabis in the previous 12 months.  
 
The proportion of school children who reported cannabis use at some point in their life 
increased with each year of age between 13 and 17 in all three HBSC surveys, except 
for 17-year-olds in 1998 (Figure 2.3.2.4). In 2006, 6% of 13-year-olds reported lifetime 
  33 
use of cannabis, and the proportion increased steadily with each year of age, to 38% 
for those aged 17 years. The proportions of those who had used cannabis in each age 
group from 14 to 17 years increased between 1998 and 2006. 
 
13 years 14 years 15 years 16 years 17 years
1998 7.7 13.7 22.9 27.8 27.4
2002 4.5 9.4 21.2 29.5 32.4
2006 6.3 14.8 24 30.3 37.7
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Figure 2.3.2.4   Proportion of children who used cannabis at least once in their life, by age, HBSC 
1998, 2002 and 2006 
Source: Unpublished data from HBSC surveys  
 
The proportion of children who reported commencing cannabis use at 13 years or 
under was considerable, and similar in both the HBSC and ESPAD surveys (Figure 
2.3.2.5).   
 
Did not use
13 years or 
under
14 years or 
over
HBSC All 15 years 79.1 7.3 13.6
HBSC All 16 years 75.9 6.6 17.5
ESPAD All 15-16 years 80 7 13
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Figure 2.3.2.5   Age commenced cannabis use for children aged 15–16 years, HBSC 2006 and 
ESPAD 2007 
Source: Unpublished data from HBSC survey 2006 and published data from ESPAD (2009) 
 
In 2006/7, the proportion who had used cannabis three or more times was higher in the 
HBSC (10.4% and 12.3%) and than in the ESPAD survey (8%) (Figure 2.3.2.6).  
  34 
None
Once or 
twice 
3-9 times 
10  times 
or more
HBSC All 15 years 81.2 8.4 5.6 4.8
HBSC All 16 years 75.8 12 6.6 5.7
ESPAD All 15-16 years 85 6 3 5
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Once or twice 3-9 times 10  times or more
HBSC All 15 years 8.4 5.6 4.8
HBSC All 16 years 12 6.6 5.7
ESPAD All 15-16 years 6 3 5
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Figure 2.3.2.6   Frequency of cannabis use in the 12 months prior to the survey among 15–16-year-
olds, HBSC 2006 and ESPAD 2007 
Source: Unpublished data from HBSC survey 2006 and published data from ESPAD (2009) 
 
Overall, the HBSC surveys show a steady increase in cannabis use between 1998 and 
2006, whereas the ESPAD surveys show a large increase between 1999 and 2003 and 
a larger, unexpected, decrease between 2003 and 2007. The HBSC survey results are 
in line with those of the NACD survey and other epidemiological indicators.  
 
It is important to investigate the reasons for the marked decrease in cannabis use 
reported in the ESPAD survey of 2007; these figures could represent a genuine fall in 
the use of cannabis, or a change in the profile (age, gender or socio-economic group) 
of the sample chosen, or in the way the questionnaire was administered (Long, J and 
Mongan 2010).   
 
2.3.3 Drug and alcohol use among adolescents in south-eastern Ireland 
 
In the 2009 National Report (Alcohol and Drug Research Unit 2009), two reports on a 
study of drug and alcohol use in south-eastern Ireland were described (Van Hout 
2009a) (Van Hout 2009b). The study included interviews with young people, service 
providers, and parents. 
 
2.3.4 Exposure to illicit drug use and alcoholism among 9-year-old Irish 
children  
On 7 December 2009 the Minister for Children and Youth Affairs, Barry Andrews TD, 
launched the first major report from Growing Up in Ireland (Williams, et al. 2009), the 
national longitudinal study of children, tracking the lives of over 8,500 nine-year-olds. 
The data were collected between September 2007 and June 2008.  
 
The nine-year-old cohort was selected through the primary school network. A random 
sample of schools was drawn and, subject to the school‟s participation, age-eligible 
children in those schools and their families were invited to participate. The study 
included a wide range of perspectives, with information being recorded from parents, 
teachers, principals and carers, and the „study child‟ him or herself. Aspects explored 
included the children‟s living situations; experiences of family life; state of health; use of 
health care services; emotional health and wellbeing; education; peer relationships; 
activities; and neighbourhood and community settings.  
 
With regard to the children‟s experiences of stressful life, their mothers were presented 
with a list of 13 potentially stressful events and asked to report which ones, if any, their 
child had experienced. Just over 78% of children were reported to have experienced 
some form of stressful life event; 4% had experienced drug taking/alcoholism in their 
immediate family. As the following table shows (Table 2.3.4.1), in comparison with 
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children from two-parent families, children from single-parent families were more likely 
to have experienced drug taking/alcoholism in their immediate family. 
 
Table 2.3.4.1 Proportion of 9-year-olds experiencing drug-taking/alcoholism in their immediate 
family, 2007/8 
Family unit 
Percentage of 9-year-olds experiencing drug-
taking/alcoholism in their immediate family 
Single-parent – 1 or 2 children 10.0 
Single-parent – 3 or more children 10.7 
Two-parent – 1 or 2 children 2.0 
Two-parent – 3 or more children 2.0 
Source: Williams, 2009 
 
2.3.5 Solvent and volatile inhalant use in Ireland 
Under the Irish Child Care Act 1991 it is an offence to sell, offer or make available 
solvents to a person aged 17 or under if there is reasonable cause to believe that 
he/she is likely to inhale them.  
 
Solvents or volatile inhalants are a diverse group of substances whose chemical 
vapors, when inhaled, can have psychoactive or mind-altering effects. These 
substances vaporise at room temperature. A variety of products common in the home, 
school and workplace contain volatile substances that can be inhaled (Table 2.3.5.1); 
however, people do not typically think of these products as drugs because they were 
never intended to induce intoxicating effects (National Institute on Drug Abuse (NIDA) 
2007). Yet, young children and adolescents can easily obtain these toxic substances 
and are among those most likely to abuse them.  
 
Table 2.3.5.1   Type, descriptor and examples of volatile inhalants and solvents 
Type Descriptor Examples 
Volatile solvents Liquids that vaporise at room temperature 
Found in a multitude of inexpensive, easily 
available products used for common household 
and industrial purposes 
Paint thinners and removers 
Dry-cleaning fluids, degreasers 
Gasoline, glues 
Correction fluids 
Felt-tip marker fluids 
Aerosols Sprays that contain propellants and solvents Spray paints 
Deodorants, hairsprays 
Vegetable oil sprays  
Fabric protector sprays 
Gases Medical anesthetics as well as gases used in 
household or commercial products  
Butane lighters, propane tanks 
Whipped cream dispensers  
Refrigerants 
Chloroform, ether, halothane 
Nitrous oxide (laughing gas) 
Nitrites Nitrites, unlike most other inhalants, act primarily 
to dilate blood vessels and relax the muscles. 
While other inhalants are used to alter mood, 
nitrites are used primarily as sexual enhancers. 
Amyl nitrite 
Butyl nitrite 
Source: US National Institute on Drug Abuse (2007)
 
 
The majority of volatile inhalant or solvent users are teenage boys and girls who are 
still in school.  Only a small number seek treatment for problematic use of these 
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substances. Nonetheless, there are a number of fatalities each year as a result of 
inhaling these everyday household products.  
 
NACD general population survey – volatile inhalant use (National Advisory 
Committee on Drugs and Drug and Alcohol Information and Research Unit 2008) 
According to the 2006/7 survey, the proportion of the adult population who reported 
using a solvent or volatile inhalant in their lifetime was 1.9%, a small increase on the 
2002/3 figure of 1.7%. Reported use was more common among men (2.3%) than 
women (1.4%). Lifetime use was highest among adults aged 15–24 years, at 4.2%.  
 
Surveys of school children – volatile inhalant use  
A study completed in 2004 examined the extent of tobacco, alcohol and drug use 
among primary school children aged 11 to 14 years in Limerick City, Limerick County,  
and counties Clare and North Tipperary (the Mid-West Region) (Houghton, et al. 2008). 
Of the 1,254 respondents to the survey questionnaire, 53 (4.2%) had used 
glue/solvents at least „once or twice‟ in their lives. Forty-four out of the 53 said that they 
had only ever done this „once or twice‟. Thirty-three of the solvent users were male and 
20 were female. 
 
The fourth ESPAD survey (Hibell, et al. 2009) was conducted in 35 European countries 
during 2007 and collected information on alcohol and illicit drug use among 15–16-
year-olds. Lifetime use of solvents or inhalants decreased in Ireland over three time 
points, from 22% in 1999 to 18% in 2003 and to 15% in 2007, but remained higher than 
the European average (9%).  Girls were marginally more likely to have used solvents or 
inhalants than boys, 16% compared to 14%. Half of the users reported that they had 
taken these substances three or more times during their life. 
 
Volatile inhalant use among young people in the south-east of Ireland  
A recent study explored practices, social dynamics and effects of solvent or volatile 
inhalant use and suggested methods to deter or stop use among young people (Van 
Hout and Connor 2008). This inquiry was part of a much larger study on drug use. The 
authors interviewed 11 males and nine females (average age 13.2 years) living in the 
south-east of Ireland about their solvent or volatile inhalant use. The average age of 
first solvent use was 10.3 years; frequency of subsequent use was sporadic and 
opportunistic. Half of the solvent users also smoked cigarettes, despite the obvious 
danger associated with co-use. Solvent use was followed by initiation into alcohol use 
(average age of first use 12.5 years) and then a small number experimented with 
cannabis. Most used solvents outdoors with their peer group and during the summer 
holidays. There were some reports of solvent use during school breaks.  
 
The type of solvent used was determined by cost, access and place of residence. 
Children who lived in rural areas used a limited number of products, namely, wood 
glue, diesel and petrol, whereas children in urban areas used a wide variety of 
products, including Pritt Stick, methylated spirits, hairspray, deodorant, chrome paint, 
butane, nitrous oxide and Vicks nasal spray. Some products were inhaled using a 
plastic bag, others by placing the spray nozzle in the mouth or nostril, and others by 
pouring the product on a damp cloth and placing this over the face. Participants 
reported a variety of reasons for continuing to use solvents, such as to be part of the 
peer group, to relieve boredom, to experience a high, to deal with stress or to escape 
from reality. They reported a variety of physical effects such as fainting, vomiting, 
inflamed nostrils or headache. Some reported doing things following use that they 
would not normally do, such as having sex, being involved in vandalism or acting on a 
dare. All respondents knew someone who had died as a result of solvent use. In 
general, they reported that teachers were uncomfortable delivering information about 
drug use. They suggested that shopkeepers should not sell these substances to 
children. They also suggested that use would be deterred if the negative effects of 
these substances were explained and life stories shared. The latter suggestion is not in 
line with the current evidence-based practice.  
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See section 5.5 for the most recent data on treated volatile inhalant use and deaths as 
a result of volatile inhalant use. 
 
 
2.4 Drug use among targeted groups/settings at national and local level 
(university students and conscript surveys, migrants, music venues, gay 
clubs, gyms) 
2.4.1 Mental health and well-being of LGBT people – the role of alcohol and 
drugs  
On 2 February 2009 an exploratory study of the mental health and well-being of 
lesbian, gay, bisexual and transgender (LGBT) people in Ireland was published. 
Commissioned by the Gay and Lesbian Equality Network (GLEN) and BeLonG To 
Youth Services, and funded by the Health Service Executive‟s National Office for 
Suicide Prevention, the research was undertaken by a team of researchers from TCD, 
UCD and UCC (Mayock, P , et al. 2009). 
 
The purpose of the study was to examine mental health and well-being, including an 
investigation of suicide vulnerability (risk) and resilience, among LGBT people in 
Ireland, and to make recommendations on policy, service delivery and practice related 
to mental health promotion and suicide prevention.  
 
The research adopted a multi-modal approach, including the administration of a 
primarily quantitative on-line survey, and the conduct of a community assessment 
process and of in-depth individual interviews with 40 individuals who identified as 
LGBT. The researchers used the „minority stress model‟ to aid their understanding of 
the negative impacts on health and well-being caused by a stigmatising social context. 
External stressors were found to include presumed heterosexuality, homophobia, 
prejudice and victimisation; internal stressors related to the anxiety of coming out. 
Negative reactions from others when an individual „came out‟ to them also featured, as 
did the stress of self-concealment. 
 
The findings on mental health indicators suggested that the stigma and discrimination 
encountered by LGBT people can result in an extremely negative experience of being 
LGBT. Many participants in the study described having experienced depression, and a 
significant minority reported engaging in self-injurious behaviour, including hazardous 
drinking or problem alcohol use, and suicidal thoughts. 
 
The „resilience narratives‟ of LGBT individuals were explored, with special reference to 
self and others, and also in relation to the social environments or contexts where LGBT 
people interact. Five key sources of social resilience were discerned – friends, family, 
the LGBT community, school and the work place.   
 
With regard to „self-resilience‟, the researchers found evidence to suggest that 
resilience is an ongoing and emerging process rather than simply a trait possessed by 
some LGBT individuals and not by others. Positive life experiences and turning points 
were observed to have led to greater self-esteem and self-efficacy among participants.  
 
Many also identified „coping strategies‟ that they used to alleviate stress. Six of the 20 
coping strategies listed in the survey instrument related to the use of licit and illicit 
substances, and participants (N=1,110) identified using these strategies as follows:  
 drink alcohol to get drunk 28.2% (n=313), 
 drink alcohol (not to get drunk) 25.5% (n=283), 
 smoke cigarettes 24.5% (n=272), 
 take medication prescribed by a doctor/psychiatrist (e.g. anti-depressants) 
17.3% (n=192), 
 take prescription drugs (without advice of a doctor or medical worker) 12.3% 
(n=136), and 
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 take illegal drugs 10.0% (n=111). 
 
2.4.2 Substance use among Travellers and new communities  
The 2009 National Report (Alcohol and Drug Research Unit 2009) described two 
reports commissioned by the Western Region Drugs Task Force (WRDTF). The first, 
on the nature and extent of drug use in the Traveller population in the WRDTF area 
(Van Hout 2009c), reported similar findings to those of a 2006 study (Fountain 2006) 
and showed that levels of illicit drug use among Travellers are low compared to those 
in the general population, particularly in the case of substances scheduled under the 
MDA such as heroin and cocaine. 
 
 The second on substance use in new communities in the WRDTF area (Kelly, C, et al. 
2009b) uncovered little evidence of substance use as a substantial problem, or one 
that required immediate action, among new communities in the west of Ireland. 
However, the reluctance of members of new communities to access health services, as 
acknowledged in this report, suggests that the views of service providers as to the 
extent of substance use may not reflect the true situation in the communities. 
Alternative methods of collecting primary data, such as training people from new 
communities to undertake in-depth fieldwork, including interviews and observation, may 
yield a different picture to that conveyed here. A 2004 study using these methods found 
that heroin and cocaine use were becoming a problem among some sections of new 
communities in Dublin (Corr 2004).   
 
2.4.3 Psychoactive substances sold in head shops and on line 
Type of drugs sold and their effects or possible effects 
On 26 January 2010 the regional drugs task forces held a national conference on „legal 
highs‟ in Mullingar. Dr Des Corrigan, chairman of the National Advisory Committee on 
Drugs, presented an overview of the products available in head shops, their ingredients 
and their effects (Long, Jean 2010). He said that it was common for head shops to use 
the Latin name of plants and chemicals in their list of ingredients. He said that a 
number of plants were used as stimulants and that there were many strong caffeine-
based products on the market. In addition, he noted that many head-shop drugs 
contained piperine, the main chemical in black pepper, which increases the ability of 
the body to absorb the drugs.  
 
Dr Corrigan's description of the main psychoactive drugs sold in head shops in Ireland 
is summarised below: 
 Ephedrine, which is chemically similar to amphetamine, is available in head shops 
in the form of Sida cordifolia, which is not controlled in Ireland.  Two other forms of 
the drug, Ma Hung and synthetic ephedrine, are available in Ireland only on 
medical prescription dispensed by a pharmacist. The producers of one product 
containing Sida cordifolia state on the packaging that they take no responsibility for 
any consequences associated with its use. Chemically similar to amphetamine, 
ephedrine can induce dependence, psychosis, high blood pressure and increased 
heart rate.  
 Morning glory (Ipomoea) and Hawaiian baby woodrose (Argyreia nervosa) are 
listed as ingredients in a number of head-shop products that may be labelled 'not 
for human consumption'.  Both plants contain LSA (lysergic acid amide), a relative 
of LSD. The side effects of LSA and related chemicals include: apathy, tiredness, 
decreased psychomotor activity and feelings of unreality. As a form of lysergamide, 
LSA is controlled under the Misuse of Drugs Act. 
 Salvia divinorum (divine mint) contains chemicals called salvinorins that have a 
potency similar to that of LSD. Its use can lead to euphoria, feelings of levitation, 
out-of-body experience and, at high doses, uncontrolled delirium. The duration of 
its effects is short and the come-down is quick and therefore severe. It can induce 
mental health symptoms such as paranoia and derealisation.   
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 Three types of hallucinogenic cacti containing mescaline are sold in head shops. 
Their common names are peyote, San Pedro and Peruvian torch. Mescaline from 
peyote induces hallucinations as well as nausea and vomiting.   
 Kratom, which contains mitragynine (an opioid agonist), is a leaf chewed in south-
east Asia as a stimulant at low doses and as a painkiller or sedative at higher 
doses. It can cause constipation, weight loss, dependence, psychosis and 
withdrawal symptoms. It is not controlled in Ireland. 
 Piperazines such as 1-benzylpiperazine (BZP), methylbenzylpiperazine, meta 
chlorophenyl-piperazine (mCPP) and 1-(4-fluorophenyl) piperazine are synthetic 
drugs with psychedelic and euphoric effects which mirror those of ecstasy. They 
are sold as an ingredient in recreational drugs known as „party pills‟. Examples 
include Loved up, E bomb. BZP was banned in Europe in March 2008 and in 
Ireland in March 2009. Other forms of piperazine are not controlled in Ireland. BZP 
can lead to hyperthermia, high blood pressure, fast pulse, and convulsions.   
 Spice products are largely a mix of innocuous herbs, but six synthetic 
cannabinoids have been detected in the various spice products sold across 
Europe. Synthetic cannabinoids are more potent than the main psychoactive 
compound (THC) in natural cannabis, and do not contain the anti-psychotic 
substances found in natural cannabis.  They may therefore lead to a higher 
incidence of psychosis associated with cannabinoid use. There is also potential for 
dependence. These products have been banned in eight countries across Europe.  
 Cathinone is a naturally occurring stimulant found in the khat plant, and cathinones 
are a group of drugs related to amphetamine compounds. Methcathinone, 
methylmeth-cathinone (mephedrone) and methedrone, derivatives of cathinone, 
are sold as 'legal highs' online and in head shops in Ireland and across Europe 
under a variety of names, such as MCAT, Snow, and Charge. Some of these 
products are sold as bath salts or plant food. The contents listed on the package 
may contain the word 'ketones'. These compounds are advertised as a replacement 
for „Charlie‟ (cocaine). Some users have reported injecting the compounds. The 
use of these drugs can induce anxiety and paranoia. Reports say that their use can 
become compulsive and can create a state of psychological dependence. 
Mephedrone was linked to two deaths in Sweden in 2008. The authors reported 
that the negative effects of cathinones were: dehydration, erectile dysfunction, 
discolouration of the knees attributable to vascular damage („blue knees‟), cardiac 
arrhythmias, and paranoia. They also said that mephedrone had been linked with at 
least one death in Europe and was suspected in other deaths. Dr Pierce Kavanagh 
and colleagues (at Trinity College and the Drug Treatment Centre Board) identified 
the active ingredients and other constituents in 51 products sold in head shops in 
Dublin and illustrated their results in two posters (Table 2.4.3.1). These posters are 
useful for staff working in emergency departments and drug treatment centres. 
Eighteen of the products analysed contained cathinone derivatives, either in 
isolation or in combination: mephedrone (28% of cathinone products), flephedrone 
(17%), methylone (22%), butylone (17%) and MDPV (22%) (Kavanagh, et al. 
2010). In June 2010 and sometime after the conference mentioned in this section 
ethcathinone and iso ethcathinone were identified in White Columbia by Dr Pierce 
Kavanagh and colleagues at Trinity College. This was the first time these 
psychoactive substances were identified in Ireland.  
Table 2.4.3.1 Active ingredients identified in head shop products, in Dublin up to 11 May 2010 
Product Cathinone Other constituents 
The Business mephedrone 
 
Diablo XXX mephedrone 
 
Magic mephedrone 
 
Blow mephedrone benzocaine 
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Product Cathinone Other constituents 
Wild Cat mephedrone benzocaine, caffeine 
Oceanic Deeper flephedrone lignocaine, caffeine 
Charge + flephedrone lignocaine, caffeine 
White Ice flephedrone lignocaine, caffeine 
Snow methylone 
 
Mint Mania methylone 
 
Craic methylone 
 
Dog’s Bollox methylone, MDPV 
 
Hurricane Charlie MDPV 
 
Ivory Wave MDPV lignocaine 
Sextacy MDPV lignocaine 
Doves butylone 
 
Summer Craze butylone 
 
Ethcathnone White Columbia 
 
Iso-ethcathinone White Columbia 
 
Source:  Kavanagh, 2009 
 
Several additional psychoactive substances were identified in June 2010: 
 
Pyrovalerone  
Pyrovalerone is a psychoactive drug with stimulant effects that was developed in the 
late 1960s for the clinical treatment of chronic fatigue and as an appetite suppressant 
for weight loss purposes. Because of problems with abuse and dependence, it is now 
less frequently prescribed, but there are reports of its continued use in France and 
South-East Asia. Its side effects include loss of appetite, anxiety, sleep disturbance, 
and tremors. The user may become depressed when use is discontinued. Its use is 
controlled in Ireland, Australia, Britain and the US.  Pyrovalerone is closely related in 
structure to a number of other stimulants, such as methylenedioxypyrovalerone 
(MDPV) (banned in Ireland under Order of 11 May 2010).  Naphyrone (O-2482, NRG-
1, Energy 1), also known as naphthylpyrovalerone, is a drug derived from pyrovalerone 
that has stimulant effects and has been reported as a novel designer drug. It is sold as 
a plant food on line. No safety or toxicity data are available on naphyrone. 
 
Aminoindans  
2-Aminoindan is an uncommon short-acting stimulant with effects that have been 
compared to those of 1-benzylpiperazine or methamphetamine. Little is known about 
its recreational use, but aminoindans are the active ingredient in at least one head-
shop product, Pink Champagne pills, which also contain cola vera and caffeine. The 
pills may cause an increased heart rate and short-term insomnia. Online sellers of 
these products indicate that they should not be consumed in combination with alcohol 
or other drugs, particularly anti-anxiety or anti-depressant drugs, or by people with any 
medical condition (in particular, heart or liver disease), with mental illness, or who are 
pregnant or breast feeding.  
 
1,3-dimethylamylamine (DMAA) 
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1,3-dimethylamylamine or DMAA, also known as methylhexaneamine, is a derivative of 
geranium oil which acts as a central nervous system stimulant. Methylhexaneamine is 
registered for use as a nasal decongestant. In combination with caffeine and other 
ingredients, it has been marketed as a dietary supplement under trade names such as 
Geranamine and Floradrene. Methylhexaneamine, at extremely low concentrations 
(less than 1%), is a component of geranium oil which is approved for use in foods. In 
New Zealand, DMAA is emerging as an active ingredient in party pills. Recreational 
drug users have reported adverse effects of DMAA, including headache, nausea, and 
stroke. Online user reports describe a desire to reuse the drug, episodes of profuse 
sweating, and feeling depressed and paranoid. In November 2009, the New Zealand 
government indicated that methylhexanamine would be scheduled as a restricted 
substance. Products containing DMAA are available in head shops and on line under 
names such as Iced Diamond, Vegas Nights and Blessed.  
 
Dimethocaine, also known as larocaine, is a local anesthetic with stimulant properties 
that are nearly as potent as those of cocaine. However, anecdotal user reports indicate 
no euphoria and only mild stimulating effects. This drug may induce a fast and irregular 
heart beat which could be problematic for those who continuously redose. The drug 
has induced respiratory arrest. Dimethocaine was identified in the head-shop products 
Amplified, Mint Mania and Mind Melt. The Ana Liffey Drug Project reported that a 
number of clients experienced negative effects of a product called Amplifier (most likely 
Amplified). The clients reported that the drug is available in two forms; a rock which is 
smoked by pipe and a tablet which is broken down to inject. According to the users of 
this drug, it has a stimulant effect and a bad come down. Some users reported 
paranoia or auditory or visual hallucinations.. In August 2010 three users, who had a 
previous mental health diagnosis, were admitted to a psychiatric hospital following 
hallucinations and depression. 
 
AM-694 is a drug which acts as a potent and selective agonist for the cannabinoid 
receptor CB1. No public data about AM-694 metabolism is known. AM-694 has 
emerged as a designer drug, and in Ireland, it was detected in the product Shamrock. 
Concerns have been raised over the possible toxicity of this compound, because of its 
likely metabolism to ω-fluoroalkanoic acids.  
 
Glaucine is an alkaloid found in several different plant species. It has bronchodilator 
and anti-inflammatory effects and is used as a cough suppressant in some countries. 
Glaucine may induce fatigue or hallucinations (which are usually colourful visual 
images). This substance was detected as the active ingredient in the head-shop 
product Entrophy.  
Phenethylamine (PEA) is a natural monoamine alkaloid and a psychoactive drug with 
stimulant effects. This substance was detected in the head-shop products Diablo, Dr 
Feelgood, Entrophy, Nemesis, and Party On. 
 
Metamfepramone also known as dimethylcathinone, dimethylpropion, or dimepropion, 
is a stimulant drug of the phenethylamine, amphetamine, and cathinone chemical 
classes. Dimethylcathinone was evaluated as an appetite suppressant and for the 
treatment of hypotension, but was never widely marketed. Metamfepramone is used for 
the treatment of the common cold. This substance was detected in a product sold in 
tablet form as BluE. 
 
Synephrine is the main active compound found in the bitter orange which is an extract 
of a plant called Citrus aurantium. It is a stimulant that constricts the blood vessels, 
increases metabolic and heart rates. Synephrine has been identified in the head shop 
products Energy, Go-E, Empathy, Bio Happiness, Exotic and Molotov. 
 
Mitragynine, an opioid agonist, is a stimulant at low doses and a painkiller or sedative 
at higher doses. It can cause constipation, weight loss, dependence, psychosis and 
withdrawal symptoms. It is not controlled in Ireland. Mitragynine is an active ingredient 
in the products Kratom and Xscape. 
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Hordenine occurs in a variety of grassy plants and grains, and in some species of 
cactus. It stimulates the release of norepinephrine in humans, and also has 
antibacterial and antibiotic properties. There are unsubstantiated claims that hordenine 
helps people lose weight. It was detected in the products Go-E and Dr Feelgood. 
 
5-hydroxytryptophan (5-HTP) is a naturally-occurring amino acid and a metabolic 
intermediate in the biosynthesis of the neurotransmitters serotonin and melatonin from 
tryptophan. 5-HTP sourced from the seeds of the plant Griffonia simplicifolia is sold 
over the counter in the US and Canada as a dietary supplement and as an 
antidepressant, appetite suppressant, and sleep aid. It is marketed in many European 
countries for the treatment of major depression. Several double-blind placebo-
controlled clinical trials have demonstrated the effectiveness of 5-HTP in the treatment 
of depression, though the quality of the studies has been disputed. There are no 
regulated manufacturing standards in place for many herbal compounds and some 
marketed supplements have been found to be contaminated with toxic metals or other 
drugs. 5-HTP was detected in the head-shop product Dr Feelgood. 
 
L-dopa (levodopa) is a naturally occurring dietary supplement and psychoactive drug 
found in certain kinds of food and herbs. It is synthesised from the essential amino acid 
L-tyrosine in humans. L-dopa is the precursor to the neurotransmitters dopamine, 
norepinephrine (noradrenaline), and epinephrine (adrenaline). Aside from its natural 
and essential biological role, L-dopa is also used in the clinical treatment of Parkinson's 
disease (PD) and dopamine-responsive dystonia (involuntary spasms of the limbs). It 
was detected in the product Raz. 
 
Desoxypipradrol was developed in the 1950s, and has been researched for 
applications such as the treatment of narcolepsy (a condition which results in 
uncontrolled sleeping) and attention deficit hyperactivity disorder (ADHD), and 
facilitation of rapid recovery from anesthesia; for various reasons its development for 
application in these areas was not continued. The hydroxylated derivative, pipradrol, 
was introduced as a clinical drug for the treatment of depression, narcolepsy and 
cognitive enhancement in organic dementia. Desoxypipradrol was detected in the 
head-shop product Whack. 
 
A number of psychoactive substances identified in recent weeks. There is very little 
information on these drugs available on the web. They include: 
 
3',4'-Methylenedioxy-α-pyrrolidinobutiophenone (MDPBP) is a stimulant compound 
developed in the 1960 which has been reported as a novel designer drug.  
 
Oleamide was found in the smoking blends "Smoke" and "Skunk" alongside the 
synthetic cannabinoid JWH-018 which was classified as the active ingredient. 
However, there is no evidence that this drug is used specifically as a recreational drug. 
 
Octopamine and synephrine are the adrenergic amines in bitter orange.  
 
Buphedrone, also known as α-methylamino-butyrophenone, is a stimulant of the 
phenethylamine, amphetamine, and cathinone chemical classes that was first 
synthesised in 1928. It has similar effects to methcathinone but is several times more 
potent by weight. 
 
4-methylethcathinone for which there is no information available 
 
Caffeine and lignocaine were found in numerous head shop products.  
 Caffeine is a legal psychoactive stimulant and easy to acquire. Caffeine was found 
in the products Blowout, Bliss Bomb, Diablo, Dr Feelgood, Energy, Embrace, 
Extreme Star Dust, Go-E, Koru, Nemesis, NRG Now, Pure NRG, Pinkys, Raz, 
Sno*berry, Star Dust, and Party On. 
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 Lignocaine (or lidocaine) is an anaesthetic drug; it is found in Extreme Star Dust, 
Pure NRG, Raz, Star Dust.  
 
Methods for the identification of the active ingredients in head shop products  
 
(Pierce Kavanagh, Trinity College Dublin, Personal Communication, 2010). 
 
The product (1 mg) was extracted from basic (NH3) aqueous solution/suspension 
(500:l) into toluene (500:l).  
 
The toluene extract and, in the case of dimethylamylamine which was derivatised by 
addition of an equal volume of pentafluoropropionic anhydride to the toluene extract 
and heating at 90oC for 20 minutes, evaporation and reconstitution in dichloromethane 
beforehand, was analysed by GCMS under the following conditions: Agilent 6890 gas 
chromatograph with split‐splitless injection (2:l injected) and a HP‐5MS column (30 m x 
0.25 mm, 0.25 μm film thickness). Helium (He) was used as the carrier gas at a flow 
rate of 1.0ml/minute. The GC was coupled to an Agilent 5973 MSD (EI, 70eV, TIC 
mode scanning m/z 40‐800) and injector port was set at 300oC, the transfer line at 
280oC, the ionization source at 220oC and the quadrupole at 150oC. 
 
The following temperature program was used for mephedrone, methylone, 
flephedrone, ethcathinone, iso‐ethcathinone, butylone, MDPV, naphyrone, 
dimethocaine, fluorotropacocaine and 2‐aminoindane: 90oC for 1 minute, 15oC/minute 
to 280oC, 280oC for 6.33 minutes, 10oC/minute to 300oC, 300oC for 13 minutes. 
 
The following temperature program was used for dimethylamylamine (PFP derivative) 
and 2‐phenylethylamine (PFP derivative): 50oC for 1 minute, 15oC/minute to 280oC, 
280oC for 6.33 minutes, 10oC/minute to 300oC, 300oC for 10.34 minutes. 
 
Samples were diluted appropriately if overloading was observed. A mass spectral 
library of the above compounds for Agilent Chemstation software is available on 
request (contact pierce.kavanagh@tcd.ie). 
 
Standards of methylone, mephedrone, butylone, flephedrone, ethcathinone and MDPV 
were kindly provided by Ms. Sinéad McNamara (Drug Treatment Centre Board, 
Dublin). Naphyrone was synthesised in our laboratory. 2‐Aminoindane was purchased 
from Alfa Aesar (UK). Dimethylamylamine and 2‐phenylethylamine were purchased 
from Sigma Aldrich (Ireland). Dimethocaine and fluorotropacocaine were identified from 
their mass spectra as it is currently not possible to buy authentic standards from a 
reputable company. „iso‐Ethcathinone‟ was identified from mass spectral evidence as it 
is not commercially available. Our laboratory is currently in the process of synthesizing 
it. 
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3. Prevention 
3.1 Introduction 
Drug prevention is one of the four pillars in the National Drugs Strategy (interim) 2009–
2016 (Department of Community Rural and Gaeltacht Affairs 2009). The Strategy 
states that „a tiered or graduated approach to prevention and education measures in 
relation to drugs and alcohol should be developed with a view to providing a framework 
for the future design and development of interventions‟ (para. 3.56).  It identifies three 
levels in this framework: 
 Universal (primary) prevention programmes, aimed at the general population such 
as students in schools, to promote overall health of the population and to prevent 
the onset of drug and alcohol misuse.  Measures often associated with this type of 
programme include awareness campaigns, school drug/alcohol education 
programmes and multi-component community initiatives. 
 Selected (secondary) prevention programmes, aimed at groups at risk, as well as 
subsets of the general population including children of drug users, early school 
leavers and those involved in anti-social behaviour, to reduce the effect of risk 
factors present in these subgroups by building on strengths and developing 
resilience and protective factors. 
 Targeted (tertiary) prevention programmes, for people who have already started 
using drugs/alcohol, or who are likely/vulnerable to engage in problematic 
drug/alcohol use (but may not necessarily be drug/alcohol dependent), or to 
prevent relapse. These programmes are aimed at individuals or small groups and 
address specific needs. 
 
This framework combines universal, selected and targeted with the old classificatory 
framework of primary, secondary and tertiary, which is misleading in that it implies that 
universal prevention is also the primary step in prevention. In Ireland young people and 
their families are the main target groups for drug prevention activities, which consist 
mainly of universal and selected prevention, with little focus on targeted prevention. 
 
The NDS identifies as priorities for Prevention, improving the delivery of SPHE in 
primary and post-primary schools and co-ordinating the activities and funding of youth 
interventions in out-of-school settings to optimise their impacts. Drug prevention 
interventions in schools are delivered through the Walk Tall (primary schools) and the 
Social, Personal and Health Education (SPHE) (post-primary schools) programmes. 
The SPHE programme aims to improve social and personal competencies in students 
so they can understand and counter the many social influences that are seen as 
contributing to their use of drugs and alcohol. In the community, prevention 
programmes are provided in different settings, such as youth clubs and youth cafés, 
and by means of diversion activities provided by the statutory, voluntary and 
community sectors.  
 
The National Drugs Strategy calls for a continued focus on orienting educational and 
youth services towards early interventions for people and communities most at risk. 
Actions are to be developed to further support the families of drugs users, and 
community development is acknowledged as an important step in building the capacity 
of local communities to avoid, or respond to and cope with, drug problems. Early 
school leavers are targeted through measures such as the School Completion 
Programme and embedding the government‟s DEIS (Delivering Equality of Opportunity 
in Schools) Action Plan, which tackles disadvantage among the school-going 
population, in schools in LDTF areas. The Department of Education and Science (DES) 
has also developed a strategy to tackle educational disadvantage and early school 
leaving in the Traveller community.  
 
Stand-alone mass media awareness and information campaigns are regarded as less 
effective than multi-component, multi-level interventions that reflect the complex nature 
of drug prevention and harm reduction. The NDS proposes that preference be given to 
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the development of timely awareness campaigns targeted in a way that takes individual 
social and environmental conditions into account key areas such as third-level 
institutions, workplaces, sports and other community and voluntary organisations. 
 
3.2 Universal prevention 
3.2.1 School 
Recent research by the (Office of the Minister for Children and Youth Affairs 2010b) 
surveyed a cohort of students in post-primary schools on their experience of receiving 
SPHE. Questionnaires were administered by young people who had been trained by 
the lead researcher in peer research skills and in compiling the questionnaires. The 
questionnaires were distributed to secondary school students while they were 
participating in youth council meetings; participants included representatives of 
secondary schools, youth organisations and hard to reach groups. A total of 134 young 
people (aged 12–16) from 68 secondary schools in 12 different counties completed the 
questionnaire on the SPHE programme, 53% male and 47% female. The report does 
not contain information on whether or how young people were sampled. 
 
The majority of young people that completed the questionnaire (88%) received SPHE 
classes in 2009 and 84% had SPHE classes once a week during that year. SPHE is 
timetabled as a class in almost all schools surveyed (97%). Respondents were asked 
to indicate the emphasis placed on the various themes covered in the SPHE syllabus in 
their school, marking whether there was a high or a low emphasis put on them; 83% of 
respondents indicated that alcohol, drug and solvent use was the most emphasised 
theme in the SPHE syllabus. 
 
Respondents to the survey reported the following outcomes as a result of participation 
in SPHE classes: 
 helped understanding of how to make good decisions: 60%  
 provided the chance to think and talk about interesting subjects: 56%  
 improved self-respect: 48%  
 improved physical health and well-being: 45%  
 improved emotional health and well-being: 41%  
 developed personal and social skills, such as self-confidence and self-esteem: 41% 
 improved mental health and well-being: 37%  
 not improved physical, emotional or mental health: 22%  
 
The National Drugs Strategy [interim] 2009-2016 was launched in September 2009 and 
has 63 actions to be implemented in the lifetime of the Strategy (Department of 
Community Rural and Gaeltacht Affairs 2009) Actions 20 and 21 of the NDS relate to 
prevention and education in primary and post-primary schools. The DES has 
responsibility as lead agency for both actions, and is supported by the Department of 
Health and Children (DoHC) and the Health Service Executive (HSE) on Action 20.  
 
Action 20: Improve the delivery of SPHE in primary and post-primary schools through 
the implementation of the recommendations of the SPHE evaluation in post-primary 
schools, and the development of a whole-school approach to substance use education 
in the context of SPHE. (The SPHE evaluation referred to in Action 20 had reported 
that support and training for teachers were regarded as essential for the success of 
SPHE (Geary and McNamara 2003). 
 
Implementation of Action 20 is under way (John Moloney, Department of Education 
and Science, personal communication). In 2008/9 there were 33 SPHE in-service 
training events, attended by 185 teachers.  Twenty of these events were school-based. 
In 2009/10 seven events were scheduled, and at the time of reporting three events had 
taken place with 29 teachers attending.  Guidelines for visitors to primary and post-
primary schools, such as GardaÍ or drug prevention workers, are currently being issued 
to schools.  The DES is currently reconfiguring the delivery of support for teachers in 
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light of the current resources available.  Support across a range of educational areas, 
including SPHE, is to be provided by multidisciplinary regional teams, which will be part 
of the newly-formed Professional Development Service for Teachers (PDST), which will 
work in cooperation with the national network of Education Centres. It is intended that 
support for substance misuse prevention will be further integrated with SPHE support.   
 
Action 21: Ensure that substance use policies are in place in all schools and are 
implemented; monitor the effectiveness of the implementation of substance use 
policies in schools through the whole-school evaluation process and the inspectorate 
system and ensure that best practice is disseminated to all schools. 
 
Recent feedback from the DES suggests that implementation of Action 21 is under way 
(Liam Hughes, Department of Education and Science, personal communication). For 
example, a Life Skills postal survey was undertaken by the DES in 2009 to ascertain if 
substance use policies were being developed as part of SPHE in both primary and 
post-primary schools. An initial analysis of the data indicated that up to 12 December 
2009:  
 Primary level (67.8% response rate):  84% schools had a substance use policy. 
 Post-primary level (55.1% response rate):   95.8%schools had a substance use 
policy. 
 
In addition, the DES reports that there is a plan to monitor the implementation and 
effectiveness of substance use policies in schools through the whole-school evaluation 
process. In 2009, the number of Whole-School Evaluations (WSE) completed was as 
follows: 
 WSE Primary: 246 
 WSE Post-primary: 48 
 Subject inspections SPHE Jan 2007–March 2010: 66 inspections (approx.) 
 
In June 2009 a preliminary analysis of qualitative findings from 29 published SPHE 
subject inspection reports was undertaken.  This information was used to refine the 
inspection process, inform policy development and highlight continuous professional 
development (CPD) needs among teachers. In the 2010/11 school year, the team of 
post-primary inspectors plans to conduct approximately 40 SPHE evaluations in post-
primary schools.  The team of post-primary inspectors who conduct SPHE subject 
inspections is being expanded, and training is being provided for all team members in 
2010.  
 
3.2.2 Family 
 
The Family Support Network (FSN) published a set of good-practice guidelines for 
peer-led family support groups, the purpose of which is to support families coping with 
a drug-using member(s)  (Family Support Network 2010).The compilation of the 
guidelines was overseen by a steering group and involved extensive consultation with 
a large number of family support groups and relevant stakeholders, visits to family 
support groups, and a review of the literature with particular emphasis on the peer-led 
model of family support. A draft set of guidelines was developed and workshops were 
undertaken with nine family support groups to allow for further feedback. Family 
support groups attending their national conference in 2009 were also consulted on the 
draft guidelines and feedback was received on the training needs of groups.  
 
The objectives of the guidelines are to:  
 assist family support groups to develop good practice in all areas of the 
work of the group, 
 identify training and other resources required to support good practice, 
 ensure consistency of practice among family support groups throughout the 
country, and 
 provide a basis for affiliation to the FSN.  
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The document has six sections and each section concludes with reflective exercises 
and „top tips‟, which are also available in the form of a separate resource pack. The 
sections are:  
1. Introduction: outlines whom the guidelines are intended for and how best to use 
them. 
2. Starting a peer-led family support group: discusses the composition of groups, 
drawing up a code of ethics and a code of practice, and advises on how to convene 
meetings. 
3. Providing support in a group: examines aspects of confidentiality, the identification 
of members‟ needs, and group development; 
4. Facilitation: describes the role and attributes of a good facilitator; 
5. Seeking external support: deals with identifying information, self-development and 
training needs of a group; and 
6. Setting up a family support network: outlines the benefits and issues involved in 
setting up a network of support groups.  
 
3.2.3 Community 
Youth cafés 
The OMCYA recently published a best-practice guide and an accompanying toolkit to 
maintain and develop youth cafés around Ireland (Office of the Minister for Children 
and Youth Affairs 2010b). The best-practice guide was developed following an 
extensive literature review, which examined peer-reviewed studies, grey literature, 
technical reports, working papers and information retrieved from international experts. 
Interviews were undertaken with stakeholders in youth cafés in Ireland and among 
those working in the youth sector. Interviews were also undertaken with young people 
who use youth cafés in Ireland and with a panel of young people recruited through the 
OMCYA. It is estimated that there are more than 20 youth cafés in operation around 
Ireland.  
 
The guidelines provide a conceptual model and framework for the development of 
youth cafés. They suggest that „one of the most attractive features of a youth café is 
that it can work with young people across all levels of need, including universal 
populations through to those “at risk” ‟(page 2). The guidelines also set out guiding 
principles and discuss operational issues and monitoring and evaluation systems.  
 
The youth café toolkit describes the processes involved in setting up and operating a 
youth café in Ireland. It provides guidance on the types of activities and programmes 
that might be organised in youth cafés, the role of staff and volunteers, and the training 
of staff, volunteers and young people. Guidance is also provided on the design and 
location of youth cafés, their management and funding, and the promotion and 
development of policies for youth cafés.  
 
To ensure the success of a youth café, the toolkit recommends that policies be 
developed regarding respect and behaviour – to ensure the café remains a safe, drug- 
and alcohol-free space in which young people can hang out – and on drug and alcohol 
use. 
 
Youth work standards 
The OMCYA recently published the National Quality Standards Framework (NQSF) for 
Youth Work (Office of the Minister for Children and Youth Affairs 2010a). For the first 
time in Ireland, this framework provides the basis for youth organisations and groups 
involved in working with young people in Ireland to be subject to external assessment 
by Vocational Education Committee (VEC) officers and NQSF officers. The framework 
encourages self-assessment by youth organisations, and invites practitioners to assess 
their work under the following headings:  
 components of practice  
 progression 
 monitoring and assessment 
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 policies and procedures 
 governance and operational management 
 volunteers 
 human resources management  
 collaboration and integration.  
 
The framework list five core principles that should underpin youth work including the 
protection and safety of young people, equality and inclusiveness.  
 
3.3 Selective prevention in at-risk groups and settings 
3.3.1 At-risk groups  
Young people at-risk of offending  
The Garda Youth Diversion Projects (GYDPs) are a community-based, multi-agency 
crime prevention initiative, which seeks to divert young people from becoming involved 
(or further involved) in anti-social and/or criminal behaviour by providing suitable 
activities to facilitate personal development and promote civic responsibility. 
Participation by young people and their families is on a wholly voluntary basis.  
 
In 2009 the Irish Youth Justice Service (IYJS) undertook a baseline analysis of 96 of 
the existing 100 projects, in order to gain a deeper understanding of the nature and 
extent of risk factors that participants were presenting with and the local context within 
which the projects were operating (Irish Youth Justice Service 2009). The aim of this 
work was to improve the effectiveness of the projects.  
 
The analysis was based on data gathered during site visits, which took place between 
March and July 2008. The person with responsibility for the project (usually the project 
co-coordinator) was present in all cases and local Gardaí were present during 66 of the 
96 visits. Interviews were undertaken with management and front-line staff. Eighty-two 
of the 96 projects visited (85%) put alcohol  and public-order-related crime at the top of 
the list of offences committed in their catchment area; other offences included theft, 
drug-related matters, violent offences, unauthorised taking of motor vehicles, burglary 
and road traffic matters. Table 3.3.1.1 summarises the types of risk factors identified in 
the lives of participants in the projects.  
 
Table 3.3.1.1 Profile of GYDP participants according to individual, family, educational and 
neighbourhood risk factors, 2008 
Type of Risk Factor Risk profile of GYDP participants No of 
GYDPs 
Individual Participants „normalised‟ their offending behaviour. 47 
 Participants verbally or physically aggressive.  34 
 Participants prone to impulsivity.  14 
 Participants presented with delayed social and emotional competence.  9 
 Participants experienced chaotic lifestyle patterns; active during night-time and sleeping 
during daytime. 
8 
 Participants presented with learning difficulties.  6 
 Participants did not show empathy. 5 
Family Parents had problematic drugs and/or alcohol use problems. 37 
 Family member(s) had involvement with the criminal justice system. 36 
 Parents were involved in alcohol-related anti-social behaviour.  15 
 Absence of a positive male parental influence. 10 
 Participants experienced violence at home. 11 
Educational Participants performed poorly at school. 58 
 Participants had mixed or poor school attendance.  55 
 Participants presented with discipline problems at school. 31 
Neighbourhood Neighbourhoods accepting of receiving stolen goods.  18 
 Neighbourhoods tolerant of under-age drinking, drugs misuse and/or anti-social activity. 13 
 Neighbourhoods accepting of drug dealing. 11 
 Neighbourhoods with adult criminal activity. 11 
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Type of Risk Factor Risk profile of GYDP participants No of 
GYDPs 
 Neighbourhoods with negative attitudes towards the Garda. 6 
Source: Adapted from Irish Youth Justice Service, 2009 
 
Early school leavers 
Action 23 of the NDS gives lead responsibility to the DES to implement SPHE in 
Youthreach Centres of Education (YCsE) and in Youth Encounter Projects (YEPs) and 
ensure that substance misuse policies are in place in these recognised centres for 
education; implement age-appropriate substance prevention/awareness programmes 
in training settings, including the Vocational Training Opportunities Scheme (VTOS) 
and community training facilities; introduce monitoring and follow-up procedures in 
relation to substance prevention activity in the above settings. The YCsE and other 
settings mentioned in this action cater for the educational and training needs of early 
school leavers.  
 
In response to Action 23, the following initiatives are under way (John Moloney, 
Department of Education and Science, personal communication). 
 A Quality Framework Initiative (QFI) has been developed for YCsE and Senior 
Traveller Training Centres (STTCs).  As part of the QFI, the overall social, personal 
and health education needs of learners are assessed.  Following this, a programme 
of learning in the area of SPHE is developed and delivered.   
 Health promotion is an integral part of policy and practice in YCsE and STTCs, and 
learners have access to information and training on health-related issues.   
 All YCsE have implemented internal evaluation and development planning 
processes.   
 All YCsE and STTCs have staff trained in the Substance Abuse Prevention 
Programme and they offer the programme.   
 Drug education is included in VTOS and other adult education programmes as 
necessary.   
 Community training centres, operated by FÁS, include a module on drugs and 
substance abuse, prevention and awareness, in their life and social skills 
programme.   
 Community training workshops, which operate in LDTF areas, have appointed a 
drugs education and prevention officer.  
 Youth Encounter Projects include SPHE among the subjects taught.  
 
The DES Regional Office Inspectorate has been undertaking a programme of 
evaluation of YCsE and STTCs since 2006.  A composite report based on the first 25 
evaluations has been prepared and the DES is considering the recommendations. 
 
Action 31 of the NDS gives responsibility to the DES to maintain the focus of existing 
programmes targeting early school leavers and the retention of students in schools and 
improve the measurement of the outcomes of such programmes in order to target and 
expand them in areas of greatest need. 
 
In response to Action 31, the following measures are under way (John Moloney, 
Department of Education and Science, personal communication). The DEIS 
programmes support some 151,000 children in 881 schools.  46,000 at-risk children 
are directly targeted in schools through the Home School Community Liaison (HSCL) 
programme and the School Completion Programme (SCP). The SCP targets those 
most at risk of early-school leaving as well as those who are already outside of the 
formal system.  Provision includes in-school, after-school and holiday-time supports. 
Integration of HSCL, SCP and the Visiting Teacher Service for Travellers with the 
National Educational Welfare Board, which commenced on 1 September 2009, is 
expected to be largely completed by June 2010. DEIS is currently being evaluated, and 
at the time of completing this National Report, a report was due to be submitted to 
DEIS.  
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Schools' Business Partnership 
The Schools‟ Business Partnership (SBP) is operated by Business in the Community 
Ireland (BITC) and aims to develop partnerships between schools in disadvantaged 
areas and a local business. According to the BITC website, the number of schools 
currently matched nationwide is 158. The businesses involved in the SBP are drawn 
from a number of sectors including financial, manufacturing, pharmaceutical, 
technology, retail and food.  
 
The objectives of the SBP include assisting schools in disadvantaged areas to increase 
the number of students completing the Leaving Certificate examination and to reduce 
early school leaving. The SBP partnership operates four sub-programmes: student 
mentoring, management excellence for school principals, skills at work and the 
summer work placement programme (School‟s Business Partnership 2008). 
 
Research with regard to early school leavers  
A recently-published study of early school-leavers in Ireland (Byrne, Delma  and Smyth 
2010) may be useful to policy makers and practitioners when designing interventions to 
prevent early school-leaving or improve the life chances for those students that have 
left school early. Although the researchers did not focus on the role of substance 
misuse in the lives of early school-leavers, the findings provide useful information on 
their school experience and reasons for leaving school. 
 
A mixed-methods approach was used, combining quantitative data from the Post-
Primary Longitudinal Study (PPLS) with in-depth qualitative interviews with young 
people who had left school before completing the senior cycle. Undertaken by the 
Economic and Social Research Institute (ESRI),5  the PPLS drew on data gathered 
from a theoretical sample of 12 Irish schools, identified on the basis of a postal survey 
of all post-primary principals. These schools were selected to capture varying 
approaches to ability grouping, subject choice and student integration, and 
encompassed a range of sectors, sizes, locations and student characteristics. The 
study followed a cohort of approximately 1,000 students from their entry to first year to 
their completion of second-level education. Students completed a written questionnaire 
each year, covering their attitudes to schools, their choice of programmes and subjects, 
and their aspirations for the future. In addition, in-depth interviews were carried out with 
groups of the students, and with key personnel in the school, including principals and 
guidance counsellors.  
 
By matching PPLS data collected on individuals from their first to their fifth year, Byrne 
and Smyth were able to compare young people who left school early with those who 
completed second-level education on a range of dimensions, including background, 
aspects of the transition to post-primary education, school experiences in junior cycle, 
ability grouping, and out-of-school activities. The authors also conducted in-depth life 
history interviews with 25 young people  between January and May 2008 to obtain a 
detailed understanding of their school experiences, their decision to leave school and 
their post-school plans and pathways. These 25 young people were drawn from a pool 
of early-school leavers, who had been identified by going through the year-on-year 
questionnaires completed in the course of the PPLS; a list of potential school-leavers 
was identified and sent to the principals of the 12 schools that had participated in the 
PPLS. Following advice from the principals regarding the status and contact details of 
those on the list, attempts were made to contact 145 individuals. As an incentive to 
participate and in order to maximise response, each school-leaver was offered €50 for 
the expenses involved in travelling to the place of interview. 
 
The authors reported that patterns of early school-leaving in Ireland are strongly 
differentiated by gender and social class, with males from working-class and/or 
unemployed households being the most likely to leave school early.  According to the 
                                               
5
 The PPLS has been extensively described in a series of reports, the first of which was published in 2004, 
which may be accessed on the ESRI‟s web site at www.esri.ie  
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authors, the higher drop-out rate among this category is largely related to their school 
experiences: these young men are more frequently allocated to lower stream classes, 
and are more likely to be reprimanded by teachers for „acting up‟.   
 
The authors reported that those in lower-stream classes were almost 13 times more 
likely to drop out than those in mixed-ability classes, even controlling for social class 
background, academic ability on entry into second-level, school climate, and student 
engagement. The authors noted, moreover, that in recent years streaming had been 
disproportionately prevalent in disadvantaged schools. This has important implications 
for the implementation of Action 31 in the NDS, which calls for the maintenance of the 
focus of existing programmes targeting early school-leavers and the retention of 
students in schools, with particular regard to  the operation of the DEIS programme, 
which is delivered to disadvantaged schools.  
 
The authors reported the following school experiences of early school leavers: 
 Academic struggle: Students who have low reading and maths test scores on entry 
to post-primary education are significantly more likely to drop out of school.  
 Negative relations with teachers: Many of the young people stated that their 
teachers did not listen to them, showed little interest in them and tended to „put 
them down‟. 
 Interaction with peers: Poor interaction with peers was more prevalent in schools 
that used streaming; bullying interfered with school attachment and had a lasting 
negative influence on victims.  
 Nature of classroom environment: Many young people experienced their education 
in particularly disruptive classroom environments. It was suggested that some 
schools and classes had a culture of early school leaving. 
 
According to the authors, the decision to leave school at an early stage is heavily 
influenced by negative experiences of school, these experiences leading young people 
either to feel rejected by the school or to reject the school themselves, and in some 
cases these factors combined. Young people from particularly disadvantaged or 
Traveller backgrounds are more likely to leave school without gaining any 
qualifications.  
 
3.3.2 At-risk families 
Action 29 of the NDS calls on the HSE and the DES to lead the development of a 
series of prevention measures that focus on the family under the following programme 
headings:  
 supports for families experiencing difficulties due to drug/alcohol use;  
 parenting skills; and   
 targeted measures focusing on the children of problem drug and/or alcohol users 
aimed at breaking the cycle and safeguarding the next generation. 
 
In response to this action, the HSE plans to develop an integrated service group, 
including representatives of addiction services, children and families (Gretta Crowley 
and Eddie Matthews, HSE, personal communication).  
 
3.3.3 Recreational settings (incl. reduction of drug and alcohol related harm) 
See National Report 2008 for most recent information (Alcohol and Drug Research Unit 
2008). 
 
3.4 Indicated prevention  
3.4.1 Children at risk (e.g.  children with AD(H)D, children with externalising or 
internalising disorders) 
Research with young homeless people in Ireland has established that „leaving state 
care‟ is a distinct pathway into homelessness and addiction. Between September 2004 
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and February 2005, Mayock and colleagues (Mayock, Paula and Vekic 2006) 
interviewed 40 young homeless people living in Dublin. Forty per cent of the cohort 
reported a history of state care, of varying duration, in foster homes, residential care 
placements or residential placement homes; respondents also reported moving 
between care settings. Half the cohort reported having used heroin, with the majority of 
heroin users initiating use when they became homeless. In a later study, Mayock and 
colleagues (Mayock, Paula and Carr 2008) again highlighted the association between 
leaving state care and becoming homeless and using drugs. Thirty-seven young 
homeless people living in Cork City were interviewed; the majority had spent time in 
state care and a feature of their pathway into homelessness was inadequate 
preparations for leaving the care setting and lack of aftercare. The vast majority 
reported lifetime use of alcohol and drugs and 22 reported past or ongoing problems 
associated with substance use.  
 
In July 2009 the government (Office of the Minister for Children and Youth Affairs 2009) 
published its plan to implement the 20 recommendations contained in the report of the 
Commission to Inquire into Child Abuse (commonly referred to as the „Ryan Report‟), 
which was published in May 2009.  The implementation plan contained 99 actions to be 
taken by government departments and agencies. It acknowledged the association 
between state care and future poor outcomes for children who have been in state care, 
including addiction and homelessness: „those with a care history continue to be over-
represented among those who are, for example, accessing addiction services, coming 
into contact with the criminal justice system and experiencing homelessness in 
adulthood…‟ (page xii). 
 
The implementation plan included an appraisal of the gaps in service provision around 
pre-release planning and aftercare for young people leaving care, and called for 
recognition of the fact that „there has been a serious deficit of implementation over the 
past decade in areas such as the allocation of social workers to children in care, care 
planning and aftercare services‟  (page 3).The plan included two actions to improve 
care planning: 
 Action 33: The HSE will ensure that all children in care will have an allocated social 
worker and a care plan, in accordance with the regulations. 
 Action 67: The HSE will ensure that care plans include aftercare planning for all 
young people of 16 years and older.  
 
The implementation report also highlighted the gaps in aftercare services for young 
people. While acknowledging that some attempts to provide aftercare have been 
effective in the past, the report stated that, „Aftercare services are not provided 
consistently to all children across the State. Some HSE areas have dedicated aftercare 
workers, but most do not. …The provision of aftercare by the HSE should form an 
integral part of care delivery for children who have been in the care of the State. It 
should not be seen as a discretionary service or as a once-off event that occurs on a 
young person‟s 18th birthday, but rather a service that he or she may avail of up to the 
age of 21…‟ (page 48). 
 
The plan includes two specific actions to provide and monitor the provision of an 
enhanced system of aftercare, which, if implemented consistently and effectively, could 
contribute to a reduction in youth homelessness and a concomitant reduction in 
exposure to substance use. 
 Action 64: The HSE will ensure the provision of aftercare services for children 
leaving care in all instances where the professional judgment of the allocated social 
worker determines it is required  
 Action 65: The HSE will, with their consent, conduct a longitudinal study to follow 
young people who leave care for 10 years, to map their transition to adulthood.  
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3.5 National and local media campaigns 
On 7 July 2010 the HSE launched a national drug awareness campaign about head 
shop drugs, with the slogan „Legal or illegal highs [head shop drugs] can cause serious 
health problems – they‟re anything but safe‟. The physical health risks highlighted by 
the campaign include heart problems, kidney failure, impotence and seizures; mental 
health problems, such as paranoia, and acting foolishly when high are also highlighted. 
The campaign is aimed at people aged between 15 and 40 years of age.   
 
The campaign consists of a series of slogans on A4 size posters; the posters show a 
male or female dressed in a tee-shirt emblazoned with different messages, which are 
linked to the over-riding message on the poster about the risks. The posters will be 
distributed in bars and clubs and at festivals. The campaign will also use radio 
advertisements and on-line „pops-ups‟ for Facebook.  
 
An information booklet has been prepared for parents and guardians. It explains what 
legal highs are and the current legal situation, and advises how to talk to your child 
about these drugs and what to do if they are using them.  It also includes harm-
reduction messages and what to do if someone is having a bad reaction to a drug.  
This booklet is also available as a handy Zed card (concertina credit card size), which 
can be carried in a wallet. Both the booklet and the wallet card can be downloaded 
from the website used to support the campaign www.drugs.ie  The website also 
contains a number of video clips, which answer frequently asked questions (FAQs); the 
information in the clips is provided by health professionals and covers powders, pills, 
smokeable products and hallucinogenic substances. There is no information available 
on whether the campaign will be evaluated.  
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4. Problem Drug Use (PDU)  
4.1 Introduction 
This chapter provides an overview of developments and trends in the prevalence and 
characteristics of problem drug use in Ireland ranging from data for 2006 relating to the 
prevalence and incidence estimates of PDUs, to more recent studies relating to data 
on problem drug users from non-treatment sources and on varieties of problematic 
drug use. A PDU is defined as an „injecting drug user or long duration/regular user of 
opiates, cocaine and/or amphetamines‟ (EMCDDA 2004). 
 
It is not possible to estimate the number of injecting drug users or problem drug users 
in Ireland as the National Drug Treatment Reporting System (NDTRS) does not use a 
unique identifier. This issue has been raised in strategy submissions and it is hoped 
that it will be addressed in the forthcoming health information bill. Three sources 
containing information indicative of the nature of problem drug use in Ireland are 
described below. 
A national 3-source capture-recapture study, to provide statistically valid estimates 
of the prevalence of opiate drug use in the national population during 2006, was 
commissioned by the National Advisory Committee on Drugs (NACD).  The three data 
sources used in the study were the Central Drug Treatment List (CTL), the Hospital In-
patient Enquiry (HIPE) database and the Garda list of opiate users. The findings were 
published in 2009 (Kelly, Alan, et al. 2009a): they updated a similar study for the year 
2001 (Kelly, Alan, et al. 2003). The new study indicates that use has increased since 
the previous survey.  There were 11,807 known opiate users in 2006. The major 
expansion of the national methadone treatment programme between 2001 and 2006 is 
the main reason for the inflation of the figures. There is considerable doubt over the 
estimate produced of a possible further 8,983 opiate users who have not come into 
contact with any of the drug treatment services, hospital in-patient services or the 
Gardaí. 
The following are among the trends (2001–2006) seen in the study results: 
 the rate of opiate use among females and males aged 15–24 decreased, indicating 
a significant reduction in the number of young people commencing opiate use,  
 an increase in opiate use outside of Dublin, and 
 a higher proportion of opiate users in treatment in Dublin than elsewhere, reflecting 
the more recent spread of opiate use outside Dublin and the later development of 
treatment services.  
The National Registry of Deliberate Self-Harm is a national system of population 
monitoring for the occurrence of deliberate self-harm, established at the request of the 
Department of Health and Children, by the National Suicide Research Foundation 
(National Parasuicide Registry Ireland 2004).  Since 2006–2007 the Registry has 
achieved complete national coverage of hospital-treated deliberate self-harm. 
 
The Registry defines deliberate self-harm as „an act with non-fatal outcome in which an 
individual deliberately initiates a non-habitual behaviour, that without intervention from 
others will cause self harm, or deliberately ingests a substance in excess of the 
prescribed or generally recognised therapeutic dosage, and which is aimed at realising 
changes that the person desires via the actual or expected physical consequences‟. All 
methods of deliberate self-harm are recorded in the Registry, including drug overdoses 
and alcohol overdoses, where it is clear that the self-harm was intentionally inflicted. All 
individuals who are alive on admission to hospital following a deliberate act of self-
harm are included. Not considered deliberate self-harm are accidental overdoses, e.g. 
an individual who takes additional medication in the case of illness, without any 
intention to self harm; alcohol overdoses alone, where the intention was not to self-
harm; accidental overdoses of street drugs (drugs used for recreational purposes), 
  55 
without the intention to self harm; and individuals who are dead on arrival at hospital as 
a result of suicide. 
In 2005 new Prison Rules were introduced, dealing with all aspects of prison life, 
including accommodation, visiting rights, discipline, health and education (Department 
of Justice Equality and Law Reform 2005). They also provided for the introduction of 
compulsory or mandatory drug testing (MDT) of prisoners. Section 28 (5) (a) of the 
Rules states: „In the interest of good order, safety, health and security and in 
accordance with directions set down by the minister, a prisoner … shall, for the 
purpose of detecting the presence or use of an intoxicating liquor or any controlled drug 
… provide all or any of the following samples, namely – urine, saliva, oral buccal 
transudate, hair.‟  
4.2 Prevalence and incidence estimates of PDUs 
4.2.1 Indirect estimates of problem drug use 
Problem opiate users in Ireland  
An opiate is a drug containing opium or any of its derivatives which acts as a sedative 
and narcotic.  Examples include heroin, methadone, morphine, codeine, hydrocodone, 
oxycodone, fentanyl and tramadol. Heroin is synthesised from morphine, a naturally 
occurring substance extracted from the seed pod of the Asian opium poppy plant. 
Heroin is available in three forms – a white powder, a brown powder, or a black sticky 
substance, known as „black tar heroin‟. 
 
In a repeat of a prevalence study in 2001 (Kelly, Alan, et al. 2003), Dr Alan Kelly and 
colleagues estimated the prevalence of problem opiate users in Ireland in 2006 using a 
three-source capture-recapture method (Kelly, Alan, et al. 2009a). The three data 
sources used were the Central Treatment List (of clients on methadone), the Hospital 
In-Patient Enquiry scheme and the Garda PULSE data.  
 
Data from the three sources indicated that there were 11,807 opiate users aged 15–64 
years known to services in Ireland in 2006, and an estimated 8,983 users not known to 
the services (hidden population) (Table 4.2.1.1). These data were presented in 
Standard Tables 7 and 8 in 2009. The national prevalence estimate of opiate users in 
2006 was between 18,136 and 23,576; the point estimate was 20,790 (Table 4.2.1.2). 
This estimate is likely to be inflated. The respective rates per 1,000 of the 15–64-year-
old population in Dublin and in the rest of Ireland are 17.6 and 2.9. These estimated 
figures are likely to be inflated because the population was not closed, that is, it 
continued to recruit significant numbers of people into treatment (in Dublin and outside 
Dublin) and police custody (outside Dublin) in 2006. In addition, the overlap between 
the three population sources was small. These two factors are known to inflate 
estimates obtained by the capture-recapture method. Twenty-eight per cent (5,886) of 
the estimated number lived outside Dublin and 72% (14,904) lived in Dublin. 
 
Table 4.2.1.1   Number of opiate users known, estimated number hidden, prevalence estimate and 
population rate in Ireland, in Dublin and in the rest of Ireland, 2006 
 Age group 
Known 
number 
Estimated 
number hidden 
Estimated 
prevalence 
Rate/1,000 
population 
Ireland 15–64 11,807 8,983 20,790 7.2 
Dublin 15–64 9,442 5,462 14,904 17.6 
Rest of 
Ireland 15–64 2,365 3,521 5,886 2.9 
Source: Kelly et al. (2009) 
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Table 4.2.1.2   Estimated prevalence of opiate use in Ireland, in Dublin, and in the rest of Ireland, 
2001 and 2006 
 2001 2006 
 Estimate 
Lower 
bound 
Upper 
bound 
Rate/1000 
population Estimate 
Lower 
bound 
Upper 
bound 
Rate/1000 
population 
Ireland 14,681 13,405 15,819 5.6 20,790 18,136 23,576 7.2 
Dublin 12,456 11,519 13,711 15.9 14,904 13,737 16,450 17.6 
Rest of 
Ireland 2,225 1,934 2,625 1.2 5,886 4,399 7,126 2.9 
Source: Kelly et al. (2003, 2009) 
 
The national point estimate increased by 42%, from 14,681 in 2001 to 20,790 in 2006. 
The point estimate for Dublin increased by 20%, while the point estimate for the rest of 
Ireland increased by 165% – albeit from a low estimate in 2001. The rate of opiate use 
per 1,000 of the 15–64-year-old population living outside Dublin increased from 1.2 in 
2001 to 2.9 in 2006.  
 
Table 4.2.1.3 shows the 2006 estimate by age, gender and place of residence. 
Seventy-one per cent were male. One in five (21%) was between 15 and 24 years old 
and half (51%) were between 25 and 34 years old. In Dublin, the rate of opiate use per 
1,000 of the 15–24-year-old female population decreased by 62%, from 18.7 in 2001 to 
7.2 in 2006, which indicates that the number of younger women commencing opiate 
use has decreased. A smaller but still notable decrease in the rate of opiate use in 
Dublin was seen among males aged 15–24 years. 
 
In an unpublished study, Kelly and colleagues report that retaining opiate users in 
treatment reduces their likelihood of being in contact with the Gardaí (Dr A Kelly, 
personal communication). For example, only 12% of males aged 25–34 years who 
were known to the Gardaí in 2001 and were attending treatment services between 
2001 and 2006 were reported to be committing crime in 2006. This is in line with 
findings from the ROSIE study and indicates that methadone treatment reduces the 
incidence of crime. 
 
Table 4.2.1.3   Prevalence estimate by age, gender and place of residence, 2006 
Gender Age group Ireland Dublin Rest of Ireland 
All 15–64 20,790 14,904 5,886 
     
Males 15–64 14,787 10,395 4,392 
 15–24 3,150 1,892 1,258 
 25–34 7,238 5,172 2,066 
 35–64 4,399 3,331 1,068 
     
Females 15–64 6,003 4,509 1,494 
 15–24 1,159 701 458 
 25–34 3,298 2,605 693 
 35–64 1,546 1,203 343 
Source: Kelly et al. (2009) 
 
Research on data sources and methods 
The NACD is commissioning research into methods and data sources which can be 
used to estimate the number of problem opiate and cocaine users and the prevalence 
of problematic opiate and cocaine use in Ireland.  The objectives of the study are to: 
 determine indirect statistical approaches to estimating numbers and rates of 
problematic opiate and cocaine users in Ireland, 
 identify statistical or practical adaptations that would improve the reliability of the 
current capture-recapture estimate, 
 identify all data sources in Ireland, which can be used in the estimation of the 
prevalence of problematic opiate and cocaine use and using a systematic approach 
evaluate their potential for use, and 
 design pilot studies to test the preferred approaches. 
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The NACD will be able to estimate the number of problem cannabis and alcohol users 
from the general population survey on drug use 2010/11 (Jean Long, NACD committee 
member, 2010). 
 
Health Information Bill 
The Department of Health and children (DoHC) launched a public consultation on a 
health information bill in June 2008. The response was very positive in terms of the 
number and quality of submissions. The DoHC has now prepared a thematic synopsis 
document setting out the main points raised. With regard to public opinion on a unique 
personal identifier for individual health records and health-related information systems, 
there was general support but many commentators (including the Data Protection 
Commissioner) recommended that this identifier should not be the PPSN used for 
taxation and social welfare purposes. It was also recommended that confidentiality and 
privacy be protected in any new system (Department of Health and Children, et al. 
2009). 
  
As part of its commitment to the consultation process and in line with the philosophy of 
engaging with individuals in Your Service, Your Say,6 the DoHC in conjunction with the 
Health Service Executive (HSE) and the Health Services National Partnership Forum, 
held a consultative workshop on 20 January 2009. Once again there was general 
support for a unique identifier in health-related records but many people had 
reservations about the use of the PPSN (without specific protections) as the identifier, 
principally because of linkages fears.  
 
4.2.2 Estimates of incidence of problem drug use 
There are no estimates of the incidence of problem drug use in Ireland. 
 
4.3 Data on PDUs from non-treatment sources (police, emergency, 
needle exchange etc) 
4.3.1 National registry of deliberate self-harm annual report 2009 
The annual report or the National Registry of Deliberate Self-Harm contains information 
on every presentation of deliberate self-harm to hospital emergency departments in 
2009, giving complete national coverage of hospital-treated deliberate self-harm 
(National Registry of Deliberate Self Harm Ireland 2010).  
In 2009, there were 11,966 presentations of deliberate self-harm, involving 9,493 
individuals, to emergency departments. The rate of presentations increased from 
200/100,000 of the population in 2008 to 209/100,000 in 2009, a 5% increase. Repeat 
presentations accounted for more than one in five (21%) of all presentations. The 
biggest rise in the number of presentations was observed in men, with a 10% increase 
on the 2008 figure. The 2008 figure was itself an 11% increase on the number of men 
presenting with self harm in 2007. 
 
For the first time, the report details and maps the incidence of male and female 
deliberate self-harm by HSE local health office (LHO) area of residence. This, the 
authors hope, will raise awareness of the problem of deliberate self-harm among LHO 
primary and community care service providers. Limerick LHO area had the highest 
male rate and the second highest female rate. Cork North Lee and Louth LHO areas 
had high rates of deliberate self-harm for men only. Four of the eight Dublin LHO areas 
(Dublin North Central, Dublin West, Dublin South West and Dublin North West) were 
                                               
6
 The Office of Consumer Affairs has responsibility for developing and implementing best-practice models 
of customer care within the HSE and promotes service user involvement throughout the organisation 
through the concept of 'Your Service Your Say'.  
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associated with high rates of deliberate self-harm for both men and women. In contrast, 
the incidence of male and female self-harm was low in Dublin South East and Dun 
Laoghaire.  
 
Concordant with previous reports, deliberate self-harm was largely confined to the 
younger age groups. Almost half (45%) of all presentations were by people aged under 
30 years. Among females, those aged 15–19 years were most likely to present with 
deliberate self-harm. The increase in male presentations was observed in several age 
groups. The rate among men aged 20–24 years increased by 21%. There was also an 
increase in the number of 10–14-year-olds presenting. 
 
Drug overdose was the most common form of deliberate self-harm, occurring in 71% of 
all episodes reported in 2009. Overdose rates were higher among females (78%) than 
among males (64%). On average, at least 31 tablets were taken in episodes of drug 
overdose. The total number of tablets taken was known in 74% of cases. Forty-two per 
cent of all drug overdoses involved a minor tranquilliser, 29% involved paracetamol-
containing medicines and 21% involved anti-depressants/mood stabilisers. The number 
of deliberate self-harm presentations involving street drugs increased by 26% in 2009 
(from 461 in 2008 to 579). 
 
There was evidence of alcohol consumption in 41% of all episodes of deliberate self-
harm and this was more common among men (45%) than women (37%). Alcohol may 
be one of the factors underlying the pattern of presentation by time of day and day of 
week. Presentations peaked in the hours around midnight and almost one-third 
occurred on Sundays and Mondays. 
 
Attempted hanging was involved in 608 of all deliberate self-harm presentations (7% of 
men and 3% of women). This is the highest number of attempted hangings recorded by 
the Registry, and was 18% higher than in 2008. Self-cutting was used in one in five 
cases (22%) and significantly more often by men (25%) than by women (19%).  
 
The emergency department was the only treatment setting for 44% of all deliberate 
self-harm patients, that is, they did not proceed to further treatment. 
 
The report recommends the following measures to reduce the incidence of deliberate 
self-harm: 
 provide increased support for evidence-based prevention and mental health 
promotion programmes; 
 develop and implement initiatives to increase awareness of mental health issues 
among the general public and service providers supporting the unemployed or 
people experiencing financial difficulties; 
 develop a system to enable deliberate self-harm data to be linked with suicide 
mortality data to enhance insight into predictors of suicide risk;  
 restrict access to minor tranquillisers as they are the most common type of 
medication involved in intentional acts of drug overdose; 
 increase awareness among addiction service professionals and service users of 
the risk of suicidal behaviour related to drug abuse; 
 enhance health service capacity at specific times and increase awareness of the 
negative effects of alcohol misuse and abuse, such as increased depressive 
feelings and reduced self-control; 
 consideration should be given by LHOs to the development of response plans and 
intervention programmes related to suicidal behaviour; 
 minimum guidelines for the assessment of deliberate self-harm patients should be 
implemented by the HSE in line with the guidelines of the National Institute for 
Clinical Excellence in the UK;  
 provide uniform psychosocial and psychiatric assessment to all self-harm patients, 
paying particular attention to patients using highly lethal methods; and 
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 prioritise national implementation of evidence-based treatments shown to reduce 
risk of repetition, such as cognitive behavioural, dialectical behavioural and 
problem-solving interventions. 
 
4.4 Intensive, frequent, long-term and other problematic forms of use 
4.4.1 Description of the forms of use falling outside the EMCDDA’s PDU 
definition (in vulnerable groups) 
Head shop compounds abuse amongst attendees of the Drug Treatment Centre 
Board  
The use of „head shop‟ compounds has received much media attention lately, but there 
is very little research with regard to the extent of the usage of these substances among 
the drug-using population in Ireland. A study to examine the extent of the usage of 
Mephedrone, Methylone and BZP was undertaken among attendees at methadone 
maintenance programmes at the Drug Treatment Centre Board (DTCB) (MacNamara, 
et al. 2010).  Two hundred and nine samples were tested. The results showed 
significant use of the compounds, with 29 (13.9%) samples tested being positive for 
Mephedrone, 7 (3.3%) positive for Methylone and 1 (0.5%) positive for BZP. 
 
Homeless problem drug users’ experiences of head shop products 
Carol Murphy and colleagues (Murphy, et al. 2010) presented an abstract of their 
survey, displayed as a poster titled „Head shop bath salts – not good clean fun‟, at the 
College of Psychiatry of Ireland‟s spring meeting on 25 March 2010. This survey 
sought to estimate the extent, and describe the experience, of „bath salts‟ use among 
problem drug users living in a hostel for homeless people in Dublin city centre.  Nurses 
or key workers administered a questionnaire to a random sample of 20 clients during 
December 2009, of whom 17 participated in the survey. The researchers found that: 
 Twelve of those surveyed had tried bath salts on at least one occasion. 
 Some of the 12 had tried more than one product; 10 had taken „Snow‟; five had 
taken „Blow‟; three had taken „Vanilla Sky‟.  
 The 12 respondents either snorted or injected the products. 
 Ten respondents had experienced a rush or euphoria similar to that after using 
cocaine, ecstasy or crystal methamphetamine. 
 The products were cheaper than cocaine.  
 The unwanted side effects included difficulty in sleeping, anxiety, agitation, 
hallucinatory experiences and paranoia. 
 The „come down‟ was associated with agitation, depression and paranoia. 
 
Drug-using sex workers  
A large-scale qualitative study has highlighted the need for adequately-resourced 
support structures to reduce the risk of harm to drug-using sex workers in Ireland. The 
first of its kind, this study by the NACD (Cox and Whitaker 2009) explored the local risk 
environment within which drug-using sex workers in Dublin live and work. The authors 
concluded that wider social and situational factors, such as poverty, housing, health, 
educational needs and employment prospects, are as important to reducing risk of 
harm in this vulnerable group as addressing drug use. 
In-depth interviews were conducted with 35 drug users currently or formerly engaged in 
sex work, and biographical, drug use and offending behaviour data were collected by 
means of brief questionnaires. In addition, interviews were held with 40 professionals 
across the community, voluntary and statutory sectors whose work either directly or 
indirectly impacted on drug-using sex workers. This intensive, qualitative approach 
revealed that there was a range of behaviours associated with drug use and its 
accompanying lifestyle which placed individuals at particular risk of harm.  
For the most part, participants in the study grew up in communities associated with 
social and economic marginalisation and high levels of unemployment. They moved 
more or less continuously through drug and alcohol services, homeless hostels, the 
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judicial system and other social care agencies.  Participants used a range of strategies 
to reduce danger, but their perception of risk was relative to their situation, thus leading 
them to treat some risks as acceptable or necessary.  Current harm reduction 
interventions tend to focus on individual risk behaviour, often overlooking the wider 
social context in which members of this group live and work. 
Arising from analysis of the research, the NACD recommended:   
 continued and adequate funding of existing services that deal with this client group;  
 expansion of outreach services (particularly out of hours) to target existing and 
developing street sex markets, and development of peer outreach to areas of the 
city with known networks of drug-using sex workers; 
 continued funding of programmes (such as specialist Community Employment (CE) 
schemes for drug users) aimed at getting drug users back to work; 
 provision of flexible hostel accommodation for drug-using sex workers who are 
homeless, ranging from low-threshold facilities to accommodation that assists 
recovery and rehabilitation; and  
 recognition of the role of drug services in identifying male and female clients 
involved in sex work and in providing advice on safer sex practices in order to 
reduce sexual risk in personal intimate relationships and commercial sex 
transactions. 
In terms of policy, the authors recommended that „harm reduction be explicitly stated 
as a guiding principle of the new National Drugs Strategy‟ (p.26), and that the strategy 
outline a continuum of harm-reduction activities, a „model package‟ of interventions, 
minimum standards for services and optimal levels of service coverage. 
 
Drug tests in Irish prisons 
Information on drug testing in prisons in 2009 was obtained from the Irish Prison 
Service. These data indicate that more than 28,000 voluntary tests were carried out to 
monitor drug use and responses to treatment in 2009. These tests included those 
carried out on some committals (new entries) as well as those carried out on existing 
inmates. It may be assumed therefore that some of the positive test results relate to 
drugs or alcohol consumed outside the prison.  
 
Excluding methadone, between one-tenth and two-fifths of those screened tested 
positive for at least one drug. The common metabolites detected indicate use of 
cannabis, benzodiazepines and opiates (Table 4.4.1.1). It is not clear whether the 
number of positive cases excludes prisoners who were prescribed benzodiazepines; if 
they do not, these figures overstate the extent of unregulated use of benzodiazepine in 
prisons. Cocaine, amphetamines and alcohol were detected in a small number of tests. 
The profile of positive opiate and benzodiazepine tests indicates moderate use of such 
drugs among prisoners tested in Mountjoy, Wheatfield and Portlaoise prisons. A 
moderate number of women tested positive for benzodiazepines in the Dóchas Centre. 
The proportion of positive tests was very low in St Patrick‟s Institution and in the 
Training Unit. It would be useful if the test results of prisoners who were tested at 
committal interview could be removed from this analysis as this would provide a more 
accurate assessment of drug use in Irish prisons.  
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Table 4.4.1.1   Number of drug tests, by prison, and number (%) of positive tests, by prison and by 
drug type, 2009 
Prison 
No. of 
tests 
Cannabis 
(%) 
Benzodiaze
pines (%) 
Methadone 
(%) 
Opiates 
(%) 
Cocaine 
(%) 
Ampheta-
mines 
 (%) 
Alcohol 
(%) 
 
Mountjoy Male 6102 2661 (44) 2717 (45) 5148 (84) 3519 (58) 46 (0.8) 1 (0.02) 28 (0.5) 
 
Mountjoy Medical Unit 4366 679 (16) 664 (15) 2018 (46) 667 (15) 7 (0.2) 3 (0.07) 7 (0.2) 
 
Dóchas Centre  2491 450 (18) 1214 (49) 2045 (82) 557 (22) 53 (2) 4 (0.2) 21 (0.8) 
 
Training Unit 2607 24 (0.9) 15 (0.6) 1 (0.04) 38 (1.5) 0 (0) 1 (0.04) 4 (0.2) 
 
          
Wheatfield 4131 1303 (32) 1229 (30) 3664 (89) 1499 (36) 12 (0.3) 2 (0.04) 16 (0.4) 
 
Cloverhill * 2328 290 (12) 414 (18) 1604 (69) 389 (17) 43 (2) 3 (0.1) 36 (2) 
 
St. Patrick's Institution 1312 105 (8) 66 (5) 158 (12) 16 (1) 1 (0.1) 0 (0) 6 (0.5) 
 
          
Castlerea 126 33 (26) 33 (26) 23 (18) 36 (29) 1 (0.8) 1 (0.8) 2 (1.6) 
 
Loughan House  486 157 (32) 88 (18) 4 (0.8) 44 (9) 2 (0.4) 5 (1) 5 (1) 
 
Shelton Abbey  770 150 (19) 55 (7) 3 (0.4) 15 (1.9) 7 (0.9) 1 (0.1) 10 (1.3) 
 
          
Limerick 695 120 (17) 236 (34) 593 (85) 176 (25) 2 (0.3) 3 (0.4) 4 (0.6) 
 
Cork 165 26 (16) 18 (11) 0 (0) 3 (2) 0 (0) 1 (1) 1 (0.6) 
 
Midlands 2529 400 (16) 551 (22) 2287 (90) 908 (36) 15 (0.6) 3 (0.1) 27 (1) 
 
          
Portlaoise 107 31 (29) 39 (36) 59 (55) 32 (30) 2 (1.9) 0 (0) 0 (0) 
 
Arbour Hill 27 3 (11) 2 (7) 1 (4) 1 (4) 1 (4) 1 (4) 0 (0) 
 *Results for Cloverhill exclude all committals; those for all other facilities include some committals. 
Source: Irish Prison Service, unpublished data, 2010 
 
4.4.2 Prevalence estimates of intensive, frequent, long-term and other 
problematic forms of use, not included in the PDU definition 
Alcohol use among opiate users in methadone treatment  
 
Ryder and colleagues (Ryder, et al. 2009) estimated that 35% (95% CI = 28%–41%) of 
a sample of current or former heroin users attending general practice for methadone 
treatment were problem alcohol users, and that 14% of the sample were dependent 
users. According to data from the NDTRS, 24% of opiate users entering opiate 
treatment reported alcohol as an additional problem drug, which is lower than the 
estimate presented here. 
 
The authors surveyed 196 patients, which represented 8% of those on the Central 
Treatment List. A random sample of 634 patients on the CTL was originally selected 
but of these, 358 were not invited to participate in the study because their GP declined 
to take part. This resulted in a smaller sample of 276 patients. In the event, only 71% 
(196) of the randomly-selected patients whose GPs agreed to participate took part. 
This final sample represented just 31% of the original random sample from the CTL. 
The response rate was lower than desired – an indication of the difficulty that can be 
associated with doing research among patients attending private general practitioners 
in Ireland.  
 
The survey questionnaire included the Alcohol Use Disorders Identification Test 
(AUDIT) to assess participants‟ alcohol use. The questionnaire also collected data on 
socio-demographic, medical and substance use characteristics. The median age of the 
196 participants was 32 years, 68% were male, 79% said that they had used one or 
more illicit drugs in the previous month, and 76% had ever injected drugs. Of those 
who knew their blood-borne viral status, 55% said that they were hepatitis C positive 
and 5% said that they were HIV positive. Other research indicates that self-reported 
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hepatitis C and HIV status can both over- and under-estimate the prevalence of these 
infections and should be interpreted with caution.  
 
The cases classified as problem alcohol users were significantly more likely to have 
attended a local emergency department in the previous year and less likely to have 
attended a hospital clinic in the previous year compared to those who were not problem 
alcohol users. Among the 107 respondents who reported that they were hepatitis C 
positive, those who were problem alcohol users were significantly less likely to have 
attended a specialist hepatology clinic than those who were hepatitis C positive but 
were not problem alcohol users.  
 
The authors concluded that problem alcohol use has a high prevalence among current 
or former heroin users attending primary care for methadone treatment, and that 
interventions that address this issue should be explored as a priority.  
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5. Drug-Related Treatment: treatment demand and treatment 
availability  
5.1 Introduction 
Two broad philosophies underlie the approaches to drug-related treatment in Ireland: 
medication-free therapy and medication-assisted treatment. Medication-free therapy 
uses models such as therapeutic communities and the Minnesota Model, though some 
services have adapted these models to suit their particular clients‟ needs. Medication-
assisted treatment includes opiate detoxification and substitution therapies, alcohol and 
benzodiazepine detoxification, and psychiatric treatment. Various types of counselling 
are provided through both philosophies of treatment and independent of either type of 
treatment. Alternative therapies, such as acupuncture, are provided through some 
community projects.  
 
The Health Service Executive (HSE), which manages Ireland‟s public health sector, 
provides an addiction service, including both illicit drugs and alcohol, delivered through 
Social Inclusion Services, which is part of its Integrated Services Directorate.  Addiction 
treatment services are provided through a network of statutory and non-statutory 
agencies. Some of the principal non-statutory agencies include: 
 
The Ana Liffey Drug Project (ALDP) is a „low threshold - harm reduction‟ service, 
based in north inner city Dublin. The project works with people, experiencing addiction, 
to minimise the harm that problematic drug use causes them, their families and the 
wider community.  In 2007, ALDP recorded a total of 3,267 client visits to the project.  
Coolmine Therapeutic Community provides a comprehensive range of programmes 
designed to support and empower individuals and communities affected by alcohol and 
drugs.  It was one of the first dedicated rehabilitation centres offering a range of vital 
support services to people all over Ireland.    
Cuan Mhuire is a registered charity offering a comprehensive, structured, abstinence-
based, residential programme to persons suffering from alcohol, other chemical 
dependencies and gambling in Ireland.  Approximately 2,500 people are treated for 
addiction in its centres every year. 
Inchicore Community Drugs Team is a community-based drug addiction service, 
offering locally-based supports including assessment for treatment on methadone 
programme, counselling, holistic healing, personal development courses and group 
work. It offers drop-in, outreach service and community work, prison links worker, 
family support and youth outreach services, and a children's project.  
Merchants Quay Ireland (MQI) is a voluntary organisation, based in South Inner City 
Dublin, which provides a wide range of services to homeless people and drug users. In 
2009, MQI worked with over 5,000 drug users and people who were homeless. 
 
Progression Routes, located in ALDP‟s premises in north inner city Dublin, seeks to 
improve service delivery to those attending drugs services. It does this by working with 
multiple agencies to formulate and implement strategic interagency solutions to 
identified barriers to progression. 
 
In 1998 a Methadone Treatment Protocol (MTP) was introduced, to ensure that 
treatment for opiate misuse could be provided wherever the demand exists. New 
regulations pertaining to the prescribing and dispensing of methadone were introduced, 
and a joint Health Board/Irish College of General Practitioners (ICGP) committee was 
formed to provide training, ongoing education and regular audit for general practitioners 
(GPs) taking part in the programme. Under this protocol, any GP wishing to take part in 
the provision of treatment services to drug users, must undertake training as provided 
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by the ICGP.  Under the MTP, GPs are contracted to provide methadone treatment at 
one of two levels – Level 1 or Level 2.   Level 1 GPs are permitted to maintain 
methadone treatment for misusers who have already been stabilised on a methadone 
maintenance programme. Each GP qualified at this level is permitted to treat up to 15 
stabilised misusers. Level 2 GPs are allowed to both initiate and maintain methadone 
treatment. Each GP qualified at this level may treat up to 35 misusers. Practices where 
two Level 2 GPs are practising are permitted to treat up to 50 misusers. Locally-based 
methadone treatment for opiate misusers is now provided through drug treatment 
clinics, satellite clinics or through GPs in the community.  
 
Under the Community Pharmacy Contractor Agreement the HSE can agree with 
individual pharmacies to dispense methadone mixture DTF1mg/ml to opiate dependent 
persons in their local areas on a special methadone prescription form. The involvement 
of community pharmacists in the dispensing of methadone also ensures that a large 
number of opiate dependent persons may be treated in their own local areas.  
 
The Irish Prison Service (IPS) has a comprehensive drug treatment clinical policy 
document (Irish Prison Service 2008).  It contains an extensive section on methadone 
treatment, outlining the background and rationale for methadone treatment, as well as 
the clinical management of a prisoner on methadone and the logistics of dispensing. 
The document also outlines the processes necessary for methadone treatment – 
whether a prisoner is already on methadone on admission, or treatment is to be 
initiated in prison, and for planned release of a prisoner on methadone.  Issues around 
blood-borne viruses, including testing, clinical management and immunisation, are also 
addressed. The document states that the misuse of benzodiazepines is an endemic 
problem in the Irish prison population and recommends policies and guidelines around 
assessment of dependence, prescribing and detoxification.   
 
Data on drug treatment in Ireland are collected through two national data collection 
tools – the National Drug Treatment Reporting System and the Central Treatment List. 
These two tools are described below. 
 
The National Drug Treatment Reporting System (NDTRS) is a national 
epidemiological database which provides data on treated drug and alcohol misuse in 
Ireland. The NDTRS collects data from both public and private outpatient services, 
inpatient specialised residential centres and low-threshold services.  For the purposes 
of the NDTRS, treatment is broadly defined as „any activity which aims to ameliorate 
the psychological, medical or social state of individuals who seek help for their 
substance misuse problems‟.  The NDTRS is a case-based, anonymised database. 
The NDTRS is co-ordinated by staff at the Health Research Board (HRB) on behalf of 
the Department of Health and Children. The number of drug treatment services 
participating in the NDTRS continues to increase (Standard Table TDI 34).  Although 
treatment is provided within the Irish Prison Service, it was only in 2009 that 
counsellors working in the prison service began to return information to the NDTRS.   
 
The Central Treatment List (CTL) was established under Statutory Instrument No 225 
following the Report of the Methadone Treatment Services Review Group 1998 
(Methadone Treatment Services Review Group 1998). This list is administered by the 
Drug Treatment Centre Board on behalf of the HSE and is a complete register of all 
patients receiving methadone (for treatment of opiate misuse) in Ireland and provides 
all data on methadone treatment nationally. 
 
The Research Outcome Study in Ireland (ROSIE) was the first prospective study of 
treatment outcomes for opiate users to be conducted in Ireland. The objective was to 
evaluate the effectiveness of treatment and other intervention strategies for opiate use. 
The study recruited 404 opiate users entering treatment between September 2003 and 
June 2004. Three treatment modalities, provided through both inpatient and outpatient 
settings, were the focus of attention – methadone maintenance, structured 
detoxification, and abstinence-based treatment programmes. In addition, a sub-sample 
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of individuals was recruited from needle exchange interventions. Participants were 
interviewed at treatment intake, or as soon as possible thereafter, and again at 6 
months, 12 months and 3 years after the baseline interview. Data were collected by 
means of a structured interview. The interview instrument contained a comprehensive 
set of outcome measures detailing the social and psychological characteristics of the 
cohort, and a range of treatment process factors in relation to treatment outcomes. 
Between September 2006 and October 2008 seven papers in the ROSIE Findings 
series, concentrating on particular aspects of the study, were published; in June 2009 a 
report on outcomes at 1-year and 3 years for the whole population and the „per 
protocol‟ population, i.e. participants who completed all three interviews, was published 
(Comiskey, Catherine M, et al. 2009). 
 
5.2 Strategy/policy 
5.2.1 HSE National Service Plan 2010 
The HSE National Service Plan 2010 (NSP) sets out the agency‟s plans in the drugs 
and alcohol area for 2010 (Health Service Executive 2010). On foot of the HSE‟s 
Transformation Programme (see Section 5.3.1 below), a key focus for the HSE in 2010 
has been to integrate the recommendations in the national drugs and homeless 
strategies into the provision of mainstream health services, and to put in place a 
national framework for rehabilitation in addiction services (see Table 5.2.1.1). 
 
Table 5.2.1.1 HSE’s key result areas and deliverables in relation to illicit drugs, 2010 
Key result area Outputs 2009 Deliverables 2010 Due 
Implementation of 
the National Drugs 
Strategy (NDS) 
Input into preparation of NDS 
completed and strategy 
launched 
National rehabilitation framework in 
place 
Q2 
 
2009–2016 
 
Planning undertaken for 
implementation of HSE 
components 
National liaison pharmacist appointed Q1 
 Rehabilitation Co-ordinator 
appointed 
Harm reduction and treatment 
services further developed, including 
needle-exchange and methadone 
services 
Q1 
 National Drug Rehabilitation 
Implementation Committee 
established 
  
 Recruitment of national 
liaison pharmacist under way 
  
 National Addiction Training 
Programme (NATP) 
developed from pilot stage 
  
Development of  
National Substance 
Misuse Strategy  
 Input into development of National 
Substance Misuse Strategy 
completed (co-led by Department of 
Health and Children) 
Q4 
Source: NSP (2010: 43–44)  
 
Regarding drug treatment, in 2010 the HSE planned to increase its level of activity and 
performance as follows: 
 Average number of clients in methadone treatment per month per area: in 2009 the 
HSE exceeded by 136 its target of having an average of 7,636 clients in 
methadone treatment per month per area; it plans to maintain this increased level 
of throughput in 2010, i.e. 7,762 clients in methadone treatment per month per 
area.  In prisons, the HSE set a target of an average of 612 clients in methadone 
treatment per month in 2009; however, the projected outturn came in 115 below 
this target and the HSE adopted this lower figure of 497 as the target for 2010. 
 Number of substance misusers under 18 years of age for whom treatment, as 
deemed appropriate, commenced within one calendar month:  in 2009 the 
percentage of substance misusers under 18 years of age for whom appropriate 
treatment was commenced within one calendar month exceeded the target of 88%, 
reaching 97%. For 2010 the HSE set its sights even higher, aiming to commence 
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appropriate treatment within one calendar month for 100% of drug treatment clients 
aged under 18 years. 
 Number and percentage of substance misusers for whom treatment, as deemed 
appropriate, commenced within one calendar month: in 2009, 81% (1,365) of 
substance misusers aged 18 years and over entered appropriate treatment within 
one month, which was 3% below the target of 1,406 set for the year. In 2010, the 
HSE anticipated that 1,380 substance misusers would seek treatment for drug 
misuse and it aimed to ensure that 100% of these clients would commence 
appropriate treatment within one calendar month. 
 
5.2.2 Community and voluntary organisations 
 
Strategic review and planning process in LDTFs 
In 2007/08 local drugs task forces (LDTFs) completed a strategic review and planning 
process, undertaken at the invitation of the National Drugs Strategy Team (NDST). The 
object of the exercise was to identify the needs in LDTF areas in relation to drug 
misuse, to contribute to the „renewal‟ of LDTFs by enabling the sharing among all 
agencies and sectors of a clear strategic focus, and to help inform the choice of future 
drug strategies. The following summarises the findings of an unpublished analysis of 
the reports furnished to the NDST by the 13 LDTFs (Foran 2008). 
 
Community profiles 
The LDTFs identified a number of common themes indicating continuing social 
deprivation in their areas, including levels lower than the national average of 
educational attainment and higher levels of unemployment, local authority housing and 
lone parent households than the national average. They also outlined how local 
settlement patterns appeared be affecting their work. LDTF catchment areas contained 
neighbourhoods experiencing deprivation interspersed with neighbourhoods 
experiencing „significant advantage‟: this presented challenges for targeting services 
effectively. Certain LDTFs had seen the „gentrification‟ of their areas: this had led to 
heightened feelings of isolation and marginalisation among some of the original 
residents. 
 
Nature and extent of drug use 
The LDTFs reported that heroin was still the primary drug of misuse. However, there 
had been a significant increase in the use of cocaine, alcohol and prescription drugs. In 
line with this expansion, the incidence of polydrug use had also increased. With regard 
to users, the LDTFs highlighted the much higher drug-use prevalence among males 
than females. They drew attention to the increased drug use among non-Irish and 
Traveller communities, and among the homeless. They also noted the increased 
prevalence of blood-borne viral infections and the relationship between drug misuse 
and mental health. These patterns of drug use raised challenging issues with regard to 
the design and delivery of effective drug-related services.   
 
Gaps in services  
A range of gaps in service provision was highlighted by the LDTFs, including: 
 services accessible to non-national communities 
 childcare services for clients wanting to attend treatment and rehabilitation services  
 drug services catering exclusively for the needs of young drug users 
 prevention initiatives for people in the early stages of drug use 
 services for people misusing alcohol 
 supply reduction initiatives at local level.  
 
Strategic priorities 
The role of the LDTFs is to prepare action plans that will ensure the implementation of 
the national drugs strategy at local level. The LDTFs identified strategic priorities under 
the pillars of the 2001–2008 national drugs strategy following its mid-term review, 
including the following: 
  67 
 Research: develop a comprehensive monitoring and evaluation system to measure 
the effectiveness of drug projects; encourage projects piloting new programmes and 
evaluate them on a regular basis; and conduct locally-based research projects. 
 Prevention: refocus prevention work to take into account peer processes, family 
support and community development, e.g. increase early intervention programmes in 
pre-school and early primary school years, with a special focus on children of drug 
users and children of families in difficult circumstances. 
 Treatment and rehabilitation: adopt the continuum of care approach to meeting the 
needs of clients, and develop an appropriate range of treatment and rehabilitation 
services for young people (aged 12–18 years), e.g. develop a separate strategy for 
under-18s, or pilot psychosocial support projects for under-18s in collaboration with 
the HSE. 
 Supply reduction: support existing anonymous „dial to stop drug dealing‟ initiatives and 
establish similar schemes in LDTF areas where they do not exist; hold community 
information evenings to exchange information, network and build and develop 
partnerships between the gardaí, the community and drug-related services. 
 Family support and co-ordination: establish training in strengthening families for all 
workers, and put in place early intervention initiatives to build capacity within families; 
develop policies and procedures to improve communication across the various groups 
and projects active within the LDTF areas. 
 
Effectiveness of LDTF structures 
LDTFs were generally positive about their role in introducing and supporting drug-
related services and initiatives and were also confident that their structures and 
processes were functioning effectively. The management of mainstreamed projects, 
and the ongoing role and responsibility of LDTFs with regard to these projects, was 
raised as an issue. In parallel, some LDTFs highlighted the limited input and in some 
cases lack of interest on the part of statutory services regarding the task force process, 
and lack of clarity about their own roles on the LDTFs.  Strategic priorities included:  
 increasing the profile and understanding of the work of the LDTFs in the community 
through the development of comprehensive communication strategies,   
 facilitating the involvement of people affected by drug addiction in the work of the 
task forces by supporting the establishment of service-user forums, and 
 developing key performance indicators and systems to monitor progress and inform 
future development across programmes.   
 
LDTF strategic plan 
The Dublin 12 Local Drugs Task Force Strategic Plan 2009–2013 was launched in May 
2009 (Dublin 12 Local Drugs Task Force 2009).  The plan is the product of extensive 
consultation with stakeholders in the catchment areas of Crumlin, Drimnagh, Kimmage 
and Walkinstown in Dublin city. The aims and objectives of the new strategy include: 
 Treatment: continue to develop the cross-task force harm reduction/needle 
exchange service and increase collaboration between drug treatment and alcohol 
services.   
 Rehabilitation: lobby for a rehabilitation/integration service (RIS) and increased 
rehabilitation options, and develop forums and networks such as the D12 Service 
Users Forum. 
 Education: consolidate and develop interventions aimed at young people at risk, 
develop links with schools and provide accredited addiction studies courses locally. 
 Supply control: work towards implementing initiatives such as the Joint Policing 
Committees and the Dial to Stop Drug Dealing campaign, and develop the 
Community Safety Partnership with the Gardaí and other community stakeholders. 
 Research: strengthen data collection systems, commission local research to inform 
service planning, and participate in national-level studies. 
 Family-support: re-establish family support groups and support the development of 
child care facilities for drug-using families. 
 Alcohol: develop a plan to address alcohol misuse, identify local alcohol services 
and form stronger relationships with them.   
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Therapeutic community strategic plan  
Coolmine Therapeutic Community (CTC) launched its strategic plan for 2009–2011 in 
September 2009 (Coolmine Therapeutic Community 2009).  Recent developments in 
Coolmine reflect the community‟s continuing commitment to the provision of a 
continuum of care, and to a vision of recovery which emphasises an enhanced quality 
of life rather than mere abstinence from drugs. The chief executive‟s overview lists 
Coolmine‟s achievements of note under the 2006–2008 strategy: 
 creation of formal client consultation and participation structures, 
 initiation of a stabilisation day-programme for active drug users in partnership with 
other service providers, 
 establishment of clinical governance structures and procedures, including the 
creation of a limited detoxification service within its residential facilities, 
 provision of full-time staff cover in residential facilities, 
 reduction in the length of stay in all three residential facilities to an average of six 
months, 
 change of institutional culture and styles at Ashleigh Hose to reflect the fact that the 
facility caters for mothers and children, 
 provision of five community aftercare houses to facilitate clients who have 
completed primary treatment programmes, 
 establishment of a part-time career guidance and counselling service and 
enhanced use of the Community Employment scheme to benefit clients, 
 completed refurbishment of two of its main facilities and commencement of work on 
the third, and  
 creation of an improved fundraising strategy. 
 
The new strategy identifies two key objectives:  
 
1. To consolidate and develop existing quality services, 
 establish an advisory group to ensure clinical governance, ongoing training and 
best practice is achieved, 
 increase resources and training to ensure that existing programmes are accessible 
to a greater range of people,  
 develop a volunteer programme and foster stronger links with external service 
providers, and  
 develop strategic partnerships with a number of housing providers to ensure that 
clients have the best opportunities for accommodation. 
 
2. To build a strong and sustainable organisation,   
 complete capital works,  
 improve internal communications structures, and implement an effective IT 
strategy,  
 develop an external communications strategy to raise Coolmine‟s profile and to aid 
fundraising efforts, and  
 explore potential development opportunities at Coolmine Lodge site for housing 
units or a residential detoxification unit. 
 
Community drug team strategic plan 
The Inchicore Community Drug Team (ICDT) launched its strategic plan for 2010–
2012, Taking stock and moving forward, in April 2010 (Inchicore Community Drug 
Team 2010). The vision set out in the strategic plan is „that all those living with drug 
addiction in Inchicore will have access to a holistic addiction service locally‟.  
 
Six strategic goals are identified: 
 to provide a safe environment where people affected by drug addiction can explore 
in a non-judgemental way the issues affecting their lives, 
 to promote opportunities for individuals to move out of the cycle of drug addiction,  
 to develop opportunities for children and young people to reach their full potential,  
 to identify gaps in service provision and initiate local responses,  
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 to promote a better understanding of how the drug problem affects the local area, 
and to increase the community‟s awareness of drug issues, and 
 to develop ICDT structures, roles and responsibilities in accordance with the 
strategic plan.  
 
The plan outlines a number of actions to be undertaken by ICDT: 
 develop a minimum service level for those on low-threshold programmes,  
 develop a needle exchange in Inchicore in partnership with the Canal Communities 
Local Drugs Task Force and the HSE,  
 develop holistic interventions in response to drug-use trends among service users,  
 develop programmes to meet the needs of children aged 10–14 years who have 
outgrown the Children‟s Project, 
 develop an inter-agency youth programme targeted at those involved in drug 
dealing, 
 establish a working group and develop a local strategy in response to 
benzodiazepine dependency, 
 establish an inter-agency response to meet the mental health needs of service 
users,  
 develop a family welfare forum in conjunction with local agencies, with the aim of 
improving the quality of life of children living in vulnerable families, and 
 develop the ICDT website and publish a regular newsletter.   
 
5.3 Treatment systems 
5.3.1 Organisation and quality assurance 
HSE Addiction Services  
The HSE‟s Drug and Alcohol Services are delivered as part of the HSE‟s Social 
Inclusion Services (SIS), which also include homeless services, services for minority 
ethnic communities, Traveller health services, community development, HSE RAPID 
and CLAR programmes, HIV/STI services, services for LGBT communities, and 
community welfare services. SIS was part of the Primary Community and Continuing 
Care (PCCC) directorate. However, in late 2009, as part of its Transformation 
Programme, the HSE merged the PCCC directorate and the National Directorate for 
Hospitals into a single national Integrated Services Directorate (ISD). This directorate 
has responsibility for the delivery, reconfiguration, performance and financial 
management of all health and personal social services, including drug and alcohol 
services. A Quality and Clinical Care Directorate has also been established. This 
directorate is intended to strengthen clinical leadership and improve clinical 
performance, as well as support the working relationship between clinicians and 
managers across the organisation; the participation of clinicians in the management 
process is regarded as a key driver of service development at national, regional and 
local levels. Responsibility for implementation of this process lies with the Integrated 
Services Directorate (ISD) (Health Service Executive 2010). 
 
National Quality Standards framework 
The NDS includes two actions under the heading „Treatment and Rehabilitation – 
Quality and Standards Framework‟. They are: 
 
 Action 45: Develop a clinical and organisational governance framework for all 
treatment and rehabilitation services, in line with the Report of the Working Group 
Examining Quality & Standards for Addiction Services, and subject to a timeframe 
for compliance given the resource implications involved.  
 Action 46: Develop a regulatory framework on a statutory basis for the provision of 
counselling within substance misuse services.  
 
The HSE has lead responsibility for implementing Action 45, in collaboration with the 
voluntary sector. Work is under way and development of a framework is expected to be 
completed by the end of 2010. The Department of Health and Children (DoHC) has 
  70 
lead responsibility for Action 46, in collaboration with the HSE. The DoHC is in the 
process of registering twelve health and social care professional grades under the 
Health and Social Care Professionals Act 2005.  However, given the importance of 
having a robust regulatory framework in place for substance misuse counsellors, this 
category of counsellor is not included in this first tranche, and further work is planned. 
 
Primary medical care in Irish prisons 
Between November 2007 and February 2008, primary health care provision was 
assessed in 11 out of the 14 prisons in Ireland (Barry, et al. 2010). The independent 
assessment used a checklist based on the Competence Assurance Exercise in 
General Practice, which includes items such as state of premises, equipment, 
contracted hours, time allocation and support staff.   
 
The report found that the medical facilities in six prisons were unsuitable (many had 
been built in the 19th century) but refurbishment was planned for some of them.  In 
general, the standard of medical equipment was not at the same level usually available 
in Irish general practice outside the prison services.  However, it should be noted that 
there is no international benchmark for the type, quality or quantity of essential medical 
equipment for prison medical facilities.  The number of patients a doctor saw per hour 
varied between 3.7 and 18.7, depending on the facility.  Much of this time was taken up 
with committals and transfers of prisoners.  At the time of the assessment, seven 
prisons that took part in the study provided methadone maintenance treatment.  The 
study also found that most medical facilities did not have a medical secretary.  The 
authors stated that medical secretaries would increase the efficiency of the medical 
units. 
 
The authors suggested that the IPS should consider adopting the UK strategy, whereby 
the Department of Health has responsibility for health care in the UK prison system, 
and proposed the HSE take responsibility for delivering health care in the IPS. 
 
General clinical audit for the Methadone Treatment Protocol 
The findings of the general clinical audit of the operation of the Methadone Treatment 
Protocol (MTP) between July and December 2009 were summarised in the Methadone 
Treatment Protocol Newsletter (Irish College of General Practitioners 2010).  The audit 
found the most common issues requiring a review were: vaccination and virology, 
record keeping, and supervision of dispensing. The newsletter gave examples of 
discrepancies between the standard expected and the actual practice among a small 
proportion of the GPs who participate in the MTP scheme, and suggested ways to 
improve practice in these areas.  
 
 On transfer from Level 1 to Level 2 doctors, not all clients had their virology 
screening or vaccination completed, as required by the MTP.  In some cases, 
screening or vaccination history was not documented.  
 In relation to record keeping, in some cases transfer summaries were difficult to find 
or were missing, and not every consultation record was complete.   
 In some cases where at least one supervised dose per week in the pharmacy was 
the expected standard, no request for such supervision was found in the file.  In 
some cases, „supervised dispensing did not appear to be responsive to clinical 
conditions‟, for example in failing to provide for increased supervision if a client 
appeared to be destabilising. 
 
International quality improvement award 
Cuan Mhuire, which has provided detoxification and residential rehabilitation services 
in Ireland since 1966, has won the prestigious CHKS Quality Improvement Award 2010 
(Carey, Pat 2010). This international award recognises significant improvements in 
patient care and patient experience, as well as in staff welfare, safety and morale. 
Candidate institutions are evaluated by experts representing medical and nursing 
colleges, healthcare associations and national quality institutes. It is the first time that 
this award has been give to a rehabilitation service.  Speaking at the award ceremony 
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in London in May, Cuan Mhuire founder Sister Consilio Fitzgerald said: „This Award 
shows how vocationally driven organisations such as Cuan Mhuire can deliver cost-
effective services with the highest possible standards of care.  The intrinsic value of 
each human being before God demands no less than our committed love.‟   
 
5.3.2 Availability and diversification of treatment 
Merchants Quay Ireland annual review, 2008  
Merchants Quay Ireland (MQI) published its annual review for 2008 in September 2009 
(Merchants Quay Ireland 2009). MQI‟s needle-exchange service recorded that the 
number of client visits in 2008 remained steady at just under 40,000; however, almost 
1,000 of those visits were by new clients. The report also highlighted a continuing high 
level of demand for homeless services, with a 4% increase in the number of meals 
provided for homeless people. There was a decrease in the numbers seeking help from 
MQI‟s primary health care services, resulting from a decision to limit the number of 
attendees and give adequate time to those presenting. 
 
In 2008 MQI completed the implementation of a national prison-based addiction 
counselling service to 13 prisons and was providing in excess of 1,000 counselling 
hours per month and working with 440 prisoners. With the support of the Vodafone 
Ireland Foundation, MQI expanded its family support service, to include a confidential 
helpline, counselling, support groups and drug education awareness for families. In late 
2008 MQI in association with the Midland Regional Drugs Task Force introduced the 
Midlands Family Support and Community Harm Reduction Service, providing outreach 
and working with families of those actively using drugs. 
 
Table 5.3.2.1 Types of service offered by MQI, the numbers of people accessing them, and the 
outcomes, 2008  
Service Type of intervention No. of participants Outcomes 
Needle-exchange 
and health-
promotion 
services 
Promoting safer injecting techniques  
HIV and hepatitis prevention 
Safe sex advice 
Information on overdose 
Not available  
(1,000 new clients) 
904 
Not available  
 
Not available 
Stabilisation 
services 
Methadone substitution 
Supportive day programmes 
Gateway programme 
Counselling 
20 
Not available 
Not available 
382 
Not available 
Not available 
Not available 
Not available 
 
Settlement 
service 
Assist service users to access 
interim and long-term 
accommodation 
 
34 (monthly average) Not available 
  
 
Integration 
programmes 
Access to transitional 
accommodation Ballymount House 
and Athlone for up to 24 weeks  
 
Group and one-to-one therapeutic  
sessions 
 
15 
 
 
 
Not available 
11 clients moved to 
longer-term 
accommodation 
 
Not available 
Training and work 
programmes 
FÁS Community Employment 
scheme 
 
124 32% secured 
permanent 
employment or 
moved to further 
education 
High Park 17-week, drug-free residential 
programme including individual 
counselling, group therapy, 
educational groups, work 
assignments and recreational 
activities 
 
59 (of whom 18 were 
admitted for 
detoxification) 
14 completed detox  
St Francis Farm Therapeutic facility offering a 6–12-
month programme 
29 14 completed three 
months or more 
Source: Merchants Quay Ireland, 2009 
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Drug and alcohol use in the Midland region 
The Midland Regional Drugs Task Force commissioned a study in order to establish an 
evidence base regarding drug-related issues in the Midland region to inform the 
development of appropriate response strategies (Lyons, Suzi, et al. 2010b).  The study 
used information from several different sources, including national drug prevalence 
data, the National Drug Treatment Reporting System and the Central Statistics Office. 
Interviews and focus groups were also conducted with key informants (e.g. service 
providers, drug users, family members) in four selected communities in the region.  
 
Many of the issues identified were common to all four communities and could be 
generalised to the whole of the Midland region. The report highlights these issues and 
makes the following recommendations: 
 
 Expand and improve existing addiction services to cope with increasing numbers of 
individuals requiring treatment for drug and alcohol problems. 
 Facilitate access to addiction services by reducing waiting lists and by addressing 
issues of distance and adequate transportation when locating new or expanded 
services. 
 Expand harm reduction programmes and set up additional ones as needed.  
 Improve access to methadone treatment and reduce waiting lists by increasing the 
number of GPs providing methadone in the community and by expanding and 
improving existing services.  
 Improve access to detoxification, rehabilitation and aftercare services in line with 
the recommendations of the report of the HSE Working Group on Residential 
Treatment and Rehabilitation (O'Gorman and Corrigan 2008). 
 Address problem alcohol use in a more comprehensive way, not only by providing 
adequate treatment facilities but also by adopting broader strategies, including 
education, increased taxation and regulation.  
 Address the lack of adequate services for under-18s by providing adolescent-
specific services offering a complete, integrated range of services, in line with the 
recommendations of the Department of Health and Children (Working Group on 
treatment of under 18 year olds 2005). 
 Improve drug awareness education for all age groups.  
 Reduce drug-related deaths by using strategies such as providing education in 
overdose prevention and training in basic life support. 
 Provide social reintegration services to recovering and former drug users through 
accommodation, re-training and employment supports. 
 Evidence of drug crime, such as drug markets, was found in the region. A 
partnership approach involving all the key stakeholders is one strategy to tackle this 
problem. 
 
Nurse prescribing in addiction services 
In 1998 An Bord Altranais, the nursing board, which is the regulatory body for the 
nursing profession in Ireland, recommended that nurse prescribing be introduced in 
Ireland (An Bord Altranais 2000). Internationally, this practice has been found to 
improve the quality of patient care when used in appropriate circumstances. The 
advantages of nurse prescribing in addiction services include increased access to 
services for clients, improved continuity of care, reduced waiting times and improved 
quality of service and care (Gallagher, et al. 2006). 
 
In May 2007, the Minister for Health and Children signed the legislation to provide the 
legal authority for nurses and midwives to prescribe medication: Irish Medicines Board 
(Miscellaneous Provisions) Act 2006 (Commencement) Order 2007 (SI No. 194 of 
2007), Medicinal Products (Prescription and Control of Supply) (Amendment) 
Regulations 2007 (SI No. 201 of 2007) and Misuse of Drugs (Amendment) Regulations 
2007 (SI No. 200 of 2007). 
 
Prospective nurse prescribers must complete an approved six-month course and 
adhere to a set of practice standards and competencies for prescribing. In addition, An 
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Bord Altranais requires any health facility employing nurse prescribers to have certain 
support structures in place. Currently, nurse prescribers cannot prescribe methadone. 
However, they can, where appropriate, prescribe certain controlled drugs under 
specific conditions of the Misuse of Drugs Regulations, including drugs for the purpose 
of midwifery, such as pethidine, or drugs for palliative care, such as morphine sulphate. 
 
In December 2009 two nurses working at the Drug Treatment Centre Board graduated 
as the first nurse prescribers in addiction in Ireland (Drug Treatment Centre Board 
2009).   
 
Nursing in the Irish Prison Service  
Nurses first began working in the Irish Prison Service (IPS) in 1999. The IPS and the 
Nursing and Midwifery Planning and Development Unit (NMPDU) of the HSE Eastern 
Region collaborated in a recent study exploring the opportunities for the development 
of nursing services in prisons (Nursing and Midwifery Planning and Development Unit 
& Irish Prison Service 2009). 
 
The study included a literature review of the role of nurses in prison healthcare, a 
descriptive review of the IPS and the professional framework for nursing in Ireland, and 
a quantitative questionnaire completed by nurses and medical orderlies working in the 
IPS (32% response rate). The qualitative components were participant observation and 
semi-structured interviews with key informants, including prison management and 
those internally and externally involved in prison healthcare.  Focus groups were held 
with three groups of nurses and three groups of prisoners.  Data collection took place 
between November 2005 and December 2007.   
 
The findings of the study covered a wide range of health and professional issues, but 
only the results related to substance misuse and addiction are repeated here.  In the 
quantitative questionnaire, care related to substance misuse featured among the 14 
most frequently performed clinical tasks, and was carried out on a daily basis by 50% 
or more of respondents.  More than half of the nurse respondents identified addiction 
as one of the areas where specialist training should be developed. 
 
In the qualitative part of the study, participants highlighted addiction and its 
consequences as an important healthcare problem.  Participants reported that 
cannabis, benzodiazepines and heroin were the most common illicit substances used 
in prisons, although availability varied between prison sites.  While methadone 
maintenance treatment was available in most prisons, the need for improved treatment 
for problem use of other substances, in particular benzodiazepines and alcohol, was 
raised by many participants.  Treatment for addiction was reported to be inconsistent, 
with a lack of counselling services,7 and there was 'some confusion in relation to 
approaches to detoxification, methadone dose and access to treatment' (p. 82).  Most 
participants reported a need for improved education and training in addiction care for 
nurses.  Prisoners also highlighted the need for peer support and improved discharge 
planning in relation to addiction care.   
 
Mental health problems among prisoners, especially those who had a dual diagnosis 
(both a mental health issue and a substance use disorder), were identified as a 
significant and challenging health issue by all participant groups.    
 
The authors concluded that nurses have a very important role in addressing the health 
needs of prisoners.  They found that there was a strong awareness of the importance 
of prison healthcare and that nurses did receive recognition and support from all the 
stakeholders involved.  However, they also found that nurses could be used more 
effectively within the IPS. 
 
                                               
7
 Since 2008 Merchants Quay Ireland has provided national prison-based addiction counselling services to 
13 prisons. 
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The report set out 16 goals for the future development of prison nursing and healthcare 
in Ireland, each with its own set of recommendations. The authors stated that many of 
the associated recommendations did not require additional resources or funding, but 
restructuring and integration of existing services and resources and effective 
collaboration at all levels. The goals include: 
 enhance the strategic development of prison healthcare, 
 identify and meet prisoner health needs, 
 develop and implement policies, procedures, protocols and guidelines, 
 develop nursing role including role definition, advance capacity for specialist and 
advanced nursing practice, and advance skills and competencies, 
 develop professional development infrastructure, 
 support practice within the Scope of Nursing and Midwifery Practice Framework, 
 enhance quality and governance, 
 develop workforce planning, 
 strengthen nursing practice with regard to access, and committal assessment and 
care planning, 
 balance the therapeutic and custody roles, 
 develop prison healthcare infrastructure, and  
 implement recommendations through collaborative working by healthcare staff in 
partnership with prison management. 
 
Inpatient treatment of opiate dependence 
A study published in 2010 (Smyth, et al. 2010) examined the factors associated with 
lapse and relapse. (A lapse was defined as any misuse of an opiate after discharge, 
and a relapse as a return to a pattern of daily opiate use.) The study was a prospective 
follow-up study of opiate users who had been admitted to an Irish residential 
detoxification facility between June 1995 and December 1996. Follow-up interviews 
were conducted by outreach workers between June 1998 and March 1999.  
 
Of the 109 participants, 99 (91%) reported a relapse.  Within the first week of 
discharge, 72 (66%) had lapsed and 64 (59%) had relapsed. Only 42 (32%) of those 
recruited had completed the full six-week programme. 
 
The study identified several factors independently associated with early relapse: being 
aged 20 to 24, having a partner who had not used opiates, history of injecting drug use, 
using 1.5 to 3 „quarters‟ (a quarter-gram bag of heroin) per day, and failure to complete 
treatment or enter aftercare (Table 5.3.2.2). 
 
Table 5.3.2.2   Factors independently associated with early relapse following inpatient treatment*  
Characteristic  Odds ratio 95% CI P value 
    
Age    
Under 20 1.0   
20 to 24 0.5 0.3 – 0.8 0.007 
25 and over 0.6 0.4 – 1.1 0.11 
    
Status of partner/spouse           
Partner has history of opiate use 1.0   
Partner has not used opiates/no partner 1.7 1.0 – 2.7 0.04 
    
Quantity of heroin used    
Up to 1.5 „quarters‟ per day 1.0   
1.5 to 3 „quarters‟ per day 2.2 1.2 – 3.9 0.008 
More than 3 „quarters‟ per day 1.4 0.7 – 2.5 0.3 
    
Imprisonment    
Never in prison 1.0   
In prison 1.4 0.9 – 2.3 0.15 
    
History of injecting drug use    
No injecting 1.0   
Injecting previously 1.8 1.0 – 3.3 0.05 
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Characteristic  Odds ratio 95% CI P value 
Type of discharge    
Planned 1.0   
Unplanned 2.6 1.6 – 4.4 <0.001 
    
Aftercare    
None 1.0   
Commenced aftercare 1.7 1.1 – 2.8 0.03 
*Identified by multivariate analysis using the Cox proportional hazards model. 
Source: Smyth et al. (2010) 
 
This study, based on data collected in the late 1990s, found that lapse and relapse 
occurred very soon after opiate detoxification: 80% of participants had lapsed within the 
first month. The study findings are similar to those of international studies based on 
more recent data. The authors recommended that clients be provided with improved 
psychological supports before and after entering residential opiate detoxification, for 
example encouraging clients to remain for the full treatment period, improving relapse 
prevention supports, especially during the first week after discharge, and providing 
prompt access to aftercare.  
 
Regulating administration of suboxone  
The Department of Health and Children has commissioned an independent agency to 
evaluate the Suboxone feasibility study (see chapter 5.3.2 of National Report 2009 for 
an account of the feasibility study).  The scope of the evaluation is to: 
 conduct an audit using a recognised audit tool, 
 evaluate the processes – how clients were recruited, prescribing and dispensing 
practices and the practical operation of the study, 
 identify the core elements of the regulatory framework needed for safe and 
appropriate use of Suboxone in the Irish setting, and 
 ascertain the views of patients, prescribers and pharmacists. 
 
The results of the evaluation are expected in late 2010. 
 
Opiate users entering a detoxification programme  
An Irish study was conducted to determine the outcome and factors influencing 
outcome among a cohort of drug users commencing detoxification from opiate use 
(Mullen, et al. 2010, 21 February. Published online).  This was a national cohort study 
of randomly-selected opiate users commencing methadone detoxification treatment in 
1999, 2001 and 2003 (n=327).  The study found that 25.6% (n=62) of opiate users had 
a successful detoxification within 3 months, which was the criterion of success set by 
the authors. Receiving some inpatient treatment as part of a detoxification programme 
resulted in completion by 56% of drug users compared to completion by 21% of drug 
users undergoing treatments as outpatients. The factors found to be independently 
influencing detoxification were having some inpatient treatment (AOR 5.9, 2.63–13.64), 
and never having injected (AOR 2.25, 1.20–4.25). 
 
An additional 31 (9%) opiate users had a detoxification between 3 months and 1 year 
and 27 (8%) moved into methadone maintenance.  The authors concluded that having 
some inpatient treatment increases the likelihood of a successful opiate detoxification 
within three months. They recommended that offering opiate detoxification early in a 
drug-using career, i.e. during pre-injecting drug use, should be considered for suitable 
and motivated patients. 
 
Community detoxification  
The Progression Routes Initiative carried out an evaluation of a community 
detoxification pilot project which commenced in 2007 (Lyons, S 2008).  They conducted 
a survey of those involved in the project in December 2009.  Not all services who 
participated in the pilot participated in the evaluation, so it may not be a true 
representation of the programme.   
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Since the start of the programme, out of the 29 individuals who started the programme, 
16 engaged fully with it. Seven successfully completed the programme and a further 
seven were still engaged at the time of the evaluation (Caroline Gardiner, Progression 
Routes Initiative, personal communication).   
 
Requests for detoxification were for heroin, methadone, codeine and benzodiazepines.  
The majority of clients (14) were self-referrals.  Of the 7 clients who started a 
methadone detoxification, 2 had successfully completed, 3 were still engaged and 2 
had left the programme.  Of the 9 clients who started a benzodiazepine detoxification, 5 
had successfully completed the programme and 4 were still engaged. 
 
Overall, key workers (9) had a positive response to the programme, although 
insufficient communication and support from the GP was identified as an issue.  All the 
service users (6) who participated in the evaluation stated that they would recommend 
the programme to a friend and would be willing to go through the programme again, if 
necessary.  They reported high satisfaction levels with the support provided by their 
key workers.  Of the three doctors who responded, two reported that they would 
participate in the programme again. 
 
Self-detoxification  
Exploratory research, using a grounded theory approach, was undertaken to describe 
opiate users' experiences of self-detoxification (McDonnell and Van Hout 2010).  
Twenty-one in-depth interviews (n=12 heroin users, n=9 drug service providers from 
the statutory, community and voluntary sectors) were analysed. The study generated a 
substantive theory of self-detoxification as a subjective process of seeking heroin 
abstinence. Self-detoxification emerged as a frequent and reactive or proactive process 
in collaboration with others (heroin users, family and drug service providers). The 
authors suggested that this study has implications for drug service delivery in rural 
Ireland by increasing information provision and access to opiate detoxification through 
the development of low threshold services and community-based detoxification. 
 
A guide to case management in the area of homelessness and drug use 
The Homeless Agency and Progression Routes Initiative have published a case 
management guidebook for those working with clients who are homeless, many of 
whom have drug and alcohol misuse problems (Homeless Agency Partnership and 
Progression Routes Initiative 2010).  The book is intended as a companion to the 
Holistic Needs Assessment and Care Plan, the assessment tool developed by the 
Homeless Agency. The book and its accompanying protocols were piloted among 
those working with the homeless, and their feedback was incorporated into the final 
document.   The online version of the guide will be updated as necessary to ensure 
that the information is up to date. 
 
There are three sections in the guidebook: key support interventions, interagency 
protocols and a listing of services. Among the 12 chapters on key support areas are 
chapters on mental health, alcohol use and drug use. These three chapters are 
summarised here. (See Chapter 8.3.1 for a brief description of the interagency 
protocols.) 
 
Mental health 
Chapter 9 covers how to access mental health services, with a section on dual 
diagnosis (including both addiction and mental health problems). The role of the 
service provider outlined in the document is to make appropriate referrals, either to a 
GP or to the psychiatric services (within the addiction services). Other areas covered 
include how to make an application for involuntary admission to psychiatric care on 
behalf of a person deemed to be a risk to themselves or others, dealing with exclusion 
from the drug services because of mental health issues, and non-compliance with 
medication. 
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The second part of the mental health chapter deals with suicide and deliberate self-
harm, and how the service provider should handle such issues. The association 
between mental health problems and suicide is well known, and although self-harm is 
not necessarily associated with suicide, it is an indicator of mental health issues. 
 
Alcohol use  
Chapter 10 cites evidence that alcohol, frequently combined with drugs, may be the 
most widely-misused substance among homeless people. The key interventions 
identified are access to detoxification and access to rehabilitation and supports. This 
chapter also deals with the issue of a service user who is misusing alcohol while on 
prescribed methadone. The guide advises that in cases of polysubstance use an 
alcohol detoxification should be carried out before an opiate detoxification, but that 
problem use of cocaine or amphetamines may have to be addressed before that of 
either alcohol or opiates. Any interventions should be made with the support of the 
prescribing doctor, with aftercare in place, along with a relapse prevention plan, 
including social support from family and friends. 
 
Drug use  
Chapter 11 outlines key interventions in drug treatment services, stressing that they 
should be seen as a continuum of care across services. The interventions are: harm 
reduction services, methadone treatment, stabilisation services, detoxification, 
rehabilitation (day and residential), aftercare and support services. Some of these 
interventions are described below. 
 
Harm reduction  
The book states that, as many problem drug users start injecting before accessing 
formal drug treatment, it is important that the service provider ensures that clients have 
access to harm reduction information and services in order to reduce drug-related 
harm. Such resources may be accessed through a client‟s own service or by referral to 
another appropriate service. This section summarises the types of intervention typically 
provided by harm reduction services.  
 
Methadone treatment  
This section gives the service provider an overview of the issues around methadone 
treatment, including assessment, changing a prescription, take-aways and polydrug 
use. It includes practical advice, for example what documentation the client needs 
when attending an assessment of suitability for treatment.  
 
Stabilisation services  
Stabilisation in this context is taken to mean compliance with a methadone treatment 
programme. This process requires the support of different services, such as 
counselling, relapse prevention or day programmes, to assist and support the client. 
This section outlines some of the different options and how to access them. 
 
Detoxification  
In general, a person must be on a reduced daily dose of between 40mg and 60mg of 
methadone in order to qualify for residential detoxification, according to this book. The 
criteria for other facilities vary, for example some require the person to be alcohol free 
or benzodiazepine free before entry. Inpatient facilities give priority to medical 
emergency cases (the nature of the emergency is not specified), and to people who are 
pregnant or are under the age of 18. While benzodiazepine detoxification can be 
carried out by a GP or by the doctor prescribing methadone, the guidebook notes that 
doctors are not obliged to carry out such detoxification in the community. 
 
 
5.4 Characteristics of treated clients (TDI data included) 
5.4.1 Treated problem drug use in Ireland, 2008  
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Figures from the NDTRS for treated problem drug use in Ireland in 2008 were analysed 
by HSE area of residence (Carew, A.M. 2010b). Some of the main results are noted 
below. 
 
In total, 14,518 cases were treated in 2008, of whom 6,576 entered treatment in that 
year. The majority of cases attended outpatient services.   
 
New cases entering treatment are an indirect indicator of recent trends in problem drug 
use.  The incidence of treated problem drug use among 15–64-year-olds living in 
Ireland, per 100,000 of the population, increased from 79.6 in 2007 to 85.8 in 2008 
(Figure 5.4.1.1). The prevalence of treated problem drug use among 15–64-year-olds 
living in Ireland, per 100,000 of the population, increased by 5%, from 444 in 2007 to 
466 in 2008.   
 
 
Figure 5.4.1.1   Incidence and prevalence of treated problem drug use among 15–64-year-olds, per 
100,000 population, 2004–2008  
Source: Carew AM, 2010 
 
An opiate (mainly heroin) was the most common main problem drug reported by cases 
entering treatment.  Alcohol was reported as an additional problem substance in 41.4% 
of all treated cases.  The majority of cases treated in 2008 reported problem use of 
more than one substance (70.0%), which was almost 3% higher than the 2007 figure.  
Cannabis (40.7%) and cocaine (36.8%) were the two most common additional problem 
drugs reported in 2008. The proportion of cases treated for benzodiazepines as an 
additional problem substance increased by 7.5% between 2007 and 2008.  
Polysubstance use increases the complexity of these cases, and is associated with 
poorer treatment outcomes.   
 
In total, 561 new injector cases entered treatment in 2008, an increase of 88 cases on 
the 2007 figure.  More than two in five of these cases were still injecting on entry to 
treatment, and 43% reported sharing injecting equipment, a decrease on the 2007 
figure.   
 
Many problem drug users in treatment are young and male, have low levels of 
education and are unlikely to be employed. 
 
Over 14% of new cases and more than 3% of previously treated cases in 2008 were 
aged under 18 years, a slight increase on the 2007 figure in both cases.  The 
proportion of new cases in employment decreased by more than 5% between 2007 
and 2008.  For further information please see Standard Table 24. 
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Treated problem alcohol use in Ireland, 2008  
Figures from the National Drug Treatment Reporting System (NDTRS) for treated 
problem alcohol use in Ireland in 2008 were analysed by HSE area of residence 
(Carew, A. M. 2010a). Some of the main results are: 
 
In total, 7,940 cases were treated for problem alcohol use in 2007, an increase of 628 
on the 7,312 cases treated in 2007. This may be attributed to an increase in the 
number of people presenting for treatment, or it may reflect the increase in the number 
of treatment centres participating in the NDTRS in 2008. 
The incidence of treated problem alcohol use among 15–64-year-olds living in Ireland, 
expressed per 100,000 of the population, increased from 118.3 in 2007 to 120.0 in 
2008 (Figure 5.4.1.2).  The prevalence of treated problem alcohol use among 15–64-
year-olds living in Ireland, expressed per 100,000 of the population, increased from 
222.6 in 2007 to 243.3 in 2008 (Figure 5.4.1.2).  These increases in incidence and 
prevalence may be explained by an increase in problematic alcohol use in the 
population, an increase in reporting to the NDTRS, or a combination of both. 
 
Figure 5.4.1.2   Incidence and prevalence of treated problem alcohol use, among 15–64-year-olds, 
2004–2008 
Source: Carew AM, 2010 
 
Almost one in five of those treated for problem alcohol use in 2008 also reported using 
at least one other substance, a similar proportion to that observed in 2007 and 2006.  
In 2008, the most common additional drugs used by treated alcohol cases were 
cannabis, cocaine, ecstasy and opiates.  This ranking reflects a minor change since 
2007, when benzodiazepines were the fourth most common additional drug. Use of 
more than one substance increases the complexity of cases and leads to poorer 
outcomes for the patient.  Information about combinations of substances used is 
important in terms of individual clients‟ care plans. 
In 2008, the median age at which both new and previously treated cases began 
drinking was 16 years, similar to previous years.   
The age profile of cases treated for problem alcohol use was the same in 2007 and 
2008.  The median age for all treated cases was 39 years; for new cases, the median 
age continued to be younger (36 years). While the proportion of cases under the age of 
18 remained small, the number of new cases in that age group continued to rise. The 
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majority of those treated for problem alcohol use were male, with low levels of 
employment.   
5.4.2 Substance misuse in the HSE South Eastern Area  
The HSE South published a report Data co-ordination overview of drug misuse 2008 in 
August 2009 (Kidd 2009). The report comprises sections relating to treatment services, 
substance-related offences and cases dealt with by the Probation Service in the HSE 
South Eastern Area, comprising counties Carlow, Kilkenny, Tipperary South, Waterford 
and Wexford.  
 
The section on treatment services analyses data collected from statutory and voluntary 
drug and alcohol treatment agencies, acute general hospitals and psychiatric hospitals 
in the HSE South Eastern Area.  
 
The total number of individuals seeking treatment in 2008 was 2,686, a decrease of 
265 on the 2007 figure.  Some 60 concerned persons (family members or close friends 
of substance users) contacted treatment services in the south east in 2008. 
 
The combined total of continuous care clients and new referrals who were treated was 
2,376. Of these: 
 68% were male and 32% were female. 
 13% were under the age of 20, and 41% were aged between 20 and 34.  
 Alcohol was the most common main problem substance for which treatment was 
sought (62%), followed by heroin (12%), cannabis (11%), and cocaine (5%). 
Cannabis, which had been second in this ranking for a number of years, was 
overtaken by heroin in 2008. 
 The numbers seeking treatment for alcohol and cannabis have decreased annually 
from 2007. Up to 2007, cocaine figures were rising, but the numbers seeking 
treatment for cocaine decreased in 2008. The numbers seeking treatment for 
heroin, MDMA, amphetamines and volatile inhalants increased.  
 
A total of 1,972 clients exited the services in 2008. Less than half (44%) of these clients 
completed treatment; 27% refused further sessions or did not return for subsequent 
appointments; 13% did not wish to attend further sessions as they considered 
themselves to be stable; 11% were transferred to another site for further treatment; 4% 
exited because of non-compliance; 1% exited for other reasons; and 0.6% died.  
 
The client‟s condition on discharge was classified by service providers as stable if they 
had responded to treatment, and unstable if they had not responded. Of the 1,972 
cases analysed, 1,347 (68%) were stable on exit from the services, 597 (30%) were 
unstable, the condition of 17 (0.9%) was classified as „not known‟ and 11 (0.6%) had 
died. 
 
5.5 Trends of clients in treatment (incl. numbers) 
5.5.1 Solvent and volatile inhalant use in Ireland 
See Chapter 2.3.7 for an outline of the legal situation with regard to solvents and 
inhalants in Ireland, an overview of the types of substances that are available and the 
most recent data on volatile inhalant use prevalence in Ireland. 
 
NDTRS data relating to treated volatile inhalant users shows that the numbers who 
entered treatment in the years 2003–2007 and reported solvents or volatile inhalants 
as their main problem substance ranged between 24 and 32, with a total of 137 for the 
five-year period. The vast majority (112) of these cases were entering drug treatment 
for the first time. Just over half (53%) were male and four-fifths were aged 17 years or 
under. Only 13% lived in Dublin (possibly an indication of service availability in Dublin) 
and 70% were still in school. The vast majority (97%) were Irish. The solvents or 
volatile inhalants most commonly reported as the main problem substance were 
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solvents (reported by 78 cases), nitrites (by 16), petrol (by 12) and butane (by 7), and 
the most common additional problem substances were alcohol and cannabis. In the 
same five-year period 164 cases reported solvents or volatile inhalants as an additional 
problem substance, of whom 106 were treated for the first time.  
 
5.5.2 Alcohol usage and associated treatment outcomes for opiate users 
entering treatment in Ireland 
An Irish study published in 2010 looked at alcohol usage and associated treatment 
outcomes for opiate users entering treatment in Ireland (Stapleton and M 2010). 
Evidence has shown that frequency and quantity of drug usage are reduced after 
treatment but the effect of opioid addiction treatment on alcohol consumption remains 
unclear. Data on drug and alcohol use among the 404 opiate users recruited by ROSIE 
was analysed. 
 
The analysis revealed that those who abstained from alcohol use at 3 years were less 
likely to be using heroin at 3 years than non-abstainers. In addition, those who 
abstained from alcohol use at 3 years were also less likely to be using methadone, 
benzodiazepines and cocaine at 3 years than alcohol users. Outcomes for medium and 
heavy drinkers were found not to be as good as alcohol abstainers. Finally, males 
tended to reduce the frequency and level of alcohol usage after entering treatment 
more frequently than females. Results demonstrated to clinicians that an alcohol 
strategy is a key component of opiate treatment planning and a comprehensive and 
regular assessment of the client's alcohol and drug use profile is essential if treatment 
interventions are to have maximum impact on outcomes.  
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6. Health Correlates and Consequences 
6.1 Introduction 
Problematic drug use can be associated with a number of other health conditions or 
lead to a range of health consequences, including drug-related infectious diseases, 
drug-related overdoses, a range of chronic illnesses and acute conditions, and 
psychiatric comorbidity. Information on these various health correlates and 
consequences is collected in a variety of information systems, which are described 
below. 
 
The Health Protection Surveillance Centre (HPSC) is Ireland‟s specialist agency for 
the surveillance of communicable diseases.  Part of the Health Service Executive, and 
originally known as the National Disease Surveillance Centre, the HPSC endeavours to 
protect and improve the health of the Irish population by collating, interpreting and 
disseminating data to provide the best possible information on infectious disease. The 
HPSC has recorded new cases among injecting drug users of HIV since 1982, hepatitis 
B since 2004, and hepatitis C since 2006.  
 
The HIPE (Hospital In-Patient Enquiry) is a computer-based health information 
system, managed by the Economic and Social Research Institute (ESRI) in association 
with the Department of Health and Children (DoHC) and the Health Service Executive 
(HSE). It collects demographic, medical and administrative data on all admissions, 
discharges and deaths from acute general hospitals in Ireland. It was started on a pilot 
basis in 1969 and then expanded and developed as a national database of coded 
discharge summaries from the 1970s onwards. Each HIPE discharge record 
represents one episode of care; each discharge of a patient, whether from the same or 
a different hospital, or with the same or a different diagnosis, gives rise to a separate 
HIPE record.  The scheme, therefore, facilitates analyses of hospital activity rather than 
of the incidence of disease. HIPE does not record information on individuals who 
attend accident and emergency units but are not admitted as inpatients.  
 
The National Poisons Information Centre (NPIC), located in Beaumont Hospital, 
Dublin, provides a national telephone information service on the toxicity, features and 
management of cases of poisoning. This 24-hour service is offered mainly to doctors 
and other health care professionals. Queries are dealt with by poisons information 
officers at the Centre between 8 am and 10 pm daily, while out-of-hours calls are 
automatically diverted to the UK National Poisons Information Service (NPIS). Data 
from this source provide indications of the pattern of human cases of poisoning, 
including age, gender and agent. 
 
The data collected by the Primary Care Re-imbursement Service (PCRS), previously 
called the General Medical Services (GMS) Payments Board, are another source of 
information on the health correlates and consequences of problematic drug use among 
those who have medical cards, which are means-tested.  Medical-card holders 
received certain health services, including approved prescribed drugs and medicines, 
free of charge up to December 2009 and since January 2010 for a minimal charge. 
Operated by the HSE, the PCRS administers payments to doctors, pharmacists and 
dentists who provide services under the PCRS scheme.  
 
The National Psychiatric In-Patient Reporting System (NPIRS), administered by the 
Health Research Board (HRB), is a national psychiatric database that provides detailed 
information on all admissions to and discharges from 56 inpatient psychiatric services 
in Ireland. It records data on cases receiving inpatient treatment for problem drug and 
alcohol use. NPIRS does not collect data on the prevalence of psychiatric comorbidity 
in Ireland. The HRB publishes an annual report on the data collected in NPIRS, entitled 
Activities of Irish psychiatric units and hospitals.  
 
  83 
Problematic drug use can also lead to premature death. Death can occur as a result of 
overdose (either intentional or unintentional), actions taken under the influence of 
drugs, medical consequences or incidental causes. Although illicit drugs are involved in 
many cases of drug-related death, licit (including prescribed) drugs are also frequently 
involved, either alone or in conjunction with an illicit drug. Alcohol has been reported as 
the third greatest risk factor for ill health and premature death in Europe. Established in 
2005, the National Drug-Related Death Index (NDRDI), which is maintained by the 
HRB, is an epidemiological database which records cases of death by drugs poisoning, 
and deaths among drug users in Ireland, extending back to 1998. The NDRDI also 
records data on alcohol-related deaths, deaths among alcoholics, and deaths from 
alcohol-related diseases, extending back to 2004. 
 
The number of deaths as a result of poisoning fluctuated between 1998 and 2003; 
however, since 2003 the number of cases has risen from 107 cases to 169 cases in 
2007. The rise is attributed to cocaine, opiates and/or poly-substance use. 
 
The Central Statistics Office (CSO), acting on behalf of the DoHC, compiles quarterly 
and annual statistical reports on deaths in the Irish population. These reports are based 
on administrative data supplied by the General Register Office. The principal variables 
collected include date of death, address of residence of deceased, place of death, 
underlying cause of death, occupation, age, sex, and marital status. Since 1 January 
2007 the underlying cause of death has been coded according to ICD10 rather than 
ICD9.  
 
For a description of the National Registry of Deliberate Self-Harm, see Section 4.1 
above. 
 
6.2 Drug-related infectious diseases 
6.2.1 HIV/AIDS and viral hepatitis 
HIV surveillance in 2009 
Voluntary linked testing for antibodies to HIV has been available in Ireland since 1985. 
According to the most recent report of the HPSC (Jackson, et al. 2010), at the end of 
2009 there were 5,369 diagnosed HIV cases in Ireland, of which 1,417 (27%) were 
probably infected through injecting drug use.  
 
Figure 6.2.1.1 presents the number of new cases of HIV among injecting drug users 
reported in Ireland, by year of diagnosis; data from 1982 to 1985 were excluded as 
these four years were combined in the source records. The number of HIV cases 
among injecting drug users fell between 1994 and 1998, with about 20 cases per year, 
compared to about 50 cases each year in the preceding years. There was a sharp 
increase in 1999 (69 new cases), which continued into 2000 (83 new cases). Between 
2001 and 2009 there was an overall decline in the number of new injector cases (38, 
50, 49, 71, 66, 57, 54, 36 and 30 respectively) when compared to 2000. It is difficult to 
interpret the trend owing to the relatively small numbers diagnosed each year, so a 
smoother curve (grey broken plot line in Figure 6.2.1.1) was calculated using a rolling 
centred three-year average. This curve presents a new baseline of between 40 and 60 
cases each year since 2006 and a declining trend.  
 
Of the 30 new HIV cases among injecting drug users reported to the HPSC in 2009, 24 
were male and six were female, and the average age was 36 years (range 22–57). 
Nineteen of the 30 cases with a known address lived in the HSE Eastern Region 
(Dublin, Kildare and Wicklow). These data are presented in Standard Table 9.4. 
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Figure 6.2.1.1   Actual number and rolling average number of new cases of HIV among injecting 
drug users, by year of diagnosis, reported in Ireland, 1986–2009 
Source: Unpublished data reported to DoHC, National Disease Surveillance Centre and HPSC  
 
Hepatitis B surveillance in 2009  
Hepatitis B is a vaccine-preventable disease which is transmitted through contact with 
the blood or body fluids of an infected person. The main routes of transmission are 
mother-to-baby, child-to-child, sexual contact and unsafe injections. The number of 
cases notified to the HPSC increased each year between 2006 and 2008 (Table 
6.2.1.1). These data are presented in Standard Table 9.4. In 2009 the number 
decreased by 12% (from 931 to 820). Of the 820 cases in 2009, 647 had a chronic 
infection, 78 had an acute infection and the disease status of 95 cases was unknown.  
 
The surveillance system has recorded risk factor data since 2004 and the percentage 
of cases notified to the HPSC that include data on risk factors increased from 31% in 
2006 to 44% in 2009. In 2009 44% (358) of all cases had risk factor data reported, of 
whom ten (2.8%) reported injecting drug use as their main risk factor. The number of 
such cases remained consistently low between 2006 and 2009, indicating the 
effectiveness of routine administration of the hepatitis B vaccine. 
 
Table 6.2.1.1 Number (%) of acute and chronic hepatitis B cases reported to the HPSC, by risk 
factor status, 2006–2009 
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No. 
(%) 
No. 
(%) 
No. 
(%) 
No. 
(%) 
No. 
(%) 
No. 
(%) 
No. 
(%) 
No. 
(%) 
No. 
(%) 
No. 
(%) 
No. 
(%) 
No. 
(%) 
All cases 93 655 59 52 705 103 82 747 102 78 647 95 
 
(11.5) (81.2) (7.3) (6) (82) (12) (8.8) (80.2) (11) (9.5) (78.9) (11.6) 
Cases with 
reported risk 
factor data 
59 
(63.4) 
184 
(28.1) 
5 
(8.5)  
44 
(84.6) 
314 
(44.5) 
16 
(15.5) 
73 
(89.0) 
427 
(57.2) 
55 
(53.9) 
57 
(73.1) 
277 
(42.8) 
24 
(25.3) 
 Of which:   
 
  
  
  
  
  
  
  
 Injecting drug 
users 
0 
 (0) 
3 
(1.6) 
1  
(2.0) 
1  
(2.3) 
5  
(1.6) 
1  
(6.3) 
0 
 (0) 
6  
(1.4) 
1  
(1.8) 
1 
(1.8) 
9 
(3.2) 
0 
 (0) 
Cases without 
reported risk 
factor data 
34 
(36.6) 
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(71.9) 
54 
(91.5) 
8 
(15.4) 
391 
(55.5) 
87 
(84.5) 
9 
(11.0) 
320 
(42.8) 
47 
(46.1) 
21 
(26.9) 
370 
(57.2) 
71 
(74.7) 
Total 807 860 931 820 
Source:  Unpublished data from the HPSC 
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Hepatitis C surveillance in 2009  
Hepatitis C is one the most common blood-borne viral infections among injecting drug 
users and is transmitted through contact with the blood of an infected person. The main 
routes of transmission are mother-to-baby, unsafe injections, transfusion of blood and 
blood products, and unsterile tattooing and skin piercing. There were 1,255 cases of 
hepatitis C reported to the HPSC in 2009 (Table 6.2.1.2), compared to 1,527 cases in 
2008. These data are presented in Standard Table 9.4.  
 
Table 6.2.1.2 Number of cases and notification rate per 100,000 population for hepatitis C, 2004–
2009 
Year Number of cases Notification rate per 100,000 
2004 1126 26.6 
2005 1409 33.2 
2006 1217 28.7 
2007 1552 36.6 
2008 1527 36.0 
2009 1255 29.6 
Source:  Unpublished data from the HPSC 
 
An enhanced surveillance system for hepatitis C was introduced in Ireland in 2007. 
Enhanced surveillance is essential to identify risk factors and for planning prevention 
and treatment strategies. In 2009, 40% of newly reported hepatitis C cases had risk 
factor status reported (Table 6.2.1.3). As expected, the majority of these cases (70.9%) 
reported injecting drug use as the main risk factor. Four per cent of cases said that they 
were recipients of blood or blood products at some time in the past and according to 
the HPSC were late reports to the system (N Murphy, HPSC, personal communication, 
2009).  
 
Table 6.2.1.3 Number (%) of hepatitis C cases reported to the HPSC, by risk factor status, 2007–
2009 
Risk factor status Hepatitis C 
  2007 2008 2009 
Total number of cases 1552 1527 1255 
       
Cases with reported risk factor data 
662 (42.7%) 575 (37.7%) 
506 
(40.3%) 
       Of which:      
       Injecting drug users 505 (76.3%) 442 (76.9) 359 (70.9) 
       Recipients of blood/blood products 31 (4.7%) 23 (4.0) 20 (4.0) 
       Other risk factors 90 (13.6%) 78 (13.6) 80 (15.8) 
       No known risk factor could be identified by patient or doctor 36 (5.4%) 32 (5.6) 47 (9.3) 
 
   
Cases without reported risk factor data 890 952 749 
Source:  Unpublished data from the HPSC 
 
In 2009, 83% of cases reporting injecting drug use as their main risk factor were 
notified by services in Dublin, Kildare and Wicklow (Table 6.2.1.4). Seventy-three per 
cent were male and 62% were under 35 years old.  
 
Table 6.2.1.4 Number (%) of hepatitis C cases who reported injecting drug use as their risk factor, 
by age, gender and place of residence, 2007–2009 
Risk factor status Hepatitis C 
 
2007 2008 2009 
Total number of known injector cases 505 442 359 
    Gender 
   Male 338 (66.9%) 316 (71.5%) 261(72.7%) 
Female 166 (32.9%) 124 (28.1%) 96 (26.7%) 
Unknown 1 (0.2%) 2 (0.5%) 2 (0.6%) 
    Age 
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Risk factor status Hepatitis C 
 
2007 2008 2009 
Mean 32.8 33.2 34.1 
Median 31 31.5 33 
Under 25 years 48 (9.5%) 45 (10.2%) 35 (9.7%) 
25 to 34 years 284 (56.2%) 231 (52.3%) 189 (52.6%) 
More than 34 years 171 (33.9%) 162 (36.7%) 134 (37.3%) 
Age not known 2 (0.4%) 4 (0.9%) 1 (0.3%) 
    Place of residence 
   Dublin, Kildare and Wicklow 448 (88.7%) 377 (85.3%) 299 (83.3%) 
Elsewhere in Ireland 57 (11.3%) 65 (14.7%) 60 (16.7%) 
Source:  Unpublished data from the HPSC 
 
The development of a qualitative RT-PCR assay for the detection of hepatitis C 
virus  
Real-time polymerase chain reaction (RT-PCR) represents a favourable option for the 
detection of hepatitis C virus (HCV). A real-time reverse transcriptase PCR (RT-PCR) 
assay was developed as a qualitative diagnostic screening method for the detection of 
HCV using the ABI PRISM® 7500 Sequence Detection System (Clancy, et al. 2008). A 
total of 650 serum samples were used for the development and optimisation of the RT–
PCR assay. A further 200 samples were used in a clinical trial. All samples were 
collected from randomly selected patients attending the hepatology clinic in St James‟s 
Hospital, Dublin, Ireland.   
 
The primers and probe were designed to target the 5′-untranslated region of the 
hepatitis C viral genome. A second heterologous probe assay was developed for the 
detection of the haemagglutinin gene of phocine distemper virus (PDV) and was used 
as an internal control. A semi-automated HCV extraction method was also 
implemented using the ABI PRISM™ 6100 Nucleic Acid PrepStation. The HCV assay 
was optimised as a qualitative singleplex RT-PCR assay with parallel testing of the 
target and internal control.  
 
The assay results (n = 200) were compared to the COBAS AMPLICOR™ HCV Test 
v2.0 assay. The assay demonstrated a high rate of sensitivity (99%), specificity (100%) 
and an acceptable limit of detection (LOD) of 100 IU/ml. The development of a 
qualitative multiplex assay for the simultaneous detection of HCV and internal control 
indicates the same high rates of sensitivity and specificity. This sensitive real-time 
assay may prove to be a valuable method for the detection of HCV.  
 
Proposed NACD and Irish Prison Service study to estimate the prevalence of 
drug use and blood-borne viruses in Irish prisons 
The National Advisory Committee on Drugs (NACD) is commissioning a study to  
 
1. describe the nature, extent and pattern of consumption of different drugs among 
the prisoner population when in the community and when in prison; 
2. describe methods of drug use, including intravenous drug use, among the 
prisoner population; 
3. estimate the prevalence of blood-borne viruses among the prisoner population 
and to identify associated risk behaviours; and 
4. measure the uptake of individual drug treatment and harm reduction 
interventions (including hepatitis B vaccination) when in the community and 
when in prison.  
 
This study is being done to determine the need for drug treatment and harm reduction 
(including needle exchange) services in Irish prisons (Jean Long, personal 
communication, NACD committee member, 2010).    
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6.2.2 STIs and tuberculosis 
The surveillance data available in Ireland does not identify drug use as a risk factor for 
these infections. 
 
6.2.3 Other infectious morbidity (e.g. abscesses, sepses, endocarditis, wound 
botulism) 
See National report 2009 for most recent information (Alcohol and Drug Research Unit 
2009). 
 
6.2.4 Behavioural data 
There are no behavioural data recorded in Ireland. 
 
6.3 Other drug-related health correlates and consequences 
6.3.1 Non-fatal overdoses and drug related emergencies 
Data extracted from HIPE were analysed to determine trends in cases of non-fatal 
overdoses discharged from Irish hospitals in 2008. There were 4,815 overdose cases 
in that year, of which 43 died in hospital.  The 4,772 discharged cases are included in 
this analysis. The number of overdose cases decreased by 2.9% between 2007 and 
2008 (Figure 6.3.1.1). 
 
 
Figure 6.3.1.1   Overdose cases by year, 2005–2008 (N=19,542) 
Source: Unpublished data from HIPE 
 
Characteristics of cases 
 
Gender 
Between 2005 and 2008 there were more overdose cases among females than among 
males (Figure 6.3.1.2), with females accounting for 55% of all overdose cases in 2008. 
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Figure 6.3.1.2   Overdose cases by gender, 2005–2008 (N=19,542) 
Source: Unpublished data from HIPE 
 
Age group 
In the four-year period 2005–2008, one quarter of overdoses occurred in those aged 
15–24 years, with the incidence of overdose decreasing with age (Figure 6.3.1.3). The 
pattern was similar for each of the years reported. 
 
Figure 6.3.1.3   Overdose cases by age group, 2005–2008 (N=19,542) 
Source: Unpublished data from HIPE 
 
Area of residence 
In 2008, 26 overdose cases were resident outside of Ireland and 10 cases were 
recorded as having no fixed abode; these 36 cases were excluded from this analysis. 
Figure 6.3.1.4 shows the area of residence of cases with an Irish address for the years 
2005–2008.  One fifth of cases in 2008 were resident in Dublin. 
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Figure 6.3.1.4   Overdose cases by area of residence, 2005–2008 (N=18,510) 
Source: Unpublished data from HIPE 
 
Drugs involved 
Table 6.3.1.1 presents the positive findings per category of drugs and other substances 
involved in all cases of overdose in 2008. Non-opioid analgesics were present in 
34.8% (1,660) of cases. Paracetamol is included in this drug category and was present 
in 25% (1,198) of cases. Psychotropic agents were taken in 21.5% (1,025) and 
benzodiazepines in 20.8% (993) of cases. There was evidence of alcohol consumption 
in 14.0% (669) of cases. Cases involving alcohol are included in this analysis only 
when the alcohol was used in conjunction with another substance. 
 
Table 6.3.1.1   Category of drugs involved in overdose cases, 2008 (N=4,772) 
Drug category 
Positive findings per drug 
category* 
 n % 
Non-opioid analgesics 1660 34.8 
Psychotropic agents 1025 21.5 
Benzodiazepines 993 20.8 
Alcohol 669 14.0 
Narcotics and hallucinogens 599 12.6 
Anti-epileptic / sedative / anti-Parkinson agents 569 11.9 
Other chemicals and noxious substances 316 6.6 
Systemic and haematological agents 169 3.5 
Autonomic nervous system agents 117 2.5 
Cardiovascular agents 110 2.3 
Hormones 109 2.3 
Systemic antibiotics 92 1.9 
Anaesthetics 90 1.9 
Gastrointestinal agents 65 1.4 
Other gases and vapours 52 1.1 
Muscle and respiratory agents 52 1.1 
Anti-infectives / Anti-parasitics 40 0.8 
Diuretics  38 0.8 
Topical agents 24 0.5 
Other and unspecified drugs 969 20.3 
*The sum of positive findings is greater than the total number of cases because some cases involved more than one 
drug or substance.  
Source: Unpublished data from HIPE 
 
Overdoses involving narcotics or hallucinogens 
Narcotic or hallucinogenic drugs were involved in 12.6% (599) of overdose cases in 
2008. Figure 6.3.1.5 shows the number of positive findings of drugs in this category by 
the type of drug. The sum of positive findings is greater than the total number of cases 
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because some cases involved more than one drug from this category.  Opiates were 
used in over half the cases, cocaine in one fifth and cannabis in 7%. 
 
 
Figure 6.3.1.5   Narcotics and hallucinogens involved in overdose cases, 2008 (N=599) 
Source: Unpublished data from HIPE 
 
Overdoses classified by intent 
In two-thirds (65.5%) of cases the overdose was classified as intentional (Figure 
6.3.1.6). 
 
Figure 6.3.1.6   Overdose cases by classification of intent, 2008 (N=4,772) 
Source: Unpublished data from HIPE 
 
Table 6.3.1.2 presents the positive findings per category of drugs and other substances 
involved in cases of intentional overdose in 2008. Non-opioid analgesics were involved 
in 43.1% (1,346) of cases, psychotropic agents in 25.8% (806) and benzodiazepines in 
24.7% (772). 
 
Table 6.3.1.2   Category of drugs involved in intentional overdose cases, 2008 (N=3,126) 
Drug category 
Positive findings per drug 
category* 
 n % 
Non-opioid analgesics 1346 43.1 
Psychotropic agents 806 25.8 
Benzodiazepines 772 24.7 
Alcohol 476 15.2 
Anti-epileptic / sedative / anti-Parkinson agents 461 14.7 
Narcotics and hallucinogens 304 9.7 
Systemic and haematological agents 96 3.1 
322
131
44
129
0
50
100
150
200
250
300
350
Opiates Cocaine Cannabis Other hallucinogens
N
u
m
b
e
r
1118
3126
528
0
500
1000
1500
2000
2500
3000
3500
Accidental Intentional Undetermined
N
u
m
b
e
r
  91 
Drug category 
Positive findings per drug 
category* 
Other chemicals and noxious substances 84 2.7 
Autonomic nervous system agents 77 2.5 
Cardiovascular agents 75 2.4 
Hormones  70 2.2 
Systemic antibiotics 69 2.2 
Gastrointestinal agents 50 1.6 
Anaesthetics 44 1.4 
Muscle and respiratory agents 29 0.9 
Anti-infectives / Anti-parasitics 28 0.9 
Diuretics  22 0.7 
Other gases and vapours 16 0.5 
Topical agents 9 0.3 
Other and unspecified drugs 576 18.4 
*The sum of positive findings is greater than the total number of cases because some cases involved more than one 
drug or substance.  
Source: Unpublished data from HIPE 
 
6.3.2 Other topics of interest 
Trends in drug admissions to psychiatric facilities 
Activities of Irish psychiatric units and hospitals 2008 (Daly and Walsh 2009), the 
annual report published by the Mental Health Research Unit of the Health Research 
Board, showed that the total number of admissions to inpatient care has continued to 
fall.  
 
In 2008, 778 cases were admitted to psychiatric facilities with a drug disorder, of whom 
289 were treated for the first time. The report does not present data on drug use and 
psychiatric co-morbidity, so it is not possible to determine whether or not these 
admissions were appropriate. Figure 6.3.2.1 presents the rates of first admission 
between 1990 and 2008 of cases with a diagnosis of drug disorder, per 100,000 of the 
population. The rate was almost three times higher in 2001 than it was in 1990.  
Notable dips in the rate occur in the census years 1996, 2002 and 2006, and can be 
partly explained by the increased population figure used as the denominator in 
calculating the rate for those years.  
 
The overall increase in the rate of drug-related first admissions between 1990 and 
2001 reflects the increase in problem drug use in Ireland and its burden on the 
psychiatric services.  The overall decrease in the rate since 2001 possibly reflects an 
increase in community-based specialised addiction services during this period. The 
increased rate in 2005 may be accounted for by the use of the 2002 census figure in 
calculating the rate. The decrease to 5.9 in 2006 reflects the new census figure used 
as denominator. The rate increased marginally to 6.8 in 2008. Of the 791 discharges 
with a drug disorder, 51% spent less than one week in hospital and just under 15% 
spent more than one month in hospital.   
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Figure 6.3.2.1   Rates of psychiatric first admission of cases with a diagnosis of drug disorder 
(using the ICD-10 three character categories) per 100,000 of the population in NPIRS, 1990–2008  
Source: Daly and Walsh, 2003; Daly et al, 2004, 2005, 2006, 2007, 2008  
 
Chronic illness and multimorbidity among problem drug users: a comparative 
cross-sectional pilot study in primary care 
Although multimorbidity has important implications for patient care in general practice, 
limited research has been undertaken on chronic illness and health service utilisation 
among problem drug users. A study was undertaken to determine chronic illness 
prevalence and health service utilisation among problem drug users attending primary 
care for methadone treatment, to compare these rates with matched 'controls' and to 
develop and pilot test a valid study instrument (Cullen, et al. 2009).  A cross-sectional 
study of patients attending three large urban general practices in Dublin, Ireland, for 
methadone treatment was conducted, and this sample was compared with a control 
group matched by practice, age, gender and General Medical Services (GMS) status. 
All patients attending each practice for methadone treatment on 1 July 2008 were 
eligible for the study. 
 
Data were collected on 114 patients. Fifty-seven patients were on methadone 
treatment, of whom 52 (91%) had at least one chronic illness (other than substance 
use) and 39 (68%) were prescribed at least one regular medication. Frequent use of 
primary care services and secondary care services in the previous six months was 
observed among patients on methadone treatment and among the control group, 
although the former had significantly higher chronic illness prevalence and primary care 
contact rates. The authors conclude that multimorbidity is common among problem 
drug users attending general practice for methadone treatment. Primary care may 
therefore have an important role in primary and secondary prevention of chronic 
illnesses among this population. This study instrument facilitated data collection with 
minimal inter-observer variation and the authors consider it a feasible option for further 
work on this issue. 
 
Learning and memory deficits in ecstasy users and their neural correlates during 
a face-learning task 
Research has consistently shown that ecstasy users display impairments in learning 
and memory performance. In addition, working memory processing in ecstasy users 
has been shown to be associated with neural alterations in hippocampal and/or cortical 
regions as measured by functional magnetic resonance imaging (fMRI).  
 
Using functional imaging and a face-learning task, Robert and colleagues investigated 
neural correlates of encoding and recalling face-name associations in 20 recreational 
drug users whose predominant drug use was ecstasy, and in 20 controls (Roberts, et 
al. 2009). To address the potential confounding effects of cannabis use by the ecstasy-
using group, a second analysis included 14 previously tested cannabis users (Nestor, 
et al. 2010). 
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Ecstasy users performed significantly worse in learning and memory compared to 
controls and cannabis users. A conjunction analysis of the encode and recall phases of 
the task revealed ecstasy-specific hyperactivity in bilateral frontal regions, left temporal, 
right parietal, bilateral temporal, and bilateral occipital brain regions. Ecstasy-specific 
hypoactivity was evident in the right dorsal anterior cingulated cortex  and left posterior 
cingulated cortex.  
 
In both ecstasy and cannabis groups, brain activation was decreased in the right 
medial frontal gyrus, left parahippocampal gyrus, left dorsal cingulate gyrus, and left 
caudate. These results elucidated ecstasy-related deficits, only some of which might be 
attributed to cannabis use. These ecstasy-specific effects may be related to the 
vulnerability of isocortical and allocortical regions to the neurotoxic effects of ecstasy. 
 
Lifetime history of substance misuse in first-episode psychosis: Prevalence and 
its influence on psychopathology and onset of psychotic symptoms 
Substance misuse (drug/alcohol dependence or abuse) in psychotic illness is an 
increasingly recognised problem. Kamali and colleagues aimed to estimate the 
prevalence and examine the influence of substance misuse on age at onset of 
psychosis and psychopathology among patients with first-episode psychosis (Kamali, 
et al. 2009). 
 
One hundred seventy-one consecutive patients with first-episode psychosis were 
assessed. Substance misuse, age at onset of psychosis and psychopathology were 
determined using valid instruments. Seventy-seven (46%) patients had a lifetime 
history of substance misuse and were predominately males, had more positive 
symptoms, and in the majority of cases (84%) started misusing substances before the 
onset of psychosis (SM-BP). There was no difference in age at onset between patients 
with SM-BP and the rest of the sample. Lifetime history of substance misuse is 
common and may influence psychopathology, but does not appear to influence or bring 
forward the age at onset of psychotic symptoms. 
 
First national report from sexual assault treatment units 
There are currently six sexual assault treatment units (SATUs) in Ireland, located at the 
Rotunda Hospital (Dublin), South Infirmary Victoria University Hospital (Cork), 
Waterford Regional Hospital, Midlands Hospital (Mullingar), Letterkenny General 
Hospital and Galway (Ballybrit). Clinical reports from each of these units are combined 
in the first annual SATU report, for 2009 (Eogan 2010). 
 
There were 529 attendances at the six units in 2009; 95% were female and the mean 
age was 24 years. Half (51%) of all patients who attended had consumed at least four 
units of alcohol in the 12 hours prior to the incident reported, 8% disclosed that they 
had taken illegal drugs and 3% were concerned that drugs had been used to facilitate 
sexual assault. Irish research has shown that alcohol consumption, especially drinking 
to intoxication, is a feature in a high proportion of rape and sexual abuse cases in 
Ireland (Hanly, et al. 2009); (McGee, et al. 2002) and this report further corroborates 
those findings. 
 
Emergencies related to cocaine use 
Illicit drug use can lead to acute reverse reactions leading to admission to emergency 
departments. Cocaine-related emergencies have been monitored in the USA, but the 
following is the first such investigation undertaken in Europe. The study investigates 
patterns of cocaine emergencies in eight European cities in a multicentre cross-
sectional study conducted in Barcelona, Budapest, Dublin, Hamburg, London, Rome, 
Vienna and Zurich (de Millas, et al. 2010). The reported frequency differed from city to 
city, with some emergency centres having less than one case per half year, and some 
centres having more than one case per month. Patterns of complaints among cocaine 
users were associated with the psychomotor-stimulant or cardiovascular effects of 
cocaine. Urine screens and referrals to the addiction services were infrequent. The 
authors concluded that a closer link between emergency departments and addiction 
  94 
services would help in guiding problematic drug users towards appropriate treatment at 
an earlier stage in their addiction.  
 
 
6.4 Drug-related deaths and mortality of drug users 
Data on drug-related deaths in Ireland are provided by the NDRDI. Data on directly 
drug-related deaths (poisonings) in 2008 have been collected and analysed, and these 
data are described below in Section 6.4.1.  Data on indirectly drug-related deaths (non-
poisonings) from 1998 to 2007 are described in Section 6.4.3. A more detailed 
description of drug-related deaths in Ireland is provided in Chapter 12 Mortality related 
to drug use: a comprehensive approach and public health implications.  
 
6.4.1 Drug-induced deaths 
In 2008, the number of deaths owing to poisoning (as per Selection D) increased very 
slightly, from 204 in 2007 to 208 (Table 6.4.1.1, also see Standard Table 6).  Since 
2003 there has been a steady increase in the number of poisonings reported. It should 
be noted that annual data previously reported have changed as the database has been 
updated as new information has become available. 
 
Table 6.4.1.1  Poisonings (Selection D) by year, 1998 to 2007 (N=1474) 
 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 
Selection D 115 113 109 127 109 128 173 188 204 208 
Source: Unpublished data NDRDI 
 
In 2008, the median age of those dying from poisoning was 34 years and the majority 
of individuals were aged between 20 and 39 years of age (144, 69.2%).  The majority 
were male (164, 78.8%), although there was a difference between the median age of 
males (32 years) and of females (38 years).  This pattern is similar to findings from 
previous years and also reflects international trends (see Standard Table 5).    
 
Of the 208 cases of poisoning recorded in 2008, heroin or unspecified opiates 
accounted for 34 (16.3%) cases, while methadone accounted for 20 (9.6%).  This is 
similar to the pattern reported for previous years. Deaths attributable to polysubstances 
increased: more than half of all deaths owing to poisoning (124, 59.3%) were 
attributable to polysubstances, including an opiate, which is higher than in previous 
years (Health Research Board 2010).   
 
Opiates continued to be associated with the majority of fatal overdoses in 2008, with 
180 (86.1%) deaths being associated with opiate use. This is higher than reported for 
previous years.  Deaths as a result of poisoning from cocaine, alone or with another 
drug, accounted for 27.8% (58) of deaths by poisoning in 2008, which was a decrease 
compared to 2007, when the proportion was 32.4% (66). 
 
The trends in drug-related deaths in 2008 are similar to the trends seen in the national 
treatment data for 2008, which show an increase in the number of cases treated for 
problem opiate use and a slight decrease in the number of cases treated for problem 
cocaine use (Carew, AM 2010b). 
 
Alcohol and other drugs, including benzodiazepines, non-benzodiazepine sedatives, 
antidepressants, other prescription medication and over-the-counter medication, 
continue to contribute significantly to the burden of drug-related deaths in Ireland but 
are not reported on in this national report.  For further information on the national 
situation, see the most recent publication from the NDRDI (Health Research Board 
2010) 
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6.4.2 Mortality and causes of deaths among drug users 
See Section 6.4.1, Section 6.4.3 and Chapter 12. 
 
6.4.3 Specific causes of mortality indirectly related to drug use 
A total of 1,345 deaths by non-poisoning among drug users were recorded between 
1998 and 2007. Of the 1,183 cases with a known cause of death, 60.3% (714) were 
due to trauma and 40% (469) were due to medical causes (Figure 6.4.3.1) (Health 
Research Board 2010)]. 
 
 
Figure 6.4.3.1   Non-poisoning deaths among drug users, NDRDI 1998 to 2007 (N=1,183) 
 
Deaths owing to trauma 
The annual number of deaths owing to trauma increased from 39 in 1998 to 116 in 
2006, but fell to 87 in 2007 (Figure 6.4.3.1).  These figures may be revised when data 
relating to late inquests become available. Half (50.4%, 360) of those who died from 
traumatic causes were aged between 20 and 29 years. The median age was 27 years.  
Almost all (90.1%, 643) were male. The most common causes of death owing to 
trauma were hanging and RTCs. 
 
Deaths owing to medical causes 
The annual number of deaths owing to medical causes rose fairly steadily over the 
reporting period, from 11 in 1998 to 98 in 2007, when it exceeded the number of deaths 
owing to trauma (Figure 6.4.3.1).  The majority of those who died from medical causes 
were aged between 30 and 44 years.  The median age was 39 years. Three-quarters 
(75.0%, 352) of those who died were male. The most common medical causes of death 
were cardiac events (25.2%, 118), respiratory infections (17.7%, 83) and liver disease 
(10.2%, 48). 
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7. Responses to Health Correlates and Consequences 
7.1 Introduction 
This chapter presents new data on preventing drug-related mortality, the management 
of blood-borne viral infections, and responses to co-morbidity. The public and voluntary 
sector institutions that have been engaged in the various initiatives described in the 
following sections are briefly described here. 
 
The purpose of the Ballyfermot Advance Project is to support the Ballyfermot Local 
Drugs Task Force by creating and monitoring specific roles complementary to the 
delivery of the Task Force plan. It oversees a number of initiatives within the 
Ballyfermot area to address different needs in relation to drugs and drug use. 
 
The Ana Liffey Drug Project (ALDP) is a voluntary organisation offering a low-
threshold harm-reduction service in north inner-city Dublin. It works with people 
experiencing addiction, to minimise the harm that problematic drug use causes them, 
their families and the wider community. It provides a range of services including a drop-
in service, outreach service, family care and case management service, peer-support 
and literacy tutoring.  
 
The Health Service Executive (HSE) is responsible for managing and delivering 
health and personal social services in Ireland. It supports numerous responses to the 
health correlates and consequences of problematic drug use.  
 
The Irish Needle Exchange Forum (INEF) exists to actively develop, support, and  
sustain a network of high quality, comprehensive needle exchange and other harm  
reduction services across Ireland. Membership is open and free. 
 
The Mental Health Commission (MHC) is an independent statutory body established 
under the Mental Health Act 2001. It is tasked with promoting high standards in the 
delivery of mental health services in Ireland and ensures the interests of those 
involuntarily admitted to „approved centres‟ are protected. 
 
Written by an „expert group‟ and published in 2006, A Vision for Change set out a  
comprehensive model of mental health services for Ireland {Expert Group on Mental  
Health Policy, 2006 #744}. It emphasised the development of mental health services in  
the community over the next ten years. According to the authors, „individuals whose  
primary problem is substance abuse and who do not have mental health problems will  
not fall within the remit of mental health services‟; as a result, the expert group  
recommended that  major responsibility for the care of those with substance abuse  
(dependence) should lie outside the mental health services, with separate services with  
their own funding structure within the HSE. 
 
In relation to substance abuse (dependence), the report recommended: 
 Mental health services for both adults and children should be responsible for 
providing mental health services to individuals who have another mental illness 
in addition to their substance abuse (dependence).  
 General adult community mental health teams should care for adults with 
substance abuse and another mental health problem when the mental health 
problem is the primary problem.  
 Specialist substance abuse mental health teams for adults with complex severe 
substance abuse and mental disorders should be established.  These specialist 
teams should establish clear links with local community mental health services, 
and clarify pathways in and out of their services.  
 Two additional specialist substance abuse teams for children with substance 
abuse (dependence) and mental disorders should be established outside 
Dublin.  
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 A post of national co-ordinator should be established in the Primary Community 
and Continuing Care (PCCC) Directorate of the HSE.  This co-ordinator should 
develop standards for the delivery of interventions to address alcohol and drug 
abuse (dependence) in Ireland and establish how such interventions should be 
linked to mental health. 
 
The National Office for Suicide Prevention (NOSP) was established by the HSE in 
2005. Its functions are to oversee the implementation of Reach Out, the National 
Strategy for Action on Suicide Prevention, co-ordinate suicide prevention efforts around 
the country, and speak regularly with agencies and individuals interested and active in 
suicide prevention. The NOSP works closely with the HSE Resource Officers for 
Suicide Prevention. 
 
7.2 Prevention of drug-related emergencies and reduction of drug-
related deaths 
Patients who have overdosed on drugs commonly present to emergency departments, 
with only the most severe cases requiring intensive care unit (ICU) admission. Such 
patients typically survive hospitalisation. A study was made of these patients‟ longer 
term functional outcomes and recovery patterns (O'Brien, et al. 2009). All patients 
admitted to the 18-bed ICU of a university-affiliated teaching hospital following drug 
overdoses between 1 January 2004 and 31 December 2006 were identified. With 
ethical approval, the researchers evaluated the functional outcome and recovery 
patterns of the surviving patients 31 months after presentation, by telephone or 
personal interview. These data were recorded as Glasgow outcome score, Karnofsky 
performance index and present work status.  
 
During the three years of the study, 43 patients were identified as being admitted to the 
ICU because of an overdose. The average age was 34 years, 72% were male and the 
mean APACHE II score was 16.7. Of these, 32 were discharged from hospital alive. 
Follow-up data were collected on all of them. At a median of 31 months follow-up, a 
further eight had died. Of the 24 surviving, there were 13 unemployed, seven employed 
and four in custody. The median Glasgow outcome score of survivors was 4.5, their 
Karnofsky score 80.  
 
Admission to ICU for treatment of overdose is associated with a very high risk of death 
in both the short and long term. While excellent functional recovery is achievable, 16% 
of survivors were held in custody and 54% unemployed. 
 
7.3 Prevention and treatment of drug-related infectious diseases 
Needle-exchange services 
In July 2009, the HSE East Coast Area needle-exchange service launched an 
information leaflet for people who inject drugs (John Craven, personal communication, 
2009).  The aim of the leaflet is to encourage injectors not to share and never to re-use 
injecting equipment.  
 
The leaflet includes advice about safer injecting practices and provides guidance on 
how to look after veins and limit vein damage.  It stresses the importance of never 
sharing drug-taking equipment in order to help prevent the transmission or acquisition 
of hepatitis and HIV.  While the main focus is on injecting drug use, the leaflet states 
that blood-borne viruses can also be transmitted or acquired by sharing snorting 
equipment.  
 
Service users are encouraged to seek further advice from needle-exchange services, 
which are listed in the leaflet, with their opening hours and contact details. Information 
is also provided on services providing HIV/AIDS prevention, drug treatment and 
counselling, and the community addiction teams, in the East Coast area. For people 
seeking treatment and counselling services in other areas, a helpline number is given. 
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Needle and syringe exchange services were first provided in Ireland in 1989, when five 
exchanges were established. There are now over 30 exchanges in the country, 
operating three models of service: fixed-site exchanges, home visit exchanges, and 
exchanges in public locations. Peer-based, prison-based or vending machine 
exchange services are not available in Ireland. 
 
The Irish Needle Exchange Forum (INEF) held its inaugural conference at the Malton 
Hotel, Killarney, Co Kerry, on 5 November 2009 (Keane, M 2010). At the conference, 
Dr Denis O‟Driscoll, chief pharmacist at HSE Addiction Services Dublin Mid-Leinster, 
and Mr Rory Keane, Regional Drug Co-ordination Unit HSE Mid-West, presented an 
overview of plans to provide additional needle-exchange services through community 
pharmacies in 65 new locations across the country. It was envisaged that the services 
would be targeted to areas outside Dublin and the former Eastern Regional Health 
Authority. The services proposed would come from a new partnership between the Irish 
Pharmacy Union (IPU), the Health Service Executive (HSE) and the Elton John Aids 
Foundation (EJAF). The service would be part-funded by the EJAF for three years, with 
matching funding by the HSE. The HSE would take responsibility for funding in year 
four. Needle-exchange services will be provided free in pharmacies and will include 
both custom-made and standard packs. It was envisaged that the service will exchange 
new injecting equipment for old, provide sharps bins and advice on safe disposal of 
used equipment, information on safer-injecting and safe sex practices, and advice on 
drug use and other health-related issues.  
 
In the second half of 2010, the HSE and the Irish Pharmacy Union commenced 
recruitment of a National Liaison Pharmacist to supervise and support pharmacists who 
are participating in the pharmacy-based needle exchange service outside Dublin. 
These exchanges will be provided in all counties and in most urban areas outside of 
Dublin. The HSE are in the process of agreeing a fee structure with the IPU in regard to 
payment for participating community based pharmacists. The Irish Centre for 
Continuing Pharmaceutical Education training programme on needle-exchange for 
participating pharmacists commenced on 11 October  2010 and will be completed by 
16 November, in time for planned roll-out of the programme at the beginning of 2011.  
(Joe Doyle, HSE, personal communication, September 2010) 
 
Strategy to deal with hepatitis C 
As reported in last year‟s National Report, in January 2007 the HSE established a 
working group on hepatitis C. The brief of this group was to build on a 2004 
unpublished report on hepatitis C carried out by the then Eastern Regional Health 
Authority. Unlike the 2004 report, the 2007 initiative had a national brief. It examined 
how Ireland could best respond to hepatitis C in the areas of surveillance, education 
and treatment. The working group commented on how the recommendations of the 
2004 report had progressed. The group completed its report, presented it to senior 
management and is awaiting approval of HSE senior management.   
 
Legal highs and head shops: the basic facts  
In response to interest among drug workers regarding „legal high‟ drugs available in 
head shops, Ballyfermot Advance Project and The Base youth and child centre in 
Ballyfermot have produced an information leaflet (Ballyfermot Advance Project and 
Base Youth and Child Centre 2010). 
 
The leaflet outlines the current legal status and effects of common drugs such as 
Salvia, Spice, Piperazine, BZP and Kratom.  There is also harm reduction information 
that may be used to advise clients of risks.  
 
Content has been approved by Dr Des Corrigan, chairperson of the NACD, and Dr 
Bobby Smyth, consultant child and adolescent psychiatrist. 
 
Information on what to do if you have side effects from legal highs  
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ALDP has developed a web page on legal highs which contains links to published harm 
reduction information (Ana Liffey Drug Project 2010a). Peer workers at Ana Liffey have 
produced a booklet, Use Your Head – Harm Reduction Information – Legal Highs or 
Otherwise (Ana Liffey Drug Project 2010b), which provides guidelines on how to 
minimise harm when taking drugs and how to intervene if someone experiences harm 
caused by drugs  
 
 
 
 
SMS service for drug users  
On 30 June 2009 the ALDP launched the „Duck, Dive and Survive‟ SMS service (Duffin 
and Galvin 2009). This service enables Ana Liffey to offer real time information on 
reducing the risks associated with drug use and provide essential health and service-
related information. There is a high rate of mobile telephone use among Ana Liffey‟s 
clients and this innovative approach adopts this technology to communicate with 
people who use drugs. 
  
Ana Liffey used the special bursary it received as winner of the New Initiatives category 
of the Crystal Clear MSD Health Literacy Award 2009 to establish the service.  
 
Information provided by SMS includes: 
 changes to opening times of key services, 
 advice on overdose risks and prevention, particularly during festive/holiday periods 
which Ana Liffey suspects are times when overdoses are more likely, 
 new trends and dangers relating to illicit drug use – the North Inner City Drugs Task 
Force will use the SMS service to get key information to service users, and 
 information from service users – Ana Liffey works with the service users‟ 'Peer 
Support Group' to identify key messages to be sent to their peers. 
 
An example of a group text message sent to people who attended the Ana Liffey 
project during June 2009 is: 
 
OVERDOSE: Don't panic. Put them in the recovery position, dial 999, ask for an 
ambulance and stay with them until the ambulance arrives. Ana Liffey: 1800786828 
 
Following feedback from service users, the providers of the service realised that, to be 
effective, the messages sent must get to the point quickly and should ideally name the 
issue and the action to be taken.  Messages can be no more than 160 characters 
(including spaces) to allow for the message to be sent in one go.  Messages can be 
personalised by having the person‟s first name appear at the beginning of the text, but 
this also uses up text characters.   
 
A total of 2,243 text messages were sent during the first 13 weeks after the launch of 
the service, and by mid-August, 73 Ana Liffey service users had signed up.  
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The Swansea Drugs Project (Wales) has followed the example of the „Duck, Dive and 
Survive‟ SMS service and they are establishing an SMS service of their own. 
 
To date, messages have been developed in a reactive way, addressing issues 
identified by the Ana Liffey team and external issues affecting the client group.  A 
reactive service is necessary, and is one of the strengths of such a mass 
communication tool. However, the next phase of SMS delivery will involve the 
development of targeted health campaigns sent at strategic times.  This campaign will 
build on the success of the texts as developed to date. 
 
Guide to substance misuse for health professionals  
Sinead O‟Mahony Carey (O'Mahony Carey 2008), drug education officer with HSE 
South, compiled a pocket-sized reference manual, A guide to substance misuse for 
medical professionals. The first section of the guide presents drugs with potential for 
misuse by category and by type. The major categories of drugs covered include 
hallucinogens, opiates, stimulants and volatile inhalants. Details of individual drugs are 
presented under each category, described by street name(s), expected effects, 
negative or side effects, appearance, method(s) of use, dependency potential, 
withdrawal symptoms, overdose risk and effects of long-term use. The second section 
contains information on the signs of drug use. The third section presents an overview 
of the reasons people use drugs, while section four presents the dangers of drug use. 
The fifth section presents a summary of Irish law and drug use, and the final section 
covers the jargon related to drug use.  This book is a useful guide for health 
professionals, counsellors, key workers and social workers who work with drug users.  
 
 
7.4 Responses to other health correlates among drug users e.g 
psychiatric and somatic co-morbidity 
Psychiatric co-morbidity 
In September 2009 the Mental Health Commission (MHC) published the Report of Joint 
Working Group on Mental Health Services and the Police 2009 (Mental Health 
Commission and An Garda Síochána 2009). The authors stated that a considerable 
proportion of social crises in the community are of a psychiatric nature, involving both 
adults and children and are often connected not just with mental illness but with a 
range of other social factors including alcohol and drug abuse. They recommended the 
urgent implementation of national policy in relation to the document Vision for Change 
and the Primary Care Strategy; the creation of a 24-hour, 7-day a week statutory social 
work service; expanding training for An Garda Síochána on community and social 
services, together with mental illness in crisis; joint protocols between the mental health 
services and An Garda Síochána, and involving users and carers in the drawing up of 
these protocols; a feasibility study on jointly-staffed crisis intervention teams, made up 
of mental health personnel and members of An Garda Síochána; and court diversion 
programmes for dealing with minor criminal matters involving individuals with mental 
health problems. 
 
In November 2009 the MHC published an analysis of progress towards implementation 
of A Vision for Change by the HSE (Mental Health Commission 2009). The MHC 
acknowledged that implementation of a complex policy with many recommendations in 
a system already undergoing significant change was a challenging process. It needs 
co-ordinated change at system, organisation, programme and practice levels. The 
MHC stated that the evidence-based requirements for successful implementation were 
largely missing, and that the HSE‟s implementation plan should include: 
 an overall sense of the HSE vision for mental health services, 
 a statement of specific outcomes, 
 a map of the steps needed to achieve these outcomes with real targets, timelines, 
resources and responsible agents clearly described, and 
 an outline of the measurable benefits arising from the implementation including the 
monitoring of the outcomes as they are being achieved. 
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Published in June 2010, the MHC‟s annual report for 2009 noted that the fundamental 
changes to mental health services as recommended in A Vision for Change, including 
the separation of mental health from other mental health services, had still not taken 
place (Mental Health Commission 2010). The 2009 annual report of the Inspectorate of 
Mental Health Services, published as part of the MHC‟s 2009 annual report, noted 
among „encouraging developments‟ in 2009 the appointment of an HSE Assistant 
National Director with responsibility for the implementation of A Vision for Change. 
While the appointment fell short of a separate national directorate for mental health 
services, the Inspectorate anticipated that a number of reforms could be achieved on 
foot of the appointment. The Inspectorate also welcomed the opportunities to progress 
the development of a separate mental health service provided as a consequence of the 
HSE‟s Transformation Programme (see Section 5.3.1 for details of this organisational 
change programme). Specifically: 
 The establishment of a Directorate of Clinical Care and Quality: the Inspectorate 
anticipated that mental health services would be an integral part of the deliberations 
of this directorate, whose initial aim is to audit services against practice guidelines 
on a national basis.  
 The integration of the Hospital and Primary Community and Continuing Care 
(PCCC) divisions: the Inspectorate‟s report states: „The 2008 Inspector‟s Report 
was concerned at the “lumping” of mental health services into primary care and 
community services. During 2009, we saw many examples of “raiding of the 
monasteries” with respect to leakage of mental health resources to other services.    
Concern was also expressed that mental health services could be almost 
exclusively delivered at a primary care level. It is to be hoped that, in the new 
integrated system, especially with the influence of an Assistant National Director for 
Mental Health, these concerns will be addressed and a more coherent and 
transparent funding stream for mental health services will be established.‟ (page 
81) 
 
Among areas of concern identified in its 2009 report, the Inspectorate of Mental Health 
Services noted the following: „We are concerned by the occupation of scarce CAMHS 
[Child and Adolescent Mental Health Services] beds by individuals with no diagnosable 
mental disorder often with social problems with “nowhere else to go”. This is 
inappropriate and potentially damaging to these individuals as well as depriving others 
of needed beds.‟ (page 83) 
 
In its report published in June 2010 (Independent Monitoring Group 2010), the 
independent group set up by the Minister for Equality, Disability and Mental Health, 
John Moloney TD, to monitor the implementation of A vision for change reported that 
there had been no progress at national level in 2009 regarding the development of 
mental health services for persons with co-morbid severe mental illness and substance 
abuse problems.  
 
Training programme in dual diagnosis 
The clinical nurse specialist (CNS) in addictions based in the Central Mental Hospital in 
Dublin has played a key role in developing a pathway of therapeutic group programmes 
for people with a dual diagnosis of mental illness and substance abuse.  
 
Dual diagnosis is a very recent concept in the Irish mental health service. The concept 
was highlighted by MacGabhann and colleagues (MacGabhann, et al. 2004), who 
recommended incorporating training for dual diagnosis into undergraduate and 
continuing education programmes for those working in addiction and mental health 
services. Because such training is not widely available in Ireland, an innovative five-day 
training programme was developed by Hanora Byrne, CNS in addictions at the Central 
Mental Hospital, and Dr Shobha Rani, lecturer in nursing at Trinity College Dublin. The 
programme has been awarded category 1 approval by An Bord Altranais.  
The programme development was based on a six-step approach devised by Kern and 
colleagues (Kern, et al. 1998). The six steps are: problem identification needs 
assessment, objectives, implementation, educational strategies and evaluation. 
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Analysis of a needs assessment involving 20 psychiatric nurses and 20 probation 
officers showed that it was clearly necessary to develop a training programme in dual 
diagnosis.  
 
The main objectives of the programme are to provide information on dual diagnosis 
and the treatment programmes that can be applied in service delivery. The programme 
has four modules delivered through lectures, group discussions, role play, video 
recording and feedback, and vignettes. A workbook has been developed to accompany 
the delivery of the training.  
 
The first training programme was run on one day a week for five weeks at the end of 
2008. It was delivered by the CNS and members of the multidisciplinary teams within 
the Central Mental Hospital. Participants were assessed using formative evaluation 
tools, such as questions and answers and three short written assignments. The course 
was evaluated using the following: pre- and post-test evaluation, daily evaluation by the 
participants, and a focus group carried out 12 weeks after the course completion.  
 
The programme co-ordinators envisage running an annual one-day refresher course.  
 
Review of progress in addressing suicide in Ireland 
A Joint Oireachtas sub-committee 8 was established in 2005 to examine in detail the 
issue of suicide in Irish society; to engage with those who work in suicide prevention; 
and to hear evidence from those involved in post-suicide counselling and support.  
According to the World Health Organization, suicide is among the three leading causes 
of death worldwide among people in the 15–44-year-old age bracket.  In 2004, there 
were 27.1 deaths/100,000 population among men in Ireland, compared to 6.1 in 
England.  For females the rate was 2.9/100,000 population, compared to 1.7 in 
England.  Youth suicide rates in Ireland are the fifth highest in the European Union.     
 
The sub-committee‟s report, The high level of suicide in Irish society, was published in 
2006 (Joint Committee on Health and Children 2006) and accepted for implementation.  
It provided detailed information on the extent of suicide in Ireland and made 33 specific 
recommendations on how to address the problem.  An updated report by a new sub-
committee, published in June 2009 (Joint Committee on Health and Children 2009), 
reviewed the extent to which these recommendations had been implemented, and 
identified the obstacles that had prevented their implementation. The recommendations 
and progress as at mid 2009 were listed in Table 7.2.1 of the 2009 National Report 
(Alcohol and Drug Research Unit 2009). A brief summary is provided here. 
 
Very limited or no substantial progress was reported on implementing those 
recommendations dealing with the building of evidence around suicide through 
research and information gathering.  These recommendations include agreement on a 
national programme of research into self-harm, suicide and suicide prevention and the 
publishing of suicide research guidelines for donors providing funding.   
 
Similarly little progress was reported regarding recommendations on making more 
information available to people at risk of suicide, to the general population, to specific 
groups such as school children, and to groups and individuals who could play a role in 
suicide prevention such as teachers, voluntary organisations, primary care teams and 
mental health staff.  However, there was some progress in the organisation of 
consultation with young people and in the provision of information by primary care 
services to those bereaved by suicide.   
 
More progress was achieved in the development of services such as a pilot fast-track 
referral systems from primary care to mental health services for suicidal individuals and 
the development of a service plan for bereavement services.  Other recommended 
services, including a coordinated response from various voluntary agencies working in 
                                               
8
 A Joint Oireachtas Committee comprises the select committees of both Houses of the Oireachtas 
(Parliament), i.e. Senate and Dáil.  
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the area of suicide bereavement support and a standardized pre-discharge and 
transfer between mental health services, have not been developed. 
 
The sub-committee that compiled the 2009 report concluded that the few 
recommendations that had been completed or mostly completed now needed financial 
resources and political drive in order to develop and implement their findings.  The 
report concluded that immediate change was required to properly address the ongoing 
serious problem of suicide in Ireland.  The National Office for Suicide Prevention 
needed adequate and sustained funding, a higher level of interagency collaboration, 
and the requisite political support if it was to have any chance of fully implementing the 
recommendations made in the 2006 Oireachtas report.   
 
Management of neonatal abstinence syndrome: a national survey and review of 
practice 
O‟Grady and colleagues (O'Grady, et al. 2009) reviewed the present management of 
neonatal abstinence syndrome (NAS) in neonatal units in the UK and Ireland. They 
posted a questionnaire to 235 neonatal units, with telephone follow-up of non-
respondents. The response rate was 90% (211/235), and 96% (190/211) of 
respondents had a formal NAS guideline. The median number of infants treated 
annually for NAS was six (range 1–100). The method of Finnegan was the most widely 
used scoring system (52%) for the UK and Ireland combined and 93% for Ireland. 
Morphine sulphate was the most commonly used first line agent for both opiate (92%) 
and polysubstance (69%) withdrawal. Phenobarbitone was used as a first line therapy 
in 62% of units based in Ireland. Dosing regimens varied widely. Units using a 
maximum daily morphine dose of <400 microg/kg/day were more likely to require the 
addition of a second agent (76% vs 58%, p = 0.027). Phenobarbitone was the drug of 
choice to treat seizures secondary to both opiate and polydrug withdrawal in 73% and 
81% of units, respectively. Fifty-seven (29%) units allowed infants to be discharged 
home on medication; of these, 58% allowed administration of opiates in the community 
and in almost half of cases, this was managed by a parent. Mothers on methadone 
whose serology was positive for hepatitis B and/or hepatitis C were four times more 
likely to be discouraged from breastfeeding. Over half (55%) of the units had a liaison 
midwife. The majority of units currently use an opiate as the drug of first choice as 
recommended. Doses utilised and second agents added vary significantly between 
units. According to the authors, many of the findings reflect the lack of high-quality 
randomised studies regarding management of NAS. 
 
Alcohol and drug screening of occupational drivers for preventing injury 
A review was undertaken with the objective of assessing the effectiveness of alcohol 
and drug screening of occupational drivers who operate motorised vehicles, in 
preventing injury or work-related effects such as sickness absence related to injury 
(Cashman, et al. 2009).  
 
Studies included in this review were selected from among the following:  randomised 
controlled trials (RCTs), cluster-randomised trials, controlled clinical trials, controlled 
before and after studies (more than three time points to be measured before and after 
the study) and interrupted time-series (ITS) studies that evaluated alcohol or drug 
screening interventions for occupational drivers (compared to another intervention or 
no intervention) with an outcome measured as a reduction in injury or a proxy measure 
thereof. 
 
Two review authors independently extracted data and assessed study quality. Authors 
of the included studies were contacted for further information. 
 
The review authors included two interrupted time-series studies conducted in the USA. 
One study was conducted in five large US transportation companies (n = 115,019) that 
carried passengers and/or cargo. Monthly injury rates were available from 1983 to 
1999. In the study company, two interventions of interest were evaluated: mandatory 
random drug testing and mandatory random and for-cause alcohol testing 
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programmes. The third study focused only on mandatory random drug testing and was 
conducted on federal injury data that covered all truck drivers of interstate carriers. 
Results were recalculated from raw data provided by the study authors. Following re-
analysis, it was found that in one study mandatory random and for-cause alcohol 
testing was associated with a significant decrease in the level of injuries immediately 
following the intervention (-1.25 injuries/100 person years, 95% CI -2.29 to -0.21) but 
did not significantly affect the existing long-term downward trend (-0.28 injuries/100 
person years/year, 95% CI -0.78 to 0.21). 
 
Mandatory random drug testing was significantly associated with an immediate change 
in injury level following the intervention (1.26 injuries/100 person years, 95% CI 0.36 to 
2.16) in one study, and in the second study there was no significant effect (-
1.36/injuries/100 person years, 95% CI -1.69 to 0.41). In the long term, random drug 
testing was associated with a significant increase in the downward trend (-0.19 
injuries/100 person years/year, 95% CI -0.30 to -0.07) in one study, the other study 
was also associated with a significant improvement in the long-term downward trend (-
0.83 fatal accidents/100 million vehicle miles/year, 95% CI -1.08 to -0.58). 
The authors concluded that there was insufficient evidence to advise for or against the 
use of drug and alcohol testing of occupational drivers for preventing injuries as a sole, 
effective, long-term solution in the context of workplace culture, peer interaction and 
other local factors. Cluster-randomised trials are needed to better address the effects 
of interventions for injury prevention in this occupational setting. 
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8. Social Correlates and Social Reintegration 
8.1  Introduction 
The links between social exclusion and drug use in Ireland have been well established 
(Keane, Martin 2007).  Problem drug users in treatment tend to be young and male, 
have low levels of education and are unlikely to be employed. For a small proportion, 
around 10%, homelessness and insecure accommodation are persistent problems. In 
recent times there has been a modest increase in the proportion of other nationalities 
seeking treatment (Reynolds, et al. 2008). Research also shows that there are 
problems with illicit drug use among socially-excluded groups such as sex workers, 
homeless people and new communities.  
 
The aim of social reintegration is to empower individuals to plan and pursue alternative 
activities to those they engaged in when using drugs. It achieves this through providing 
accommodation, education, training and employment opportunities for recovering drug 
users.  
 
This chapter presents new data on the social correlates of drug use in Ireland, and 
describes policy and programmes initiated in the past year to support the social 
reintegration of recovering drug users. The broad policy approach and funding to 
support social reintegration are briefly outlined in this section. 
 
The National Drugs Strategy (interim) 2009–2016 (NDS) (Working Group on drugs 
rehabilitation 2007) lists as a priority the implementation of the recommendations 
contained in the report of the Working Group on Drugs Rehabilitation. It proposes that 
the recommendations be incorporated in a comprehensive integrated national 
treatment and rehabilitation service, using a four-tier model approach.  
 
The Homeless Agency, a non-statutory agency, jointly funded by the Department of 
the Environment, Heritage and Local Government (DEHLG) and the Health Service 
Executive (HSE) to plan, manage and co-ordinate services to tackle homelessness in 
the Dublin area, has been identified as a key player in developing an integrated 
national treatment and rehabilitation service for problem drug users. The Agency made 
a detailed submission to government with regard to the new national strategy on 
homelessness, The way home (Department of the Environment Heritage and Local 
Government 2008a), which has been described as „a blueprint for change‟. It is about 
creating the conditions for change to realise the aim of eliminating long-term 
homelessness and the need to sleep rough in Dublin: it forms the basis for reorienting  
homeless services towards a „pathways to housing‟ approach, also known 
internationally as the „housing first‟ policy. The Homeless Agency points out that the 
housing first policy does not mean „housing only‟: a variety of services are needed to 
promote housing stability and individual well-being, using means such as the assertive 
community treatment model or case management.  
 
The Community Employment (CE) scheme, funded by FÁS, the national training and 
employment authority, includes 1,000 places ring-fenced for recovering drug users. 
The scheme operates through local projects primarily in LDTF areas, where community 
and voluntary groups are required to sign service agreements that outline the work 
programme and the target outcomes for the individuals placed on the CE schemes. 
The objective is to prepare participants for entry into the labour force, but the outcomes 
outlined by most projects tend to refer to personal development, improved literacy skills 
and education capital, and support progression to more specialised training and 
education, rather than help the individual to find employment.  
 
Acknowledging the CE scheme for helping recovering drug users to develop their 
personal and employment skills and find a pathway back to work, the NDS suggests 
that implementation of the Individual Learner Plan (ILP) would help to identify 
participants‟ needs and design progression routes towards labour market reintegration.  
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The development of targeted programmes by FÁS is seen as essential and should be 
an integral part of the national drugs strategy in the future.  
 
In 2007 the Family Support Network (FSN), established in 2000 under the auspices 
of Citywide Drugs Crisis Campaign, gained recognition as an autonomous national 
organisation. It aims to improve the situation of families coping with drug use by 
developing, supporting and reinforcing the work of family support groups and regional 
family support networks, by working for positive change in policy and 
practice and by raising public awareness about the problem of drugs for families and 
communities. It is funded through the Office of the Minister for Drugs (OMD) and the 
Family Support Agency of the Department of Social Protection. In addition, over 100 
Family Resource Centres (FRCs) throughout the country, also funded by the Family 
Support Agency, while not having a specific remit to tackle problematic alcohol or drug 
use, provide support to families experiencing such problems. 
 
 
8.2 Social exclusion and drug use 
8.2.1 Social exclusion among drug users 
Early school-leaving among individuals reporting for drug treatment increased between 
2004 and 2008 (Carew, A.M. 2010b). The increases are modest, up 1% for all cases 
entering treatment and less than 1% for new cases (Table 8.2.1.1).  
 
A large number of targeted interventions in high-risk communities, which aim to prevent 
and/or reduce early school-leaving among at-risk youth, are delivered in schools and in 
community settings in local drug task force areas, which have been identified in the 
past on the basis of their acute levels of heroin use. However, as Table 8.2.1.2 shows, 
early school-leaving among individuals presenting for treatment and reporting opiates 
as their main problem substance increased by just over 2% for all cases between 2002 
and 2007 (Carew, Anne Marie, et al. 2009).  
 
The proportion of individuals presenting for drug treatment (including previously treated 
and new cases), who were also experiencing homelessness, increased between 2004 
and 2008 (Table 8.2.1.1).  Between 2002 and 2007, the proportion of those presenting 
for treatment with opiates as their main problem drug and experiencing homelessness 
almost doubled (Table 8.2.1.2). This data suggests that although the numbers may be 
small, homelessness among individuals in treatment for problem drug use remains an 
important issue to tackle.  
 
Table 8.2.1.1 Socio-demographic characteristics of cases entering treatment, by treatment status, 
NDTRS 2004–2008 
Characteristics 2004 
n (%) 
2005  
n (%) 
2006  
n (%) 
2007  
n (%) 
2008  
n (%) 
All cases  entering 
treatment 
     
Homeless 197 (4.4) 217 (4.4) 265 (5.1) 279 (4.9) 351 (5.6)  
Early school leavers 892 (19.8) 986 (20.2)  1040 (20.0)  1132 (19.9)  1303 (20.8)  
Previously treated cases      
Homeless 136 (5.3) 155 (5.6) 156 (5.6) 177 (5.7) 243 (7.0) 
Early school leavers 599 (23.4) 685 (24.8) 660 (23.7) 735 (23.8) 871 (25.1) 
New cases      
Homeless 52 (2.9) 54 (2.7) 103 (4.6) 90 (3.7) 99 (3.7) 
Early school leavers 264 (14.7) 274 (13.9) 339 (15.2) 366 (15.1) 410 (15.4) 
Source: Carew, 2010b 
 
 
Table 8.2.1.2 Socio–economic characteristics of cases entering treatment who reported opiates as 
their main problem substance, by treatment status, NDTRS 2002–2007 
Characteristics 2002  
n (%) 
2003 
n (%) 
2004 
n (%) 
2005 
n (%) 
2006 
n (%) 
2007 
n (%) 
All cases  entering 
treatment 
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Characteristics 2002  
n (%) 
2003 
n (%) 
2004 
n (%) 
2005 
n (%) 
2006 
n (%) 
2007 
n (%) 
Homeless 91 (3.0) 146 (4.8) 153 (5.3) 171 (5.5) 182 (5.5) 196 (5.5) 
Early school leavers 686 
(22.3) 
712 
(23.5) 
666 
(23.3) 
754 (24.4) 779 (23.8) 875 (24.5) 
Previously treated cases       
Homeless 61 (2.8) 101 (4.6) 119 (5.6) 133 (5.8) 124 (5.5) 145 (6.0) 
Early school leavers 502 
(23.0) 
514 
(23.5) 
514 
(24.4) 
584 (25.6) 564 (25.2) 633 (26.3) 
New cases       
Homeless 26 (3.4) 39 (5.1) 26 (4.0) 32 (4.4) 54 (5.9) 42 (4.1) 
Early school leavers 165 
(21.7) 
185 
(24.4) 
134 
(20.5) 
149 (20.6) 182 (20.0) 219 (21.2) 
Source: Carew et al,  2009 
 
8.2.2 Drug use among socially excluded groups 
Substance use among children subject to an application for an order of special 
care  
The Child Care Act 1991 provides for a statutory special care scheme, whereby a court 
can make a special care order if it is satisfied that the behaviour of a child aged 
between 12 and 17 years poses a real and substantial risk to his or her health, safety, 
development or welfare. The order of the court involves the detention and secure 
placement of the child in a special care unit under the management of the HSE. In a 
recently-published report (Brierley 2010), the author examined data on the 
characteristics of 70 applications for special care orders in 2007; 59% (n=41) were 
female and 41% (n=29) were male. The author pointed out that although „special care 
units are not intended to deal with children who require medically supervised 
detoxification for drug misuse...most children who were subject to an application for 
special care in 2007 had problems in this area. 79% of the applications (n=55) 
identified alcohol and/or substance misuse as a risk factor, the largest single category 
against the criteria for „real and substantial risks to self‟‟ ‟(page 37). The author noted 
that the nature of the substance misuse was often unclear in the data recorded in the 
application documentation. To explore this issue further, the author sought to match the 
limited amount of data in the application documents with information gathered through 
interviews with social workers (n=41). The collated data suggested the following 
substances associated 55 applications: 
 alcohol use in 45 (28 females; 17 males) 
 cannabis use in 34 (19 females; 15 males)  
 ecstasy in 15 (12 females; 3 males)  
 cocaine in 13 (female = 10; male = 3)  
 prescription drugs in 13 (8 females; 5 males) 
 heroin in 10 ( 9 females; 1 male) 
 
Regarding the greater proportion of females than males recorded in the data, the 
author noted that there had been 41 applications for females, with 25 gaining 
admission, compared to only 29 applications for males, of whom only 7 were admitted. 
The author observed: „Special care appears to cater more for the needs of females 
than the needs of males‟ (page 106). He also highlighted what appeared to be a 
significant gap in service provision for children using heroin: „Those using heroin were 
less likely to be admitted to special care than those using other substances... this may 
suggest that children whose behaviour is concerning but who are also misusing heroin 
are not receiving a sufficiently joined-up service from the various agencies involved‟ 
(page 37). 
 
Homelessness among children subject to an application for an order of special 
care 
In the same report described above regarding substance use among children subject to 
an application for an order of special care (Brierley 2010), the author also reported that 
only 38% (5/13) of the applications for special care orders for children at risk of youth 
homelessness were successful. By November 2009, of the 16 individuals who had 
either been at risk of homelessness at the time of the application or who had become 
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at risk of homelessness in the intervening period, 56% (n=9) had overall risk factors 
that either worsened or were a new feature, and 75% (n=12) had experienced 
homelessness after the application. According to the author, „this suggests that the 
needs of children who are at acute risk who have experienced homelessness are not 
being addressed adequately‟ (page vi).  
 
To conclude, the report highlighted the apparent gap in services for children with 
potentially problematic substance use issues and homelessness. However, these were 
only two of the many risk factors that these children presented with. According to 
Brierley, „When the application [for an order of special care] was made, the 
combination of risk factors was so acute that in many situations the social work 
department even feared for the child‟s life. ...The child‟s behaviour was perceived as 
being out of control‟ (page 57). 
 
Substance use among children presenting to the Child and Adolescent Mental 
Health Service  
In November 2008 a month-long survey of children and young people aged 0–17 seen 
by the community-based Child and Adolescent Mental Health Service (CAMHS) teams 
was undertaken (Health Service Executive 2009). This was the first fully 
comprehensive survey of the age and gender of children and the mental health 
problems they were presenting with. The primary presentations of 6,629 cases were 
recorded; only one disorder/problem was entered for each case.  
 
As the data in Table 8.2.2.1 show, the prevalence of substance use among these at-
risk young people is quite low, with less than 1% of cases presenting with substance 
misuse. Drugs played a minor role in cases presenting with drug-induced psychosis 
(1.2%) and with deliberate self-harm through drug/medications or alcohol overdose 
(4.6%). Perhaps the low prevalence rates of substance use observed among these 
children can be explained by reference to the methods of data collection. The CAMHS 
teams records the primary disorder/problem that each case presented with, meaning 
that those with substance misuse as a secondary or related issue were not captured in 
this data set. Also, it is possible that children with substance misuse problems did not 
present to CAMHS but to other services.  
 
Table 8.2.2.1: Mental health disorders/problems among children presenting to the CAMHS, 
November 2008 
Disorder/Problem Prevalence 
Hyperkinetic disorders/problems, e.g. ADHD 1,925 (29.1%)cases 
Emotional disorders/problems, e.g. anxiety, depression 1,734 (26.3%) cases 
Conduct disorders/problems, e.g. aggression, anti-social behaviour 617 (9.3%) cases 
Eating disorders/problems, e.g. pre-school eating problems, anorexia nervosa, 
bulimia nervosa 
159 (2.4%) cases 
 
Psychotic disorders/problems, e.g. manic depressive disorder, drug-induced 
psychosis 
81 (1.2%) cases 
Deliberate self harm, e.g. lacerations, drug/medication and alcohol overdose 328 (4.6%) cases 
Substance abuse, e.g. drug and alcohol misuse 37 (0.6%) cases 
Habit disorders/problems, e.g. sleeping problems 64 (1%) cases 
Autistic spectrum disorders/problems  608 (9.1%) cases 
Developmental disorders/problems referred to delay in acquiring certain skills such 
as speech, and social abilities 
325 (4.9%) cases 
 
Gender role / identity disorder/problems  10 (0.2%) cases 
Source: Health Service Executive, 2009 
 
Substance use and related problems among homeless people in Cork 
The Cork Simon Community, which works with homeless people, undertook a health 
audit of clients using the service in the first week of September 2009 (Cork Simon 
Community 2009).  A total of 183 individuals were supported by services during the 
week; 86% were male, 87% had a medical card, and 63% were in receipt of a social 
welfare disability allowance.   
 
Table 8.2.2.2 gives a profile of clients by type of service used, health status and 
substance use. Individuals using high-support accommodation were more likely to have 
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a diagnosed physical or mental health condition; this entire group had medical cards, 
and had the highest proportion of people receiving disability benefit. Rates of alcohol 
use were relatively high among all service users. 
 
Table 8.2.2.2 Health profile of users of Cork Simon services, September 2009  
Service No of 
clients 
Diagnosed physical 
condition 
n (%) 
Diagnosed 
mental condition 
n (%) 
Alcohol use 
n (%) 
Drug use 
n (%) 
Emergency 
Shelter 
55 21 (38) 20 (36) 43 (78) 24 (44) 
High Support (5 
houses) 
43 37 (86) 34 (86) 37 (86) 20 (47) 
Housing Plus * 79 28 (35) 28 (35) 64 (81) 25 (32) 
*Includes Simon and Galton flats for independent living (38 clients), private rented accommodation (21 clients), council 
accommodation (7 clients), and „other‟ (13 clients) 
Source: Cork Simon Community, 2009 
In the week of the health audit, 36% (n=20) of the residents in the Emergency Shelter 
were long-term homeless, defined as being in emergency accommodation for more 
than six months.  All 20 were male; 80% had a medical card; 60% were receiving a 
disability payment; 55% had at least one diagnosed physical health condition; 55% had 
at least one diagnosed mental health condition; 90% used alcohol and 55% used 
drugs; 55% had a diagnosed mental health condition and used alcohol and/or drugs.   
During the week of the audit, 16 people were recorded as sleeping rough for at least 
one night, and six of these were consistent rough sleepers. Fifteen were male; 50% 
had a medical card; 31% were in receipt of a disability payment; 56% had a diagnosed 
physical health condition; 44% had a diagnosed mental health condition; 81% used 
alcohol and 56% used drugs; 44% had a diagnosed mental health condition and used 
alcohol and/or drugs.  
 
The data paint a picture of homeless people in Cork as having poor physical and 
mental health, high dependence on social welfare payments, relatively high levels of 
alcohol and drug use and, for some, unstable accommodation. The relatively high 
prevalence of substance use among people who are long-term homeless and/or 
sleeping rough may exacerbate their situation and prolong their experience of 
homelessness. Individuals presenting with diagnosed mental health conditions who are 
substance users are also a concern.  
 
On a slightly brighter note, among the people who are being helped with independent 
living, the outcomes are less severe, as this group reports lower levels of heavy alcohol 
use and lower levels of drug use and heavy drug use compared to people in 
emergency accommodation.  
 
Health of the homeless in Dublin 
O‟Carroll and O‟Reilly (O‟Carroll and O‟Reilly 2008) undertook a census of homeless 
adults living in temporary accommodation (10 hostels and 12 B&Bs) in north Dublin city 
in 2005, using an interviewer-administered questionnaire. In total, 356 people were 
interviewed about their health status, risk behaviours and use of services, and the 
responses were compared with those given eight years earlier.  
 
Compared to 1997, the census population of 2005 was younger and contained a higher 
proportion of women. In 2005, a higher proportion was homeless for longer. Women, in 
particular, were remaining homeless for longer: in 2005, 58% of women reported being 
homeless for a year or longer, compared to 5% in 1997. In 2005, 69% of respondents 
had children, with only 20% reporting that the children were currently living with their 
parents. Depression and anxiety levels had increased since 1997, and there was a 
sharp increase in morbidity (Table 8.2.2.3). 
 
Table 8.2.2.3 Socio-demographic profile and health status of homeless people, Dublin, 1997 and 
2005  
Characteristic 1997  ( n=192) 2005 (n=356) 
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Characteristic 1997  ( n=192) 2005 (n=356) 
Age (under 45) 70% 81% 
Homeless for 1 year or longer 44% 66% 
Gender (female) 29% 39% 
Drug use (current use or past use) 32% 64% 
Morbidity (presence of a mental or physical health 
problem) 
65% 84% 
Depression 35% 51% 
Anxiety 32% 42% 
Source: Adapted from O‟Carroll and O‟Reilly, 2008 
 
The most significant difference between 1997 and 2005 was that drug addiction had 
more than doubled and superseded alcohol as the main addiction among the homeless 
population. In 2005, 48% of those reporting drug use had used or were current users of 
heroin and 55% had injected heroin; there were high rates of blood-borne infections, 
such as HIV (6%), hepatitis B (5%) and hepatitis C (36%); and drug and alcohol 
addiction (39%) was the main reason given for becoming homeless. Access to free 
healthcare had not increased between 1997 and 2005 and homeless people continued 
to make greater use of secondary care services than the general population.  
 
Risk and protection factors for substance use among young people  
Haase (Haase and Pratschke 2010) estimated drug use among 479 early school 
leavers and 512 school attendees, aged 16–18 years, and identified risk and protection 
factors for substance use. Data were collected throughout Ireland during two periods: 
March–May and September–December 2008. For information on the methodology and 
data relating to drug use prevalence, see Chapter 2.3.1. 
 
The data showed strong statistical associations between the use of different 
substances. For both early school-leavers and students attending school, having tried 
cigarettes was a strong predictor of drinking alcohol and using cannabis. Having drunk 
alcohol at least once predicted having smoked cigarettes. For students attending 
school, having used cannabis increased the likelihood of using other drugs and having 
dabbled in „other‟ drugs increased the likelihood of using cannabis.  
 
The authors analysed the relationship between drug use and other factors using multi-
level models. The main relationships are highlighted below.  
 
Personal characteristics and attitudes 
Age had a small influence on drug use. Among both school attendees and early school 
leavers, alcohol consumption increased with age, particularly among  those who had 
reached the age of 18. Gender had no influence on alcohol, tobacco or other drug use. 
Ethnicity influenced alcohol consumption and cannabis use among early school-
leavers. Travellers and non-white ethnic minorities were less likely to use alcohol and 
cannabis than white Irish early school-leavers. Ethnicity had no influence on alcohol, 
tobacco, cannabis or other drug use among students attending school.  
 
Low self-concept, or self-esteem, increased the likelihood of smoking cigarettes among 
early school-leavers and school attendees. Aggressive „acting-out‟ behaviour was 
associated with use of alcohol, cannabis and other drugs among early school leavers 
and school attendees. Low self-esteem and aggressive behaviour are risk factors for 
drug use. 
 
Among both early school-leavers and school attendees, having a girlfriend or boyfriend 
increased the likelihood of smoking cigarettes. 
 
Parents and home 
Parental involvement with and concern for their children were protective factors for 
alcohol and drug use, although these influences appeared to affect different substance 
classes in each of the two groups. For school-attending students, parental concern 
reduced the likelihood of drinking alcohol and the risk of using drugs other than 
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cannabis. For early school-leavers, parental concern reduced the likelihood of drinking 
alcohol and using cannabis. Parenting had little effect on smoking in both groups. 
 
Substance use by either parents or siblings increased the risk of a young person using 
the same substance. If a parent or sibling smoked or used cannabis, there was an 
increased likelihood that the early school-leaver and school student would smoke 
cigarettes or use cannabis. If a parent or sibling drank alcohol or used other drugs, 
there was an increased likelihood that the school attendee would do likewise.   
 
Training centre or school 
Factors relating to the centre or school attended by the respondent were measured at 
the individual level and at the level of the educational establishment. The latter data 
were collected through a separate questionnaire completed by the staff of the school or 
training centre.  
 
If a school student had a positive relationship with supportive teachers or had a positive 
school experience, this had a large protective effect, reducing the risk of drinking 
alcohol, using cannabis or other drugs. However, it had no effect on the likelihood of 
smoking cigarettes. No protective effects were detected among the early school-
leavers attending training centres. From these observations, the authors concluded two 
things. Firstly, the relationship between these aspects of the school experience and 
substance use was likely to involve reciprocal effects. Students who had a satisfying 
and enjoyable school experience were less likely to use substances, and those who did 
not use substances were more likely to have a good relationship with teachers and 
school. Secondly, this effect was remarkable by its absence amongst early school-
leavers, suggesting that those who had left school early were relatively homogeneous 
in relation to this characteristic. They were, logically, young people who did not have a 
good experience at school or a good relationship with teachers. 
 
Small protective effects were identified in relation to the educational establishment. The 
provision of drug awareness and information sessions for staff working in training 
centres reduced the likelihood that early school leavers used cannabis or other drugs. 
Early school-leavers with unmet counselling needs, who attended training centres, 
reported higher alcohol consumption than those who did not have unmet counselling 
needs. Within the school sector, the number of substance use classes or information 
sessions for parents was associated with a lower risk of cigarette smoking among 
students attending school. 
 
Peer group 
Substance use among the peer group was a risk factor for both early school-leavers 
and students attending school. If most of the interviewee‟s friends smoked cigarettes, 
drank alcohol, used cannabis or used other drugs, there was a greater likelihood that 
he or she would do likewise. The authors stated that it was equally possible that young 
people chose their friends partly on the basis of substance use behaviour or on the 
basis of factors causally related to substance use. 
 
Smoking cigarettes was not affected by ease of access, indicating that access to 
cigarettes did not affect smoking rates among early school-leavers and students 
attending school. Early school-leavers did not report that access to alcohol influenced 
their alcohol consumption. Interestingly, however, ease of access to alcohol increased 
the likelihood of drinking alcohol for those still attending school. Use of cannabis and 
other drugs was significantly higher where access was easier for both early school-
leavers and students attending school. Ease of access to alcohol and other drugs 
(except tobacco) increased consumption and is therefore a risk factor.  
 
Neighbourhood 
The influence of factors related to the neighbourhood was comparatively small. The 
neighbourhood relationships identified were not easy to explain and may mask other 
unanswered questions.   
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Conclusion 
This study identified a number of risk and protective factors which increase or decrease 
the risk of using substances among 15–18 year-olds in Ireland. The authors concluded 
that if attention were focused on factors amenable to change, the most important 
conclusion would be that both the family (the young person‟s parents in particular) and 
the educational institution could have a major impact on the young person‟s decision 
with regard to substance use. In addition, access to alcohol and other drugs increases 
the likelihood of their being used, and this is a factor that society as a whole can 
address.  
 
Substance use among children at risk of suicide 
McNicholas and colleagues (McNicholas, et al. 2010) undertook a study of all children 
(n=197) presenting to an acute paediatric hospital in Dublin with deliberate self-harm 
(DSH) or suicidal ideation between 1993 and 2003. The ages of those in the sample 
ranged from 6 to 16, and three quarters were female. Among the 93% (n=183) who 
were admitted for DSH, overdose was the method used by 81% (n=160). The study did 
not discuss the nature of overdose, but 8% (n=16) of the whole sample had ingested 
alcohol prior to admission. The study found that of the 172 children for whom the time 
of presentation at the hospital was recorded, 80% (n=137) had presented outside 
normal working hours, i.e. 9 am to 5 pm, Monday to Friday; 57% (n=98) of those 
presenting outside normal working hours had presented between 7 pm and 7.30 am . 
According to the authors, „These children represent an at-risk group, and were more 
likely to have consumed alcohol, to have made a suicide attempt, and to have a family 
history of psychiatric illness compared with children presenting within “normal working 
hours”...access to an out of hours on-call Child and Adolescent Psychiatry service is 
essential...‟ (page 11). 
 
8.3 Social reintegration 
In line with the recommendations outlined in the report of the Working Group on Drug 
Rehabilitation (Working Group on drugs rehabilitation 2007), a National Drugs 
Rehabilitation Framework has been published (Doyle and Ivanovic 2010). Approved by 
the National Drugs Rehabilitation Implementation Committee (NDRIC), this Framework 
has been constructed to enhance the provision of rehabilitation services to current and 
former drug users by creating integrated care pathways (ICPs) with the cooperation of 
different service providers. It is recognised that service users may present with diverse 
needs, including treatment, education, vocational training, employment support and 
accommodation, and that no single agency can cater for all possible needs. An 
individual care plan will be developed for each service user, and will be delivered by a 
multi-disciplinary team comprising the necessary range of disciplines and skills drawn 
from a variety of service providers. Where a service user has complex and multi-
faceted needs, a more intensive case management approach may be used. According 
to the authors of the Framework, ‘The provision of rehabilitation pathways is a shared 
responsibility of the education, training and employment sectors alongside the health, 
welfare and housing sector, non-governmental organizations, communities, families 
and the individual themselves‟ (page 7).  
 
The ICP will comprise four steps, which will be linked to the 4-tier model of service 
provision:  
1. Initial contact (Tier 1 services): Screening and referral, using a brief intervention 
screening instrument. 
2. Initial Assessment and Identification of Appropriate Service (Tier 2 services 
upwards): Matching person to service – the aim is to determine the seriousness 
and urgency of the drug/alcohol problem. 
3. Comprehensive assessment – key working and care planning (Tier 3 services 
upwards): Matching services to the person, i.e. identifying appropriate services for 
service users with more complex needs. Following the comprehensive assessment, 
a case manager will be identified, who will support the individual on their 
rehabilitation pathway. 
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4. Implementation of the care plan to support an individual rehabilitation pathway. 
 
Services drawn from the 4-tier model of service provision will be characterised by the 
following attributes:  
 Settings may include general healthcare, structured drug treatment, community-
based specialist addiction services, and residential detoxification and treatment 
followed by supported step-down accommodation as part of aftercare.  
 Services may include information and advice, brief interventions, methadone, harm 
reduction and therapeutic interventions.  
 Target groups may range from those experimenting with drugs to those with drug-
related problems and dependence.  
 
The development of a competent workforce in the addiction services will be supported 
and maintained through the development of a quality standard framework. The national 
standards for drug and alcohol treatment services that have been agreed by the Health 
Service Executive (HSE) are the Quality in Alcohol and Drug Services (QuADS) 
organisational standards. See Chapter 5.x.x for a report on progress in introducing the 
quality standard framework. 
 
The NDRIC has responsibility for developing national protocols and service-level 
agreements (SLAs) to facilitate the implementation of the National Drugs Rehabilitation 
Framework. The NDRIC is currently piloting the integrated care pathway model at 
regional/local level, with a view to informing the development of the protocols (National 
Drugs Rehabilitation Implementation Committee 2010). The objectives of the pilot 
projects are to:  
 support the implementation of the National Drugs Rehabilitation Framework and 
integrated care pathways model in line with the recommendations of the Report of 
the Working Group on Drugs Rehabilitation,  
 build awareness and knowledge of the National Drugs Rehabilitation Framework 
amongst key stakeholders,  
 identify progress in implementation,  
 identify gaps in services and drivers/obstacles in respect of implementation,  
 assess the initial impact of the Framework, and 
 help to clarify roles and inform implementation of the Framework.  
 
8.3.1 Housing 
The Homeless Agency has published a case management guidebook for those working 
in the area of homelessness and drugs (Homeless Agency Partnership and 
Progression Routes Initiative 2010) The purpose of the guidebook is to provide 
comprehensive information, guidance and support to key workers, case managers and 
line managers working in the field of homelessness and drugs. It is divided into three 
sections – key support interventions, interagency protocols and listings.  
Twelve key support interventions are described, including:  
 accommodation/homelessness  
 family and current relationships 
 early life experience and childhood 
 education 
 work and job training 
 legal issues/offending behaviour 
 income and finance  
 general physical health 
 mental health 
 alcohol use 
 drug use   
 independent living skills 
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Each of the chapters on support interventions lists the goals to be achieved when 
working with service users, gives an overview of the context for the services and 
supports available, and lists key supportive interventions that may be accessed.  
The guidebook also describes nine case management interagency protocols, including: 
 holistic assessment/establishing lead agency 
 referral process 
 interagency case meetings 
 confidentiality and data protection 
 gaps and blocks in services 
 grievance procedure for service users  
 grievance procedure for service providers 
 service user disengagement  
 positive case closure 
Accommodation for people in drug treatment  
There is no regular or standardised reporting on the provision of accommodation for 
people in drug treatment. Where reports are compiled regarding service provision for 
the homeless, very often they do not explicitly record what proportion of those housed 
are using drug treatment services. One exception is Merchants Quay Ireland (MQI), 
which has reported on two initiatives to support people in drug treatment to access 
appropriate accommodation (Merchants Quay Ireland 2009). 
 
The MQI Integration Programme provides transitional accommodation to drug users 
who find themselves homeless after completing residential drug treatment. The 
programme aims to assist in the integration of former drug users into mainstream 
society by providing opportunities to participate in group and one-to-one therapeutic 
sessions and activities. Transitional accommodation is provided in two houses for a 
period of up to six months. Residents are offered one-to-one counselling and support, 
an aftercare group and a weekly community night with staff. In 2008, there were nine 
clients residing in one house. Of these, six moved on to longer-term accommodation; 
two persons relapsed, although both were still reported to be linking in with services; 
and one remained in the house into 2009. The drug-free aftercare group worked with 
an average of 6–8 people each week. In the second house, there were six residents in 
the course of 2008, with five of these moving on to independent accommodation, three 
taking up further education and two taking up employment. One resident had relapsed 
but was reported to have re-engaged in treatment.  
 
The MQI Settlement Service supports clients who are seeking to exit homelessness, 
including those with a history of drug or alcohol problems. The service works with 
homeless people from a number of settings including rough sleeping, hostels, B&Bs, 
short-term arrangements with friends/families, and  transitional and supported 
accommodation. A dedicated Settlement Worker works with clients leaving residential 
drug treatment services who have no home to go to. Methods used to assist users of 
the MQI Settlement Service to find, access, and sustain appropriate long-term 
accommodation include assessment interviews, individual support plans, one-to-one 
key working sessions, group support, personal development and life skills training, 
advocacy and pre- and post-settlement support.  
 
In 2008 the Settlement Service carried out 86 assessments, and provided support to 96 
persons, working with an average of 34 service users each month. Use of services 
such as money advice services and counselling increased in 2008. The Service also 
provided assistance with repairing family breakdown among clients and support to 
access employment, education or vocational training. 
 
8.3.2 Education, training 
Development/Education Bursary Fund, Tallaght 
The Tallaght Drugs Task Force (TDTF) commissioned an evaluation of its 
Development/Education Bursary Fund (Mullan Consulting 2009).  
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Tallaght is situated to the west of Dublin and, according to the 2006 census, has a 
population of 80,000 people. The community has high levels of unemployment, early 
school-leaving and local authority housing and in 1997 a local drugs task force, the 
TDTF, was established to tackle problematic drug use in the area. In 2005, the TDTF 
established the Development/Education Bursary Fund to target (1) individuals/groups 
contributing to the work of the TDTF and (2) those recovering from drug addiction and 
returning to education.  
 
Mullan Consulting undertook a review of the relevant background documents, 
consulted with TDTF personnel and associated stakeholders, and conducted a 
telephone survey with 47 individuals who had secured funding through the bursary 
fund. The review of documentation revealed that from 2006 to 2009, an average of 
43% of people granted funding for education were recovering drug users, and an 
average of 55% were either working or volunteering in a local drugs agency. Among 
participants in the telephone survey, 36% identified themselves as recovering drug 
users when they applied for funding. The documentation review also revealed that the 
average grant per individual from 2006 to 2008 was €1,500; in 2009 this was reduced 
to just over €1,000.  
 
The information on the impacts and benefits of the course are not reported by target 
group, so the specific benefits that may have accrued for recovering drug users are not 
known. Among the 47 individuals granted funding who were interviewed by telephone, 
64% completed their education course and 32% were on schedule to complete. The 
overwhelming majority reported that the course they had undertaken had met their 
needs. Sixty per cent had progressed to other training or education, in some cases 
from certificate/diploma level to degree level. In terms of progression to employment, 
28.6% had retained their job, 12% had secured what was their first ever job or first job 
in a long time, and 26% had obtained a „better job‟. When asked to comment on their 
overall experience of their return to education, 82.6% rated it as having had a very 
positive impact. The authors noted, „a number of recovering users commented upon 
the importance of the course in terms of getting them out into the real world‟ (page 37). 
Finally, there was unanimous agreement among all non-grantees consulted that 
participation in education and training is a progression route for stabilised and 
recovering drug users. One of the recommendations of the report is that recovering 
drug users should remain the fund‟s priority target group.  
 
A similar training and education bursary fund operates in most local and regional drugs 
task force areas. The target groups that can avail of funding include recovering drug 
users. However, in most cases, the criteria for application stipulate that funding will be 
allocated to individuals wishing to pursue education through the Diploma in Drug and 
Alcohol Studies. While this approach benefits those who want to work in the addiction 
field, recovering drug users who wish to pursue education and employment outside the 
addiction field will not benefit.  
 
Vocational training supported by FÁS 
FÁS, the national training and employment authority, is responsible for providing 1,000 
ring-fenced drugs rehabilitation places on its Community Employment (CE) Scheme, to 
facilitate the vocational training needs of recovering drug users. A specially-convened 
working group recently developed a set of nine revised conditions to improve the 
operation and accessibility of the scheme (Eamonn Carey, FÁS, personal 
communication). The revised conditions include:  
 Age of entry reduced to 18. 
 Only participants identified as in rehabilitation referred for a place on the special CE 
Scheme.  (Family members/relatives affected by drugs may be eligible under the 
normal CE eligibility for a place as a Support Worker.) 
 Participants eligible for up to 3 years, based on annual renewal contracts.   
 Supervisor to participant ratio 1:7. 
 Access to quality-assured recognised certification recommended but up to 30% 
non-accredited activities allowed, pending periodic review. 
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Other enhancements introduced by FÁS, which may assist drugs rehabilitation include: 
 FÁS has piloted a module on drug awareness as part of its CE Supervisors 
Development Programme (Level 6 FETAC Award) (Miriam Conway, FÁS, personal 
communication).   
 A number of CE schemes that provide drugs rehabilitation places operate a pre-CE 
initiative, in recognition of the fact that participants may need to stabilise 
themselves and in order to determine levels of commitment, motivation and 
readiness for recovery.  
 In addition to the 1,000 ring-fenced places, FÁS has a policy of positive integration 
of participants into mainline training.  
 
Data from the MQI 2008 annual report illustrate the levels of activities and progression 
for some participants engaged in vocational training through FÁS (Merchants Quay 
Ireland 2009) Training and Work Programmes are provided by MQI in partnership with 
FÁS through the FÁS CE Scheme to prospective drugs workers, clients and post-
treatment service users. The programme provides participants with skills that enable 
them to access employment. In 2008,124 persons participated in CE programmes at 
MQI. Fifty-three completed their FÁS placement at MQI, and of these, 17 (28%) 
secured permanent employment, and two (4%) moved into full-time further education; 
20 (38%) completed an MQI residential- or community-based drugs intervention 
programme as part of their CE project. 
 
8.3.3 Employment 
See National report 2009 for most recent information (Alcohol and Drug Research Unit 
2009). 
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9. Drug-related crime, prevention of drug-related crime and 
prison 
9.1 Introduction 
This chapter presents the most recent statistical data on drug-related crime in Ireland. 
It also describes policies and programmes initiated in the past year to prevent drug-
related crime both in the community and in prisons as well as research studies on drug-
related crime, prevention and prison. In this section the data sources and types of drug-
related crimes in Ireland are described, and the approaches to preventing drug-related 
crime, both in the community and in prisons, are also briefly outlined. 
 
Since 2006 reporting crime statistics has been the responsibility of the Central 
Statistics Office (CSO). The CSO data are derived from the Garda Síochána 
computerised PULSE system (Police Using Leading Systems Effectively).  
 
The vast majority of drug offences reported come under one of three sections in the 
Misuse of Drugs Act (MDA) 1977: section 3 – possession of any controlled drug 
without due authorisation (simple possession); section 15 – possession of a controlled 
drug for the purpose of unlawful sale or supply (possession for sale or supply); and 
section 21 – obstructing the lawful exercise of a power conferred by the Act 
(obstruction). Other MDA offences regularly recorded relate to the importation of drugs 
(section 5), cultivation of cannabis plants (section 17) and the use of forged 
prescriptions (section 18).  
 
Driving under the influence of drugs (DUID) has been a statutory offence in Ireland 
since the introduction of the 1961 Road Traffic Act. The principal legislation in this area 
is contained in the Road Traffic Acts 1961 to 2002. Section 10 of the Road Traffic Act 
1994 prohibits driving in a public place while a person is under the influence of an 
intoxicant to such an extent as to be incapable of having proper control of the vehicle. 
Intoxicants are defined as alcohol or drugs and any combination of drugs or of drugs 
and alcohol. Although penalties for driving under the influence of alcohol are graded 
according to the concentration of alcohol detected, the law does not set prohibited 
concentrations for drugs. Neither does it distinguish between legal and illegal drugs. 
Tests to identify the level of impairment can only take place where there is a 
reasonable suspicion that an offence is being committed. 
 
In reading the tables in this chapter, please note that ‘relevant proceedings’ refer to 
the legal proceedings, such as prosecution, taken in relation to an offence as it was 
originally recorded in the PULSE system. ‘Proceedings’ is a list of charges and 
proceedings which do not necessarily relate to an offence as originally recorded in the 
PULSE system. 
 
Over and above the „inherent‟ drug crimes, that is crimes under the Misuse of Drugs 
Acts or the Road Traffic Acts, „non-inherent‟ drug crimes are also recorded in Ireland, 
for example acquisitive crime to pay for drugs, crimes of intimidation and violence 
inflicted by drug gangs, money laundering, smuggling or other finance-related crimes, 
or public nuisance. However, they are not reported in this chapter as it is not possible 
to separate those associated with the operation of the illicit drug market from those not 
associated with illicit drugs. 
 
Crime prevention in Ireland proceeds on several fronts. Tackling community 
disadvantage is one important approach. Disadvantage in communities is recognised 
as a risk factor in contributing to, among other things, the spread of drug-related crime. 
A wide range of national initiatives exist to tackle disadvantage and its consequences, 
including community and local development programmes, the RAPID and CLAR 
programmes, and targeted urban regeneration projects. These initiatives all contain 
components relating specifically to illicit drugs. Specifically in relation to the drug 
problem, in 1998 local drugs task forces (LDTFs) were established in areas identified 
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as having the highest concentrations of drug misuse; without exception, these areas 
were all also experiencing high levels of disadvantage. The purpose of the LDTFs is to 
co-ordinate local action plans in relation to curbing local supply as well as treatment, 
rehabilitation, education and prevention.  A central feature of the LDTFs is that as well 
as co-ordinating the provision of services locally, they also allow local communities and 
voluntary organisations to participate in the planning, design and delivery of services.  
Diversion is another important means of seeking to prevent crime including drug-
related crime – both before, and after, a crime has been committed. Garda Youth 
Diversion Projects are local community activities which work with children. These 
projects aim to help children move away from behaving in a way that might get them or 
their friends into trouble with the law.  In 2005 the Irish Youth Justice Service (IYJS) 
was established to develop a co-ordinated partnership approach among agencies 
working in the youth justice system, to improve service delivery in the system through 
diversion, restorative justice, rehabilitation and detention as a last resort. Garda (Irish 
police force) statistics show that the types of offence committed by children under the 
age of 18 years are primarily theft, alcohol-related offences, criminal damage, assault, 
traffic offences, drugs possession, public order offences and burglary. The Garda 
Juvenile Diversion Programme is used to deal with children under 18 years of age who 
have committed offences, including alcohol-related and drug possession offences. This 
programme exists across the country and is included as part of the Children Act 2001. 
First established on a pilot basis in 2001 the Drug Treatment Court is a specialised 
District Court which offers long-term court-monitored treatment, including career and 
education support, to offenders with drug addictions as an alternative to a prison 
sentence. The idea is that by dealing with the addiction, the need to offend is no longer 
present.  
Finally, individuals and communities are encouraged to participate in helping to prevent 
and/or detect crime. For example, the Customs Drugs Watch Programme, first 
launched in 1994, encourages those living in coastal communities, maritime personnel 
and people living near airfields to report unusual occurrences to Customs. Under the 
Garda Síochána Act 2005, Joint Policing Committees (JPCs) have been established in 
local authority areas to bring together public representatives, representatives of local 
authorities, the Garda Síochána and representatives of the voluntary and community 
sectors to assess levels of crime and anti-social behaviour, including that related to 
alcohol use and illicit drug use, and to make recommendations as to how to prevent 
and address such problems. The JPCs are empowered to establish local policing fora 
(LPF), to deal specifically with drugs and associated issues such as estate 
management and anti-social behaviour. In September 2008 a Dial-to-Stop Dealing 
campaign was launched and operates nationwide; individuals and communities 
affected by drug dealing are urged to pass information by dialling a confidential 
number.  
The presence of drugs in prisons led the Irish Prison Service (IPS) to develop a policy 
based on three underlying principles (Irish Prison Service 2006): 
 the presence of drugs in prison will not be tolerated; 
 prisoners will be encouraged and supported to develop a responsible attitude to 
drugs, both while in prison and following release, through a range of measures 
including education and counselling; and 
 prisoners who are addicted to drugs or have other medical problems caused by the 
misuse of drugs will be offered every reasonable care and assistance. 
 
In the accompanying strategy the IPS lists two aims in relation to illicit drugs in prisons: 
(1) to eliminate the supply of drugs into prisons, and (2) to provide prisoners with a 
range of opportunities which encourage them to adopt a drug-free lifestyle, before and 
after release, thereby reducing demand for drugs. 
 
The Probation Service works in partnership with communities, local services and 
voluntary organisations to reduce offending and to make communities safer. It funds 
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and supports organisations and projects providing drug treatment to offenders, as well 
as other important services such as employment placement, accommodation, 
education and training, restorative justice initiatives. Probation Service staff in the 
community and in prisons may refer clients to these community-based projects, to 
enhance their re-integration and resettlement as positive, contributing members of their 
communities. 
 
9.2 Drug-related crime 
9.2.1 Drug law offences 
Figures 9.2.1.1 and 9.2.2.2 show trends in proceedings for drug offences from 2003 to 
2008. As can be seen from Figure 9.2.1.1, criminal proceedings for the possession of 
drugs for personal use (simple possession) continue to increase. Possession offences 
accounted for almost 75 % of total drug offences (n = 14,374) in 2008. The sharp 
upward trend in total drug offences since 2003 is largely accounted for by the increase 
in simple possession offences. Proceedings for drug supply continued to increase 
marginally, from 2,654 in 2007 to 2,967 in 2008.  
2003 2004 2005 2006 2007 2008
Total drug offences 5324 5798 8290 8924 11647 14374
Drug possession for personal use 3276 3761 5864 6107 8352 10746
Drug possession for supply 1715 1654 1983 2291 2654 2967
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Figure 9.2.1.1 Trends in relevant legal proceedings for total drug offences, drug possession for 
personal use and for supply, 2003–2008 
Source: CSO 2008, 2009, unpublished data from CSO, July 2009 
 
Figure 9.2.2.2 shows trends in legal proceedings for a selection of other drug offences 
between 2003 and 2008. Although the offence of obstructing the lawful exercise of a 
power conferred by the Misuse of Drugs Act, 1977 (s21) continues to be the largest 
category, proceedings for such offences decreased in 2008, following a steady 
increase since 2003. Obstruction offences often involve an alleged offender resisting a 
drug search or an arrest or attempting to dispose of drugs to evade detection. In 2008 
there was an increase in the number of proceedings for drug importation and forging a 
prescription to obtain drugs in a chemist or pharmacy. Proceedings for the cultivation or 
manufacture of drugs have continued to increase since 2005. In 2005 there were 29 
proceedings for such offences. In 2008, the number of proceedings for drug 
cultivation/manufacture more than quadrupled to 136 proceedings. It is unclear whether 
this increase reflects a genuine growth in the commission of such offences or whether 
it reflects a greater concentration of law enforcement on detecting such offences.      
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2003 2004 2005 2006 2007 2008
Obstruction 208 239 290 349 407 348
Forged/altered prescriptions 51 85 95 91 90 121
Cultivation or manufacture 50 32 29 54 109 136
Importation 24 27 29 32 35 56
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Figure 9.2.2.2 Trends in relevant legal proceedings for selected drug offences, 2003–2008  
Source: CSO 2008, 2009, Personal communication, Central Statistics Office, July 2009 
 
In July 2009 the Courts Service annual report for 2008 was released (Courts Service 
2009). It reported among other matters that drug offence cases before the District 
Court had increased by 58% – to 15,658 from 9,870 in 2007 – and that 18% of cases 
before the Circuit Court were for drug offences.  
 
Data on prosecutions for the offence of driving under the influence of drugs (DUID) for 
2008 and 2009 are not available. 
 
9.2.2 Other drug-related crime 
A report on drug and alcohol use in the Midland region was published in May 2010 
(Lyons, Suzi, et al. 2010b).  The study was commissioned by the Midland Regional 
Drugs Task Force. The aim of the study was to establish an evidence base for drug-
related issues in the Midland region and to inform the development of appropriate 
response strategies. The study used information from several different sources, 
including national drug prevalence data, the National Drug Treatment Reporting 
System (NDTRS) and the CSO. Interviews and focus groups were also conducted with 
key informants (e.g. service providers, drug users, family members) in four selected 
communities in the region. The study findings included evidence of drug crime, such as 
drug markets, in the region. A partnership approach involving all the key stakeholders 
was one strategy highlighted by the study to tackle this problem. 
 
The issue of gun crime in Ireland was the subject of an article in the British Journal of 
Criminology (Campbell 2010). The article identified a clear link between the illicit drug 
market and an increase in gun crime. Comparing the percentage of murders and 
manslaughters in Ireland, England and Wales the author found that „proportionally 
speaking, between twice and five times as many homicides involving guns occur in 
Ireland‟ (page 415). She also cited police statements and media reports which 
indicated that many firearms-related deaths occurred among those involved (or at least 
suspected of being involved) in the illegal drugs trade. In asserting the link between 
guns and the trade in illicit drugs the author highlighted the fact that drugs and guns 
were often imported together and the view of the Customs Service that the rise in the 
detection and seizure of illicit firearms being imported was linked to the increased level 
of violence involved in drug trafficking and smuggling. The author concluded that policy 
responses to gun crime needed to consider the link between masculinity and gun crime 
and also the link between poverty, the illicit drug market and gun crime. An adequate 
and comprehensive response to gun crime, she concluded, „should be cognisant of the 
link to poverty and the drug market and incorporate educational rather than legal 
approaches alone‟ (page 429). Targeted psychology programmes for „at risk‟ young 
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men to address the violent expression of masculinity which underlies much gun crime 
and targeted policing at high-risk areas where gun violence takes place are necessary. 
These should, according to the author, be coupled with an increase in economic 
equality and a holistic educational approach. Such measures, she concluded, would be 
more effective in reducing gun crime than increasing prison sentence lengths or 
abrogating the rights of accused people.      
 
9.3 Prevention of drug-related crime 
In July 2009 the IYJS published Designing effective local responses to youth crime: a 
baseline analysis of the Garda Youth Diversion Projects (Irish Youth Justice Service 
2009). The first part of an improvement programme for Garda Youth Diversion 
Projects, this baseline analysis provided a qualitative profile of youth crime in each 
locality and analysed the way that Garda Youth Diversion Projects impact upon youth 
offending. Currently there are 100 projects located around the country, representing a 
€13 million investment annually in youth crime prevention.  
 
In February 2010, at the IYJS‟s second  biennial conference, Barry Andrews TD, 
Minister for Children and Youth Affairs, launched the online learning community 
YJforum for those working on Garda Síochána Youth Diversion Projects. This web-
based forum provides an opportunity for practitioners working in the youth justice 
system to share their experiences and work together to strengthen the system.  
 
 
9.4 Interventions in the criminal justice system 
9.4.1 Alternatives to prison 
Drug Treatment Court to continue operating 
In May 2010, the Minister for Justice and Law Reform, Dermot Ahern TD, published a 
review by his department of the Drug Treatment Court (DTC) which has been operating 
in Dublin since 2001 (Department of Justice Equality and Law Reform 2010b).  
 
According to the department‟s press release (Ahern 2010): „Participants who engage 
with the programme have reduced rates of recidivism and improved health, education 
and social skills, which impact positively on the participants and the community. 
 However, the review also confirmed that the DTC, as currently operating, is not 
dealing with sufficient numbers of participants and programme completion rates are 
very low.‟ 
 
 The press release quoted Minister Ahern: „Drug treatment courts can make an 
important contribution as a restorative justice measure but international studies also 
indicate they need to evolve and develop on an ongoing basis. This review stems from 
my concern about the very low throughput of participants in the DTC programme, 
despite the dedicated team attached to the Court and considerable goodwill on the part 
of all the agencies involved. I am pleased therefore that the report has identified a 
number of recommendations which should lead to a marked improvement in the 
programme's throughput and effectiveness.‟  
 
The review sought to ascertain why so few people were going through the DTC, how 
throughput could be increased and whether further expansion was desirable given poor 
results thus far. It identified the following costs and outcomes: 
 Average annual justice sector cost for the years 2001–2009 was €300,000. 
 A total of 374 people were referred in the nine-year period, of whom 174 were 
deemed unsuitable (90% of whom were outside the DTC catchment area). 
 Twenty-nine people have graduated from the programme (14% of 200). 
 Involvement in the court led to significant reduction in offending. 
 Estimated weekly cost of DTC per offender in 2008 was €320. 
 Weekly cost of a prison space in 2008 was €1,783. 
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The press release continued: „The review identifies particular issues to be addressed in 
terms of the management and operation of the DTC which, when implemented will, it 
concludes, enable the DTC to fulfil its potential in terms of the numbers participating in 
the programme and increasing the numbers who successfully complete it.  The review 
recommends that, having implemented the  recommendations, the DTC should 
continue its operations for a further two years with an interim assessment to consider if 
the improvements are being achieved.‟ The review identified the following reasons for 
the low number of referrals to the DTC: 
 Eligibility criteria exclude offenders aged under 18, those from outside the defined 
catchment area, and those whose offences involve violence. 
 Offenders can only be referred to the DTC when they have pleaded guilty and/or 
have been convicted of certain offences where a prison sentence is likely. 
 Judges/solicitors are unaware of the DTC as an option. 
 There is a lack of management support and resources. 
 
The press release concluded: „The DTC operates on a multi-agency basis and all the 
agencies involved have confirmed their continued commitment to support the work of 
the Court. The Courts Service has agreed that the administration of the project will now 
be led by the Chief Clerk of the Dublin Circuit and District Courts, supported by a 
designated Deputy Chief Clerk who will be appointed shortly. The review also 
recommends the establishment of an Advisory Committee to oversee the project. This 
will be chaired by the Courts Service and made up of senior staff members of the 
Garda Síochána, the Health Service Executive, the Probation Service and the City of 
Dublin Vocational Educational Committee, and will consider the entry requirements to 
the programme, expectations of participants and measures of success and how the 
numbers of participants in the programme can be increased quickly. The Committee 
will also look at the questions of research into the work and effectiveness of the DTC 
process and examine how third-level institutions might assist the Court in this work.‟ 
 
Restorative Justice 
The National Commission on Restorative Justice which was established to consider the 
potential for a restorative perspective on crime and criminal justice to be introduced in 
Ireland published its final report in December 2009 (National Commission on 
Restorative Justice 2009). The Commission defined restorative justice in the following 
terms: „Restorative justice is a victim-sensitive response to criminal offending, which, 
through engagement with those affected by crime, aims to make amends for the harm 
that has been caused to victims and communities and which facilitates offender 
rehabilitation and integration into society‟ (page 20). Models of restorative justice 
favoured by the Commission include family conferencing, victim-offender mediation 
and reparation panels. The precise model adopted should, according to the 
Commission, be determined by the circumstances of each case. The Commission 
concluded that the establishment of a national system of restorative justice which 
targets cases involving custodial sentences of up to three years‟ imprisonment has the 
potential to divert some offenders from a custodial sentence. Although the Commission 
does not identify a definitive range of offences for which restorative justice would be 
applicable, many of those imprisoned for drug-related offences receive custodial 
sentences of less than three years duration. 
 
The Commission on Restorative Justice also concluded that the Probation Service 
should be the lead agency in implementing any wider application of restorative justice. 
The Annual Report of the Probation Service for 2009 provides information on the 
various community-based drug services which receive funding support through the 
Probation Service (Probation Service 2010). 
 
9.4.2 Other interventions in the criminal justice system 
According to the 2009 annual report of the Revenue Commissioners (Revenue 
Commissioners 2010) the Revenue‟s Customs Drug Law Enforcement (CDLE) has put 
in place strategic and operational drugs enforcement plans; furthermore, additional 
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resources have been deployed. CDLE‟s response to the threat posed by drug 
smuggling includes promoting co-operation, exchange of intelligence and proactively 
profiling drug-trafficking networks with the relevant national and international law 
enforcement agencies, along with effective operational interventions. The CDLE‟s 
capacity to counter smuggling was enhanced during 2009 by the commissioning of a 
second Revenue Customs Cutter, RCC Faire, and the deployment of a second X-ray 
container scanner. The new scanner will be mainly deployed around Dublin Port, while 
the other scanner has been redeployed and will be managed from Rosslare. The 
complement of detector dog teams has been increased to thirteen. 
 
The Department of Justice and Law Reform has launched the second discussion 
document as part of the consultation process to develop a White Paper on crime 
(Department of Justice Equality and Law Reform 2010a). The White Paper, due to be 
completed in 2011, will provide a high-level statement of government policy, its 
rationale and the strategies to give effect to that policy. The process of consultation 
involves the publication of thematic discussion documents. The first discussion 
document, published in July 2009, was entitled Crime prevention and community safety 
and invited submissions on a range of subjects such as: reducing opportunities for 
crime; developing locally based partnerships; preventing first-time criminality among 
those most at risk; and reducing re-offending. The process of consultation also involved 
regional seminars and meetings with key stakeholders. The second discussion 
document, Criminal sanctions, considered the purpose of sanctions, non-custodial 
sanctions, imprisonment, and sentencing policy and practice, and was published in 
February 2010.  
 
In February 2010 Policing Priorities 2010 were announced by the Minister for Justice, 
Equality and Law Reform, Dermot Ahern TD. In addition to the continuing fight against 
gangland crime (including targeting drug trafficking and low-level street dealing), the 
Minister has prioritised security, and policing communities (including adopting a low 
tolerance to alcohol- and drug-related anti-social behaviour and youth crime). The 
policing priorities set by the Minister are reflected in the Garda Síochána Policing Plan 
for 2010 (An Garda Síochána 2010).  
 
In June 2010, Pat Carey TD, Minister for Community, Equality and Gaeltacht Affairs 
(with responsibility for the National Drugs Strategy) announced his intention to extend 
the Dial to Stop Drug Dealing Campaign across local and regional drugs task forces 
(Carey, P 2010, 6 June). Speaking at the presentation of certificates to graduates of 
the TURAS programme in the Canal Communities Local Drugs Task Force area, 
Minister Carey said:  
 
„The benefits of the Dial-to-Stop Drug Dealing are manifold. Since the campaign has 
been in operation, well over 6,000 calls have been made to the line, resulting in over 
1,800 reports to the Garda. In addition to this obvious benefit, the campaign has given 
communities and individuals a sense of empowerment and a feeling that they can 
make a difference and help stop the spread of drug misuse in their communities‟. He 
continued, „I hope to be in a position to extend the phone-line and provide additional 
funding for promotional materials in the coming weeks. Officials in my Department will 
be in contact with local and regional drugs task forces with a view to maximising the 
impact of the campaign.‟ 
 
 
9.5 Drug use and problem drug use in prisons 
Prevalence data regarding drug use and problem drug use in Irish prisons are not 
routinely collected. The Inspector of Prisons includes his findings with regard to drug 
and alcohol use in prisons in his reports.9   
                                               
9
 The Office of the Inspector of Prisons is a statutory, independent office established under the Prisons Act 
2007. The key role assigned to the Inspector is to carry out regular inspections of the 14 prisons in the 
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In a report of an inspection in 2008–2009 of Castlerea Prison, which serves Connacht 
and counties Longford, Cavan and Donegal, the Inspector of Prisons stated that he had 
reason to believe that, contrary to the views expressed by prison management and 
medical staff, the use of illicit drugs and alcohol by prisoners in Castlerea Prison was 
cause for serious concern.  The prison authorities did acknowledge that the use of 
prescription drugs was a serious problem: 
 
„I was informed that the abuse of prescription medication is a serious problem 
particularly addiction to sleeping tablets. I was further informed that prisoners are on 
prescribed sleeping tablets before entering Castlerea Prison, either from other prisons 
or from the community. It is the policy of the medical unit in Castlerea Prison not to 
prescribe sleeping tablets to prisoners unless exceptional circumstances justify their 
use. ... The management of Castlerea Prison conducted a survey of 230 prisoners and 
found that 57% of those surveyed were on prescribed high dependency mind altering 
drugs‟ (Reilly 2009b) (paras. 5.40–41). 
 
With regard to drug use in Irish prisons in general, the Inspector of Prisons reported in 
his annual report for 2008:  
 
‘I uncovered evidence of illicit drug use in our prisons. During my inspection of 
Loughan House Open Centre (2008) I found that of the 553 prisoners transferred there 
from other prisons in 2007, 529 were selected for drug testing. Those not selected 
were elderly or prisoners with other medical complaints. 12.48% of those selected 
refused or failed to be tested. A refusal or failure was deemed by management for the 
purpose of their statistics as a positive finding. Of those tested, 31.76% tested positive 
for illicit drugs. Taking those who tested positive and those who either refused or failed, 
the percentage testing positive in 2007 was 44.24%. (The most common drug was 
cannabis). Given that this is supposed to be a coterie of prisoners who are drug free 
this is a matter of serious concern and suggests that the overall level of drug abuse in 
our prisons is very high. This prompts the observation that drugs were available in the 
closed prisons that these prisoners came from. The prisons from which transferred 
prisoners tested positive were Castlerea, Wheatfield, Midlands, Limerick, St. Patrick‟s 
Institution, Mountjoy, Portlaoise and Cloverhill‟ (Reilly 2009a) (para. 10.3). 
 
The Inspector recommended that the IPS consider introducing mandatory testing of all 
prisoners in all prisons in order to get a clear picture of the extent and nature of drug 
use in the prison population, and to enable planning to deal with the problem.  
 
Unpublished data obtained from the IPS regarding the results of the mandatory drug 
testing programme, as carried out in Irish prisons in 2009, indicates that, excluding 
methadone, between one-tenth and two-fifths of those screened tested positive for at 
least one drug. For more details, see Section 4.4.1. 
 
The National Advisory Committee on Drugs (NACD) is currently in the process of 
commissioning a study to estimate the prevalence of drug use, including intravenous 
drug use, among the prisoner population in Ireland. For more details, see Section 9.6.3 
below. 
 
With regard to security in prisons to eliminate the supply of contraband items, primarily 
mobile phones, drugs and weapons, the IPS annual report for 2009 (Irish Prison 
Service 2010) reported on the roll-out of further security measures, to supplement 
those announced in the IPS strategy Keeping drugs out of prisons (Irish Prison Service 
2006), which included stricter visiting arrangements, examination of incoming mail, 
search procedures, drug testing of prisoners, and enhanced perimeter security. The 
new measures included the following: 
                                                                                                                                         
State and to present his report(s) on each institution inspected as well as an Annual Report to the Minister 
for Justice and Law Reform. 
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 Operational Support Units:  now operating in all closed prisons (excluding the 
Training Unit and Arbour Hill). These Units act as dedicated search teams, the first 
responders to any alarm or incident, the designated control and restraint team for 
cell removals and relocations and the on-call fire pickets. They are also responsible 
for gathering and collating intelligence information in the prison. 
 Security screening: now fully operational for all staff and visitors entering all closed 
prisons (except the Training Unit and Arbour Hill). Every visitor and member of staff 
is required to pass through an airport-style walk-through detector before being 
granted access to the prison. In addition, x-ray scanners screen all hand bags, 
briefcases, packages, coats, etc.  
 A Canine Unit (i.e. drug detection dog unit):  operational in all prisons in 2009, 
comprising 31 staff. 
 
With regard to mobile phones, the IPS reported in its 2009 annual report that a pilot 
scheme using technology to prevent the use of mobile phones in prisons had begun in 
2007, was extended in 2008 with the introduction of inhibitors designed to prevent the 
use of 3G phones, and testing and evaluation continued in 2009. A Body Orifice 
Security Scanner (BOSS) chair, which is used to scan prisoners for contraband 
secreted in their body cavities, has also now been introduced in all prisons. It was 
piloted in Cloverhill Prison, and in its annual report for 2008, the Cloverhill Prison 
Visiting Committee (Cloverhill Prison Visiting Committee 2009) reported that its use 
had reduced mobile phone trafficking into the prison by 39%.  
 
Regarding prisoner safety, the 2009 IPS annual report stated that on 4 December 
2009, 760 people were serving sentences for drug offences, an increase of 34% on the 
2008 figure of 567. During the whole year, there were 814 incidents of violence among 
prisoners, including some very minor incidents, an increase of 56 since 2007 (759). 
The IPS commented, „...attacks by prisoners on prisoners are not usually random acts 
of violence – they are related to matters on the outside – such as drug debts, gang 
rivalries, etc‟ (Irish Prison Service 2010) (p. 28). In his annual report for 2008, the 
Inspector of Prisons (Reilly 2009a) suggested that internal factors also threatened the 
provision of safe and secure custody for prisoners including overcrowding, boredom, 
the reduced availability of illicit drugs, which led to irritability among prisoners, and the 
use of drugs by prisoners, which increased levels of aggressiveness.  
 
9.6 Responses to drug-related health issues in prisons (and other 
custodial settings) 
9.6.1 Drug treatment 
The 2009 IPS annual report states that drug treatment continues to be one of the 
biggest issues facing the Irish prison health services (Irish Prison Service 2010).  
Those who present with a history of problem opiate use are offered detoxification if it is 
clinically indicated, or stabilisation on methadone as a treatment option. As a matter of 
policy, those who are already on methadone when committed can continue to receive 
this treatment for the duration of their sentence.  
 
The number of prisoners on methadone maintenance treatment increased by 20% 
between 2008 and 2009. There was a 10% increase in the number of people new to 
treatment. Over 20% of those on the Central Treatment List (CTL), i.e. clients receiving 
methadone treatment, in 2009 were treated within the IPS, and 31% of all new entrants 
on the CTL in 2009 were treated within the IPS. Since 2008, pharmacists have 
provided the methadone treatment in Mountjoy and in the Dóchas Centre. Provision of 
treatment plays an important part in reducing drug-related deaths.  
 
In 2009, 1,130 prisoners underwent detoxification treatment, and there were 
approximately 1,500 prisoner contacts per month with the addiction counselling 
services (both drug and alcohol). The report noted the benefit of the multidisciplinary 
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approach to the care of drug-using prisoners in Mountjoy prison, which aims to provide 
a personalised therapeutic relationship. 
 
The IPS offers a range of care and rehabilitation services to inmates, including those 
with drug and alcohol problems. These services include education, vocational training, 
and psychological and spiritual services, which aim to improve re-integration into the 
community on release. The IPS also continues to work to enable prisoners at risk of 
homelessness to access appropriate accommodation on release through partnership 
with voluntary and statutory services in the community. 
 
9.6.2 Prevention and reduction of drug-related harm 
International research has found an increased risk of mortality among prisoners within 
the days and weeks following their release from prison (Binswanger, et al. 2007). Many 
of these deaths are drug related and the increased mortality risk is thought to be 
caused by the altered tolerance to drugs which an individual may develop while in 
prison (Jones, et al. 2002) (Seymour, et al. 2000). A recently published paper based on 
data from the National Drug-Related Deaths Index (NDRDI) for the years 1998–2005 
examined the relationship between date of release from prison and drug-related death 
(Lyons, Suzi, et al. 2010a).  This was the first study of its kind in Ireland. 
 
Profile of cases examined  
Between 1998 and 2005, 2,442 drug-related deaths were recorded on the NDRDI. One 
hundred and thirty of the individuals who died had a documented history of 
imprisonment. Of the 130 individuals, 105 were not in prison at the time of death.  The 
analysis presented in this article is based on these 105 individuals, of whom: 
 the majority (93, 88.6%) were male;  
 most (69, 65.7%) were aged between 20 and 29 years (median age 29 years); 
 the majority (88, 83.8%) were unemployed;  
 21 (20.0%) were living in unstable accommodation, and 10 (9.5%) were homeless; 
 64 (61.0%) had a history of injecting, and 36 (34.3%) were injecting at the time of 
death; 
 11 (10.5%) had a blood-borne viral infection recorded in their history, of whom five 
were co-infected with two or more viruses. 
 
Time between release from prison and death 
Of the 105 individuals, 89 had a known date of release (Figure 9.6.2.1). Of these, nine 
(10.1%) died on day one or day two, and 16 (18.0%) died between day three and day 
seven. Almost half (42, 47.2%) of the 89 deaths occurred within the first month of 
release.   
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Figure 9.6.2.1   Time between release from prison and death (N=89), NDRDI 1998–2005 
 
Deaths by poisoning within the first month of release  
Of the 42 deaths within the first month of release, 38 were due to poisoning, and 18 of 
those who died were injecting drugs at the time of their death. Of the 14 deaths 
involving a single drug, 11 involved an opiate, mainly heroin and/or methadone (Table 
9.6.2.1). Of the 24 deaths involving polysubstances, 23 involved an opiate (in addition 
to one or more other substances). 
 
Table 9.6.2.1   Substances involved in deaths by poisoning within the first month of release from 
prison (N=38) 
Substance n (%)* 
Heroin 19 (50.0) 
Methadone 18 (47.4) 
Benzodiazepines 11 (28.9) 
Antidepressants 6 (15.8) 
Stimulants
† 
7 (18.4) 
Other
‡
 11 (28.9) 
* The sum of percentages in this column exceeds 100% as most deaths involved more than one substance. 
† Includes cocaine and methamphetamine. 
‡ Includes non-benzodiazepine sedatives, unspecified opiates, analgesics containing an opiate compound, anti-
psychotics, non-opiate analgesics, alcohol, solvents, cardiac and all other types of medication, including over-the-
counter products. 
 
The findings of this study are consistent with those of international studies in this area. 
The number of cases reported in this study is likely to be underestimated, as history of 
imprisonment is not routinely recorded in the NDRDI data sources. The study highlights 
the need for education and awareness among prisoners and their families and friends 
about the risk of overdose in the days and weeks following release. Many of these 
deaths are preventable and the findings of the study support the need for an overdose 
prevention strategy. 
 
9.6.3 Prevention, treatment and care of infectious diseases 
The National Advisory Committee on Drugs (NACD) is commissioning a study to 
estimate the prevalence of drug use, including intravenous drug use, among the 
prisoner population in Ireland in order to determine the need for drug treatment and 
harm reduction (including needle exchange) services in Irish prisons.    
 
The objectives of the study are to: 
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 describe the nature, extent and pattern of consumption for different drugs among 
the prisoner population when in the community and when in prison, 
 describe methods of drug use, including intravenous drug use, among the prisoner 
population, 
 estimate the prevalence of blood-borne viruses among the prisoner population and 
to identify associated risk behaviours, and 
 measure the uptake of individual drug treatment and harm reduction interventions 
(including hepatitis B vaccination) when in the community and when in prison.  
 
The study will be jointly funded by the NACD and the IPS and the tender will be 
awarded in the fourth quarter of 2010 (National Advisory Committee on Drugs 2010).  
 
A consultant-led infectious disease service has been contracted from St James‟s 
Hospital to provide treatment to prisoners who suffer from infectious diseases, 
including Hepatitis C and HIV. The development of this service has demonstrably 
decreased the number of prisoners transferred to St James‟s Hospital Guide Clinics for 
screening and treatment. It has also been effective in increasing compliance with 
complicated drug regimes and improving patient outcomes. The IPS in collaboration 
with St James‟s Hospital are finalising arrangements to introduce a hepatitis C virus 
treatment service to selected Dublin prisons (Irish Prison Service 2010). 
 
9.6.4 Prevention of overdose-risk upon prison release  
Provision of treatment plays an important part in reducing drug-related deaths.  The 
2009 IPS annual report stated that the service continued to face challenges in securing 
places in methadone clinics in the community for prisoners on methadone who were to 
be released (Irish Prison Service 2010). 
 
9.7 Reintegration of drug users after release from prison 
In May 2010, the Irish Penal Reform Trust (IPRT) published a report ‘It’s like stepping 
on a landmine…’ – Reintegration of prisoners in Ireland (Martynowicz and Quigley 
2010). The IPRT is an independent non-governmental organisation which campaigns 
for the rights of people in prison and the reform of penal policy.  
 
The study, conducted between October 2009 and February 2010, consisted of a 
literature review, a number of semi-structured interviews with service providers (in the 
statutory and non-statutory sectors), a questionnaire completed by service providers 
throughout Ireland, and two focus groups with ex-prisoners in Dublin. The report lists 
the aims of the study: 
 to review national and international practice and policy (including human rights 
standards) relating to reintegration, 
 to identify barriers to reintegration of ex-prisoners in Ireland, 
 to map, as far as possible, available services and identify possible gaps in service 
provision, and 
 to make recommendations for development of future policy and practice. 
  
The study found that, although „significant progress has been made in recent years in 
integrating post-release services ... by the Irish Prison Service and its partners, there 
remains a less than uniform approach to the provision of necessary services in 
individual prisons and access to support is dependent on the facility in which the 
prisoner finds his- or herself‟ (page 3). Service provision also varies between different 
areas of the country. The study also found that the unstructured use of Temporary 
Release, often used to alleviate pressure on overcrowded prisons and to make spaces 
available to new prisoners, impacts negatively on preparation for release. The study 
found that prisoners are sometimes given no more than a few hours‟ notice before 
being released, and some are released when outside services are unavailable, on 
Friday evenings or at the weekend for example. 
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The report notes some positive developments in recent years, such as the 
development of a system of Integrated Sentence Management (ISM) in some prisons, 
and wider provision of drug counselling services, including those provided in Dublin by 
Merchants Quay Ireland. The IPRT makes a number of recommendations arising from 
the findings of the study, including the following: 
 The IPS should provide appropriate access and facilities for practitioners working 
with prisoners on drug and alcohol addictions, including the provision of facilities 
ensuring confidentiality and a therapeutic environment for service users. 
 All prisons should provide drug-free landings. 
 The IPS, in partnership with relevant service providers, should ensure 
arrangements are made for prisoners to continue drug and alcohol addiction 
treatment upon release when required. 
 The government should make the introduction of spent convictions legislation a 
priority in 2010, to assist prisoners in entering employment post release. 
 
The authors state that during the research it became clear that they would not be able 
to address many of the issues which arose, including the specific needs of children and 
young people leaving custody, or of foreign national prisoners, and the needs of 
families who support prisoners during custody and upon release. The IPRT plans to 
follow-up on these issues in the near future. 
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10. Drug Markets 
10.1 Introduction 
There is no systematic, comprehensive information available on illicit drug markets in 
Ireland. However, there are several information sources which give indications of the 
nature and size of the market. 
 
Prevalence surveys may ask respondents about their access to illicit drugs and about 
the availability of various drugs. For example, the all-Ireland general population drug 
prevalence survey, described in detail in Section 2.1 above, asks respondents how 
they obtained individual substances  (who from and under what circumstances), where 
did they obtain them (in what type of location) and how easy were they to obtain. The 
European School Survey Project on Alcohol and Other Drugs (ESPAD), also 
described in detail in Section 2.1 above, contains a question, the answer to which 
indicates the perceived availability of some illicit substances – „How difficult do you 
think it would be for you to get each of the following (cannabis, amphetamine, 
ecstasy)?‟.The above studies are not reported in every National Report. 
 
Data on drug seizures by Customs Drug Law Enforcement (CDLE) and the Garda 
Síochána provide insights into the origins of drugs being brought into Ireland, and the 
nature of the market in terms of supply and availability. However, these data must be 
treated with caution as the number of drug seizures in any given period can be affected 
by such factors as law enforcement resources, strategies and priorities, and by the 
vulnerability of traffickers to law enforcement activities.  
 
Drug offence data published by the Central Statistics Office (CSO) can assist in 
understanding aspects of the operation of the illicit drug market in Ireland. With regard 
to the so-called middle market level, which involves the importation and internal 
distribution of drugs, data on drug supply offence prosecutions by Garda division are a 
possible indicator of national drug distribution patterns. While these data primarily 
reflect law enforcement activities and the relative ease of detection of different drugs, 
they may also provide an indicator of national drug distribution trends. These data can 
be compared with other sources such as drug treatment data, for example, to show 
trends in market developments throughout the State. Such data can also indicate 
trafficking patterns by showing whether there is a concentration of prosecutions along 
specific routes.  
 
For policing purposes Ireland is divided into six regions, each of which is commanded 
by an Assistant Commissioner. The six regions are: 
 Dublin Metropolitan Region  
 Northern Region  
 Western Region  
 Eastern Region  
 Southern Region  
 South Eastern Region 
Each region is divided into divisions commanded by a Chief Superintendent, and each 
division is then divided into districts commanded by a Superintendent, who is assisted 
by a number of Inspectors. The districts are divided into sub-districts, each normally the 
responsibility of a Sergeant.  
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Map 10.1.1 Irish Garda regions and divisions 
 
The Forensic Science Laboratory (FSL) provides impartial scientific evidence 
following examination of crime scenes, including seizures of drugs. However, not all 
drugs seized by the law enforcement agencies (the Garda Síochána or Customs Drug 
Law Enforcement) are necessarily analysed and reported on by the FSL. For example, 
if no individual is identified in relation to the drug seizure, and no prosecution takes 
place, the drugs may not be sent for analysis and may be destroyed.  Moreover, drug 
purity data are not collated in a systematic way at different market levels in Ireland. The 
primary function of the FSL in this area relates to supporting the criminal justice 
system, and not to research. Only a very small proportion of drugs seized are tested to 
ascertain the percentage purity.  
 
10.2 Availability and supply 
Study of Illicit drug market in Ireland 
 
The first comprehensive study of the Irish illicit drug market is currently being 
completed by the Health Research Board. The aims of the study are to: 
 examine the nature, organisation and structure of Irish drug markets, 
 examine the various factors which can influence the development of local drug 
markets, 
 examine the impact of drug dealing and drug markets on local communities, and 
 describe and assess interventions in drug markets with a view to identifying what 
further interventions are needed. 
 
The study, a joint publication of the Health Research Board and the National Advisory 
Committee on Drugs, employed a range of research methods. 
 
10.2.1 Perceived availability of drugs, exposure, access to drugs e.g. in general 
population, specific groups/places/settings, problem drug users 
See National Report 2009 for most recent information (Alcohol and Drug Research Unit 
2009). 
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10.2.2 Drugs origin: national production versus imported 
The origins of drugs vary according to drug type. Although there has been no specific 
research conducted on trafficking routes into Ireland, its proximity to the UK renders it 
vulnerable to transit from there, and the proximity of the southern coast of Ireland to the 
Iberian peninsula exposes it to the supply of cannabis resin originating in Morocco and 
cocaine originating in the Andean peninsula. Both cannabis resin and cocaine, 
according to the UNODC, sometimes enter Western Europe through Ireland. It is 
widely reported by gardaí and the media that many known Irish drug dealers are 
resident in Spain, which also facilitates the development of links between suppliers of 
cannabis and cocaine and drug dealers resident in Ireland (O'Keeffe, Cormac 2005). 
Finally, Ireland‟s long western Atlantic coastline renders it vulnerable to trafficking from 
the south and central Americas. It is also important to recognise that seizures made in 
Irish waters are sometimes not destined for the Irish market but are destined for the UK 
or elsewhere in mainland Europe. In recent years some of the largest cocaine seizures 
in Europe have been made off the south-western coast of Ireland (Burke 2008).  
 
The following information with regard to individual drugs was supplied by Customs 
Drug Law Enforcement (CDLE unpublished data, July 2010). 
 
Cannabis 
South Africa continues to be the main source for herbal cannabis.  In all sectors local 
profiling and national /international intelligence continue to be the dominant triggers. 
There has been an increase in the detections of herbal cannabis sent through the post. 
Herbal cannabis seems to have overtaken resin in what appears to be a seesaw 
annual trend year on year.The trend in domestic cultivation of cannabis continues to 
intensify; over the past 18 months there has been a noticeable increase in detections of 
sapling cannabis plants and seeds. As a result of these detections, joint operations 
between Custom and An Garda Síochána have led to a number of seizures of 
cannabis plants with evidence of cannabis cultivation. 
 
Cocaine 
South America continues to be the main source for cocaine but there is continuing 
evidence of West African countries, e.g. Benin and Senegal, becoming distribution 
hubs for the European market. There has also been a marked increase in detections of 
cocaine swallowers coming through the airport. 
 
Heroin 
Heroin continues to be high risk through our ports. The trend of utilising deep 
concealment methods continues. 
 
CDLE also states: „Due to the economic downturn and scarcity of criminal funding we 
have seen evidence that Organised Crime Groups are resorting more frequently to the 
„little but often‟ technique.‟ This relates to the use of drug couriers to transport small 
quantities of drugs frequently. This method, it is reported, is particularly evident in 
passenger drug couriers by air and postal and air freight packages. It is also reported 
that there has been a continued increase in seizures of medicinal products such as 
Zolpiclone and Diazepam. CDLE believes that „this could indicate a move by drug 
gangs into the medicinal market which is quite lucrative‟. A  Memorandum of 
Understanding has been signed between Revenue and the Irish Medicines Board 
aimed at improving co-operation and the sharing of intelligence in relation to this 
development (CDLE personal communication, July 2010). 
 
10.2.3 Trafficking patterns, national and international flows, routes, modi 
operandi; and organisation of domestic drug markets 
See National Report 2009 for most recent information (Alcohol and Drug Research Unit 
2009). 
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10.3 Seizures 
10.3.1 Quantities and numbers of seizures of all illicit drugs 
The number of drug seizures in any given period can be affected by such factors as 
law enforcement resources, strategies and priorities, and by the vulnerability of 
traffickers to law enforcement activities. However, drug seizures are considered indirect 
indicators of the supply and availability of drugs. See standard table 13 Number and 
quantity of seizures of illicit drugs. 
 
Cannabis seizures account for the largest proportion of all drugs seized. Figure 
10.3.1.1 shows trends in cannabis-related seizures and total seizures between 2003 
and 2009. The total number of drug seizures increased between 2005 and 2007. In 
2008 the total number decreased and in 2009 the number decreased further. This 
decrease in total seizures in 2009 can partly be explained by the significant decrease in 
cannabis-type substances seized. Cannabis-related seizures decreased by just over 
59%. In 2009 there were fewer reported cannabis seizures (n = 2,314) than there were 
in 2005 (n = 3,555). Although, as explained in section 10.1 above, not all drugs seized 
by law enforcement are necessarily analysed and reported by the Forensic Science 
Laboratory, it is difficult to know if the reduction in cannabis-related seizures reflects a 
decline in cannabis use or a reduction in law enforcement activity. However, it should 
be noted that drug offence prosecutions reported in section 9.2, most of which are 
cannabis-related, have continued to increase.  
 
2005 2006 2007 2008 2009
All seizures 6362 8417 10444 9991 5494
Cannabis-type substances 3555 4243 5176 5652 2314
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Figure 10.3.1.1 Trends in the total number of drug seizures and cannabis seizures, 2005–2009  
Source: Central Statistics Office 2008, 2009, 2010 
 
The reduction in the total number of reported seizures in 2009 shown in Figure 10.3.1.1 
may also be explained by a reduction in the number of seizures of other drugs since 
2008. Figure 10.3.1.2 shows trends in seizures for a selection of drugs, excluding 
cannabis, between 2003 and 2009. There has been a significant decline in seizures of 
cocaine, heroin and ecstasy-type substances since 2007. In 2007 there were 1,173 
ecstasy-type substances seized, and in 2009 this figure was 90; in 2007 there were 
1,749 cocaine seizures, while in 2009 there were 635. In 2007 there were 1,698 heroin 
seizures while in 2009 there were 1,455 heroin seizures. It appears that the significant 
reduction in total drug seizures reported in 2009 can be explained primarily as the 
result of a reduction in seizures of cannabis and cocaine.  
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2003 2004 2005 2006 2007 2008 2009
Ecstasy-type substances 1083 806 689 858 1173 730 90
Heroin 660 612 763 1254 1698 1611 1455
Cocaine 566 753 1045 1500 1749 1010 635
Amphetamines 211 145 125 277 235 126 72
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Figure 10.3.1.2 Trends in the number of seizures of selected drugs, excluding cannabis, 2003–2009 
Source: Central Statistics Office 2008, 2009, 2010 
* Includes MDMA, MDEA, and DOB  
 
Table 10.3.1.1 shows the particulars of all drugs seized in 2009 that were reported on 
by the Forensic Science Laboratory (FSL). As noted in Section 10.1 above, not all 
drugs seized by law enforcement agencies (the Garda Síochána and Customs Drug 
Law Enforcement) are necessarily analysed and reported by the FSL.  
 
Table 10.3.1.1 Particulars of drugs seized during 2009, and analysed by the Forensic Science 
Laboratory (unpublished data, Central Statistics Office, 2010) 
Drug Quantity No. Cases 
Alprazolam 38,414.5 tablets 42 
Amphetamine 36,508.358 grams 72 
BK-MBDB 4 tablets 2 
Bromazapam 22 tablets 3 
BZP ***  309,236.5 tablets, 4,371 grams, 2,360 capsules 348 
Cannabis 572,333.348 grams 981 
Cannabis resin 1,538,226.236 grams 1109 
Cannabis plants* 3,750 plants 224 
Chlorpheniramine **  333 tablets 4 
Clonazepam 54 tablets 2 
Cocaine 118,259.360 grams 635 
CPP ** 107  tablets 2 
Diamorphine  (Heroin) 78,668.357 grams 1455 
Diazepam 114,158 tablets, 3.222 gram 270 
Dihydrocodeine 790 tablets 9 
Ecstasy MDMA 18,711 tablets, 3,288.496 grams  90 
Flunitrazepam (Rohypnol) 152 tablets 7 
Fluoxetine** 15 tablets 5 capsules 2 
Flurazepam 339 capsules, 50 tablets 34 
Ketamine 1.231 grams 2 
Khat Plant samples 2 
Lignocaine** 106,147.501 grams 20 
Lorazapam 41,524  tablets 14 
LSD 1,122 squares 4 
Mescaline 9 plants 3 
Methandienone** 21 capsules, 711 tablets 11 
Methadone 2014 mls 15 
Methylamphetamine 1,119.929 grams 25 
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Drug Quantity No. Cases 
Nitrazepam 23 tablets 1 
Oxymetholone** 72 tablets 5 
Prazepam 4 tablets 1 
Sildenifil** 37 tablets 9 
Stanozolol** 106 tablets, 20 mls 4 
Temazepam 5 tablets 5 
Triazolam 168 tablets 7 
Zolpidem** 36 tablets 8 
Zopiclone** 76,821 tablets 67 
*The number of cannabis plants does not reflect the total number detected as only a sample of the plants are sent for 
analysis.  
**These drugs were not controlled under the Misuse of Drugs Acts, 1977 & 1984. 
*** BZP was controlled on 31 March 2009. 
 
10.3.2 Quantities and numbers of seizures of precursor chemicals used in the 
manufacture of illicit drugs 
Data on precursor chemical seizures are included in Table 10.3.1.1. 
 
10.3.3 Number of illicit laboratories and other production sites dismantled; and 
precise type of illicit drugs manufactured there 
 
See National Report 2009 for most recent information (Alcohol and Drug Research Unit 
2009) 
 
10.4 Price/purity 
10.4.1 Price of illicit drugs at retail level 
See National Report 2008 for most recent information (Alcohol and Drug Research Unit 
2008). 
 
10.4.2 Price/potency of illicit drugs 
 
See National Report 2008 for most recent information (Alcohol and Drug Research Unit 
2008). 
 
10.4.3 Composition of illicit drugs and drug tablets 
 
See National Report 2008 for most recent information (Alcohol and Drug Research Unit 
2008). 
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Part B: Selected Issues 
Summary of selected issues 
11. Selected issue: history, methods and implementation of national treatment 
guidelines 
The first move to standardise treatment for drug dependence in Ireland coincided with 
the public health scare in the mid 1980s regarding the spread of HIV/AIDS, and the 
recognition that risky practices associated with injecting drug use were contributing to 
the spread of HIV infections. Guidelines for the prescription of methadone were first 
issued in 1987. 
 
The current methadone treatment protocol (MTP), adopted in 1998, covers the 
statutory and regulatory issues around methadone prescribing and dispensing and 
does not deal with any clinical or treatment guidelines per se (buprenorphine is not 
currently available in Ireland). Guidelines specifically for general practitioners and for 
pharmacists managing opiate users in the primary care setting have been drawn up. 
Guidelines have also been developed for drug treatment in prison settings, and for 
clinicians prescribing benzodiazepines. The MTP was reviewed in 2002, and a further 
review was initiated in mid 2010.  
 
A study in 2005 of drug users‟ experiences of the Irish health services revealed many 
problems, including negative or discriminatory attitudes and treatment by health care 
staff. This finding led to steps to ensure that, in future, the opinions of drug users would 
be sought and taken into account when planning and delivering services, including the 
MTP. A study of Irish GPs‟ attitudes to the MTP in 2006 found that the vast majority 
thought it beneficial to patients.  
 
12. Mortality related to drug use: a comprehensive approach and public health 
implications 
This chapter is based on NDRDI data for the years 1998–2007.   
 
Between 1998 and 2007 there were 3,465 drug-related deaths and deaths among drug 
users in Ireland. Of these deaths, 2,120 were due to poisoning and 1,345 were due to 
traumatic or medical causes (non-poisoning).  Over the reporting period, the annual 
number of deaths by poisoning increased from 178 in 1998 to 274 in 2007. A study of 
positive toxicology reports of drug users who died owing to trauma between 1998 and 
2005 showed that in many cases, more than one substance was present. The same 
study also looked at the history of drug use among those who died from medical 
causes between 1998 and 2005. This showed that the majority of drug users who died 
of medical causes had a history of opiate use, probably reflecting the long-term effects 
of problem drug use on a person.  
 
For each death recorded by the NDRDI, any history of a blood-borne virus, including 
HIV, is documented if such data are recorded.  However, this information is not always 
available.  In total, between 1998 and 2007 there were 84 deaths where the individuals 
were HIV positive and 19 deaths where AIDS/HIV was in some way implicated in the 
death.  The HPSC reported 84 AIDS deaths during the same period.  Small numbers 
over the 10-year period make it difficult to discern trends. 
 
Data from the NDRDI illustrate the total burden of mortality related to drug use in 
Ireland.  The upward trend in deaths both by poisoning and by non-poisoning has both 
immediate and longer term implications and requires appropriate public health 
strategies.   
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11. History, methods and implementation of national 
guidelines 
11.1 Introduction 
The first move to standardise treatment for drug dependence in Ireland coincided with 
the public health scare in the mid-1980s regarding the spread of HIV/AIDS, and the 
recognition that risky practices associated with injecting drug use were contributing to 
the spread of HIV infections. This recognition saw a shift towards a decentralised 
network of drug treatment centres and satellite clinics, accessible and acceptable to 
potential service users, which provided a range of both harm reduction options, 
including substitution treatment, needle exchange and outreach services, and 
treatment options  (Butler 2002a) (Butler 2002b). This shift to a dispersed and more 
complex system of responses to problem drug use meant that the maintenance of a 
consistent standard of service was more challenging than before.  
 
In 1987 the Medical Council, a statutory body tasked with promoting and better 
ensuring high standards of professional conduct and professional education, training 
and competence among registered medical practitioners, issued guidelines for the 
prescription of controlled drugs under the Misuse of Drugs Act 1977 (Expert Group on 
the establishment of a protocol for the prescribing of methadone 1993) (Appendix B).  
 
In 1993, following a recommendation by the National AIDS Strategy Committee, the 
Minister for Health convened an Expert Group on the Establishment of a Protocol for 
the Prescribing of Methadone. This „expert group‟ comprised personnel from the Drug 
Treatment Centre, the Eastern Health Board, the Irish College of General Practitioners, 
Merchants Quay (a voluntary drug treatment service provider) and the Department of 
Health.  It was assisted by the Pharmaceutical Society of Ireland (PSI) and the Irish 
Pharmacy Union (IPU).10  The Expert Group published a report setting out a protocol 
for the management of drug users in primary care (Expert Group on the establishment 
of a protocol for the prescribing of methadone 1993).  Endorsing the Medical Council‟s 
guidelines, published 6 years earlier, the protocol covered the prescribing of 
methadone, the registration of drug users and the licensing of general practitioners to 
treat drug users.  
 
Between 1996 and 1998 a series of reports endorsed the 1993 methadone prescribing 
protocol and called for the formal adoption of national guidelines. The Ministerial Task 
Force on Measures to Reduce the Demand for Drugs (Ministerial Task Force on 
Measures to Reduce the Demand for Drugs 1996), whose reports formed the basis for 
Ireland‟s first national drugs strategy in 2001, recommended that the GP/Pharmacist 
methadone prescription/dispensing scheme should continue to be expanded, evaluated 
and strictly regulated. In its policy document on drug misuse published in 1996, the PSI 
acknowledged the valuable role played by methadone treatment in the management of 
opiate addiction. It encouraged pharmacists to participate in methadone dispensing in 
accordance with specific guidelines, which were in agreement with the 
recommendations in the Protocol and with Department of Health policy. In 1997 the 
Irish College of General Practitioners (ICGP) published a report by a task group on 
drug misuse, which recommended that general practitioners become involved in the 
treatment of opiate misusers in their own local communities. It also recommended that 
methadone treatment as described in the 1993 Protocol should continue as a valid 
form of treatment for opiate dependence.11  
                                               
10
 The Pharmaceutical Society of Ireland is the regulator of pharmacy in Ireland. The Pharmacy Act 2007 
dissolved the old Pharmaceutical Society of Ireland (established in 1875) and re-established it as a 
statutory body. The Irish Pharmacy Union is the professional, representative body for community 
pharmacists. 
11
 The executive summaries of the PSI‟s 1997 policy document on drug use and the ICGP‟s 1998 task 
group report on drug misuse are both included in the appendices to the report of the Methadone Treatment 
Services Review Group (1998). 
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In 1997 a Methadone Treatment Services Review Group was set up to consider the 
arrangements in place for the management and care of heroin dependent drug 
misusers by general practitioners and pharmacists in Ireland and to advise the Minister 
on the approach to be taken in the future. The Review Group concluded that 
methadone, as part of a comprehensive programme of care, was still a valid treatment 
for opiate-dependent persons. It recommended that services should be developed 
using the 1993 Protocol for the Prescribing of Methadone; that methadone should be 
available free of charge to all persons undergoing methadone treatment for opiate 
dependence; and that the methadone treatment protocol scheme should be available 
nationally. Recommendations were also made on the type and concentration of 
methadone to be used, on the roles of general practitioners and pharmacists, and on 
the relationships between treatment centres, general practitioners and pharmacists. 
 The Review Group also recommended that the methadone monitoring scheme should 
be placed on a statutory basis by the making of regulations under Section 5 of the 
Misuse of Drugs Act 1977 (Methadone Treatment Services Review Group 1998). 
 
On foot of the Methadone Treatment Services Review Group‟s report, the Methadone 
Treatment Protocol (MTP) was drafted and activated when the Misuse of Drugs 
(Supervision of Prescriptions and Supply of Methadone) Regulations, 1998 (S.I. No. 
225/1998) were published.  
 
To ensure compliance with the MTP, the ICGP and PSI have both published treatment 
guidelines, which are described in Sections 11.2.1 and 11.2.2. The review process for 
the MTP is described in Section 11.3.1. 
 
11.2 Existing national guidelines: narrative description of existing 
guidelines 
 
The current methadone treatment protocol covers the statutory and regulatory issues 
around methadone prescription and dispensing and does not deal with any clinical or 
treatment guidelines per se (Methadone Prescribing Implementation Committee 2005).   
 
Appendix A (dated 1993) provides a brief summary of good practice in relation to 
methadone prescribing.  It suggests that methadone should be started at a low dose 
(dose not specified) and supervised daily.  For withdrawal, it recommends starting on 
30 to 40 mg and reducing by 5 mg increments.  It recommends methadone for 
pregnant women.  There are also recommendations around providing comprehensive 
medical, social and psychological care for the client on methadone.  In relation to 
benzodiazepines, the protocol states that they can be useful in the short term but GPs 
participating in the methadone programme need to be aware of the potential for abuse 
of these drugs. 
 
Guidelines have been developed for managing opiate users in the primary-care setting 
– specifically for general practitioners (GPs) and for pharmacists. Guidelines have also 
been developed for drug treatment in prison settings, and for clinicians prescribing 
benzodiazepines. These are all described in the following sections. 
 
11.2.1 Management of opiate users in the primary care setting 
In January 2008, the ICGP published revised guidelines for working with opiate users 
in primary care (Irish College of General Practitioners 2008).  The guidelines were 
revised by a representative group of GPs who had experience in managing the care of 
individuals with an opiate misuse problem.  Service users were not involved in 
developing these guidelines.  The document deals only with methadone as a 
substitution treatment;  buprenorphine is not currently available in Ireland (a small pilot 
project with regard to the use of buprenorphine in substitution treatment is ongoing 
(Alcohol and Drug Research Unit 2009)).   
 
The review of the guidelines drew on available international evidence and guidelines, 
including the NICE guidelines, „Methadone and Buprenorphine for Managing Opioid 
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Dependence‟, which contain recommendations based on „current practice that has 
evolved over the years‟ (National Institute for Health and Clinical Excellence 2007). 
 
The document has 11 sections: 
1. Methadone Treatment Protocol 
2. Aims and objectives of treatment 
3. Assessment and management options 
4. Detoxification 
5. Methadone treatment 
6. Special groups and substitute prescribing 
7. Drug-related deaths and  overdose 
8. Other problems 
9. Management of other drugs of misuse 
10. Blood-borne viruses in opiate users 
11. Non-methadone alternative therapies 
 
Notable features of these treatment guidelines are the following: 
 
After initiation assessment 
The document states that not every client will be suitable for treatment in primary care, 
for example those with a history of violent behaviour, polysubstance addiction or a 
psychiatric problem.  
 
Commencing methadone 
The starting dose should be no more than 30 mg daily, with consumption supervised 
daily at this stage. 
 
Stabilisation/destabilisation 
It is recommended that the dose be increased by no more than 10 mg at a time until 
the client is stable.  Usually clients stabilise on doses between 60 and 80 mg.  On the 
clinical judgement of the doctor, supervision of consumption may be gradually reduced 
from daily, to thrice weekly, then twice weekly etc. However, for amounts larger than 80 
mg, the guidelines state that it may be „prudent‟ to continue with twice-weekly 
supervision because of the risk of overdose.   
 
With regard to destabilisation, advice is provided on how to respond to the early signs 
of destabilisation. The guidelines recommend that management of the client should be 
supportive rather than punitive. 
 
Pregnancy 
A short section on pregnancy emphasises the need to stabilise the woman‟s drug use 
during pregnancy.  If necessary, the woman should be offered admission to an in-
patient unit for stabilisation on methadone (pregnant women receive priority for 
inpatient admission).    
 
Use of sedation 
The guidelines recommend that the current good-practice guidelines for the 
prescription and use of benzodiazepines (The Benzodiazepine Committee 2002) 
(Department of Health and Children 2002) be followed when prescribing 
benzodiazepines (see section 11.2.4 below).  They specify that benzodiazepine 
prescriptions should be reviewed monthly (to avoid dependence) and that there should 
be regular communication between the client‟s different treatment providers to ensure 
benzodiazepine prescriptions are not duplicated. 
 
Detoxification/withdrawal 
The guidelines state that detoxification/withdrawal from methadone is more likely to be 
successful if psycho-social support is available. However, the type and location of the 
support, and the role of the GP in this process, are not outlined.  They recommend that, 
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in negotiation with the client, small reductions (amount not specified) are more likely to 
be successful when aiming to reduce or come off prescribed methadone. 
 
Use of sedation in withdrawal 
The guidelines recommend that benzodiazepines should not be prescribed for opiate 
users to help reduce withdrawal symptoms.  They state that there is no evidence of 
benefit to the client and there is a risk that the tablets may be abused or diverted.  If a 
client is on benzodiazepines, it is recommended that a detoxification from 
benzodiazepines be conducted before commencing the methadone detoxification.  
 
11.2.2 Management of service provision to opioid misusers by pharmacists 
As part of their overall guidance manual, the PSI has included a short section on the 
management of service provision to opioid users (The Pharmaceutical Society of 
Ireland (Standards and Practice Unit) 2008).  The section lists the criteria under which 
the pharmacist should operate.  Any pharmacist providing methadone should: 
 be aware of, and comply with relevant legislation, 
 ensure that persons are not stigmatised and confidentiality is maintained when they 
use the service, 
 ensure the appropriate protocols, facilities and resources are available to safely 
deliver the service, and 
 ensure all staff are properly trained to manage the programme. 
 
In particular, the document states that the pharmacist should draw up a written protocol 
with the person receiving methadone maintenance. This protocol should set out what is 
expected from both parties, standards of behaviour, confidentiality and how the 
treatment is to be provided.  Specific procedures such as the storage of the drugs or 
maintaining records are also outlined, and the importance of good communication 
between the pharmacist and client is emphasised.   
 
11.2.3 Drug treatment clinical policy in the Irish Prison Service 
In January 2008 the Irish Prison Service (IPS) published a comprehensive drug 
treatment clinical policy (Irish Prison Service 2008).  The document was created by the 
IPS, based on European methadone guidelines, but it does not give the names or 
designations of those who contributed.  There is no time line or date given for 
evaluation or review of the document. 
 
The policy contains a detailed section on methadone treatment, outlining the 
background and rationale for methadone treatment, as well as the clinical management 
of a prisoner on methadone and the logistics of dispensing. Specifically, it includes: 
 clinical interdisciplinary care planning, 
 methadone treatment guidelines, 
 assessment – treatment plans and treatment goals (induction, maintenance and 
detoxification), 
 criteria for treatment priority, 
 use of methadone – ordering and dispensing, and 
 administration and recording of methadone. 
 
Methadone treatment 
The policy outlines the processes necessary for methadone treatment under different 
circumstances, including when a prisoner is already on methadone, when treatment is 
to be initiated in prison, and when a prisoner on methadone is due to be released. 
 
The document states that in general the initial starting dose should be between 10 and 
20 mg.  The document also states that if there is considerable tolerance to opioids, the 
starting dose could be between 25 and 40 mg but cautions that, if there is any doubt, it 
is better to start on a lower dose.  Normally, an individual will stabilise on 60–120 mg 
per day. 
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Withdrawal and detoxification 
As set out in these guidelines, the policy of the IPS is to offer detoxification to clients 
who have a history of drug use unless they are (1) already on methadone maintenance 
treatment, (2) HIV positive, or (3) pregnant. 
 
The document states that evidence shows that the slower the reduction of the 
methadone dosage the greater the likelihood of successfully coming off methadone 
treatment (dosages not specified).  It recognises psychological support along with 
aftercare as critical in this process. 
 
The lofexidine detoxification and alcohol withdrawal guidelines have been adapted from 
The Maudsley Protocols. Guidelines for the use of naltrexone, as part of an overall 
programme of addiction treatment, along with psycho-social support, are outlined in the 
document. The guidelines state that naltrexone should only be prescribed by a medical 
person experienced in its use. The use of injectable naloxone for reversing accidental 
opiate overdose is not covered. 
 
Pregnancy 
Pregnant women are specifically mentioned in the document. Objectives in the care of 
pregnant women are: 
 stabilisation of mother‟s drug use, 
 retention of mother in obstetric and drug treatment service and ensuring adequate 
support and through care in the community, 
 delivery of a full-term baby with healthy birth weight, 
 avoidance of in utero exposure to HIV/hepatitis, 
 minimisation of the occurrence of neonatal abstinence syndrome, and 
 promotion and support for positive physical health, mental health and social 
wellbeing throughout and after pregnancy. 
 
The document states that during pregnancy it is advisable to stabilise the woman on 
methadone, rather than attempt to detoxify.  However, if a woman wishes to detoxify 
during her pregnancy, it is recommended that it should be done after the 12th week of 
pregnancy but before the 32nd week, to reduce the risk of premature labour. 
 
Psychological care 
The policy devotes a chapter to the importance of the psychological and social aspects 
of drug treatment.  The guiding principles are case management and care plans and a 
therapeutic and supportive environment within the prison. 
 
Other issues 
Issues around blood-borne viruses, including testing, clinical management and 
immunisation, are also addressed in the policy. The document states that the misuse of 
benzodiazepines is an endemic problem in the Irish prison population and provides 
policies and guidelines around assessment of dependence, prescribing and 
detoxification. 
 
The document states that an interdisciplinary team will provide treatment for problem 
cocaine use on an individual basis. There is a range of treatments available including 
counselling and cognitive behavioural therapy, along with appropriate referrals to 
medical or psychiatric services as necessary. 
 
The document also states that it is the policy of the IPS, in accordance with the 
standard prevailing in the community, to develop a dual diagnosis service for those 
patients with addiction problems and mental health problems. 
 
11.2.4 Good practice guidelines for the prescription and use of benzodiazepines 
In December 2002 the Minister for Health and Children, Micheál Martin TD, launched 
the Report of the Benzodiazepine Committee (The Benzodiazepine Committee 2002) 
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and its Good Practice Guidelines for Clinicians (Department of Health and Children 
2002).  
 
The Benzodiazepine Committee was set up by the Minister in June 2000 to „examine 
the current prescribing and use of benzodiazepines; to consider recommendations on 
good prescribing and dispensing practice, paying particular attention to the 
management of drug misusers‟. The Committee comprised doctors working in 
addiction, with input from psychiatrists and others working in the area of addiction 
around the country.  The Committee made no recommendations for evaluation of the 
report or review of the success of the guidelines.   
 
The report envisaged the continued use of benzodiazepines as versatile and valuable 
drugs in clinical medicine, for example in treating insomnia, epilepsy, muscle spasms, 
some forms of anxiety, panic and pre-surgical stress. They anticipated that fostering 
rational prescribing practices for these drugs would reduce the prevalence of 
inappropriate use, the number of patients who become dependent on them, and 
consumption by known opiate users.  
 
The report made 24 recommendations including the introduction of a monitoring 
system to inform GPs of their prescribing patterns and to allow appropriate action 
where there is a suspicion of irresponsible prescribing. The report signalled the need 
for greater awareness among professionals (including all hospital and institutional 
healthcare providers and pharmacists) and the general public about the use of 
benzodiazepines and made a number of recommendations in this area.  
 
The report also recommended ongoing evaluation and monitoring of the use and 
misuse of benzodiazepines in Ireland, particularly in the private sector, among older 
people and drug users attending drug treatment clinics.  
 
The good practice guidelines recommend GPs to critically and urgently review their 
current level of benzodiazepine prescribing, regard the prescription of benzodiazepines 
to opioid users (and other drug users) as an exceptional rather than a routine clinical 
decision, and routinely advise patients dependent on opioids that the concurrent use of 
benzodiazepines greatly increases the risk of overdose.  The guidelines outline four 
methods for benzodiazepine withdrawal/ detoxification. 
 
 
11.3  Implementation process 
11.3.1 Methadone Treatment Protocol and associated guidelines 
 
In 1997 the Department of Health and Children set up the Methadone Treatment 
Services Review Group to assess the use of methadone in the treatment of heroin 
dependence. Membership of this Review Group was similar to that of the 1993 Expert 
Group, and reflected the various agencies with a role in the provision of services for 
drug misusers, including the Department of Health, the then Eastern Health Board, the 
ICGP and the PSI.  Representatives from the Merchants Quay Project, Department of 
General Practice in University College Dublin, and the IPU also participated in the 
meetings of the Review Group.  
 
The Review Group examined the existing protocols for good practice in the prescribing 
and dispensing of methadone and pointed to appropriate controls that could be put in 
place. It also set out the basis on which methadone treatment should continue to be 
developed and recommended a concise framework for the future operation of the 
Scheme. The framework was enshrined in statutory regulations introduced in 1998 
(see Section 11.1). 
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11.3.2 Methadone Prescribing Implementation Committee, 2002 
A Methadone Prescribing Implementation Committee, comprising representatives from 
the then Eastern Regional Health Authority, the seven health boards outside the 
eastern region, General Medical Services (Payments) Board, the ICGP, the PSI and 
the Department of Health and Children was subsequently established to oversee the 
implementation of the 1998 MTP. In 2002 this committee commenced a review of the 
implementation of the MTP (Methadone Prescribing Implementation Committee 2005). 
 
Submissions were received from 46 interested parties and were analysed to identify 
themes and recommendations were made to address the themes identified, which 
included the following: 
 
Representation on the Methadone Prescribing Implementation Committee 
A number of submissions identified the need to invite representatives from the 
community, service users, the voluntary sector, the Drug Treatment Centre Board, the 
former Area Health Boards and the Irish Psychiatric Association on to the committee. 
The committee agreed to invite representatives of the Drug Treatment Centre Board, 
the former Area Health Boards and the Irish Psychiatric Association to be represented 
on the committee.  
 
The regulations 
Several submissions requested revisions to the prescribing of methadone. None of 
these suggestions were taken on board as it would have meant re-writing the 
regulations. 
 
Clients‟ experiences of methadone treatment services 
Clients attending methadone treatment programmes requested that all clients should 
participate in their treatment plan, stable clients should not need to attend weekly, 
individual appointment times should be given to clients, clients continuing to use drugs 
chaotically should be treated separately from more stable clients, and the issue of 
privacy with respect to urinalysis should be addressed. The committee recommended 
that it would be more appropriate to address these issues through the service users‟ 
charter in each HSE area.  
 
General practitioners 
A number of submissions stated that there was a need to take a co-ordinated approach 
to methadone treatment outside the HSE Eastern Region and to increase the 
recruitment of level 1 and level 2 general practitioners throughout the country. The 
committee stated that it would review the role of the National General Practitioner Co-
ordinator to ensure greater support to the areas outside the Eastern Region. A small 
number of general practitioners requested an increase in the number of clients that a 
practitioner was permitted to treat. The committee stated that it would deal with such 
requests on an individual basis. It was suggested that training on treating opiate 
misuse be included in undergraduate and postgraduate medical training. In addition, it 
was suggested that specialist methadone training should continue and that completion 
of such training should be one of the criteria for GMS posts in deprived areas. These 
ideas were welcomed by the committee and were to be recommended to the relevant 
authorities. It was also suggested that general practitioners be given the resources to 
comply with the requirements of the National Drug Treatment Reporting System. Such 
compliance is a condition of the general practitioners contract negotiated in 2003. 
 
Pharmacists 
Pharmacists requested joint training with other health professionals, which the 
committee considered a useful suggestion. The need to increase the recruitment of 
pharmacists was raised. The committee recommended the employment of a liaison 
pharmacist for the HSE areas outside the Eastern Region. Some pharmacists 
requested routine hepatitis B vaccination; this is available free from the HSE to all 
participating pharmacists and their staff. Pharmacists and clients raised the issue of 
security and privacy in pharmacies. The committee reported that these issues were 
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outside their remit as they had resource implications, and noted that grants were 
available through the HSE for upgrading premises. Some pharmacists reported that a 
regular client might present to a pharmacy without a prescription and the pharmacists 
experienced a dilemma: to follow the regulations, or to fulfil their duty of care to the 
client. The committee took a pragmatic view, stating that the pharmacist should provide 
the previously prescribed treatment, document the experience and ensure the client 
seek an up-dated prescription as soon as possible. Actions should be taken to prevent 
this practice being repeated on a regular basis.  
 
Co-ordination between services and continuity of care for clients 
According to the text of the submissions, the lack both of co-ordination between 
psychiatric services and drug treatment services and of continuity of care between 
prison services and drug treatment services needed to be addressed. The committee 
agreed with these statements and welcomed the establishment of a national committee 
to develop protocols for transfer of clients between the prison services and the HSE. 
The committee stated that structures should be developed to ensure that clients on 
methadone treatment who require psychiatric treatment are not at a disadvantage.  
 
11.3.3  External review of MTP, 2010 
In June 2010 an external review of the MTP was initiated to maximise the provision of 
treatment, to facilitate appropriate progression pathways (including exit from 
methadone treatment where appropriate) and to encourage engagement with services. 
The HSE has commissioned Professor Michael Farrell, Professor of Addiction 
Psychiatry and Director of Postgraduate Medical Education in the Institute of Psychiatry 
London, to carry out the review, in conjunction with Professor Joe Barry, Professor of 
Population Health Medicine, Trinity College Dublin. Submissions have been invited 
from interested parties, including the community and voluntary sectors. 
 
The terms of reference for the review are to: 
 review the MTP with regard to maximising provision of treatment including 
detoxification, stabilisation, and rehabilitation, 
 review the MTP with regard to clinical governance and audit, 
 review the MTP with regard to effectiveness of referral pathways, 
 review the MTP with regard to the enrolment of GPs, the training of GPs, the 
criteria for Level 1 and Level 2 GPs, and the GP co-ordinator role, 
 review the MTP with regard to urinalysis testing – its appropriateness and efficacy; 
 engage with the Department of Justice with regard to the prescribing of methadone 
in Garda stations, and 
 review the MTP with regard to data collection, collation and analysis. 
 
11.3.4 Drug treatment policy in Irish prisons 
To date there has been no evaluation of the new policy in prisons. 
 
11.3.5 Benzodiazepines 
Action 41 the National Drugs Strategy 2001–2008 (Department of Tourism Sport and 
Recreation 2001), tasked the Department of Health and Children with overseeing 
implementation of the recommendations in the report on benzodiazepines (Section 
11.2.4).  Speaking at the launch of the report on 10 December 2002, the Minister for 
Health and Children said, „The co-operation of key players from a wide spectrum of 
sectors will of course be pivotal in helping to realise this objective. I am confident that 
this co-operation together with a heightened public awareness of the risks inherent in 
inappropriate use will result in a reduction in misuse and dependency in this country.‟ 
 
No formal evaluation of the success of the guidelines has been conducted.  In 2009 the 
Steering Group that drafted the National Drugs Strategy (interim) 2009–2016 
(Department of Community Rural and Gaeltacht Affairs 2009) stated that the 
implementation of the recommendations had been slow and that several important 
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issues still needed to be addressed. These included a review of the benzodiazepine 
regulatory framework which deals with monitoring and application of sanctions.  The 
Steering Group noted that while there had been improvements in the system to monitor 
prescribing within the public health system, prescribing in the private sector still needed 
to be tackled.  It called for the Irish Medicines Board to review both the regulatory 
system and the implementation of the guidelines.   
 
Although no formal evaluation has been conducted, several studies have examined 
benzodiazepine use in Ireland.  A study published in 2009 (Flynn 2009)Flynn, 2009 
#1266} noted that, in spite of the introduction of the guidelines seven years previously, 
the Irish health service had doubled the amount spent on tranquillisers and sedatives.  
The author stated that there was significant incorrect prescribing and distributing of 
these drugs. Long and colleagues (Long, J and Lyons 2009) reported that the misuse 
of tranquillisers and sedative drugs (mainly benzodiazepines) was common among the 
Irish population, while benzodiazepines were implicated in 30% of drug-related deaths 
in Ireland between 1998 and 2005 (Lyons, Suzi, et al. 2008). 
 
11.3.6 Drug users’ views on the health services 
A collaborative piece of action research was published in 2005 which sought to identify 
the issues encountered by drug users in their dealings with the Irish health services 
(O'Reilly, et al. 2005).  Focus groups were held with 25 drug users from Dublin city.  
The study revealed many problems, including negative or discriminatory attitudes and 
treatment by health care staff.   
 
The study dealt with issues to do with drug treatment, particularly methadone 
maintenance treatment.  Some participants felt that GPs were reluctant to take on drug 
users and, since GPs are gate keepers for medical cards, this created obstacles to 
health care. Concerns in relation to treatment services included privacy and 
confidentiality, and a consequent reluctance to enter counselling. Another theme to 
emerge was the perceived need to develop a more holistic, individual-centred 
approach to the multi-faceted problems being encountered by users. A broad 
consensus came out of the focus groups that methadone was not the whole answer to 
these complex issues.  
 
One of the expected outcomes of the study was that the opinions of drug users would 
be considered by the health service in future. Since then, the Union for Improved 
Services Communication and Education (UISCE) has joined the Methadone 
Prescribing Implementation Committee. 
 
11.3.7 GPs’ perceptions of implementing the Methadone Treatment Protocol   
(MTP) 
Almost one-third (32%) of opiate users prescribed methadone substitution are cared for 
in private general practice in Ireland. In light of this information, the ICGP conducted a 
postal survey in 2006 to determine the attitudes of Irish GPs to the MTP (Delargy 
2008). 
 
A questionnaire was sent to 600 GPs who were recorded on the ICGP‟s drug misuse 
database as having received training in the management of methadone clients. Just 
under 35% (207) responded.  It is notable that 247 GPs had patients on the Central 
Treatment List at the time of the study.  
 
Almost half of the GPs who responded were aged between 46 and 60 years and 29% 
were female. Two out of every three practices were situated in an urban area. Just over 
two-fifths of the GPs said that illicit drugs were a major problem in their practice area; 
the majority of these GPs practised in an urban location. Ninety-two per cent confirmed 
that they had attended special training in methadone treatment. 
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Of the 207 GPs who completed the questionnaire, 72% were providing patients with 
methadone treatment at the time of the survey. Over half had 10 or fewer patients. 
Only 35 prescribing doctors or their staff did not want any more patients. Forty-six GPs 
were willing to take more patients, which suggested that there was capacity to transfer 
suitable clients to a normal health care environment.  
 
The vast majority of GPs thought that the MTP was beneficial to patients, though some 
said that methadone was addictive and difficult to get off.  
 
The types of training that GPs considered most useful were small locally-based 
continuing education networks, individual mentoring, and distance learning.  
 
The additional services most desired by GPs were addiction counselling, in-patient 
detoxification and rehabilitation beds, and employment schemes. 
  
11.4 Comparison of treatment guidelines with WHO guidelines 
Within each section above, where relevant, each item of the WHO questionnaire is 
alluded to. In general, comparison of the three Irish treatment guidelines dealing with 
methadone (Irish College of General Practitioners 2008) (Irish Prison Service 2008, 
Methadone Prescribing Implementation Committee 2005) with the WHO questionnaire 
revealed only limited congruences as the approach adopted in the Irish guidelines 
differs from that adopted by the WHO. However, since the start of methadone 
treatment in Ireland, there have been positive changes in response to previous studies 
and reviews, such as including services users in the MPIC committee, and the current 
review of Ireland‟s methadone treatment protocol is regarded as timely.   
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12. Mortality related to drug use: a comprehensive approach 
and public health implications 
12.1 Introduction 
Measuring the number of drug-related deaths and deaths among drug users is one of 
the key indicators used to monitor the consequences of problem drug use.  Drug use 
can lead to premature death owing to a range of different causes.  These include direct 
drug-related deaths (referred to as poisonings in this report) and indirect drug-related 
deaths (referred to as non-poisonings).  
 
The National Drug-Related Deaths Index (NDRDI) is an epidemiological database 
which records cases of death by drug and alcohol poisoning and deaths among drug 
users and those who are alcohol dependent in Ireland.  
 
Before the NDRDI, information on drug-related deaths in Ireland had been provided by 
the General Mortality Register (GMR), which is maintained by the Central Statistics 
Office (CSO). However, these data were felt to be an under-estimation, especially by 
families of substance users (Long, J., et al. 2005). This belief was supported by a study 
in 2001 which found that the annual numbers of opiate-related deaths recorded by the 
Dublin coroners were consistently higher than those reported by the GMR (Byrne, R. 
2001, Byrne, R. 2002). Furthermore, deaths as an indirect result of drug use had not 
been systematically documented, although there had been a number of small-scale 
studies looking at this phenomenon in Dublin city and county (Long, J., et al. 2005). 
Families of substance users in Dublin (through the Family Support Network) had been 
advocating for some years for a mechanism to measure accurately the extent of 
premature death among drug users.  
 
The NDRDI was established in September 2005 to comply with Action 67 of the 2001–
2008 National Drugs Strategy (Department of Tourism Sport and Recreation 2001). 
The aim was to put in place a mechanism for accurately recording the number of drug-
related deaths in Ireland, to enable the State to respond in a timely manner.  The 
objectives of the NDRDI are to: 
 provide accurate information on drug- and alcohol-related deaths and deaths 
among drug users and among those who are alcohol dependent, and 
 assist in identifying and prioritising areas for intervention and prevention, and to 
measure the effects of such interventions. 
 
To ensure completeness, the NDRDI records data from four sources: the Coroner 
Service, the acute hospital sector, those prescribed methadone and the GMR.   Data 
were collected retrospectively from 1998 onwards and data in Fonte have been 
updated to reflect this change (see Standard Table 5). The information from the NDRDI 
means that for the first time both directly and indirectly drug-related deaths in Ireland 
can be examined. 
 
To date, two trends papers have been published using NDRDI data, the first reporting 
trends in drug-related deaths and deaths among drug users in Ireland between 1998 
and 2005 (Lyons, Suzi, et al. 2008), and the second reporting trends in deaths among 
drug users in Ireland from traumatic and medical causes between 1998 and 2005 
(Lynn, et al. 2009). In 2010, a web-based report on drug-related deaths and deaths 
among drug users in Ireland in 2006 and 2007, including an update on previously 
published figures for the years 1998–2005, was uploaded (Health Research Board 
2010).   
 
12.2 Recent follow-up mortality cohorts studies among PDUs 
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There have been no mortality cohort studies conducted in Ireland.  There is one 
pertinent study, the Research Outcome Study in Ireland (ROSIE), which recorded 
death as an outcome among problem opiate users (Comiskey, Catherine, et al. 2008). 
 
Commissioned by the National Advisory Committee on Drugs in 2002, ROSIE was a 
prospective longitudinal study of problem opiate users who entered treatment in 
Ireland, examining the outcome of different treatment modalities over a period of three 
years. One of the variables collected was information on mortality, using information 
obtained from the participants‟ contacts and the GMR.  
 
The study recruited 404 opiate users aged 18 years or over entering treatment at 
inpatient facilities (hospitals, residential programmes and prisons) or in outpatient 
settings (community-based clinics, health board clinics and general practitioners). The 
opiate users selected were entering treatment for the first time, or were returning to 
treatment after having been absent for a period. At the end of three years, 97% of 
those initially recruited were followed up.  Overall, six participants had died and the 
mortality rate was calculated as 1.5% (95% CI 0.5% to 3.2%).  Cause of death was not 
recorded. 
 
12.3 Cause specific mortality among drug users (1998 to 2007) 
Poisonings 
Between 1998 and 2007 there were 3,465 drug-related deaths and deaths among drug 
users in Ireland (Health Research Board 2010).  A drug user is defined in this analysis 
as an individual who has a history of drug dependency or of non-dependent abuse of 
drugs and/or other substances. Of these deaths, 2,120 were due to poisoning and 
1,345 were due to traumatic or medical causes (non-poisoning) (Table 12.3.1).  Over 
the reporting period, the annual number of deaths by poisoning increased from 178 in 
1998 to 274 in 2007.  
 
Table 12.3.1  Drug-related deaths, by year of death, NDRDI 1998–2007 (N=3,465) 
 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 
All deaths 242 271 261 277 338 297 365 447 491 476 
Poisoning ( n=2120) 178 187 182 178 211 185 207 248 270 274 
Non-poisoning 
(n=1345) 64 84 79 99 127 112 158 199 221 202 
 
Over two thirds (68%) of all deaths by poisoning were male.  The median age was 34 
years, with the majority of cases aged between 20 and 40 years (Figure 12.3.1). 
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Figure 12.3.1   Deaths by poisoning, by age group, NDRDI 1998–2007 (N=2,120) 
  
Opiates, frequently heroin and methadone, were implicated in 55% of all deaths by 
poisoning (Table 12.3.2).  Prescription medication, especially benzodiazepines, and 
over-the-counter medication were implicated in many of the deaths by poisoning.  Just 
over half of all poisonings involved polysubstances. 
 
Table 12.3.2   Drugs involved in deaths by poisoning, NDRDI 1998–2007 (N=2,120) 
 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007  Total % 
All deaths* † 178 187 182 178 211 185 207 248 270 274  2120 100 
Heroin 29 48 37 48 46 28 29 48 66 63  442 20.8 
Methadone 43 37 40 28 39 34 40 43 60 50  414 19.5 
Other opiates** 39 35 45 54 47 48 65 67 55 55  510 24.1 
Cocaine 5 5 5 8 14 10 19 36 52 63  217 10.2 
MDMA 4 8 8 6 10 11 13 10 6 11  87 4.1 
Benzodiazepines 78 72 73 55 71 62 76 80 113 113  793 37.4 
Alcohol‡ 35 43 38 38 57 49 63 65 53 77  518 24.4 
Antidepressants 32 34 41 40 47 44 51 54 43 40  426 20.1 
Other 
prescription drug 
 
§ 38 37 35 18 33 37 41 37 39 60  375 17.7 
Non-opiate 
analgesics 12 17 11 16 16 11 12 22 13 16  146 6.9 
Other
¶
 14 17 13 13 21 14 9 21 21 24  167 7.9 
* Includes Selection D poisonings and also other types of poisonings collected at the national level.  
† Numbers and percentages in columns do not add up to totals shown in this row because individual deaths may be 
attributable to more than one drug or substance. 
** Includes unspecified opiates and analgesics containing an opiate compound. 
‡ Alcohol is recorded only when it contributes to a polysubstance death. 
§ Includes non-benzodiazepine sedatives, anti-psychotics, cardiac and all other types of medication, including over-the-
counter medication. 
¶ Includes solvents, insecticides, herbicides, barbiturates, other amphetamines, hallucinogens, cannabis and other 
chemicals. 
 
Non-poisonings 
Data from the NDRDI showed that between 1998 and 2007 there was a total of 1,345 
indirectly drug-related deaths among drug users in Ireland (Health Research Board 
2010).  For this analysis drug user is defined as an individual who has a history of drug 
dependency or of non-dependent abuse of drugs and/or other substances.  This 
analysis included illegal and also legal substances (e.g. benzodiazepines) if 
appropriate.  Of those cases with a known cause of death (n=1,183), 714 (60.3%) were 
owing to trauma and 469 (39.6%) were owing to medical causes (Figure 12.3.2).  The 
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annual number of deaths owing to trauma increased from 39 in 1998 to 116 in 2006, 
but decreased to 87 in 2007.   
 
1998 1999 2000 2001 2002 2003 2004 2005 2006 2007
Trauma 39 41 51 60 67 55 85 113 116 87
Medical 11 27 18 23 45 29 55 65 98 98
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Figure 12.3.2   Deaths not by poisoning among drug users, NDRDI 1998–2007 (N=1,183) 
 
Half (360, 50.4%) of those who died from traumatic causes were aged between 20 and 
29 years (Figure 12.3.3). The median age was 27 years.  Almost all (643, 90.1%) of 
those who died were male. 
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Figure 12.3.3   Deaths among drug users owing to trauma, by age group, NDRDI 1998–2007 (N=714) 
 
The most common causes of death owing to trauma were hanging and road traffic 
collisions (RTCs) (Figure 12.3.4). 
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Figure 12.3.4   Deaths among drug users owing to trauma, by type of death, NDRDI 1998–2007 
(N=714) 
 
Between 1998 and 2007, the annual number of deaths owing to medical causes rose 
steadily, from 11 in 1998 to 98 in 2007 (Figure 12.3.2) (Health Research Board 2010).    
The majority of those who died from medical causes were aged between 30 and 44 
years (Figure 12.3.5) and the median age was 39 years. Three-quarters (352, 75.0%) 
of those who died were male.  
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Figure 12.3.5   Deaths among drug users owing to medical causes, by age group, NDRDI 1998– 
2007 (N=469) 
 
Analysis of the data showed that the most frequent medical causes of death were 
cardiac events (118, 25.2%), respiratory infections (83, 17.7%) and liver disease (48, 
10.2%) (Figure 12.3.6). 
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Figure 12.3.6  Deaths among drug users owing to medical causes, by type, NDRDI 1998–2007 
(N=469) 
 
The previous report on traumatic deaths using NDRDI data for 1998 to 2005 had 
already noted that these data were consistent with data from the UK, suggesting „that 
the risk of traumatic death in drug users decreases after the age of 25, to be replaced 
by an increased risk of death from a pre-existing medical condition (often drug-related) 
in later life (Webb, et al. 2003). The NDRDI data on deaths among drug users show a 
similar pattern. Overall, those who died from medical causes were older than those 
who died from traumatic causes.  However, it should be noted that the majority of all 
cases of death by non-poisoning died prematurely, well before their peers.‟ (Lynn, et al. 
2009)  
 
Correlation between toxicology and traumatic death (NDRDI 1998 to 2005 deaths) 
The toxicology of drug users who died owing to trauma between 1998 and 2005 was 
analysed (Lynn, et al. 2009).  A positive toxicology report was available for 412 (86.5%) 
of these cases.  In many cases, more than one substance was present.  When these 
cases were analysed by type of death (Table 12.3.3), the results showed that: 
 Alcohol was present in nearly three-fifths (241, 58.5%) of deaths.  
 Cannabis was the illicit drug most commonly found (227, 55.1%). 
 Cannabis (40, 67.8%), opiates (24, 40.7%) and cocaine (18, 30.5%) were found in 
the greatest proportions among deaths owing to violence (shooting, stabbing or 
assault). 
 MDMA (ecstasy) (26, 28.6%) was found in the greatest proportion among the 
deaths owing to RTCs.  
 
Table 12.3.3  Positive toxicology in trauma cases among drug users, by type of death, NDRDI 1998 
–2005  
 
All 
trauma 
deaths Hanging RTC§ Drowning Fall Violence* 
Other 
trauma 
 Number (%) 
Positive 
toxicology cases
† 412 147 91 53 32 59 30 
        
Alcohol 241 (58.5) 82 (55.8) 50 (54.9) 40 (75.5) 22 (68.8) 35 (59.3) 14 (46.7) 
Cannabis 227 (55.1) 75 (51.0) 60 (65.9) 26 (49.1) 12 (37.5) 40 (67.8) 14 (46.7) 
Benzodiazepine 127 (30.8) 47 (32.0) 22 (24.2) 20 (37.7) 11 (34.4) 20 (33.9) 7 (23.3) 
Opiate‡ 121 (29.4) 39 (26.5) 21 (23.1) 6 (11.3) 10 (31.3) 24 (40.7) 21 (70.0) 
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All 
trauma 
deaths Hanging RTC§ Drowning Fall Violence* 
Other 
trauma 
Cocaine 87 (21.1) 36 (24.5) 15 (16.5) 7 (13.2) 6 (18.8) 18 (30.5) 5 (16.7) 
MDMA 62 (15.0) 10 (6.8) 26 (28.6) 10 (18.9) 5 (15.6) 9 (15.2) ~ 
Antidepressant 31 (7.5) 17 (11.6) ~ 7 (13.2) ~ 
~ ~ 
Other 
substance** 75 (18.2) 32 (21.8) 10 (11.0) 11 (20.7) 8 (25.0) 7 (11.9) 9 (30.0) 
§ Road traffic collision 
* Includes deaths owing to shooting, stabbing or assault.  
† This is a multi-response table taking account of up to 10 substances present on toxicology report. Therefore, numbers 
and percentages in columns may not add up to totals shown as individual cases may have more than one drug or 
substance present on their toxicology report. 
‡ Includes methadone, heroin, morphine, distalgesic, tramadol or codeine. 
** Includes antihistamines, barbiturates, unspecified amphetamines, other chemicals, antiepileptics and non-
benzodiazepine anxiolytics, non-opiate analgesics, local anaesthesia, antipsychotic drugs. 
~ Cell contains less than five cases  
 
There is a body of evidence linking psychiatric illness as a co-morbid condition with an 
increased risk of suicide (Baldacchino and Corkery 2006, Darke, Shane, et al. 2009, 
Health Service Executive, et al. 2005). The NDRDI does not analyse deaths by intent 
(accident, misadventure, suicide etc) but the presence of prescription drugs such as 
antidepressants and benzodiazepines in those cases where death was by  hanging or 
drowning suggests that some people may also have had a psychiatric illness. 
 
The analysis showed that almost two thirds of those who died owing to a RTC were 
positive for cannabis (note, the RTC category includes drivers, passengers and 
pedestrians).  This underlines the need for more reliable statistics on drink/drug driving, 
although currently there is no reliable system of road-side testing for the presence of 
drugs in a driver (EMCDDA 2009). 
 
Research has shown that drug misuse, frequently also involving alcohol, increases the 
risk of violence leading to homicide (Darke, S, et al. 2007, Shaw, et al. 2006).  As 
shown in Table 12.3.3, many of those who died owing to violence were positive for both 
drugs and alcohol. 
 
Correlation between history of drug use and medical cause of death (NDRDI 1998 
to 2005) 
History of drug use among those who died from medical causes between 1998 and 
2005 was analysed (Table 12.3.4) (Lynn, et al. 2009). The results showed that:   
 The majority (180, 66.7%) of drug users who died of medical causes had a history 
of opiate use. 
 Two fifths (13, 41.9%) of those who died of liver disease had a history of alcohol 
dependency. 
 Approximately half of all deaths among cocaine users (12/26) and cannabis users 
(24/52) were due to a cardiac event. 
 
Table 12.3.4   History of drug use in cases of death from medical causes, NDRDI 1998–2005  
 
All 
medical 
deaths 
Cardi
ac 
Respirato
ry 
infection 
Liver 
diseas
e 
Other 
infectio
n 
Respirator
y disease 
AIDS
/HIV 
Other 
medical 
cause 
Substan
ce used Number (%) 
All cases* 270 67 48 31 24 19 12 69 
         
Alcohol 78 (28.9) 
11 
(16.4) 17 (35.4) 
13 
(41.9) 6 (25.0) 6 (31.6) ~ 20 (29.0) 
Cannabis 52 (19.3) 
24 
(35.8) 7 (14.6) ~ ~ 6 (31.6) ~ 14 (20.3) 
Benzodia
zepine 10 (3.7) ~ ~ ~ ~ ~ ~ ~ 
Opiate† 180 (66.7) 
36 
(53.7) 38 (79.2) 
21 
(67.7) 
23 
(95.8) 11 (57.9) 
10 
(83.3
) 39 (56.5) 
Cocaine 26 (9.6) 12 ~ ~ ~ ~ ~ 5 (7.2) 
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All 
medical 
deaths 
Cardi
ac 
Respirato
ry 
infection 
Liver 
diseas
e 
Other 
infectio
n 
Respirator
y disease 
AIDS
/HIV 
Other 
medical 
cause 
(17.9) 
MDMA 7 (2.6) ~ ~ 
 
~ ~ ~ ~ ~ 
Other 
substanc
e‡ 13 (4.8) ~ ~ 
 
~ 
~ ~ ~ 6 (8.7) 
*This is a multi-response table taking account of illicit use of up to six drugs. Therefore numbers and percentages in 
columns may not add up to totals shown as individual cases may use more than one drug or substance. 
† Includes heroin, morphine, codeine, street methadone, unspecified opiate-type drug, other opiate analgesic. 
‡ includes hallucinogenic substances, other stimulants and volatile inhalants, prescription and over-the-counter 
medication.  
~ Cell contains less than five cases. 
 
Many of those who died from medical causes were opiate users, probably reflecting the 
long-term effects of problematic drug use on a person. Research shows that cocaine 
can cause vascular disease, including heart disease (Karch 2002), and approximately 
one in five of those who died from a cardiac event were known to have used cocaine. 
 
12.4 Risk/protective factors among PDUs 
In 2009, an Irish university received funding for a study which aims to identify risk 
factors associated with mortality among clients receiving methadone (Dr Grainne 
Cousins, personal communication, Royal College of Surgeons).  This study is still at an 
early stage and will use a variety of data sources, including data from the NDRDI. It will 
be several years before the results are published.   
 
12.5 Complementary sources with drug-related mortality information 
12.5.1 AIDS related deaths 
In Ireland, surveillance data show that the most common probable route of 
transmission for HIV is sexual contact.  The proportion of cases where injecting drug 
use is the probable route appears to be falling, from 20% in 2004 to 9% in 2009 (Health 
Protection Surveillance Centre 2010).   
 
In Ireland, the number of deaths among AIDS cases appears to have been steadily 
falling over the past decade, down to two in 2009 (Table 12.5.1) (Health Protection 
Surveillance Centre 2010).  However, the national Health Protection Surveillance 
Centre (HPSC) notes that this figure must be interpreted with caution as there is known 
to be under-reporting and late reporting (especially in more recent years), the impact of 
which is unknown.  Additionally, the probable route of transmission is not known for 
these deaths. 
 
Table 12.5.1   HIV infections, AIDS cases and deaths among AIDS cases by year of diagnosis/death, 
1998–2009 
 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 
HIV 
infections 
120 190 290 299 364 401 358 326 353 391 404 395 
AIDS 18 25 13 26 35 39 44 42 42 34 35 33 
Deaths 
among AIDS 
cases 
11 17 10 6 6 4 8 8 8 6 3 2 
Source: HPSC, 2010 
 
For each death recorded by the NDRDI, any history of a blood-borne virus, including 
HIV, is documented if such data are recorded in the coronial records, hospital or GMR 
data.  However, this information is not always available.  In total, between 1998 and 
2007 there were 84 deaths where the individuals were HIV positive and 19 deaths 
where AIDS/HIV was in some way implicated in the death.  The HPSC reported 84 
AIDS deaths during the same period.  Small numbers over the 10-year period make it 
difficult to discern trends. 
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12.5.2 Public health perspectives 
The number of drug-related deaths in Ireland has increased year on year over the past 
decade, reflecting the increasing number of people taking drugs (National Advisory 
Committee on Drugs and Drug and Public Health Information and Research Branch 
2009a). The majority of drug-related deaths owing to both poisoning and non-poisoning 
occur among people aged between 20 and 44 years, meaning that drug use is 
contributing to the burden of premature mortality among the Irish population.  Analysis 
of the data on deaths by non-poisoning recorded in the NDRDI has meant that for the 
first time a more complete picture of the effects of drug use on drug users is available.  
 
Public health has been defined as „the science and art of preventing disease, 
prolonging life and promoting health through organised efforts of society‟ (The 
Committee into the Future Development of the Public Health Function 1998).  Although 
the issues around drug-related deaths are complex, public health measures can be 
introduced that will help to reduce the burden of premature mortality among drug users.   
 
For poisonings, strategies such as timely access to treatment, reduction of supply, and 
education and health promotion measures, can help to reduce the burden.  As over half 
of all deaths owing to poisoning have involved polysubstances, this issue should be 
prioritised within education and health promotion.  The first trends paper on the NDRDI 
data stated that, „The number of deaths as a result of poisoning indicates the most 
significant response required is a strategy to address overdoses, including actions to 
deal with overdose cases in a proactive manner at all levels including family, 
community health services, gardaí and government‟ (Lyons, Suzi, et al. 2008). In the 
2009–2016 National Drugs Strategy, Action 40 calls for the development of a National 
Overdose Prevention Strategy and a co-ordinated response to the rise in deaths 
indirectly related to substance abuse (Department of Community Rural and Gaeltacht 
Affairs 2009). The HSE has convened a committee to develop this strategy. 
 
The second trends papers on the NDRDI data highlighted the public health issues 
around deaths by non-poisoning: „One-fifth of deaths among drug users that were due 
to trauma [between 1998 and 2005] were the result of RTCs, and almost half of these 
cases were driving at the time of death.  This finding supports the position of the Road 
Safety Authority, which claims that one of the main causes of death on Irish roads is 
impaired driving due to the consumption of alcohol and/or drugs (both prescription and 
non-prescription) (Road Safety Authority 2007).  The Road Safety Authority has 
campaigned for more reliable statistics on the incidence of drink/drug driving, and for 
expansion of the forensic analysis programme to ascertain the true incidence of driving 
under the influence of substances. However, there is currently no reliable road-side test 
for drugs.‟ (Lynn, et al. 2009) 
 
The NDRDI does not analyse data according to intent (suicide, accident, misadventure 
or homicide).  However, international research has shown there is a strong association 
between substance abuse and risk of suicide (Darke, S, et al. 2007, Darke, Shane, et 
al. 2009, Farrell, et al. 1996, Guaglio, et al. 2001). Many of the deaths by non-
poisoning, specifically those owing to hanging or drowning, had positive toxicology for 
antidepressants, suggesting co-morbidity among this group.  Many of these cases were 
male with a median age of 27 years.  National figures show that young men are over-
represented in national suicide statistics (Health Service Executive, et al. 2005, Walsh 
2008).  The NDRDI trends paper on deaths by non-poisoning stated that, „Overall, the 
data from the NDRDI support the argument that substance misuse is related to suicide.  
One of the objectives of the National Strategy for Action on Suicide Prevention is to 
raise awareness of the association between alcohol and/or substance abuse and 
suicidal behaviour.  There is a need for increased awareness of cases with dual 
diagnosis (an individual who has both a mental health issue and a substance misuse 
problem) given that a proportion of those who died as a result of hanging or drowning 
were in treatment for substance dependency at the time of their death.‟ (Lynn, et al. 
2009) 
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The long-term detrimental effects of drug use also have public-health implications.  
Data from the NDRDI have shown that many of those who have died from traumatic 
causes were younger than those who died from medical causes; this is similar to 
findings in the UK (Webb, et al. 2003) (Lynn, et al. 2009).  Two thirds of those who died 
from medical causes were opiate users.  The correlation of history of drug use and 
medical causes has shown the probable impact of opiate use through deaths owing to 
HIV/AIDS or liver disease, deaths from cardiac events among those with a history of 
cocaine use, and liver disease among those with a history of alcohol dependence.  
Linked to this is the need to support harm reduction strategies to help prevent blood-
borne viruses.   
 
Finally, alcohol features strongly in deaths by both poisoning and non-poisoning.  For 
example, between 1998 and 2007, alcohol was implicated in almost a quarter of all 
deaths by poisoning (and only as part of a polysubstance poisoning).  Between 1998 
and 2005, alcohol was the substance most commonly found in the toxicology of those 
who died owing to trauma.  Many of the drug users who died from medical causes were 
known to be alcohol dependent.  As well as public health strategies to reduce alcohol-
related harm, these data underline the need to integrate alcohol treatment with drug 
treatment services in Ireland. 
 
Data from the NDRDI illustrate the total burden of mortality related to drug use in 
Ireland.  The upward trend in deaths both by poisoning and by non-poisoning has both 
immediate and longer term implications and requires appropriate public health 
strategies.   
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